{"PMC6033633": [["IntroductionEAE is a T cell\u2010driven autoimmune disease sharing many clinical and pathologic features with the human demyelinating disease MS 1, 2, 3.", [["IntroductionEAE", "DISEASE", 0, 15], ["autoimmune disease", "DISEASE", 35, 53], ["demyelinating disease", "DISEASE", 115, 136], ["MS", "DISEASE", 137, 139], ["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["a T cell\u2010driven autoimmune disease", "PROBLEM", 19, 53], ["the human demyelinating disease MS", "PROBLEM", 105, 139], ["demyelinating disease", "OBSERVATION", 115, 136]]], ["In EAE, CD4+ and CD8+ T\u2010cells specific for self\u2010antigens expressed in CNS myelin initiate a localized inflammatory process that results in demyelination, axonopathy, and clinical deficits 4, 5, 6.", [["CD4+ and CD8+", "ANATOMY", 8, 21], ["T\u2010cells", "ANATOMY", 22, 29], ["CNS myelin", "ANATOMY", 70, 80], ["EAE", "DISEASE", 3, 6], ["demyelination", "DISEASE", 139, 152], ["axonopathy", "DISEASE", 154, 164], ["CD4", "GENE_OR_GENE_PRODUCT", 8, 11], ["CD8", "GENE_OR_GENE_PRODUCT", 17, 20], ["T\u2010cells", "GENE_OR_GENE_PRODUCT", 22, 29], ["self\u2010antigens", "GENE_OR_GENE_PRODUCT", 43, 56], ["CNS myelin", "CELLULAR_COMPONENT", 70, 80], ["CD4", "PROTEIN", 8, 11], ["CD8", "PROTEIN", 17, 20], ["self\u2010antigens", "PROTEIN", 43, 56], ["CD4", "TEST", 8, 11], ["CD8", "TEST", 17, 20], ["self\u2010antigens", "PROBLEM", 43, 56], ["CNS myelin", "PROBLEM", 70, 80], ["a localized inflammatory process", "PROBLEM", 90, 122], ["demyelination", "PROBLEM", 139, 152], ["axonopathy", "PROBLEM", 154, 164], ["clinical deficits", "PROBLEM", 170, 187], ["CD4", "OBSERVATION", 8, 11], ["CNS", "ANATOMY", 70, 73], ["inflammatory", "OBSERVATION", 102, 114], ["demyelination", "OBSERVATION", 139, 152], ["axonopathy", "OBSERVATION", 154, 164]]], ["The concept that the adaptive immune response is critical for new lesion development and disease progression in MS is emphasized in that FDA\u2010approved disease modifying therapies are designed to limit infiltration of encephalitogenic lymphocytes into the CNS 7.", [["lesion", "ANATOMY", 66, 72], ["lymphocytes", "ANATOMY", 233, 244], ["CNS", "ANATOMY", 254, 257], ["MS", "DISEASE", 112, 114], ["lesion", "CANCER", 66, 72], ["lymphocytes", "CELL", 233, 244], ["encephalitogenic lymphocytes", "CELL_TYPE", 216, 244], ["new lesion development", "PROBLEM", 62, 84], ["disease progression in MS", "PROBLEM", 89, 114], ["disease modifying therapies", "TREATMENT", 150, 177], ["infiltration of encephalitogenic lymphocytes", "TREATMENT", 200, 244], ["new", "OBSERVATION_MODIFIER", 62, 65], ["lesion", "OBSERVATION", 66, 72], ["encephalitogenic lymphocytes", "OBSERVATION", 216, 244], ["CNS", "ANATOMY", 254, 257]]], ["Among the mechanisms by which myelin\u2010reactive CD4+ T\u2010cells contribute to disease is through localized secretion of cytokines, e.g. IL\u201017 that increases expression of chemokines that attract myeloid cells into the CNS 8.", [["myelin\u2010reactive CD4+", "ANATOMY", 30, 50], ["T\u2010cells", "ANATOMY", 51, 58], ["myeloid cells", "ANATOMY", 190, 203], ["CNS", "ANATOMY", 213, 216], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["T\u2010cells", "CANCER", 51, 58], ["IL\u201017", "GENE_OR_GENE_PRODUCT", 131, 136], ["myeloid cells", "CELL", 190, 203], ["myelin\u2010reactive CD4", "PROTEIN", 30, 49], ["cytokines", "PROTEIN", 115, 124], ["IL\u201017", "PROTEIN", 131, 136], ["chemokines", "PROTEIN", 166, 176], ["myeloid cells", "CELL_TYPE", 190, 203], ["disease", "PROBLEM", 73, 80], ["disease", "OBSERVATION", 73, 80], ["myeloid cells", "OBSERVATION", 190, 203], ["CNS", "ANATOMY", 213, 216]]], ["Monocytes and macrophages amplify white matter damage through active stripping of the myelin sheath leading to axonal damage, presentation of novel myelin epitopes to T cells and amplifying neuroinflammation through secretion of proinflammatory molecules.", [["Monocytes", "ANATOMY", 0, 9], ["macrophages", "ANATOMY", 14, 25], ["white matter", "ANATOMY", 34, 46], ["myelin sheath", "ANATOMY", 86, 99], ["axonal", "ANATOMY", 111, 117], ["T cells", "ANATOMY", 167, 174], ["white matter damage", "DISEASE", 34, 53], ["axonal damage", "DISEASE", 111, 124], ["Monocytes", "CELL", 0, 9], ["macrophages", "CELL", 14, 25], ["myelin sheath", "CELLULAR_COMPONENT", 86, 99], ["axonal", "CELLULAR_COMPONENT", 111, 117], ["myelin epitopes", "GENE_OR_GENE_PRODUCT", 148, 163], ["T cells", "CELL", 167, 174], ["Monocytes", "CELL_TYPE", 0, 9], ["macrophages", "CELL_TYPE", 14, 25], ["myelin epitopes", "PROTEIN", 148, 163], ["T cells", "CELL_TYPE", 167, 174], ["proinflammatory molecules", "PROTEIN", 229, 254], ["Monocytes", "TEST", 0, 9], ["macrophages", "PROBLEM", 14, 25], ["white matter damage", "PROBLEM", 34, 53], ["active stripping", "TREATMENT", 62, 78], ["the myelin sheath", "TREATMENT", 82, 99], ["axonal damage", "PROBLEM", 111, 124], ["novel myelin epitopes to T cells", "PROBLEM", 142, 174], ["neuroinflammation through secretion of proinflammatory molecules", "PROBLEM", 190, 254], ["macrophages", "OBSERVATION", 14, 25], ["white matter", "OBSERVATION_MODIFIER", 34, 46], ["active", "OBSERVATION_MODIFIER", 62, 68], ["stripping", "OBSERVATION", 69, 78], ["myelin sheath", "OBSERVATION", 86, 99], ["axonal damage", "OBSERVATION", 111, 124], ["proinflammatory molecules", "OBSERVATION", 229, 254]]], ["In addition, IL\u201017 secretion increases expression of the neutrophil chemoattractants CXCL1 and CXCL2 resulting in recruitment and accumulation of these cells within the CNS 9.IntroductionIncreasing evidence in both preclinical models of MS as well as from MS patients have highlighted a potentially important role for neutrophils in demyelination 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.", [["neutrophil", "ANATOMY", 57, 67], ["cells", "ANATOMY", 152, 157], ["CNS", "ANATOMY", 169, 172], ["neutrophils", "ANATOMY", 318, 329], ["MS", "DISEASE", 237, 239], ["MS", "DISEASE", 256, 258], ["demyelination", "DISEASE", 333, 346], ["IL\u201017", "GENE_OR_GENE_PRODUCT", 13, 18], ["neutrophil", "CELL", 57, 67], ["CXCL1", "GENE_OR_GENE_PRODUCT", 85, 90], ["CXCL2", "GENE_OR_GENE_PRODUCT", 95, 100], ["cells", "CELL", 152, 157], ["patients", "ORGANISM", 259, 267], ["neutrophils", "CELL", 318, 329], ["IL\u201017", "PROTEIN", 13, 18], ["neutrophil chemoattractants", "PROTEIN", 57, 84], ["CXCL1", "PROTEIN", 85, 90], ["CXCL2", "PROTEIN", 95, 100], ["neutrophils", "CELL_TYPE", 318, 329], ["patients", "SPECIES", 259, 267], ["the neutrophil chemoattractants CXCL1", "TEST", 53, 90], ["CXCL2", "TEST", 95, 100], ["recruitment", "PROBLEM", 114, 125], ["accumulation of these cells", "PROBLEM", 130, 157], ["MS", "PROBLEM", 237, 239], ["neutrophils in demyelination", "PROBLEM", 318, 346], ["neutrophil chemoattractants CXCL1", "OBSERVATION", 57, 90], ["recruitment", "OBSERVATION_MODIFIER", 114, 125], ["accumulation of these cells", "OBSERVATION", 130, 157], ["CNS", "ANATOMY", 169, 172]]], ["Neutrophil depletion delays the onset of clinical symptoms in EAE mice arguing for a role for these cells in disease initiation and/or lesion formation 9, 13, 17, 19.", [["Neutrophil", "ANATOMY", 0, 10], ["cells", "ANATOMY", 100, 105], ["lesion", "ANATOMY", 135, 141], ["EAE", "DISEASE", 62, 65], ["Neutrophil", "CELL", 0, 10], ["mice", "ORGANISM", 66, 70], ["cells", "CELL", 100, 105], ["lesion", "PATHOLOGICAL_FORMATION", 135, 141], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70], ["Neutrophil depletion", "PROBLEM", 0, 20], ["clinical symptoms", "PROBLEM", 41, 58], ["these cells", "PROBLEM", 94, 105], ["disease initiation", "PROBLEM", 109, 127], ["lesion formation", "PROBLEM", 135, 151], ["lesion", "OBSERVATION", 135, 141]]], ["Studies designed to decipher the mechanisms by which neutrophils augment disease progression point to increases in vascular permeability as well as secretion of reactive nitrogen and oxygen species 14, 18.", [["neutrophils", "ANATOMY", 53, 64], ["vascular", "ANATOMY", 115, 123], ["oxygen", "CHEMICAL", 183, 189], ["nitrogen", "CHEMICAL", 170, 178], ["oxygen", "CHEMICAL", 183, 189], ["neutrophils", "CELL", 53, 64], ["vascular", "MULTI-TISSUE_STRUCTURE", 115, 123], ["reactive nitrogen", "SIMPLE_CHEMICAL", 161, 178], ["oxygen", "SIMPLE_CHEMICAL", 183, 189], ["neutrophils", "CELL_TYPE", 53, 64], ["Studies", "TEST", 0, 7], ["neutrophils augment disease progression", "PROBLEM", 53, 92], ["increases in vascular permeability", "PROBLEM", 102, 136], ["reactive nitrogen", "TREATMENT", 161, 178], ["oxygen species", "TEST", 183, 197], ["increases", "OBSERVATION_MODIFIER", 102, 111], ["vascular", "ANATOMY", 115, 123], ["permeability", "OBSERVATION", 124, 136], ["reactive nitrogen", "OBSERVATION", 161, 178], ["oxygen species", "OBSERVATION", 183, 197]]], ["In patients with relapsing\u2010remitting MS, there are elevated systemic levels of neutrophil\u2010activating chemokines including CXCL1, CXCL5, and neutrophil elastase accompanied by increased numbers of neutrophils having a primed phenotype 10, 12.", [["neutrophil", "ANATOMY", 140, 150], ["neutrophils", "ANATOMY", 196, 207], ["MS", "DISEASE", 37, 39], ["patients", "ORGANISM", 3, 11], ["CXCL1", "GENE_OR_GENE_PRODUCT", 122, 127], ["CXCL5", "GENE_OR_GENE_PRODUCT", 129, 134], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 140, 159], ["neutrophils", "CELL", 196, 207], ["neutrophil\u2010activating chemokines", "PROTEIN", 79, 111], ["CXCL1", "PROTEIN", 122, 127], ["CXCL5", "PROTEIN", 129, 134], ["neutrophil elastase", "PROTEIN", 140, 159], ["neutrophils", "CELL_TYPE", 196, 207], ["patients", "SPECIES", 3, 11], ["relapsing\u2010remitting MS", "PROBLEM", 17, 39], ["elevated systemic levels", "PROBLEM", 51, 75], ["neutrophil\u2010activating chemokines", "PROBLEM", 79, 111], ["CXCL1", "TEST", 122, 127], ["CXCL5", "TEST", 129, 134], ["neutrophil elastase", "PROBLEM", 140, 159], ["increased numbers of neutrophils", "PROBLEM", 175, 207], ["elevated", "OBSERVATION_MODIFIER", 51, 59], ["systemic levels", "OBSERVATION", 60, 75], ["neutrophil\u2010activating chemokines", "OBSERVATION", 79, 111], ["CXCL5", "ANATOMY", 129, 134], ["neutrophil elastase", "OBSERVATION", 140, 159], ["increased", "OBSERVATION_MODIFIER", 175, 184], ["numbers", "OBSERVATION_MODIFIER", 185, 192]]], ["Collectively, these findings from preclinical models as well as MS patients argue for a role for neutrophils in contributing to disease.IntroductionGiven the transient nature of neutrophils in terms of having a short half\u2010life, limited presence within lesions, and tightly regulated expression of chemotactic signals underscores the challenging aspects involved in understanding the role of these cells in autoimmune demyelination.", [["neutrophils", "ANATOMY", 97, 108], ["neutrophils", "ANATOMY", 178, 189], ["lesions", "ANATOMY", 252, 259], ["cells", "ANATOMY", 397, 402], ["MS", "DISEASE", 64, 66], ["autoimmune demyelination", "DISEASE", 406, 430], ["patients", "ORGANISM", 67, 75], ["neutrophils", "CELL", 97, 108], ["neutrophils", "CELL", 178, 189], ["lesions", "PATHOLOGICAL_FORMATION", 252, 259], ["cells", "CELL", 397, 402], ["neutrophils", "CELL_TYPE", 97, 108], ["neutrophils", "CELL_TYPE", 178, 189], ["patients", "SPECIES", 67, 75], ["neutrophils", "PROBLEM", 97, 108], ["disease", "PROBLEM", 128, 135], ["a short half\u2010life", "PROBLEM", 209, 226], ["limited presence within lesions", "PROBLEM", 228, 259], ["chemotactic signals", "TEST", 297, 316], ["autoimmune demyelination", "PROBLEM", 406, 430], ["disease", "OBSERVATION", 128, 135], ["transient", "OBSERVATION_MODIFIER", 158, 167], ["lesions", "OBSERVATION", 252, 259], ["autoimmune demyelination", "OBSERVATION", 406, 430]]], ["To overcome some of these limitations, we have derived a transgenic mouse whereby expression of CXCL1 is under the control of a tetracycline\u2010inducible promoter that is active within glial fibrillary acidic protein (GFAP)\u2010positive astrocytes 21.", [["glial fibrillary acidic protein (GFAP)\u2010positive astrocytes", "ANATOMY", 182, 240], ["mouse", "ORGANISM", 68, 73], ["CXCL1", "GENE_OR_GENE_PRODUCT", 96, 101], ["glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 182, 213], ["GFAP", "GENE_OR_GENE_PRODUCT", 215, 219], ["CXCL1", "PROTEIN", 96, 101], ["tetracycline\u2010inducible promoter", "DNA", 128, 159], ["glial fibrillary acidic protein (GFAP)\u2010positive astrocytes 21", "CELL_TYPE", 182, 243], ["mouse", "SPECIES", 68, 73], ["mouse", "SPECIES", 68, 73], ["a tetracycline\u2010inducible promoter", "TREATMENT", 126, 159], ["astrocytes", "TEST", 230, 240]]], ["Recent studies have emphasized an important role for CXCL1 and it is receptor CXCR2 during the effector phase of EAE 9, 22, 23, 24.", [["EAE", "DISEASE", 113, 116], ["CXCL1", "GENE_OR_GENE_PRODUCT", 53, 58], ["CXCR2", "GENE_OR_GENE_PRODUCT", 78, 83], ["CXCL1", "PROTEIN", 53, 58], ["CXCR2", "PROTEIN", 78, 83], ["Recent studies", "TEST", 0, 14], ["EAE", "TEST", 113, 116]]], ["Although resident cells of the CNS including microglia and endothelial cells express CXCL1 24, 25, astrocytes have been shown to express CXCL1 in EAE as well as in MS lesions 26, 27, 28 and this informed our decision to select astrocytes as our target cell for ectopic expression of CXCL1.", [["cells", "ANATOMY", 18, 23], ["CNS", "ANATOMY", 31, 34], ["microglia", "ANATOMY", 45, 54], ["endothelial cells", "ANATOMY", 59, 76], ["astrocytes", "ANATOMY", 99, 109], ["MS lesions", "ANATOMY", 164, 174], ["astrocytes", "ANATOMY", 227, 237], ["cell", "ANATOMY", 252, 256], ["EAE", "DISEASE", 146, 149], ["cells", "CELL", 18, 23], ["CNS", "CELL", 31, 34], ["microglia", "CELL", 45, 54], ["endothelial cells", "CELL", 59, 76], ["CXCL1", "GENE_OR_GENE_PRODUCT", 85, 90], ["astrocytes", "CELL", 99, 109], ["CXCL1", "GENE_OR_GENE_PRODUCT", 137, 142], ["MS lesions", "CANCER", 164, 174], ["astrocytes", "CELL", 227, 237], ["cell", "CELL", 252, 256], ["CXCL1", "GENE_OR_GENE_PRODUCT", 283, 288], ["resident cells", "CELL_TYPE", 9, 23], ["microglia", "CELL_TYPE", 45, 54], ["endothelial cells", "CELL_TYPE", 59, 76], ["CXCL1", "PROTEIN", 85, 90], ["astrocytes", "CELL_TYPE", 99, 109], ["CXCL1", "PROTEIN", 137, 142], ["astrocytes", "CELL_TYPE", 227, 237], ["CXCL1", "PROTEIN", 283, 288], ["endothelial cells", "TEST", 59, 76], ["CXCL1", "TEST", 85, 90], ["astrocytes", "TEST", 99, 109], ["CXCL1 in EAE", "PROBLEM", 137, 149], ["MS lesions", "PROBLEM", 164, 174], ["ectopic expression of CXCL1", "PROBLEM", 261, 288], ["CNS", "ANATOMY", 31, 34], ["endothelial", "ANATOMY", 59, 70], ["CXCL1", "OBSERVATION", 137, 142]]], ["Our present study was undertaken to better understand how elevated and sustained neutrophil recruitment into the CNS impacts EAE disease progression and white matter damage.", [["neutrophil", "ANATOMY", 81, 91], ["CNS", "ANATOMY", 113, 116], ["white matter", "ANATOMY", 153, 165], ["EAE", "DISEASE", 125, 128], ["white matter damage", "DISEASE", 153, 172], ["neutrophil", "CELL", 81, 91], ["CNS", "ANATOMICAL_SYSTEM", 113, 116], ["Our present study", "TEST", 0, 17], ["sustained neutrophil recruitment", "PROBLEM", 71, 103], ["EAE disease progression", "PROBLEM", 125, 148], ["white matter damage", "PROBLEM", 153, 172], ["neutrophil recruitment", "OBSERVATION", 81, 103], ["CNS", "ANATOMY", 113, 116], ["white matter", "OBSERVATION_MODIFIER", 153, 165]]], ["Our findings indicate that increased expression of CXCL1 within the CNS results in more severe EAE as measured by both clinical disease and demyelination.", [["CNS", "ANATOMY", 68, 71], ["EAE", "DISEASE", 95, 98], ["demyelination", "DISEASE", 140, 153], ["CXCL1", "GENE_OR_GENE_PRODUCT", 51, 56], ["CNS", "ANATOMICAL_SYSTEM", 68, 71], ["CXCL1", "PROTEIN", 51, 56], ["increased expression of CXCL1", "PROBLEM", 27, 56], ["more severe EAE", "PROBLEM", 83, 98], ["both clinical disease", "PROBLEM", 114, 135], ["demyelination", "PROBLEM", 140, 153], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["expression", "OBSERVATION_MODIFIER", 37, 47], ["CXCL1", "OBSERVATION", 51, 56], ["CNS", "ANATOMY", 68, 71], ["more severe", "OBSERVATION_MODIFIER", 83, 94], ["EAE", "OBSERVATION", 95, 98], ["demyelination", "OBSERVATION", 140, 153]]], ["The CXCL1\u2010mediated disease enhancement was not dependent on an increase in myelin\u2010reactive Th1 or Th17 cells but correlated with increased numbers of neutrophil infiltration into the spinal cord.", [["Th17 cells", "ANATOMY", 98, 108], ["neutrophil", "ANATOMY", 150, 160], ["spinal cord", "ANATOMY", 183, 194], ["CXCL1", "GENE_OR_GENE_PRODUCT", 4, 9], ["Th1", "CELL", 91, 94], ["Th17 cells", "CELL", 98, 108], ["neutrophil", "CELL", 150, 160], ["spinal cord", "ORGAN", 183, 194], ["CXCL1", "PROTEIN", 4, 9], ["myelin\u2010reactive Th1 or Th17 cells", "CELL_TYPE", 75, 108], ["The CXCL1\u2010mediated disease enhancement", "PROBLEM", 0, 38], ["an increase in myelin\u2010reactive Th1 or Th17 cells", "PROBLEM", 60, 108], ["neutrophil infiltration into the spinal cord", "PROBLEM", 150, 194], ["CXCL1", "ANATOMY", 4, 9], ["disease", "OBSERVATION", 19, 26], ["not", "UNCERTAINTY", 43, 46], ["dependent", "OBSERVATION_MODIFIER", 47, 56], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["myelin\u2010reactive Th1", "OBSERVATION", 75, 94], ["Th17 cells", "OBSERVATION", 98, 108], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["numbers", "OBSERVATION_MODIFIER", 139, 146], ["neutrophil infiltration", "OBSERVATION", 150, 173], ["spinal cord", "ANATOMY", 183, 194]]], ["Indeed, depletion of neutrophils resulted in a reduction in the severity of white matter damage highlighting a role for these cells in demyelination.Increased clinical disease following Dox\u2010induced expression of CXCL1 ::: ResultsFollowing induction of EAE, CD4+ T\u2010cell\u2010derived IL\u201017 expression in the CNS potentiates disease by enhancing expression of the neutrophil chemoattractants CXCL1 and CXCL2 9.", [["neutrophils", "ANATOMY", 21, 32], ["white matter", "ANATOMY", 76, 88], ["cells", "ANATOMY", 126, 131], ["CNS", "ANATOMY", 301, 304], ["neutrophil", "ANATOMY", 356, 366], ["white matter damage", "DISEASE", 76, 95], ["demyelination", "DISEASE", 135, 148], ["EAE", "DISEASE", 252, 255], ["neutrophils", "CELL", 21, 32], ["cells", "CELL", 126, 131], ["CXCL1", "GENE_OR_GENE_PRODUCT", 212, 217], ["CD4", "GENE_OR_GENE_PRODUCT", 257, 260], ["IL\u201017", "GENE_OR_GENE_PRODUCT", 277, 282], ["CNS", "ANATOMICAL_SYSTEM", 301, 304], ["neutrophil", "CELL", 356, 366], ["CXCL1", "GENE_OR_GENE_PRODUCT", 384, 389], ["CXCL2 9", "GENE_OR_GENE_PRODUCT", 394, 401], ["neutrophils", "CELL_TYPE", 21, 32], ["CXCL1", "PROTEIN", 212, 217], ["CD4", "PROTEIN", 257, 260], ["IL\u201017", "PROTEIN", 277, 282], ["neutrophil chemoattractants", "PROTEIN", 356, 383], ["CXCL1", "PROTEIN", 384, 389], ["CXCL2 9", "PROTEIN", 394, 401], ["depletion of neutrophils", "PROBLEM", 8, 32], ["a reduction", "PROBLEM", 45, 56], ["white matter damage", "PROBLEM", 76, 95], ["these cells", "PROBLEM", 120, 131], ["demyelination", "PROBLEM", 135, 148], ["Increased clinical disease", "PROBLEM", 149, 175], ["EAE", "PROBLEM", 252, 255], ["disease", "PROBLEM", 317, 324], ["the neutrophil chemoattractants CXCL1", "TEST", 352, 389], ["CXCL2", "TEST", 394, 399], ["depletion", "OBSERVATION_MODIFIER", 8, 17], ["neutrophils", "OBSERVATION", 21, 32], ["reduction", "OBSERVATION_MODIFIER", 47, 56], ["white matter", "OBSERVATION_MODIFIER", 76, 88], ["demyelination", "OBSERVATION", 135, 148], ["CNS", "ANATOMY", 301, 304], ["disease", "OBSERVATION", 317, 324], ["neutrophil chemoattractants CXCL1", "OBSERVATION", 356, 389]]], ["The accumulation of neutrophils in the CNS is rapid yet transient and reflects the expression kinetics of CXCL1 and CXCL2.", [["neutrophils", "ANATOMY", 20, 31], ["CNS", "ANATOMY", 39, 42], ["neutrophils", "CELL", 20, 31], ["CNS", "ANATOMICAL_SYSTEM", 39, 42], ["CXCL1", "GENE_OR_GENE_PRODUCT", 106, 111], ["CXCL2", "GENE_OR_GENE_PRODUCT", 116, 121], ["neutrophils", "CELL_TYPE", 20, 31], ["CXCL1", "PROTEIN", 106, 111], ["CXCL2", "PROTEIN", 116, 121], ["The accumulation of neutrophils", "PROBLEM", 0, 31], ["the expression kinetics of CXCL1", "PROBLEM", 79, 111], ["CXCL2", "TEST", 116, 121], ["accumulation", "OBSERVATION_MODIFIER", 4, 16], ["neutrophils", "OBSERVATION", 20, 31], ["CNS", "ANATOMY", 39, 42], ["rapid", "OBSERVATION_MODIFIER", 46, 51], ["expression kinetics", "OBSERVATION", 83, 102], ["CXCL1", "OBSERVATION_MODIFIER", 106, 111], ["CXCL2", "OBSERVATION_MODIFIER", 116, 121]]], ["To better understand how neutrophil infiltration impacts demyelination and disease progression in EAE, transgenic (tg) mice were engineered to express CXCL1 within GFAP\u2010positive astrocytes upon doxycycline administration, as previous studies have shown these cells to be the primary source of CXCL1 in models of neuroinflammation 29, 30.", [["neutrophil", "ANATOMY", 25, 35], ["astrocytes", "ANATOMY", 178, 188], ["cells", "ANATOMY", 259, 264], ["demyelination", "DISEASE", 57, 70], ["EAE", "DISEASE", 98, 101], ["doxycycline", "CHEMICAL", 194, 205], ["neuroinflammation", "DISEASE", 312, 329], ["doxycycline", "CHEMICAL", 194, 205], ["neutrophil", "CELL", 25, 35], ["transgenic (tg) mice", "ORGANISM", 103, 123], ["CXCL1", "GENE_OR_GENE_PRODUCT", 151, 156], ["GFAP", "GENE_OR_GENE_PRODUCT", 164, 168], ["doxycycline", "SIMPLE_CHEMICAL", 194, 205], ["cells", "CELL", 259, 264], ["CXCL1", "GENE_OR_GENE_PRODUCT", 293, 298], ["CXCL1", "PROTEIN", 151, 156], ["GFAP\u2010positive astrocytes", "CELL_TYPE", 164, 188], ["CXCL1", "PROTEIN", 293, 298], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 119, 123], ["neutrophil infiltration impacts demyelination", "PROBLEM", 25, 70], ["disease progression", "PROBLEM", 75, 94], ["EAE", "PROBLEM", 98, 101], ["CXCL1", "TEST", 151, 156], ["doxycycline administration", "TREATMENT", 194, 220], ["previous studies", "TEST", 225, 241], ["these cells", "PROBLEM", 253, 264], ["neuroinflammation", "PROBLEM", 312, 329], ["demyelination", "OBSERVATION", 57, 70]]], ["Doxycyline (Dox) responsive double tg mice (pBI\u2010CXCL1\u2010rtTA) or single tg controls lacking the reverse tetracycline transactivator (rtTA) were immunized with MOG35\u201355 peptide and treated daily with Dox (50 mg/kg) i.p. between days 9 through 19 postimmunization (Fig. 1A).", [["Doxycyline", "CHEMICAL", 0, 10], ["Dox", "CHEMICAL", 12, 15], ["tetracycline", "CHEMICAL", 102, 114], ["MOG35\u201355 peptide", "CHEMICAL", 157, 173], ["Dox", "CHEMICAL", 197, 200], ["Doxycyline", "CHEMICAL", 0, 10], ["Dox", "CHEMICAL", 12, 15], ["tetracycline", "CHEMICAL", 102, 114], ["Dox", "CHEMICAL", 197, 200], ["Doxycyline", "SIMPLE_CHEMICAL", 0, 10], ["Dox", "SIMPLE_CHEMICAL", 12, 15], ["double tg mice", "ORGANISM", 28, 42], ["pBI\u2010CXCL1\u2010rtTA", "ORGANISM", 44, 58], ["single tg controls", "ORGANISM", 63, 81], ["tetracycline transactivator", "GENE_OR_GENE_PRODUCT", 102, 129], ["rtTA", "GENE_OR_GENE_PRODUCT", 131, 135], ["Dox", "SIMPLE_CHEMICAL", 197, 200], ["reverse tetracycline transactivator", "PROTEIN", 94, 129], ["rtTA", "PROTEIN", 131, 135], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["Doxycyline (Dox)", "TREATMENT", 0, 16], ["double tg mice (pBI\u2010CXCL1\u2010rtTA)", "TREATMENT", 28, 59], ["single tg controls", "TREATMENT", 63, 81], ["the reverse tetracycline transactivator (rtTA)", "TREATMENT", 90, 136], ["Dox", "TREATMENT", 197, 200]]], ["Onset of clinical disease was similar between Dox\u2010treated double tg and single tg mice (day 9 p.i.), but double tg mice exhibited a significant increase in clinical disease severity compared to single tg mice (Fig. 1B).", [["single tg mice", "ORGANISM", 72, 86], ["mice", "ORGANISM", 115, 119], ["tg mice", "ORGANISM", 201, 208], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 204, 208], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 204, 208], ["clinical disease", "PROBLEM", 9, 25], ["Dox\u2010treated double tg", "TREATMENT", 46, 67], ["single tg mice", "TREATMENT", 72, 86], ["double tg mice", "TREATMENT", 105, 119], ["clinical disease severity", "PROBLEM", 156, 181], ["disease", "OBSERVATION", 18, 25], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["increase", "OBSERVATION_MODIFIER", 144, 152]]], ["Examination of mRNA transcripts encoding proinflammatory chemokines/cytokines indicated a selective >twofold increase in CXCL1 in Dox\u2010treated double tg mice versus single tg mice at day 12 postimmunization that represents a time in which there is a separation in clinical disease between double and single tg mice following MOG35\u201355 immunization.", [["MOG35\u201355", "CHEMICAL", 324, 332], ["CXCL1", "GENE_OR_GENE_PRODUCT", 121, 126], ["Dox\u2010treated double tg mice", "ORGANISM", 130, 156], ["single tg mice", "ORGANISM", 164, 178], ["tg mice", "ORGANISM", 306, 313], ["MOG35\u201355", "ORGANISM", 324, 332], ["mRNA transcripts", "RNA", 15, 31], ["proinflammatory chemokines", "PROTEIN", 41, 67], ["cytokines", "PROTEIN", 68, 77], ["CXCL1", "PROTEIN", 121, 126], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 309, 313], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 309, 313], ["Examination of mRNA transcripts", "TEST", 0, 31], ["proinflammatory chemokines", "TEST", 41, 67], ["cytokines", "TEST", 68, 77], ["CXCL1 in Dox\u2010treated double tg mice", "TREATMENT", 121, 156], ["single tg mice", "TREATMENT", 164, 178], ["a separation in clinical disease", "PROBLEM", 247, 279], ["double and single tg mice", "TREATMENT", 288, 313], ["MOG35\u201355 immunization", "TREATMENT", 324, 345], ["increase", "OBSERVATION_MODIFIER", 109, 117], ["CXCL1", "OBSERVATION", 121, 126], ["separation", "OBSERVATION_MODIFIER", 249, 259]]], ["No differences in expression of transcripts encoding CXCL2, CXCL10, CCL2, CCL5, IFN\u2010\u03b3, and IL\u201017A at day 12 between Dox\u2010treated double tg and single tg mice were observed (Fig. 1C).", [["CXCL2", "GENE_OR_GENE_PRODUCT", 53, 58], ["CXCL10", "GENE_OR_GENE_PRODUCT", 60, 66], ["CCL2", "GENE_OR_GENE_PRODUCT", 68, 72], ["CCL5", "GENE_OR_GENE_PRODUCT", 74, 78], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL\u201017A", "GENE_OR_GENE_PRODUCT", 91, 97], ["Dox\u2010treated double tg", "ORGANISM", 116, 137], ["single tg mice", "ORGANISM", 142, 156], ["CXCL2", "PROTEIN", 53, 58], ["CXCL10", "PROTEIN", 60, 66], ["CCL2", "PROTEIN", 68, 72], ["CCL5", "PROTEIN", 74, 78], ["IFN\u2010\u03b3", "PROTEIN", 80, 85], ["IL\u201017A", "PROTEIN", 91, 97], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 152, 156], ["CXCL2", "TEST", 53, 58], ["CXCL10", "TEST", 60, 66], ["CCL2", "TEST", 68, 72], ["CCL5", "TEST", 74, 78], ["IFN\u2010\u03b3", "TEST", 80, 85], ["Dox\u2010treated double tg", "TREATMENT", 116, 137], ["single tg mice", "TREATMENT", 142, 156]]], ["A significant (p < 0.05) increase in CXCL1 protein was detected only in the spinal cord (Fig. 1E) and not in the serum (Fig. 1D) of double tg mice 12 days postimmunization compared to single tg controls.", [["spinal cord", "ANATOMY", 76, 87], ["serum", "ANATOMY", 113, 118], ["CXCL1", "GENE_OR_GENE_PRODUCT", 37, 42], ["spinal cord", "ORGAN", 76, 87], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["tg mice", "ORGANISM", 139, 146], ["CXCL1", "PROTEIN", 37, 42], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 142, 146], ["A significant (p < 0.05) increase in CXCL1 protein", "PROBLEM", 0, 50], ["double tg mice", "TREATMENT", 132, 146], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["CXCL1 protein", "OBSERVATION", 37, 50], ["spinal cord", "ANATOMY", 76, 87]]], ["Notably, we also observed a significant (p < 0.05) increase in CXCL1 protein within the spinal cords of Dox\u2010treated na\u00efve mice in which EAE was not induced indicating that disease induction did not selectively enhance transgene expression (Fig. 1E).", [["spinal cords", "ANATOMY", 88, 100], ["EAE", "DISEASE", 136, 139], ["CXCL1", "GENE_OR_GENE_PRODUCT", 63, 68], ["spinal cords", "ORGAN", 88, 100], ["mice", "ORGANISM", 122, 126], ["CXCL1 protein", "PROTEIN", 63, 76], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 122, 126], ["CXCL1 protein", "TEST", 63, 76], ["disease induction", "PROBLEM", 172, 189], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["CXCL1 protein", "OBSERVATION", 63, 76], ["spinal cords", "ANATOMY", 88, 100], ["disease", "OBSERVATION", 172, 179]]], ["We did not detect differences in proteins levels of G\u2010CSF, GM\u2010CSF, or IL\u201017 (data not shown) either prior to or following Dox treatment of double tg or single tg EAE mice.", [["Dox", "CHEMICAL", 122, 125], ["EAE", "DISEASE", 162, 165], ["Dox", "CHEMICAL", 122, 125], ["G\u2010CSF", "GENE_OR_GENE_PRODUCT", 52, 57], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 59, 65], ["IL\u201017", "GENE_OR_GENE_PRODUCT", 70, 75], ["Dox", "SIMPLE_CHEMICAL", 122, 125], ["single tg EAE mice", "ORGANISM", 152, 170], ["G\u2010CSF", "PROTEIN", 52, 57], ["GM", "PROTEIN", 59, 61], ["CSF", "PROTEIN", 62, 65], ["IL\u201017", "PROTEIN", 70, 75], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 166, 170], ["proteins levels", "TEST", 33, 48], ["G\u2010CSF", "TEST", 52, 57], ["GM\u2010CSF", "TEST", 59, 65], ["Dox treatment", "TREATMENT", 122, 135], ["double tg", "TREATMENT", 139, 148]]], ["Immunofluorescence staining confirmed astrocytes (GFAP+) as the primary cellular source of CXCL1 in Dox\u2010treated double tg EAE mice (Fig. 1F).", [["astrocytes", "ANATOMY", 38, 48], ["cellular", "ANATOMY", 72, 80], ["astrocytes", "CELL", 38, 48], ["GFAP", "GENE_OR_GENE_PRODUCT", 50, 54], ["cellular", "CELL", 72, 80], ["CXCL1", "GENE_OR_GENE_PRODUCT", 91, 96], ["Dox\u2010treated double tg EAE mice", "ORGANISM", 100, 130], ["astrocytes", "CELL_TYPE", 38, 48], ["GFAP", "PROTEIN", 50, 54], ["CXCL1", "PROTEIN", 91, 96], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["Immunofluorescence staining", "TEST", 0, 27], ["astrocytes", "TEST", 38, 48], ["GFAP", "TEST", 50, 54], ["CXCL1", "TEST", 91, 96], ["Dox\u2010treated double tg EAE mice", "TREATMENT", 100, 130], ["astrocytes", "ANATOMY", 38, 48]]], ["Together, these findings indicate that CXCL1 expression was specifically elevated in the CNS of Dox\u2010treated double tg mice that correlated with an increase in clinical disease.Induced expression of CXCL1 does not increase either T\u00a0cell or macrophage infiltration into the CNS ::: ResultsMOG35\u201355\u2010induced EAE disease correlates with CNS infiltration of Th1 and Th17 CD4+ T\u2010cells reactive against the encephalitogenic MOG peptide 31.", [["CNS", "ANATOMY", 89, 92], ["T\u00a0cell", "ANATOMY", 229, 235], ["macrophage", "ANATOMY", 239, 249], ["CNS", "ANATOMY", 272, 275], ["CNS", "ANATOMY", 332, 335], ["Th17 CD4+", "ANATOMY", 360, 369], ["EAE", "DISEASE", 304, 307], ["CXCL1", "GENE_OR_GENE_PRODUCT", 39, 44], ["CNS", "ANATOMICAL_SYSTEM", 89, 92], ["double tg mice", "ORGANISM", 108, 122], ["CXCL1", "GENE_OR_GENE_PRODUCT", 198, 203], ["T\u00a0cell", "CELL", 229, 235], ["macrophage", "CELL", 239, 249], ["CNS", "ANATOMICAL_SYSTEM", 272, 275], ["ResultsMOG35", "GENE_OR_GENE_PRODUCT", 280, 292], ["CNS", "ANATOMICAL_SYSTEM", 332, 335], ["Th1", "CELL", 352, 355], ["CD4", "GENE_OR_GENE_PRODUCT", 365, 368], ["CXCL1", "PROTEIN", 39, 44], ["CXCL1", "PROTEIN", 198, 203], ["Th1", "CELL_TYPE", 352, 355], ["CD4", "PROTEIN", 365, 368], ["mice", "SPECIES", 118, 122], ["mice", "SPECIES", 118, 122], ["CXCL1 expression", "TEST", 39, 55], ["Dox\u2010treated double tg mice", "TREATMENT", 96, 122], ["an increase in clinical disease", "PROBLEM", 144, 175], ["CXCL1", "TEST", 198, 203], ["T\u00a0cell", "PROBLEM", 229, 235], ["macrophage infiltration", "PROBLEM", 239, 262], ["EAE disease", "PROBLEM", 304, 315], ["CNS infiltration", "TEST", 332, 348], ["Th1", "TEST", 352, 355], ["T\u2010cells", "TEST", 370, 377], ["the encephalitogenic MOG peptide", "TEST", 395, 427], ["CXCL1 expression", "OBSERVATION", 39, 55], ["elevated", "OBSERVATION_MODIFIER", 73, 81], ["increase", "OBSERVATION_MODIFIER", 147, 155], ["clinical disease", "OBSERVATION", 159, 175], ["CXCL1", "OBSERVATION", 198, 203], ["macrophage infiltration", "OBSERVATION", 239, 262], ["CNS", "ANATOMY", 272, 275], ["Th1", "ANATOMY", 352, 355], ["Th17 CD4", "OBSERVATION", 360, 368]]], ["In addition, other immune subsets including CD8+ T cells, B cells, and macrophages are also considered important in amplifying clinical disease and pathology 31.", [["T cells", "ANATOMY", 49, 56], ["B cells", "ANATOMY", 58, 65], ["macrophages", "ANATOMY", 71, 82], ["CD8", "GENE_OR_GENE_PRODUCT", 44, 47], ["T cells", "CELL", 49, 56], ["B cells", "CELL", 58, 65], ["macrophages", "CELL", 71, 82], ["immune subsets", "CELL_TYPE", 19, 33], ["CD8", "PROTEIN", 44, 47], ["T cells", "CELL_TYPE", 49, 56], ["B cells", "CELL_TYPE", 58, 65], ["macrophages", "CELL_TYPE", 71, 82], ["CD8", "TEST", 44, 47], ["macrophages", "PROBLEM", 71, 82], ["pathology", "TEST", 148, 157], ["immune subsets", "OBSERVATION", 19, 33], ["B cells", "OBSERVATION", 58, 65], ["macrophages", "ANATOMY", 71, 82]]], ["We determined if overexpression of CXCL1 in the CNS of Dox\u2010treated double tg mice immunized with MOG35\u201355 peptide altered the infiltration of inflammatory leukocytes into the CNS.", [["CNS", "ANATOMY", 48, 51], ["inflammatory leukocytes", "ANATOMY", 142, 165], ["CNS", "ANATOMY", 175, 178], ["MOG35\u201355 peptide", "CHEMICAL", 97, 113], ["CXCL1", "GENE_OR_GENE_PRODUCT", 35, 40], ["CNS", "ANATOMICAL_SYSTEM", 48, 51], ["Dox\u2010treated double tg mice", "ORGANISM", 55, 81], ["MOG35\u201355", "GENE_OR_GENE_PRODUCT", 97, 105], ["leukocytes", "CELL", 155, 165], ["CNS", "ANATOMICAL_SYSTEM", 175, 178], ["CXCL1", "PROTEIN", 35, 40], ["inflammatory leukocytes", "CELL_TYPE", 142, 165], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["CXCL1", "TEST", 35, 40], ["Dox\u2010treated double tg mice", "TREATMENT", 55, 81], ["MOG35", "TREATMENT", 97, 102], ["inflammatory leukocytes into the CNS", "PROBLEM", 142, 178], ["infiltration", "OBSERVATION", 126, 138], ["inflammatory leukocytes", "OBSERVATION", 142, 165], ["CNS", "ANATOMY", 175, 178]]], ["We did not detect differences in the frequency or numbers of CD45hi leukocytes (data not shown), CD4+ T cells (Fig. 2A and B), or CD8+ T cells (Fig. 2C and D) in spinal cords of Dox\u2010treated double tg mice compared to single tg mice.", [["CD45hi leukocytes", "ANATOMY", 61, 78], ["CD4+ T cells", "ANATOMY", 97, 109], ["CD8+ T cells", "ANATOMY", 130, 142], ["spinal cords", "ANATOMY", 162, 174], ["CD45hi leukocytes", "CELL", 61, 78], ["CD4", "GENE_OR_GENE_PRODUCT", 97, 100], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 111, 118], ["B", "GENE_OR_GENE_PRODUCT", 123, 124], ["CD8", "GENE_OR_GENE_PRODUCT", 130, 133], ["Fig. 2C", "GENE_OR_GENE_PRODUCT", 144, 151], ["D", "GENE_OR_GENE_PRODUCT", 156, 157], ["spinal cords", "ORGAN", 162, 174], ["mice", "ORGANISM", 200, 204], ["single tg mice", "ORGANISM", 217, 231], ["CD45hi leukocytes", "CELL_TYPE", 61, 78], ["CD4", "PROTEIN", 97, 100], ["T cells", "CELL_TYPE", 102, 109], ["CD8+ T cells", "CELL_TYPE", 130, 142], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 227, 231], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 227, 231], ["CD45hi leukocytes", "TEST", 61, 78], ["CD4", "TEST", 97, 100], ["B", "TEST", 123, 124], ["CD8", "TEST", 130, 133], ["Dox\u2010treated double tg mice", "TREATMENT", 178, 204], ["spinal cords", "ANATOMY", 162, 174]]], ["Moreover, there was no difference in intracellular CD4+ T\u2010cell cytokine expression of IFN\u2010\u03b3, IL\u201017A, or coexpressing IFN\u2010\u03b3 and IL\u201017A within the spinal cords at day 12 p.i. following PMA/ionomycin stimulation (Fig. 2E and F).", [["intracellular", "ANATOMY", 37, 50], ["spinal cords", "ANATOMY", 145, 157], ["PMA", "CHEMICAL", 183, 186], ["ionomycin", "CHEMICAL", 187, 196], ["PMA", "CHEMICAL", 183, 186], ["ionomycin", "CHEMICAL", 187, 196], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["CD4", "GENE_OR_GENE_PRODUCT", 51, 54], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 86, 91], ["IL\u201017A", "GENE_OR_GENE_PRODUCT", 93, 99], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 117, 122], ["IL\u201017A", "GENE_OR_GENE_PRODUCT", 127, 133], ["spinal cords", "ORGAN", 145, 157], ["PMA", "SIMPLE_CHEMICAL", 183, 186], ["ionomycin", "SIMPLE_CHEMICAL", 187, 196], ["CD4", "PROTEIN", 51, 54], ["T\u2010cell cytokine", "PROTEIN", 56, 71], ["IFN\u2010\u03b3", "PROTEIN", 86, 91], ["IL\u201017A", "PROTEIN", 93, 99], ["IFN\u2010\u03b3", "PROTEIN", 117, 122], ["IL\u201017A", "PROTEIN", 127, 133], ["PMA/ionomycin stimulation", "TREATMENT", 183, 208], ["no", "UNCERTAINTY", 20, 22], ["intracellular CD4", "OBSERVATION", 37, 54], ["spinal cords", "ANATOMY", 145, 157]]], ["We did not observe changes in macrophages (CD45hiF4/80+) (Fig. 3A), microglia (CD45loF4/80+) (Fig. 3B), or macrophages or microglia coexpressing MHC class II and CD80 (Fig. 3C and D) of Dox\u2010treated double and single tg EAE mice.", [["macrophages", "ANATOMY", 30, 41], ["CD45hiF4/80+", "ANATOMY", 43, 55], ["microglia", "ANATOMY", 68, 77], ["CD45loF4/80+)", "ANATOMY", 79, 92], ["macrophages", "ANATOMY", 107, 118], ["microglia", "ANATOMY", 122, 131], ["EAE", "DISEASE", 219, 222], ["macrophages", "CELL", 30, 41], ["CD45hiF4/80", "GENE_OR_GENE_PRODUCT", 43, 54], ["Fig. 3A", "GENE_OR_GENE_PRODUCT", 58, 65], ["microglia", "CELL", 68, 77], ["Fig. 3B", "GENE_OR_GENE_PRODUCT", 94, 101], ["macrophages", "CELL", 107, 118], ["microglia", "CELL", 122, 131], ["MHC class II", "GENE_OR_GENE_PRODUCT", 145, 157], ["CD80", "GENE_OR_GENE_PRODUCT", 162, 166], ["D", "GENE_OR_GENE_PRODUCT", 180, 181], ["tg EAE mice", "ORGANISM", 216, 227], ["macrophages", "CELL_TYPE", 30, 41], ["microglia", "CELL_TYPE", 68, 77], ["macrophages", "CELL_TYPE", 107, 118], ["microglia", "CELL_TYPE", 122, 131], ["MHC class II", "PROTEIN", 145, 157], ["CD80", "PROTEIN", 162, 166], ["Fig. 3C and D", "PROTEIN", 168, 181], ["mice", "SPECIES", 223, 227], ["mice", "SPECIES", 223, 227], ["changes in macrophages", "PROBLEM", 19, 41], ["CD45hiF4", "TEST", 43, 51], ["microglia", "TEST", 68, 77], ["CD45loF4", "TEST", 79, 87], ["macrophages", "PROBLEM", 107, 118], ["CD80", "TEST", 162, 166], ["Dox\u2010treated double and single tg EAE mice", "TREATMENT", 186, 227], ["macrophages", "ANATOMY", 107, 118]]], ["Collectively, these findings argue that the increase in clinical disease following Dox\u2010induced CXCL1 expression within the CNS is not due to increased infiltration of myelin\u2010reactive CD4+ T cells nor other immune cells that are known to contribute to EAE disease severity.Increased neutrophil accumulation in response to Dox\u2010induced expression of CXCL1 ::: ResultsCXCL1 is a potent chemoattractant of neutrophils expressing the chemokine receptor CXCR2 and its overexpression from astrocytes enhances the migration and accumulation of neutrophils in the white matter tracts of the spinal cords in a model of viral\u2010induced encephalomyelitis 21, 32.", [["CNS", "ANATOMY", 123, 126], ["myelin\u2010reactive CD4+", "ANATOMY", 167, 187], ["T cells", "ANATOMY", 188, 195], ["immune cells", "ANATOMY", 206, 218], ["neutrophil", "ANATOMY", 282, 292], ["neutrophils", "ANATOMY", 401, 412], ["astrocytes", "ANATOMY", 481, 491], ["neutrophils", "ANATOMY", 535, 546], ["white matter tracts", "ANATOMY", 554, 573], ["spinal cords", "ANATOMY", 581, 593], ["EAE", "DISEASE", 251, 254], ["encephalomyelitis", "DISEASE", 622, 639], ["CXCL1", "GENE_OR_GENE_PRODUCT", 95, 100], ["CNS", "ANATOMICAL_SYSTEM", 123, 126], ["CD4", "GENE_OR_GENE_PRODUCT", 183, 186], ["T cells", "CELL", 188, 195], ["immune cells", "CELL", 206, 218], ["neutrophil", "CELL", 282, 292], ["CXCL1", "GENE_OR_GENE_PRODUCT", 347, 352], ["ResultsCXCL1", "GENE_OR_GENE_PRODUCT", 357, 369], ["neutrophils", "CELL", 401, 412], ["CXCR2", "GENE_OR_GENE_PRODUCT", 447, 452], ["astrocytes", "CELL", 481, 491], ["neutrophils", "CELL", 535, 546], ["spinal cords", "ORGAN", 581, 593], ["CXCL1", "PROTEIN", 95, 100], ["myelin\u2010reactive CD4", "PROTEIN", 167, 186], ["T cells", "CELL_TYPE", 188, 195], ["immune cells", "CELL_TYPE", 206, 218], ["CXCL1", "PROTEIN", 347, 352], ["ResultsCXCL1", "PROTEIN", 357, 369], ["neutrophils", "CELL_TYPE", 401, 412], ["chemokine receptor", "PROTEIN", 428, 446], ["CXCR2", "PROTEIN", 447, 452], ["astrocytes", "CELL_TYPE", 481, 491], ["neutrophils", "CELL_TYPE", 535, 546], ["the increase in clinical disease", "PROBLEM", 40, 72], ["Dox\u2010induced CXCL1 expression", "TREATMENT", 83, 111], ["increased infiltration", "PROBLEM", 141, 163], ["myelin\u2010reactive CD4", "PROBLEM", 167, 186], ["other immune cells", "PROBLEM", 200, 218], ["EAE disease severity", "PROBLEM", 251, 271], ["Increased neutrophil accumulation", "PROBLEM", 272, 305], ["the chemokine receptor CXCR2", "TEST", 424, 452], ["accumulation of neutrophils", "PROBLEM", 519, 546], ["viral\u2010induced encephalomyelitis", "PROBLEM", 608, 639], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["CNS", "ANATOMY", 123, 126], ["not due to", "UNCERTAINTY", 130, 140], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["infiltration", "OBSERVATION", 151, 163], ["myelin\u2010reactive CD4", "OBSERVATION", 167, 186], ["immune cells", "OBSERVATION", 206, 218], ["neutrophil accumulation", "OBSERVATION", 282, 305], ["potent chemoattractant", "OBSERVATION_MODIFIER", 375, 397], ["migration", "OBSERVATION_MODIFIER", 505, 514], ["accumulation", "OBSERVATION_MODIFIER", 519, 531], ["neutrophils", "OBSERVATION_MODIFIER", 535, 546], ["white matter", "ANATOMY_MODIFIER", 554, 566], ["tracts", "ANATOMY_MODIFIER", 567, 573], ["spinal cords", "ANATOMY", 581, 593], ["viral\u2010induced", "OBSERVATION_MODIFIER", 608, 621], ["encephalomyelitis", "OBSERVATION", 622, 639]]], ["We next investigated whether Dox\u2010induced overexpression of CXCL1 promotes neutrophil accumulation in double tg mice induced with EAE.", [["neutrophil", "ANATOMY", 74, 84], ["EAE", "DISEASE", 129, 132], ["CXCL1", "GENE_OR_GENE_PRODUCT", 59, 64], ["neutrophil", "CELL", 74, 84], ["mice", "ORGANISM", 111, 115], ["CXCL1", "PROTEIN", 59, 64], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["Dox\u2010induced overexpression of CXCL1 promotes", "TREATMENT", 29, 73], ["neutrophil accumulation", "PROBLEM", 74, 97], ["double tg mice", "TREATMENT", 101, 115], ["neutrophil accumulation", "OBSERVATION", 74, 97]]], ["Histopathologic examination of spinal cord sections revealed increased localization of inflammatory cells in the anterior median fissure and meninges of the spinal cords of Dox\u2010treated double tg mice compared to single tg EAE mice (Fig. 4A).", [["spinal cord sections", "ANATOMY", 31, 51], ["inflammatory cells", "ANATOMY", 87, 105], ["anterior median fissure", "ANATOMY", 113, 136], ["meninges", "ANATOMY", 141, 149], ["spinal cords", "ANATOMY", 157, 169], ["EAE", "DISEASE", 222, 225], ["spinal cord sections", "MULTI-TISSUE_STRUCTURE", 31, 51], ["inflammatory cells", "CELL", 87, 105], ["anterior median fissure", "MULTI-TISSUE_STRUCTURE", 113, 136], ["meninges", "ORGAN", 141, 149], ["spinal cords", "ORGAN", 157, 169], ["mice", "ORGANISM", 195, 199], ["tg EAE mice", "ORGANISM", 219, 230], ["inflammatory cells", "CELL_TYPE", 87, 105], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 226, 230], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 226, 230], ["Histopathologic examination of spinal cord sections", "TEST", 0, 51], ["inflammatory cells in the anterior median fissure", "PROBLEM", 87, 136], ["Dox\u2010treated double tg mice", "TREATMENT", 173, 199], ["spinal cord", "ANATOMY", 31, 42], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["inflammatory cells", "OBSERVATION", 87, 105], ["anterior", "ANATOMY_MODIFIER", 113, 121], ["median fissure", "ANATOMY_MODIFIER", 122, 136], ["meninges", "OBSERVATION", 141, 149], ["spinal cords", "ANATOMY", 157, 169]]], ["The majority of inflammatory cells within spinal cords of double tg mice had a multilobed nucleus characteristic of neutrophils (Fig. 4B).", [["inflammatory cells", "ANATOMY", 16, 34], ["spinal cords", "ANATOMY", 42, 54], ["nucleus", "ANATOMY", 90, 97], ["neutrophils", "ANATOMY", 116, 127], ["inflammatory cells", "CELL", 16, 34], ["spinal cords", "ORGAN", 42, 54], ["mice", "ORGANISM", 68, 72], ["neutrophils", "CELL", 116, 127], ["inflammatory cells", "CELL_TYPE", 16, 34], ["neutrophils", "CELL_TYPE", 116, 127], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["inflammatory cells", "PROBLEM", 16, 34], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["inflammatory cells", "OBSERVATION", 16, 34], ["spinal cords", "ANATOMY", 42, 54], ["neutrophils", "OBSERVATION", 116, 127]]], ["Immunofluorescence staining revealed increased numbers of cells positive for the neutrophil\u2010associated surface antigen Ly6B.2 within the spinal cords of Dox\u2010treated double tg EAE mice compared to single tg mice treated with Dox (Fig. 4C).", [["cells", "ANATOMY", 58, 63], ["surface", "ANATOMY", 103, 110], ["spinal cords", "ANATOMY", 137, 149], ["EAE", "DISEASE", 175, 178], ["Dox", "CHEMICAL", 224, 227], ["Dox", "CHEMICAL", 224, 227], ["cells", "CELL", 58, 63], ["neutrophil\u2010associated surface antigen", "GENE_OR_GENE_PRODUCT", 81, 118], ["Ly6B.2", "GENE_OR_GENE_PRODUCT", 119, 125], ["spinal cords", "ORGAN", 137, 149], ["tg EAE mice", "ORGANISM", 172, 183], ["single tg mice", "ORGANISM", 196, 210], ["Dox", "SIMPLE_CHEMICAL", 224, 227], ["neutrophil\u2010associated surface antigen", "PROTEIN", 81, 118], ["Ly6B.2", "PROTEIN", 119, 125], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 206, 210], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 206, 210], ["Immunofluorescence staining", "TEST", 0, 27], ["increased numbers of cells", "PROBLEM", 37, 63], ["the neutrophil\u2010associated surface antigen", "TEST", 77, 118], ["Dox\u2010treated double tg EAE mice", "TREATMENT", 153, 183], ["single tg mice", "TREATMENT", 196, 210], ["Dox (Fig. 4C", "TREATMENT", 224, 236], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["numbers", "OBSERVATION_MODIFIER", 47, 54], ["spinal cords", "ANATOMY", 137, 149]]], ["In addition, flow analysis of spinal cords isolated from experimental mice indicated the frequency and numbers of neutrophils (CD45hiCD11b+Ly6G+) within the spinal cords of Dox\u2010treated double tg mice were significantly (p < 0.01) increased compared to single tg mice (Fig. 4D and E).", [["spinal cords", "ANATOMY", 30, 42], ["neutrophils", "ANATOMY", 114, 125], ["CD45hiCD11b+Ly6G+", "ANATOMY", 127, 144], ["spinal cords", "ANATOMY", 157, 169], ["spinal cords", "ORGAN", 30, 42], ["mice", "ORGANISM", 70, 74], ["neutrophils", "CELL", 114, 125], ["CD45hiCD11b", "GENE_OR_GENE_PRODUCT", 127, 138], ["spinal cords", "ORGAN", 157, 169], ["mice", "ORGANISM", 195, 199], ["tg mice", "ORGANISM", 259, 266], ["neutrophils", "CELL_TYPE", 114, 125], ["CD45hiCD11b", "PROTEIN", 127, 138], ["Ly6G", "PROTEIN", 139, 143], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 262, 266], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 262, 266], ["flow analysis", "TEST", 13, 26], ["spinal cords", "TEST", 30, 42], ["neutrophils", "TEST", 114, 125], ["CD45hiCD11", "TEST", 127, 137], ["Ly6G", "TEST", 139, 143], ["Dox\u2010treated double tg mice", "TREATMENT", 173, 199], ["flow", "OBSERVATION", 13, 17], ["spinal cords", "ANATOMY", 30, 42], ["spinal cords", "ANATOMY", 157, 169]]], ["Importantly, we did not observe an increase in Ly6C+ monocytes in either brain or spinal cords of double tg mice treated with Dox (data not shown).", [["Ly6C+ monocytes", "ANATOMY", 47, 62], ["brain", "ANATOMY", 73, 78], ["spinal cords", "ANATOMY", 82, 94], ["Dox", "CHEMICAL", 126, 129], ["Dox", "CHEMICAL", 126, 129], ["Ly6C+ monocytes", "GENE_OR_GENE_PRODUCT", 47, 62], ["brain", "ORGAN", 73, 78], ["spinal cords", "ORGAN", 82, 94], ["mice", "ORGANISM", 108, 112], ["Dox", "SIMPLE_CHEMICAL", 126, 129], ["Ly6C", "PROTEIN", 47, 51], ["monocytes", "CELL_TYPE", 53, 62], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 108, 112], ["an increase in Ly6C+ monocytes", "PROBLEM", 32, 62], ["double tg mice", "TREATMENT", 98, 112], ["Dox", "TREATMENT", 126, 129], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["Ly6C", "OBSERVATION", 47, 51], ["monocytes", "OBSERVATION", 53, 62], ["brain", "ANATOMY", 73, 78], ["spinal cords", "ANATOMY", 82, 94]]], ["Together, these findings argue that the Dox\u2010induced increase in CXCL1 expression within the CNS enhances the recruitment and accumulation of neutrophils within the spinal cords associated increased clinical disease severity.", [["CNS", "ANATOMY", 92, 95], ["neutrophils", "ANATOMY", 141, 152], ["spinal cords", "ANATOMY", 164, 176], ["CXCL1", "GENE_OR_GENE_PRODUCT", 64, 69], ["CNS", "ANATOMICAL_SYSTEM", 92, 95], ["neutrophils", "CELL", 141, 152], ["spinal cords", "ORGAN", 164, 176], ["CXCL1", "PROTEIN", 64, 69], ["neutrophils", "CELL_TYPE", 141, 152], ["the Dox\u2010induced increase in CXCL1 expression", "PROBLEM", 36, 80], ["accumulation of neutrophils within the spinal cords", "PROBLEM", 125, 176], ["increased clinical disease severity", "PROBLEM", 188, 223], ["Dox\u2010induced", "OBSERVATION_MODIFIER", 40, 51], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["CXCL1 expression", "OBSERVATION", 64, 80], ["CNS", "ANATOMY", 92, 95], ["recruitment", "OBSERVATION_MODIFIER", 109, 120], ["accumulation of neutrophils", "OBSERVATION", 125, 152], ["spinal cords", "ANATOMY", 164, 176], ["increased", "OBSERVATION_MODIFIER", 188, 197], ["clinical disease", "OBSERVATION", 198, 214]]], ["Using a model of viral\u2010induced demyelination, we have previously shown that Dox\u2010induced CXCL1 expression within the CNS increases the severity of white matter damage and this was correlated with enhanced neutrophil recruitment into the spinal cord 21.", [["CNS", "ANATOMY", 116, 119], ["white matter", "ANATOMY", 146, 158], ["neutrophil", "ANATOMY", 204, 214], ["spinal cord", "ANATOMY", 236, 247], ["demyelination", "DISEASE", 31, 44], ["white matter damage", "DISEASE", 146, 165], ["CXCL1", "GENE_OR_GENE_PRODUCT", 88, 93], ["CNS", "ANATOMICAL_SYSTEM", 116, 119], ["neutrophil", "CELL", 204, 214], ["spinal cord", "ORGAN", 236, 247], ["CXCL1", "PROTEIN", 88, 93], ["viral\u2010induced demyelination", "PROBLEM", 17, 44], ["Dox\u2010induced CXCL1 expression", "TEST", 76, 104], ["white matter damage", "PROBLEM", 146, 165], ["enhanced neutrophil recruitment into the spinal cord", "PROBLEM", 195, 247], ["demyelination", "OBSERVATION", 31, 44], ["CNS", "ANATOMY", 116, 119], ["severity", "OBSERVATION_MODIFIER", 134, 142], ["white matter", "OBSERVATION_MODIFIER", 146, 158], ["neutrophil recruitment", "OBSERVATION", 204, 226], ["spinal cord", "ANATOMY", 236, 247]]], ["Assessment of spinal cord pathology between Dox\u2010treated single tg and double tg mice was assessed using H&E/LFB staining at day 21 p.i.", [["spinal cord", "ANATOMY", 14, 25], ["spinal cord", "ORGAN", 14, 25], ["double tg mice", "ORGANISM", 70, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["spinal cord pathology", "PROBLEM", 14, 35], ["Dox\u2010treated single tg", "TREATMENT", 44, 65], ["double tg mice", "TREATMENT", 70, 84], ["H&E/LFB staining", "TREATMENT", 104, 120], ["spinal cord", "ANATOMY", 14, 25]]], ["We recorded an increase in both meningeal infiltration (p < 0.05) and demyelination (p < 0.05) of double tg compared to single tg was observed (Fig. 4G).Neutrophils increase the severity of demyelination in Dox\u2010treated double tg EAE mice ::: ResultsIn order to determine whether neutrophils contributed to enhancement of demyelination, MOG35\u201355\u2010immunized double tg mice treated with Dox were administered anti\u2010CXCR2 antisera which we have previously shown to effectively target neutrophils 30, 32.", [["meningeal", "ANATOMY", 32, 41], ["Neutrophils", "ANATOMY", 153, 164], ["neutrophils", "ANATOMY", 279, 290], ["neutrophils", "ANATOMY", 478, 489], ["meningeal infiltration (p < 0.05) and demyelination", "DISEASE", 32, 83], ["demyelination", "DISEASE", 190, 203], ["EAE", "DISEASE", 229, 232], ["demyelination", "DISEASE", 321, 334], ["Dox", "CHEMICAL", 383, 386], ["Dox", "CHEMICAL", 383, 386], ["Neutrophils", "CELL", 153, 164], ["mice", "ORGANISM", 233, 237], ["neutrophils", "CELL", 279, 290], ["MOG35\u201355", "GENE_OR_GENE_PRODUCT", 336, 344], ["double tg mice", "ORGANISM", 355, 369], ["Dox", "SIMPLE_CHEMICAL", 383, 386], ["neutrophils", "CELL", 478, 489], ["Neutrophils", "CELL_TYPE", 153, 164], ["neutrophils", "CELL_TYPE", 279, 290], ["MOG35", "PROTEIN", 336, 341], ["neutrophils", "CELL_TYPE", 478, 489], ["mice", "SPECIES", 233, 237], ["mice", "SPECIES", 365, 369], ["mice", "SPECIES", 233, 237], ["mice", "SPECIES", 365, 369], ["both meningeal infiltration", "PROBLEM", 27, 54], ["demyelination", "PROBLEM", 70, 83], ["double tg", "TREATMENT", 98, 107], ["single tg", "TEST", 120, 129], ["Neutrophils", "TEST", 153, 164], ["demyelination", "PROBLEM", 190, 203], ["neutrophils", "PROBLEM", 279, 290], ["demyelination", "PROBLEM", 321, 334], ["MOG35", "TREATMENT", 336, 341], ["double tg mice", "TREATMENT", 355, 369], ["Dox", "TREATMENT", 383, 386], ["anti\u2010CXCR2 antisera", "TREATMENT", 405, 424], ["neutrophils", "TEST", 478, 489], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["both", "OBSERVATION_MODIFIER", 27, 31], ["meningeal", "ANATOMY", 32, 41], ["infiltration", "OBSERVATION", 42, 54], ["demyelination", "OBSERVATION", 190, 203], ["demyelination", "OBSERVATION", 321, 334]]], ["Anti\u2010CXCR2 or NRS was administered to Dox\u2010treated double tg mice at defined times following EAE induction (Fig. 5A).", [["EAE", "DISEASE", 92, 95], ["Anti\u2010CXCR2", "GENE_OR_GENE_PRODUCT", 0, 10], ["NRS", "GENE_OR_GENE_PRODUCT", 14, 17], ["Dox\u2010treated double tg mice", "ORGANISM", 38, 64], ["Anti\u2010CXCR2", "PROTEIN", 0, 10], ["NRS", "PROTEIN", 14, 17], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["Anti\u2010CXCR2", "TREATMENT", 0, 10], ["NRS", "TREATMENT", 14, 17], ["Dox\u2010treated double tg mice", "TREATMENT", 38, 64], ["EAE induction", "TREATMENT", 92, 105]]], ["Administration of anti\u2010CXCR2 antisera to Dox\u2010treated double tg mice resulted in a dramatic reduction in clinical disease severity compared to animals treated with NRS alone (Fig. 5B) and this was correlated with reduced numbers of circulating CD45hiCD11b+Ly6C+Ly6G+ neutrophils (Fig. 5C).", [["CD45hiCD11b+Ly6C+Ly6G+ neutrophils", "ANATOMY", 243, 277], ["NRS", "CHEMICAL", 163, 166], ["anti\u2010CXCR2 antisera", "GENE_OR_GENE_PRODUCT", 18, 37], ["Dox\u2010treated double tg mice", "ORGANISM", 41, 67], ["CD45hiCD11b", "GENE_OR_GENE_PRODUCT", 243, 254], ["Ly6C", "GENE_OR_GENE_PRODUCT", 255, 259], ["anti\u2010CXCR2", "PROTEIN", 18, 28], ["CD45hiCD11b", "PROTEIN", 243, 254], ["Ly6C", "PROTEIN", 255, 259], ["Ly6G", "PROTEIN", 260, 264], ["neutrophils", "CELL_TYPE", 266, 277], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["anti\u2010CXCR2 antisera", "TREATMENT", 18, 37], ["Dox\u2010treated double tg mice", "TREATMENT", 41, 67], ["a dramatic reduction", "PROBLEM", 80, 100], ["clinical disease severity", "PROBLEM", 104, 129], ["circulating CD45hiCD11b", "TEST", 231, 254], ["Ly6C", "TEST", 255, 259], ["Ly6G", "TEST", 260, 264], ["neutrophils", "TEST", 266, 277], ["dramatic", "OBSERVATION_MODIFIER", 82, 90], ["reduction", "OBSERVATION_MODIFIER", 91, 100]]], ["The reduction in clinical disease in Dox\u2010treated double tg mice treated with anti\u2010CXCR2 correlated with a significant (p < 0.01) reduction in the severity of demyelination compared to NRS\u2010treated mice (Fig. 5D and E) and this was associated with reduced numbers of neutrophils present within the spinal cords (Fig. 5F and G).", [["neutrophils", "ANATOMY", 265, 276], ["spinal cords", "ANATOMY", 296, 308], ["demyelination", "DISEASE", 158, 171], ["Dox\u2010treated double tg mice", "ORGANISM", 37, 63], ["anti\u2010CXCR2", "GENE_OR_GENE_PRODUCT", 77, 87], ["mice", "ORGANISM", 196, 200], ["neutrophils", "CELL", 265, 276], ["spinal cords", "ORGAN", 296, 308], ["anti\u2010CXCR2", "PROTEIN", 77, 87], ["neutrophils", "CELL_TYPE", 265, 276], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 196, 200], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 196, 200], ["The reduction", "TREATMENT", 0, 13], ["clinical disease", "PROBLEM", 17, 33], ["Dox\u2010treated double tg mice", "TREATMENT", 37, 63], ["anti\u2010CXCR2", "TREATMENT", 77, 87], ["demyelination", "PROBLEM", 158, 171], ["reduced numbers of neutrophils", "PROBLEM", 246, 276], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["demyelination", "OBSERVATION", 158, 171], ["reduced", "OBSERVATION_MODIFIER", 246, 253], ["numbers", "OBSERVATION_MODIFIER", 254, 261], ["neutrophils", "OBSERVATION", 265, 276], ["spinal cords", "ANATOMY", 296, 308]]], ["Together, these findings indicate that neutrophils can enhance the severity of demyelination in MOG35\u201355\u2010induced EAE.DiscussionMS is characterized by CNS inflammatory lesions consisting of activated lymphocytes and monocyte/macrophages that are associated with demyelinating lesions within the brain and spinal cord 24, 33.", [["neutrophils", "ANATOMY", 39, 50], ["CNS inflammatory lesions", "ANATOMY", 150, 174], ["lymphocytes", "ANATOMY", 199, 210], ["monocyte", "ANATOMY", 215, 223], ["macrophages", "ANATOMY", 224, 235], ["demyelinating lesions", "ANATOMY", 261, 282], ["brain", "ANATOMY", 294, 299], ["spinal cord", "ANATOMY", 304, 315], ["demyelination", "DISEASE", 79, 92], ["MOG35\u201355", "CHEMICAL", 96, 104], ["EAE", "DISEASE", 113, 116], ["demyelinating lesions within the brain", "DISEASE", 261, 299], ["neutrophils", "CELL", 39, 50], ["CNS inflammatory lesions", "PATHOLOGICAL_FORMATION", 150, 174], ["lymphocytes", "CELL", 199, 210], ["monocyte", "CELL", 215, 223], ["macrophages", "CELL", 224, 235], ["demyelinating lesions", "CANCER", 261, 282], ["brain", "ORGAN", 294, 299], ["neutrophils", "CELL_TYPE", 39, 50], ["activated lymphocytes", "CELL_TYPE", 189, 210], ["monocyte/macrophages", "CELL_TYPE", 215, 235], ["neutrophils", "PROBLEM", 39, 50], ["demyelination", "PROBLEM", 79, 92], ["CNS inflammatory lesions", "PROBLEM", 150, 174], ["activated lymphocytes and monocyte/macrophages", "PROBLEM", 189, 235], ["demyelinating lesions within the brain and spinal cord", "PROBLEM", 261, 315], ["demyelination", "OBSERVATION", 79, 92], ["CNS", "ANATOMY", 150, 153], ["inflammatory", "OBSERVATION_MODIFIER", 154, 166], ["activated lymphocytes", "OBSERVATION", 189, 210], ["monocyte", "OBSERVATION_MODIFIER", 215, 223], ["macrophages", "OBSERVATION", 224, 235], ["associated with", "UNCERTAINTY", 245, 260], ["demyelinating", "OBSERVATION_MODIFIER", 261, 274], ["lesions", "OBSERVATION", 275, 282], ["brain", "ANATOMY", 294, 299], ["spinal cord", "ANATOMY", 304, 315]]], ["The importance of these cells to disease is highlighted in that FDA\u2010approved disease modifying therapies used in treatment of relapsing remitting MS limit immune cell infiltration and lesion development 34, 35.", [["cells", "ANATOMY", 24, 29], ["immune cell", "ANATOMY", 155, 166], ["lesion", "ANATOMY", 184, 190], ["MS", "DISEASE", 146, 148], ["cells", "CELL", 24, 29], ["immune cell", "CELL", 155, 166], ["disease", "PROBLEM", 33, 40], ["modifying therapies", "TREATMENT", 85, 104], ["treatment", "TREATMENT", 113, 122], ["relapsing remitting MS", "PROBLEM", 126, 148], ["immune cell infiltration", "PROBLEM", 155, 179], ["lesion development", "PROBLEM", 184, 202], ["immune cell infiltration", "OBSERVATION", 155, 179]]], ["Nonetheless, there is increasing interest in the potential role of other cell types, including neutrophils, in participating in demyelination.", [["cell", "ANATOMY", 73, 77], ["neutrophils", "ANATOMY", 95, 106], ["demyelination", "DISEASE", 128, 141], ["cell", "CELL", 73, 77], ["neutrophils", "CELL", 95, 106], ["neutrophils", "CELL_TYPE", 95, 106], ["neutrophils", "PROBLEM", 95, 106], ["demyelination", "PROBLEM", 128, 141], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["interest", "OBSERVATION_MODIFIER", 33, 41], ["cell types", "OBSERVATION", 73, 83], ["neutrophils", "OBSERVATION_MODIFIER", 95, 106], ["demyelination", "OBSERVATION", 128, 141]]], ["The diverse functions of neutrophils include phagocytosis, release of toxic granules, and secretion of ROS, nitrogen species, and neutrophil extracellular traps that can lead to bacterial clearance and tissue damage 36, 37, 38, 39.", [["neutrophils", "ANATOMY", 25, 36], ["granules", "ANATOMY", 76, 84], ["neutrophil extracellular", "ANATOMY", 130, 154], ["tissue", "ANATOMY", 202, 208], ["ROS", "CHEMICAL", 103, 106], ["nitrogen", "CHEMICAL", 108, 116], ["neutrophils", "CELL", 25, 36], ["granules", "CELLULAR_COMPONENT", 76, 84], ["ROS", "SIMPLE_CHEMICAL", 103, 106], ["nitrogen species", "SIMPLE_CHEMICAL", 108, 124], ["neutrophil", "CELL", 130, 140], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 141, 154], ["tissue", "TISSUE", 202, 208], ["neutrophils", "CELL_TYPE", 25, 36], ["phagocytosis", "PROBLEM", 45, 57], ["toxic granules", "PROBLEM", 70, 84], ["secretion of ROS", "PROBLEM", 90, 106], ["nitrogen species", "TEST", 108, 124], ["neutrophil extracellular traps", "TREATMENT", 130, 160], ["bacterial clearance", "TEST", 178, 197], ["tissue damage", "TEST", 202, 215], ["diverse", "OBSERVATION_MODIFIER", 4, 11], ["toxic granules", "OBSERVATION", 70, 84]]], ["In addition, neutrophils can produce many different cytokines and chemokines that participate in tailoring the immune response as well as enhancing neuroinflammation 36, 37, 38, 39.", [["neutrophils", "ANATOMY", 13, 24], ["neuroinflammation", "DISEASE", 148, 165], ["neutrophils", "CELL", 13, 24], ["neutrophils", "CELL_TYPE", 13, 24], ["cytokines", "PROTEIN", 52, 61], ["chemokines", "PROTEIN", 66, 76], ["neutrophils", "TEST", 13, 24], ["chemokines", "TREATMENT", 66, 76], ["enhancing neuroinflammation", "TEST", 138, 165], ["cytokines", "OBSERVATION", 52, 61]]], ["Although there is direct evidence that neutrophils are important in both disease initiation and progression in EAE models only indirect evidence exists showing these cells also play a role in MS pathogenesis 40.", [["neutrophils", "ANATOMY", 39, 50], ["cells", "ANATOMY", 166, 171], ["EAE", "DISEASE", 111, 114], ["MS", "DISEASE", 192, 194], ["neutrophils", "CELL", 39, 50], ["cells", "CELL", 166, 171], ["neutrophils", "CELL_TYPE", 39, 50], ["neutrophils", "PROBLEM", 39, 50], ["EAE models", "TEST", 111, 121], ["these cells", "PROBLEM", 160, 171], ["MS pathogenesis", "PROBLEM", 192, 207], ["neutrophils", "OBSERVATION", 39, 50], ["both", "OBSERVATION_MODIFIER", 68, 72], ["disease", "OBSERVATION", 73, 80]]], ["Since neutrophils are typically short\u2010lived and have a half\u2010life in circulation (between 6 and 8 hours in humans) 41, direct evidence of neutrophils in MS lesions from available autopsy tissue samples has been limited.", [["neutrophils", "ANATOMY", 6, 17], ["neutrophils", "ANATOMY", 137, 148], ["MS lesions", "ANATOMY", 152, 162], ["tissue samples", "ANATOMY", 186, 200], ["neutrophils", "CELL", 6, 17], ["humans", "ORGANISM", 106, 112], ["neutrophils", "CELL", 137, 148], ["MS lesions", "CANCER", 152, 162], ["tissue samples", "TISSUE", 186, 200], ["neutrophils", "CELL_TYPE", 6, 17], ["neutrophils", "CELL_TYPE", 137, 148], ["humans", "SPECIES", 106, 112], ["humans", "SPECIES", 106, 112], ["neutrophils", "TEST", 6, 17], ["neutrophils", "PROBLEM", 137, 148], ["MS lesions", "PROBLEM", 152, 162], ["autopsy tissue samples", "TEST", 178, 200], ["evidence of", "UNCERTAINTY", 125, 136], ["neutrophils", "OBSERVATION", 137, 148], ["lesions", "OBSERVATION", 155, 162]]], ["Nonetheless, recent studies from Segal and colleagues 12 have demonstrated increased systemic levels of the chemokines CXCL1 and CXCL5 as well as neutrophil elastase that correlated with lesion burden and clinical disability in MS patients arguing for a role for neutrophils in augmenting disease.DiscussionThe current study was performed to better understand the functional role of CXCL1 within the CNS following induction of MOG35\u201355 immunized EAE in mice.", [["neutrophil", "ANATOMY", 146, 156], ["lesion", "ANATOMY", 187, 193], ["neutrophils", "ANATOMY", 263, 274], ["CNS", "ANATOMY", 400, 403], ["disability", "DISEASE", 214, 224], ["MS", "DISEASE", 228, 230], ["MOG35\u201355", "CHEMICAL", 427, 435], ["EAE", "DISEASE", 446, 449], ["CXCL1", "GENE_OR_GENE_PRODUCT", 119, 124], ["CXCL5", "GENE_OR_GENE_PRODUCT", 129, 134], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 146, 165], ["patients", "ORGANISM", 231, 239], ["neutrophils", "CELL", 263, 274], ["CXCL1", "GENE_OR_GENE_PRODUCT", 383, 388], ["CNS", "ANATOMICAL_SYSTEM", 400, 403], ["MOG35", "GENE_OR_GENE_PRODUCT", 427, 432], ["mice", "ORGANISM", 453, 457], ["chemokines", "PROTEIN", 108, 118], ["CXCL1", "PROTEIN", 119, 124], ["CXCL5", "PROTEIN", 129, 134], ["neutrophil elastase", "PROTEIN", 146, 165], ["neutrophils", "CELL_TYPE", 263, 274], ["CXCL1", "PROTEIN", 383, 388], ["patients", "SPECIES", 231, 239], ["mice", "SPECIES", 453, 457], ["mice", "SPECIES", 453, 457], ["recent studies", "TEST", 13, 27], ["increased systemic levels", "PROBLEM", 75, 100], ["the chemokines CXCL1", "TEST", 104, 124], ["CXCL5", "TEST", 129, 134], ["neutrophil elastase", "TEST", 146, 165], ["lesion burden", "PROBLEM", 187, 200], ["clinical disability in MS", "PROBLEM", 205, 230], ["neutrophils in augmenting disease", "PROBLEM", 263, 296], ["The current study", "TEST", 307, 324], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["systemic", "OBSERVATION", 85, 93], ["chemokines CXCL1", "OBSERVATION", 108, 124], ["neutrophil elastase", "OBSERVATION", 146, 165], ["lesion", "OBSERVATION", 187, 193]]], ["CXCL1 is a member of the ELR (+) family of CXC chemokines and binds with high affinity to the chemokine receptor CXCR2 11, 42.", [["CXCL1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ELR", "GENE_OR_GENE_PRODUCT", 25, 28], ["CXC", "GENE_OR_GENE_PRODUCT", 43, 46], ["CXCR2", "GENE_OR_GENE_PRODUCT", 113, 118], ["CXCL1", "PROTEIN", 0, 5], ["ELR (+) family", "PROTEIN", 25, 39], ["CXC chemokines", "PROTEIN", 43, 57], ["chemokine receptor CXCR2 11, 42", "PROTEIN", 94, 125], ["CXC chemokines", "TREATMENT", 43, 57], ["the chemokine receptor CXCR2", "TEST", 90, 118]]], ["Neutrophils express CXCR2 and signaling enhances egress out of the BM and aids in homing to sites of inflammation 36.", [["Neutrophils", "ANATOMY", 0, 11], ["BM", "ANATOMY", 67, 69], ["sites", "ANATOMY", 92, 97], ["inflammation", "DISEASE", 101, 113], ["Neutrophils", "CELL", 0, 11], ["CXCR2", "GENE_OR_GENE_PRODUCT", 20, 25], ["BM", "CELL", 67, 69], ["Neutrophils", "CELL_TYPE", 0, 11], ["CXCR2", "PROTEIN", 20, 25], ["Neutrophils", "TEST", 0, 11], ["CXCR2", "TEST", 20, 25], ["inflammation", "PROBLEM", 101, 113], ["enhances", "OBSERVATION_MODIFIER", 40, 48], ["egress", "OBSERVATION_MODIFIER", 49, 55], ["BM", "ANATOMY", 67, 69], ["inflammation", "OBSERVATION", 101, 113]]], ["In the context of EAE, CXCL1 is detected early in the CNS 24 both prior to and following disease onset 12.", [["CNS", "ANATOMY", 54, 57], ["EAE", "DISEASE", 18, 21], ["CXCL1", "GENE_OR_GENE_PRODUCT", 23, 28], ["CXCL1", "PROTEIN", 23, 28], ["EAE", "PROBLEM", 18, 21], ["CXCL1", "TEST", 23, 28], ["disease onset", "PROBLEM", 89, 102], ["EAE", "OBSERVATION", 18, 21], ["CXCL1", "OBSERVATION", 23, 28]]], ["Mice treated with anti\u2010CXCL1 blocking antibody showed a delayed onset of disease and decreased clinical disease correlating with diminished numbers of Ly6G+ neutrophils yet CNS T\u2010cell infiltration was not affected arguing for a role for neutrophils in disease 24.", [["Ly6G+ neutrophils", "ANATOMY", 151, 168], ["CNS T\u2010cell", "ANATOMY", 173, 183], ["neutrophils", "ANATOMY", 237, 248], ["Mice", "ORGANISM", 0, 4], ["anti\u2010CXCL1", "GENE_OR_GENE_PRODUCT", 18, 28], ["Ly6G", "GENE_OR_GENE_PRODUCT", 151, 155], ["neutrophils", "CELL", 157, 168], ["CNS T\u2010cell", "CELL", 173, 183], ["neutrophils", "CELL", 237, 248], ["anti\u2010CXCL1 blocking antibody", "PROTEIN", 18, 46], ["Ly6G", "PROTEIN", 151, 155], ["neutrophils", "CELL_TYPE", 157, 168], ["neutrophils", "CELL_TYPE", 237, 248], ["Mice", "SPECIES", 0, 4], ["anti\u2010CXCL1 blocking antibody", "TEST", 18, 46], ["disease", "PROBLEM", 73, 80], ["decreased clinical disease", "PROBLEM", 85, 111], ["Ly6G", "TEST", 151, 155], ["neutrophils", "PROBLEM", 157, 168], ["CNS T\u2010cell infiltration", "PROBLEM", 173, 196], ["neutrophils in disease", "PROBLEM", 237, 259], ["disease", "OBSERVATION", 73, 80], ["decreased", "OBSERVATION_MODIFIER", 85, 94], ["diminished", "OBSERVATION_MODIFIER", 129, 139], ["infiltration", "OBSERVATION", 184, 196]]], ["Similarly, a better understanding of molecules, e.g. CXCL1 that influence neutrophil accumulation within the CNS also allows insight into the therapeutic relevance of these potential targets.", [["neutrophil", "ANATOMY", 74, 84], ["CNS", "ANATOMY", 109, 112], ["CXCL1", "GENE_OR_GENE_PRODUCT", 53, 58], ["neutrophil", "CELL", 74, 84], ["CNS", "ANATOMICAL_SYSTEM", 109, 112], ["CXCL1", "PROTEIN", 53, 58], ["neutrophil accumulation", "PROBLEM", 74, 97], ["neutrophil accumulation", "OBSERVATION", 74, 97]]], ["Lira et al. 43 have previously shown that transgenic mice in which CXCL1 was constitutively expressed from oligodendrocytes led to the development of neurologic disease associated with microglia and astrocyte reactivity that correlated with increase in neutrophil accumulation within the brain.", [["oligodendrocytes", "ANATOMY", 107, 123], ["neurologic", "ANATOMY", 150, 160], ["microglia", "ANATOMY", 185, 194], ["astrocyte", "ANATOMY", 199, 208], ["neutrophil", "ANATOMY", 253, 263], ["brain", "ANATOMY", 288, 293], ["neurologic disease", "DISEASE", 150, 168], ["mice", "ORGANISM", 53, 57], ["CXCL1", "GENE_OR_GENE_PRODUCT", 67, 72], ["oligodendrocytes", "CELL", 107, 123], ["microglia", "CELL", 185, 194], ["astrocyte", "CELL", 199, 208], ["neutrophil", "CELL", 253, 263], ["brain", "ORGAN", 288, 293], ["CXCL1", "PROTEIN", 67, 72], ["oligodendrocytes", "CELL_TYPE", 107, 123], ["microglia", "CELL_TYPE", 185, 194], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["oligodendrocytes", "PROBLEM", 107, 123], ["neurologic disease", "PROBLEM", 150, 168], ["microglia and astrocyte reactivity", "PROBLEM", 185, 219], ["neutrophil accumulation within the brain", "PROBLEM", 253, 293], ["neurologic disease", "OBSERVATION", 150, 168], ["microglia", "OBSERVATION", 185, 194], ["astrocyte reactivity", "OBSERVATION", 199, 219], ["increase", "OBSERVATION_MODIFIER", 241, 249], ["neutrophil accumulation", "OBSERVATION", 253, 276], ["brain", "ANATOMY", 288, 293]]], ["Using the animals described in this study in which transgenic Cxcl1 is selectively expressed in astrocytes upon Doxycycline treatment, we recently showed that increased and sustained expression of CXCL1 was associated with increased clinical disease and demyelination in animals infected with the neurotropic JHM strain of mouse hepatitis virus (JHMV) 21.", [["astrocytes", "ANATOMY", 96, 106], ["Doxycycline", "CHEMICAL", 112, 123], ["demyelination", "DISEASE", 254, 267], ["mouse hepatitis virus", "DISEASE", 323, 344], ["Doxycycline", "CHEMICAL", 112, 123], ["Cxcl1", "GENE_OR_GENE_PRODUCT", 62, 67], ["astrocytes", "CELL", 96, 106], ["Doxycycline", "SIMPLE_CHEMICAL", 112, 123], ["CXCL1", "GENE_OR_GENE_PRODUCT", 197, 202], ["neurotropic", "ORGANISM", 297, 308], ["JHM strain", "ORGANISM", 309, 319], ["mouse hepatitis virus", "ORGANISM", 323, 344], ["JHMV) 21", "ORGANISM", 346, 354], ["Cxcl1", "PROTEIN", 62, 67], ["astrocytes", "CELL_TYPE", 96, 106], ["CXCL1", "PROTEIN", 197, 202], ["mouse", "SPECIES", 323, 328], ["hepatitis virus", "SPECIES", 329, 344], ["mouse hepatitis virus", "SPECIES", 323, 344], ["JHMV", "SPECIES", 346, 350], ["this study", "TEST", 31, 41], ["Doxycycline treatment", "TREATMENT", 112, 133], ["CXCL1", "PROBLEM", 197, 202], ["increased clinical disease", "PROBLEM", 223, 249], ["demyelination", "PROBLEM", 254, 267], ["the neurotropic JHM strain of mouse hepatitis virus", "PROBLEM", 293, 344], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["CXCL1", "OBSERVATION", 197, 202], ["increased", "OBSERVATION_MODIFIER", 223, 232], ["demyelination", "OBSERVATION", 254, 267]]], ["Enhanced clinical and histologic disease correlated with a dramatic increase in neutrophil infiltration into the CNS; targeted ablation of neutrophils resulted in a reduction in the severity of demyelination further supporting an important role for neutrophils in augmenting white matter damage 21.DiscussionUsing this transgenic mouse in which CXCL1 expression is selectively induced within astrocytes allows for an increased understanding of how neutrophils may augment neuroinflammation and demyelination in EAE.", [["neutrophil", "ANATOMY", 80, 90], ["CNS", "ANATOMY", 113, 116], ["neutrophils", "ANATOMY", 139, 150], ["neutrophils", "ANATOMY", 249, 260], ["white matter", "ANATOMY", 275, 287], ["astrocytes", "ANATOMY", 392, 402], ["neutrophils", "ANATOMY", 448, 459], ["demyelination", "DISEASE", 194, 207], ["white matter damage", "DISEASE", 275, 294], ["neuroinflammation", "DISEASE", 472, 489], ["demyelination", "DISEASE", 494, 507], ["EAE", "DISEASE", 511, 514], ["neutrophil", "CELL", 80, 90], ["CNS", "ANATOMICAL_SYSTEM", 113, 116], ["neutrophils", "CELL", 139, 150], ["neutrophils", "CELL", 249, 260], ["mouse", "ORGANISM", 330, 335], ["CXCL1", "GENE_OR_GENE_PRODUCT", 345, 350], ["astrocytes", "CELL", 392, 402], ["neutrophils", "CELL", 448, 459], ["neutrophils", "CELL_TYPE", 139, 150], ["neutrophils", "CELL_TYPE", 249, 260], ["CXCL1", "PROTEIN", 345, 350], ["astrocytes", "CELL_TYPE", 392, 402], ["neutrophils", "CELL_TYPE", 448, 459], ["mouse", "SPECIES", 330, 335], ["mouse", "SPECIES", 330, 335], ["Enhanced clinical and histologic disease", "PROBLEM", 0, 40], ["a dramatic increase in neutrophil infiltration into the CNS", "PROBLEM", 57, 116], ["targeted ablation of neutrophils", "TREATMENT", 118, 150], ["a reduction", "PROBLEM", 163, 174], ["demyelination", "PROBLEM", 194, 207], ["neutrophils in augmenting white matter damage", "PROBLEM", 249, 294], ["this transgenic mouse", "TREATMENT", 314, 335], ["neuroinflammation", "PROBLEM", 472, 489], ["demyelination in EAE", "PROBLEM", 494, 514], ["histologic disease", "OBSERVATION", 22, 40], ["dramatic", "OBSERVATION_MODIFIER", 59, 67], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["neutrophil infiltration", "OBSERVATION", 80, 103], ["CNS", "ANATOMY", 113, 116], ["ablation", "OBSERVATION", 127, 135], ["reduction", "OBSERVATION_MODIFIER", 165, 174], ["demyelination", "OBSERVATION", 194, 207], ["demyelination", "OBSERVATION", 494, 507]]], ["Similar to our previous report using JHMV infection of CXCL1 double transgenic mice 21, we found that Dox administration resulted in elevated CXCL1 transgene expression within the brains and spinal cords of double tg mice that was restricted to astrocytes and correlated with rapid and robust neutrophil migration to the CNS compared to Dox\u2010treated controls.", [["brains", "ANATOMY", 180, 186], ["spinal cords", "ANATOMY", 191, 203], ["astrocytes", "ANATOMY", 245, 255], ["neutrophil", "ANATOMY", 293, 303], ["CNS", "ANATOMY", 321, 324], ["infection", "DISEASE", 42, 51], ["Dox", "CHEMICAL", 102, 105], ["Dox", "CHEMICAL", 102, 105], ["JHMV", "ORGANISM", 37, 41], ["CXCL1", "GENE_OR_GENE_PRODUCT", 55, 60], ["mice", "ORGANISM", 79, 83], ["Dox", "SIMPLE_CHEMICAL", 102, 105], ["CXCL1", "GENE_OR_GENE_PRODUCT", 142, 147], ["brains", "ORGAN", 180, 186], ["spinal cords", "ORGAN", 191, 203], ["mice", "ORGANISM", 217, 221], ["astrocytes", "CELL", 245, 255], ["neutrophil", "CELL", 293, 303], ["CNS", "ANATOMICAL_SYSTEM", 321, 324], ["CXCL1", "PROTEIN", 55, 60], ["CXCL1", "PROTEIN", 142, 147], ["astrocytes", "CELL_TYPE", 245, 255], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 217, 221], ["JHMV", "SPECIES", 37, 41], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 217, 221], ["JHMV infection", "PROBLEM", 37, 51], ["CXCL1 double transgenic mice", "TREATMENT", 55, 83], ["Dox administration", "TREATMENT", 102, 120], ["elevated CXCL1 transgene expression within the brains", "PROBLEM", 133, 186], ["double tg mice", "TREATMENT", 207, 221], ["rapid and robust neutrophil migration", "PROBLEM", 276, 313], ["Dox\u2010treated controls", "TREATMENT", 337, 357], ["elevated", "OBSERVATION_MODIFIER", 133, 141], ["CXCL1 transgene expression", "OBSERVATION", 142, 168], ["brains", "ANATOMY", 180, 186], ["spinal cords", "ANATOMY", 191, 203], ["neutrophil migration", "OBSERVATION", 293, 313]]], ["As a result of CXCL1 transgene expression, MOG35\u201355\u2010immunized double tg mice displayed sustained increase in clinical disease severity.", [["CXCL1", "GENE_OR_GENE_PRODUCT", 15, 20], ["MOG35\u201355", "GENE_OR_GENE_PRODUCT", 43, 51], ["double tg mice", "ORGANISM", 62, 76], ["CXCL1", "PROTEIN", 15, 20], ["MOG35", "PROTEIN", 43, 48], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["CXCL1 transgene expression", "TREATMENT", 15, 41], ["MOG35", "TEST", 43, 48], ["clinical disease severity", "PROBLEM", 109, 134], ["increase", "OBSERVATION_MODIFIER", 97, 105], ["clinical disease", "OBSERVATION", 109, 125]]], ["Increased accumulation of neutrophils in the CNS did not affect the expression of proinflammatory factors that could potentially attract inflammatory leukocytes and/or increase numbers of resident glial cells.", [["neutrophils", "ANATOMY", 26, 37], ["CNS", "ANATOMY", 45, 48], ["inflammatory leukocytes", "ANATOMY", 137, 160], ["glial cells", "ANATOMY", 197, 208], ["neutrophils", "CELL", 26, 37], ["CNS", "ANATOMICAL_SYSTEM", 45, 48], ["leukocytes", "CELL", 150, 160], ["glial cells", "CELL", 197, 208], ["neutrophils", "CELL_TYPE", 26, 37], ["proinflammatory factors", "PROTEIN", 82, 105], ["inflammatory leukocytes", "CELL_TYPE", 137, 160], ["resident glial cells", "CELL_TYPE", 188, 208], ["Increased accumulation of neutrophils in the CNS", "PROBLEM", 0, 48], ["proinflammatory factors", "PROBLEM", 82, 105], ["inflammatory leukocytes", "PROBLEM", 137, 160], ["accumulation of neutrophils", "OBSERVATION", 10, 37], ["CNS", "ANATOMY", 45, 48], ["proinflammatory factors", "OBSERVATION", 82, 105], ["inflammatory", "OBSERVATION_MODIFIER", 137, 149], ["increase", "OBSERVATION_MODIFIER", 168, 176], ["glial cells", "OBSERVATION", 197, 208]]], ["Indeed, we observed no statistical difference in the frequencies or numbers of either activated macrophages or microglia expressing MHC class II and CD80 between Dox\u2010treated double tg and single tg mice.", [["macrophages", "ANATOMY", 96, 107], ["microglia", "ANATOMY", 111, 120], ["macrophages", "CELL", 96, 107], ["microglia", "CELL", 111, 120], ["MHC class II", "GENE_OR_GENE_PRODUCT", 132, 144], ["CD80", "GENE_OR_GENE_PRODUCT", 149, 153], ["single tg mice", "ORGANISM", 188, 202], ["activated macrophages", "CELL_TYPE", 86, 107], ["microglia", "CELL_TYPE", 111, 120], ["MHC class II", "PROTEIN", 132, 144], ["CD80", "PROTEIN", 149, 153], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 198, 202], ["statistical difference in the frequencies", "PROBLEM", 23, 64], ["activated macrophages", "PROBLEM", 86, 107], ["Dox\u2010treated double tg", "TREATMENT", 162, 183], ["single tg mice", "TREATMENT", 188, 202]]], ["Furthermore, we did not detect any increase in either frequency or numbers of CNS inflammatory CD4+ or CD8+ T cells in Dox\u2010treated double tg mice compared to Dox\u2010treated single tg mice.", [["CNS inflammatory CD4+ or CD8+", "ANATOMY", 78, 107], ["T cells", "ANATOMY", 108, 115], ["CD4", "GENE_OR_GENE_PRODUCT", 95, 98], ["CD8", "GENE_OR_GENE_PRODUCT", 103, 106], ["T cells", "CELL", 108, 115], ["Dox\u2010treated double tg mice", "ORGANISM", 119, 145], ["Dox\u2010treated single tg mice", "ORGANISM", 158, 184], ["CD4", "PROTEIN", 95, 98], ["CD8", "PROTEIN", 103, 106], ["T cells", "CELL_TYPE", 108, 115], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 180, 184], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 180, 184], ["CNS inflammatory CD4", "TEST", 78, 98], ["CD8", "PROBLEM", 103, 106], ["Dox\u2010treated double tg mice", "TREATMENT", 119, 145], ["Dox\u2010treated single tg mice", "TREATMENT", 158, 184], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["CNS", "ANATOMY", 78, 81], ["inflammatory CD4", "OBSERVATION", 82, 98]]], ["In addition, there were no differences in the expression of IFN\u2010\u03b3 and/or IL\u201017A by CD4+ T\u2010cells between Dox\u2010treated double and single tg mice.", [["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL\u201017A", "GENE_OR_GENE_PRODUCT", 73, 79], ["CD4", "GENE_OR_GENE_PRODUCT", 83, 86], ["tg mice", "ORGANISM", 134, 141], ["IFN\u2010\u03b3", "PROTEIN", 60, 65], ["IL\u201017A", "PROTEIN", 73, 79], ["CD4", "PROTEIN", 83, 86], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 137, 141], ["IFN\u2010\u03b3", "TEST", 60, 65], ["Dox\u2010treated double and single tg mice", "TREATMENT", 104, 141], ["no", "UNCERTAINTY", 24, 26]]], ["Collectively, these findings indicate that the increase in MOG35\u201355\u2010induced clinical disease upon Dox\u2010induced CXCL1 expression is not the result of increased infiltration/activation of either macrophages/microglia or T cells.", [["macrophages", "ANATOMY", 192, 203], ["microglia", "ANATOMY", 204, 213], ["T cells", "ANATOMY", 217, 224], ["MOG35\u201355", "GENE_OR_GENE_PRODUCT", 59, 67], ["Dox\u2010induced", "GENE_OR_GENE_PRODUCT", 98, 109], ["CXCL1", "GENE_OR_GENE_PRODUCT", 110, 115], ["macrophages", "CELL", 192, 203], ["microglia", "CELL", 204, 213], ["T cells", "CELL", 217, 224], ["CXCL1", "PROTEIN", 110, 115], ["macrophages", "CELL_TYPE", 192, 203], ["microglia", "CELL_TYPE", 204, 213], ["T cells", "CELL_TYPE", 217, 224], ["clinical disease", "PROBLEM", 76, 92], ["Dox\u2010induced CXCL1 expression", "TEST", 98, 126], ["increased infiltration", "PROBLEM", 148, 170], ["macrophages/microglia or T cells", "PROBLEM", 192, 224], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["not the result of", "UNCERTAINTY", 130, 147], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["infiltration", "OBSERVATION", 158, 170], ["macrophages", "OBSERVATION", 192, 203]]], ["Of additional interest is our observation that Dox\u2010treatment of na\u00efve double tg mice resulted in increased expression of CXCL1 within the CNS and these findings argue that induction of EAE is dispensable in terms increased expression of this transgene.", [["CNS", "ANATOMY", 138, 141], ["EAE", "DISEASE", 185, 188], ["Dox\u2010treatment", "SIMPLE_CHEMICAL", 47, 60], ["na\u00efve double tg mice", "ORGANISM", 64, 84], ["CXCL1", "GENE_OR_GENE_PRODUCT", 121, 126], ["CNS", "ANATOMICAL_SYSTEM", 138, 141], ["CXCL1", "PROTEIN", 121, 126], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["Dox\u2010treatment of na\u00efve double tg mice", "TREATMENT", 47, 84], ["increased expression of CXCL1", "PROBLEM", 97, 126], ["this transgene", "TREATMENT", 237, 251], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["CXCL1", "OBSERVATION", 121, 126], ["CNS", "ANATOMY", 138, 141]]], ["Ongoing studies in our laboratory are determining if sustained CXCL1 expression within the CNS is sufficient to contribute to demyelination mediated by neutrophil accumulation in the absence of MOG35\u201355 immunization.DiscussionIn contrast with our findings, Omari et al. 44 demonstrated that overexpression of CXCL1 by astrocytes protected animals from EAE by limiting neuroinflammation as well as increasing numbers of oligodendrocytes associated with enhanced remyelination.", [["CNS", "ANATOMY", 91, 94], ["neutrophil", "ANATOMY", 152, 162], ["astrocytes", "ANATOMY", 318, 328], ["oligodendrocytes", "ANATOMY", 419, 435], ["demyelination", "DISEASE", 126, 139], ["MOG35\u201355", "CHEMICAL", 194, 202], ["EAE", "DISEASE", 352, 355], ["neuroinflammation", "DISEASE", 368, 385], ["CXCL1", "GENE_OR_GENE_PRODUCT", 63, 68], ["CNS", "ANATOMICAL_SYSTEM", 91, 94], ["neutrophil", "CELL", 152, 162], ["MOG35\u201355", "GENE_OR_GENE_PRODUCT", 194, 202], ["CXCL1", "GENE_OR_GENE_PRODUCT", 309, 314], ["astrocytes", "CELL", 318, 328], ["oligodendrocytes", "CELL", 419, 435], ["CXCL1", "PROTEIN", 63, 68], ["CXCL1", "PROTEIN", 309, 314], ["astrocytes", "CELL_TYPE", 318, 328], ["oligodendrocytes", "CELL_TYPE", 419, 435], ["Ongoing studies", "TEST", 0, 15], ["sustained CXCL1 expression", "PROBLEM", 53, 79], ["demyelination", "PROBLEM", 126, 139], ["neutrophil accumulation", "PROBLEM", 152, 175], ["CXCL1", "TEST", 309, 314], ["EAE", "PROBLEM", 352, 355], ["neuroinflammation", "PROBLEM", 368, 385], ["increasing numbers of oligodendrocytes", "PROBLEM", 397, 435], ["enhanced remyelination", "PROBLEM", 452, 474], ["CXCL1 expression", "OBSERVATION", 63, 79], ["CNS", "ANATOMY", 91, 94], ["demyelination", "OBSERVATION", 126, 139], ["neutrophil accumulation", "OBSERVATION", 152, 175], ["neuroinflammation", "OBSERVATION", 368, 385], ["increasing", "OBSERVATION_MODIFIER", 397, 407], ["oligodendrocytes", "OBSERVATION", 419, 435], ["enhanced", "OBSERVATION_MODIFIER", 452, 460], ["remyelination", "OBSERVATION", 461, 474]]], ["This difference in results most likely reflects that the Cxcl1 transgene employed in our study was lacking the 3\u2019 UTR resulting in an increase in the half\u2010life of CXCL1 mRNA and therefore sustained CXCL1 production and subsequently neutrophil accumulation whereas Omari et al. was using a transgene containing the 3\u2019UTR and nonsustained expression of CXCL1 44.", [["neutrophil", "ANATOMY", 232, 242], ["Cxcl1", "GENE_OR_GENE_PRODUCT", 57, 62], ["CXCL1", "GENE_OR_GENE_PRODUCT", 163, 168], ["CXCL1", "GENE_OR_GENE_PRODUCT", 198, 203], ["neutrophil", "CELL", 232, 242], ["CXCL1 44", "GENE_OR_GENE_PRODUCT", 351, 359], ["Cxcl1 transgene", "DNA", 57, 72], ["3\u2019 UTR", "DNA", 111, 117], ["CXCL1 mRNA", "RNA", 163, 173], ["CXCL1", "PROTEIN", 198, 203], ["neutrophil", "CELL_TYPE", 232, 242], ["3\u2019UTR", "DNA", 314, 319], ["CXCL1 44", "PROTEIN", 351, 359], ["the Cxcl1 transgene", "TREATMENT", 53, 72], ["our study", "TEST", 85, 94], ["the 3\u2019 UTR", "PROBLEM", 107, 117], ["CXCL1 mRNA", "PROBLEM", 163, 173], ["sustained CXCL1 production", "PROBLEM", 188, 214], ["neutrophil accumulation", "PROBLEM", 232, 255], ["a transgene containing the 3\u2019UTR", "TREATMENT", 287, 319], ["nonsustained expression of CXCL1", "PROBLEM", 324, 356], ["most likely reflects", "UNCERTAINTY", 27, 47], ["Cxcl1 transgene", "OBSERVATION", 57, 72], ["increase", "OBSERVATION_MODIFIER", 134, 142], ["CXCL1 mRNA", "OBSERVATION", 163, 173], ["CXCL1 production", "OBSERVATION", 198, 214], ["neutrophil accumulation", "OBSERVATION", 232, 255]]], ["We do not believe CXCL1 had any direct cytotoxic activity on oligodendroglia as we have previous shown that treatment of differentiating mouse oligodendrocyte progenitor cells with recombinant CXCL1 does not kill these cells 45.", [["oligodendroglia", "ANATOMY", 61, 76], ["oligodendrocyte progenitor cells", "ANATOMY", 143, 175], ["cells", "ANATOMY", 219, 224], ["CXCL1", "GENE_OR_GENE_PRODUCT", 18, 23], ["oligodendroglia", "CELL", 61, 76], ["mouse", "ORGANISM", 137, 142], ["oligodendrocyte progenitor cells", "CELL", 143, 175], ["CXCL1", "GENE_OR_GENE_PRODUCT", 193, 198], ["cells", "CELL", 219, 224], ["CXCL1", "PROTEIN", 18, 23], ["oligodendroglia", "CELL_TYPE", 61, 76], ["differentiating mouse oligodendrocyte progenitor cells", "CELL_LINE", 121, 175], ["CXCL1", "PROTEIN", 193, 198], ["mouse", "SPECIES", 137, 142], ["mouse", "SPECIES", 137, 142], ["CXCL1", "TEST", 18, 23], ["any direct cytotoxic activity on oligodendroglia", "PROBLEM", 28, 76], ["differentiating mouse oligodendrocyte progenitor cells", "PROBLEM", 121, 175], ["recombinant CXCL1", "TEST", 181, 198], ["cytotoxic activity", "OBSERVATION", 39, 57], ["mouse oligodendrocyte progenitor cells", "OBSERVATION", 137, 175]]], ["Rather, our findings argue that increased white matter damage is associated with a selective increase in neutrophil accumulation within the CNS and this is consistent with earlier studies from our laboratory using the CXCL1 transgenic animals in a model of viral\u2010induced neurologic disease 21.", [["white matter", "ANATOMY", 42, 54], ["neutrophil", "ANATOMY", 105, 115], ["CNS", "ANATOMY", 140, 143], ["neurologic", "ANATOMY", 271, 281], ["white matter damage", "DISEASE", 42, 61], ["viral\u2010induced neurologic disease", "DISEASE", 257, 289], ["neutrophil", "CELL", 105, 115], ["CNS", "ANATOMICAL_SYSTEM", 140, 143], ["CXCL1", "GENE_OR_GENE_PRODUCT", 218, 223], ["CXCL1", "PROTEIN", 218, 223], ["increased white matter damage", "PROBLEM", 32, 61], ["a selective increase in neutrophil accumulation", "PROBLEM", 81, 128], ["viral\u2010induced neurologic disease", "PROBLEM", 257, 289], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["white matter", "OBSERVATION_MODIFIER", 42, 54], ["damage", "OBSERVATION", 55, 61], ["selective", "OBSERVATION_MODIFIER", 83, 92], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["neutrophil accumulation", "OBSERVATION", 105, 128], ["CNS", "ANATOMY", 140, 143], ["consistent with", "UNCERTAINTY", 156, 171], ["neurologic disease", "OBSERVATION", 271, 289]]], ["Although recent studies suggest that Ly\u20106C+ myeloid precursor cells play a pathogenic role during autoimmune demyelination 46, our findings reveal that the increase in tissue damage was not the result of enhanced migration of these cells to the CNS of Dox\u2010treated double tg mice when compared to single tg mice.", [["Ly\u20106C+ myeloid precursor cells", "ANATOMY", 37, 67], ["tissue", "ANATOMY", 168, 174], ["cells", "ANATOMY", 232, 237], ["CNS", "ANATOMY", 245, 248], ["autoimmune demyelination", "DISEASE", 98, 122], ["tissue damage", "DISEASE", 168, 181], ["Ly\u20106C", "GENE_OR_GENE_PRODUCT", 37, 42], ["myeloid precursor cells", "CELL", 44, 67], ["tissue", "TISSUE", 168, 174], ["cells", "CELL", 232, 237], ["CNS", "ANATOMICAL_SYSTEM", 245, 248], ["Dox\u2010treated double tg mice", "ORGANISM", 252, 278], ["single tg mice", "ORGANISM", 296, 310], ["Ly\u20106C", "PROTEIN", 37, 42], ["myeloid precursor cells", "CELL_TYPE", 44, 67], ["mice", "SPECIES", 274, 278], ["mice", "SPECIES", 306, 310], ["mice", "SPECIES", 274, 278], ["mice", "SPECIES", 306, 310], ["recent studies", "TEST", 9, 23], ["myeloid precursor cells", "PROBLEM", 44, 67], ["autoimmune demyelination", "PROBLEM", 98, 122], ["the increase in tissue damage", "PROBLEM", 152, 181], ["enhanced migration of these cells", "PROBLEM", 204, 237], ["Dox\u2010treated double tg mice", "TREATMENT", 252, 278], ["myeloid precursor cells", "OBSERVATION", 44, 67], ["increase", "OBSERVATION_MODIFIER", 156, 164], ["tissue", "ANATOMY", 168, 174], ["damage", "OBSERVATION", 175, 181]]], ["Molecules that neutrophils are known to possess that potentially could impact cell survival include neutrophil elastase, cathepsin G, and matrix metalloproteinases 39.", [["neutrophils", "ANATOMY", 15, 26], ["cell", "ANATOMY", 78, 82], ["neutrophil", "ANATOMY", 100, 110], ["neutrophils", "CELL", 15, 26], ["cell", "CELL", 78, 82], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 100, 119], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 121, 132], ["matrix metalloproteinases 39", "GENE_OR_GENE_PRODUCT", 138, 166], ["neutrophils", "CELL_TYPE", 15, 26], ["neutrophil elastase", "PROTEIN", 100, 119], ["cathepsin G", "PROTEIN", 121, 132], ["matrix metalloproteinases 39", "PROTEIN", 138, 166], ["neutrophils", "PROBLEM", 15, 26], ["neutrophil elastase", "TEST", 100, 119], ["cathepsin G, and matrix metalloproteinases", "TREATMENT", 121, 163], ["neutrophil elastase", "OBSERVATION", 100, 119]]], ["Indeed, neutrophils have clearly been shown to exacerbate brain injury in a model of focal cerebral ischemia 47.", [["neutrophils", "ANATOMY", 8, 19], ["brain", "ANATOMY", 58, 63], ["cerebral", "ANATOMY", 91, 99], ["brain injury", "DISEASE", 58, 70], ["cerebral ischemia", "DISEASE", 91, 108], ["neutrophils", "CELL", 8, 19], ["brain", "ORGAN", 58, 63], ["cerebral", "ORGAN", 91, 99], ["neutrophils", "CELL_TYPE", 8, 19], ["brain injury", "PROBLEM", 58, 70], ["focal cerebral ischemia", "PROBLEM", 85, 108], ["injury", "OBSERVATION", 64, 70], ["focal", "OBSERVATION_MODIFIER", 85, 90], ["cerebral", "ANATOMY", 91, 99], ["ischemia", "OBSERVATION", 100, 108]]], ["Blocking neutrophil trafficking to the CNS or inhibition of the NAPDH complex in mouse models of ischemic injury results in a dramatic reduction in both the vascular endothelium and brain parenchyma 47, 48.", [["neutrophil", "ANATOMY", 9, 19], ["CNS", "ANATOMY", 39, 42], ["vascular endothelium", "ANATOMY", 157, 177], ["brain parenchyma", "ANATOMY", 182, 198], ["ischemic injury", "DISEASE", 97, 112], ["neutrophil", "CELL", 9, 19], ["CNS", "ANATOMICAL_SYSTEM", 39, 42], ["NAPDH", "GENE_OR_GENE_PRODUCT", 64, 69], ["mouse", "ORGANISM", 81, 86], ["vascular endothelium", "TISSUE", 157, 177], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 182, 198], ["NAPDH complex", "PROTEIN", 64, 77], ["mouse", "SPECIES", 81, 86], ["mouse", "SPECIES", 81, 86], ["Blocking neutrophil trafficking", "PROBLEM", 0, 31], ["ischemic injury", "PROBLEM", 97, 112], ["a dramatic reduction", "PROBLEM", 124, 144], ["neutrophil trafficking", "OBSERVATION", 9, 31], ["CNS", "ANATOMY", 39, 42], ["ischemic", "OBSERVATION_MODIFIER", 97, 105], ["injury", "OBSERVATION", 106, 112], ["dramatic", "OBSERVATION_MODIFIER", 126, 134], ["reduction", "OBSERVATION", 135, 144], ["both", "ANATOMY_MODIFIER", 148, 152], ["vascular endothelium", "ANATOMY", 157, 177], ["brain", "ANATOMY", 182, 187], ["parenchyma", "ANATOMY_MODIFIER", 188, 198]]], ["Moreover, both the generation of ROS and nitric oxide is thought to contribute to vascular damage as well as impact axonal integrity and oligodendrocyte viability 49, 50.", [["vascular", "ANATOMY", 82, 90], ["axonal", "ANATOMY", 116, 122], ["oligodendrocyte", "ANATOMY", 137, 152], ["ROS", "CHEMICAL", 33, 36], ["nitric oxide", "CHEMICAL", 41, 53], ["vascular damage", "DISEASE", 82, 97], ["nitric oxide", "CHEMICAL", 41, 53], ["ROS", "SIMPLE_CHEMICAL", 33, 36], ["nitric oxide", "SIMPLE_CHEMICAL", 41, 53], ["vascular", "MULTI-TISSUE_STRUCTURE", 82, 90], ["axonal", "MULTI-TISSUE_STRUCTURE", 116, 122], ["oligodendrocyte", "CELL", 137, 152], ["nitric oxide", "TREATMENT", 41, 53], ["vascular damage", "PROBLEM", 82, 97], ["oligodendrocyte viability", "TEST", 137, 162], ["vascular", "ANATOMY", 82, 90], ["damage", "OBSERVATION", 91, 97], ["axonal integrity", "OBSERVATION", 116, 132]]], ["Neutrophils are also implicated in exacerbating lesion development within spinal cords on patients with neuromyelitis optica (NMO) 51, and inhibition of neutrophil elastase, a serine protease released from the primary granules of neutrophils, within mouse models of NMO resulted in reduced neuroinflammation and myelin loss 52, 53.", [["Neutrophils", "ANATOMY", 0, 11], ["lesion", "ANATOMY", 48, 54], ["spinal cords", "ANATOMY", 74, 86], ["neutrophil", "ANATOMY", 153, 163], ["primary granules", "ANATOMY", 210, 226], ["neutrophils", "ANATOMY", 230, 241], ["myelin", "ANATOMY", 312, 318], ["neuromyelitis optica", "DISEASE", 104, 124], ["NMO", "DISEASE", 126, 129], ["NMO", "DISEASE", 266, 269], ["neuroinflammation", "DISEASE", 290, 307], ["myelin loss", "DISEASE", 312, 323], ["serine", "CHEMICAL", 176, 182], ["Neutrophils", "CELL", 0, 11], ["lesion", "PATHOLOGICAL_FORMATION", 48, 54], ["spinal cords", "ORGAN", 74, 86], ["patients", "ORGANISM", 90, 98], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 153, 172], ["granules", "ORGANISM_SUBSTANCE", 218, 226], ["neutrophils", "CELL", 230, 241], ["mouse", "ORGANISM", 250, 255], ["myelin", "CELLULAR_COMPONENT", 312, 318], ["Neutrophils", "CELL_TYPE", 0, 11], ["neutrophil elastase", "PROTEIN", 153, 172], ["serine protease", "PROTEIN", 176, 191], ["neutrophils", "CELL_TYPE", 230, 241], ["patients", "SPECIES", 90, 98], ["mouse", "SPECIES", 250, 255], ["mouse", "SPECIES", 250, 255], ["Neutrophils", "TEST", 0, 11], ["exacerbating lesion development within spinal cords", "PROBLEM", 35, 86], ["neuromyelitis optica", "PROBLEM", 104, 124], ["neutrophil elastase", "PROBLEM", 153, 172], ["a serine protease", "PROBLEM", 174, 191], ["NMO", "PROBLEM", 266, 269], ["reduced neuroinflammation and myelin loss", "PROBLEM", 282, 323], ["exacerbating", "OBSERVATION_MODIFIER", 35, 47], ["lesion", "OBSERVATION", 48, 54], ["spinal cords", "ANATOMY", 74, 86], ["neutrophil elastase", "OBSERVATION", 153, 172], ["neutrophils", "OBSERVATION", 230, 241], ["reduced", "OBSERVATION_MODIFIER", 282, 289], ["neuroinflammation", "OBSERVATION", 290, 307]]], ["Within the EAE model of chronic neurologic disease, neutrophils have recently been reported to have a role in maturating local APCs within the CNS thus potentially contributing to increased disease severity by increasing numbers of autoreactive T cells 54.", [["neurologic", "ANATOMY", 32, 42], ["neutrophils", "ANATOMY", 52, 63], ["APCs", "ANATOMY", 127, 131], ["CNS", "ANATOMY", 143, 146], ["autoreactive T cells", "ANATOMY", 232, 252], ["EAE", "DISEASE", 11, 14], ["chronic neurologic disease", "DISEASE", 24, 50], ["neutrophils", "CELL", 52, 63], ["APCs", "CELL", 127, 131], ["CNS", "ANATOMICAL_SYSTEM", 143, 146], ["autoreactive T cells", "CELL", 232, 252], ["neutrophils", "CELL_TYPE", 52, 63], ["APCs", "CELL_TYPE", 127, 131], ["autoreactive T cells", "CELL_TYPE", 232, 252], ["chronic neurologic disease", "PROBLEM", 24, 50], ["neutrophils", "PROBLEM", 52, 63], ["increased disease severity", "PROBLEM", 180, 206], ["autoreactive T cells", "PROBLEM", 232, 252], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["neurologic disease", "OBSERVATION", 32, 50], ["CNS", "ANATOMY", 143, 146], ["increased", "OBSERVATION_MODIFIER", 180, 189], ["disease", "OBSERVATION", 190, 197], ["increasing", "OBSERVATION_MODIFIER", 210, 220], ["numbers", "OBSERVATION_MODIFIER", 221, 228], ["autoreactive", "OBSERVATION_MODIFIER", 232, 244]]], ["However, we believe it unlikely that the increase in disease severity is the result of enhanced macrophages presenting antigen as we determined there was no increase in either activated macrophage or microglia in the CNS of Dox\u2010treated double tg mice nor were there increases in either Th1 and/or Th17 CD4+ T\u2010cell responses.DiscussionThe importance of neutrophils in enhancing white matter damage in Dox\u2010treated double tg mice was emphasized by demonstrating that blocking neutrophil accumulation within the CNS via anti\u2010CXCR2 treatment dramatically reduced demyelination.", [["macrophages", "ANATOMY", 96, 107], ["macrophage", "ANATOMY", 186, 196], ["microglia", "ANATOMY", 200, 209], ["CNS", "ANATOMY", 217, 220], ["Th17 CD4+", "ANATOMY", 297, 306], ["T\u2010cell", "ANATOMY", 307, 313], ["neutrophils", "ANATOMY", 352, 363], ["white matter", "ANATOMY", 377, 389], ["neutrophil", "ANATOMY", 473, 483], ["CNS", "ANATOMY", 508, 511], ["white matter damage", "DISEASE", 377, 396], ["demyelination", "DISEASE", 558, 571], ["macrophages", "CELL", 96, 107], ["macrophage", "CELL", 186, 196], ["microglia", "CELL", 200, 209], ["CNS", "ANATOMICAL_SYSTEM", 217, 220], ["Dox\u2010treated double tg mice", "ORGANISM", 224, 250], ["Th1", "GENE_OR_GENE_PRODUCT", 286, 289], ["CD4", "GENE_OR_GENE_PRODUCT", 302, 305], ["neutrophils", "CELL", 352, 363], ["Dox\u2010treated double tg mice", "ORGANISM", 400, 426], ["neutrophil", "CELL", 473, 483], ["CNS", "ANATOMICAL_SYSTEM", 508, 511], ["anti\u2010CXCR2", "GENE_OR_GENE_PRODUCT", 516, 526], ["macrophages", "CELL_TYPE", 96, 107], ["activated macrophage", "CELL_TYPE", 176, 196], ["microglia", "CELL_TYPE", 200, 209], ["Th1", "CELL_TYPE", 286, 289], ["CD4", "PROTEIN", 302, 305], ["neutrophils", "CELL_TYPE", 352, 363], ["anti\u2010CXCR2", "PROTEIN", 516, 526], ["mice", "SPECIES", 246, 250], ["mice", "SPECIES", 422, 426], ["mice", "SPECIES", 246, 250], ["mice", "SPECIES", 422, 426], ["the increase in disease severity", "PROBLEM", 37, 69], ["enhanced macrophages", "PROBLEM", 87, 107], ["activated macrophage", "PROBLEM", 176, 196], ["neutrophils", "PROBLEM", 352, 363], ["enhancing white matter damage", "PROBLEM", 367, 396], ["Dox\u2010treated double tg mice", "TREATMENT", 400, 426], ["blocking neutrophil accumulation", "PROBLEM", 464, 496], ["the CNS via anti\u2010CXCR2 treatment", "TREATMENT", 504, 536], ["reduced demyelination", "PROBLEM", 550, 571], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["disease", "OBSERVATION", 53, 60], ["enhanced", "OBSERVATION_MODIFIER", 87, 95], ["macrophages", "OBSERVATION", 96, 107], ["no", "UNCERTAINTY", 154, 156], ["increase", "OBSERVATION_MODIFIER", 157, 165], ["macrophage", "OBSERVATION", 186, 196], ["enhancing", "OBSERVATION_MODIFIER", 367, 376], ["white matter", "OBSERVATION_MODIFIER", 377, 389], ["neutrophil accumulation", "OBSERVATION", 473, 496], ["CNS", "ANATOMY", 508, 511], ["reduced", "OBSERVATION_MODIFIER", 550, 557], ["demyelination", "OBSERVATION", 558, 571]]], ["Previous studies from our laboratory 30, 32 and others 9, 47, 55, 56 have demonstrated that administration of anti\u2010CXCR2 blocking antibody limits neutrophil mobilization from the bone marrow and limits migration to the CNS in various models of neurodegeneration.", [["neutrophil", "ANATOMY", 146, 156], ["bone marrow", "ANATOMY", 179, 190], ["CNS", "ANATOMY", 219, 222], ["neurodegeneration", "DISEASE", 244, 261], ["anti\u2010CXCR2", "GENE_OR_GENE_PRODUCT", 110, 120], ["neutrophil", "CELL", 146, 156], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 179, 190], ["CNS", "ANATOMICAL_SYSTEM", 219, 222], ["anti\u2010CXCR2 blocking antibody", "PROTEIN", 110, 138], ["Previous studies", "TEST", 0, 16], ["anti\u2010CXCR2 blocking antibody", "TREATMENT", 110, 138], ["neutrophil mobilization", "TREATMENT", 146, 169], ["neurodegeneration", "PROBLEM", 244, 261], ["neutrophil mobilization", "OBSERVATION", 146, 169], ["bone marrow", "ANATOMY", 179, 190], ["migration", "OBSERVATION_MODIFIER", 202, 211], ["CNS", "ANATOMY", 219, 222], ["neurodegeneration", "OBSERVATION", 244, 261]]], ["Our findings provide further evidence that neutrophils augment neurologic disease and emphasize that therapies targeting neutrophil accumulation within the CNS may offer novel alternative therapies for treating neuroinflammatory diseases.Mice ::: Materials and methodspBI\u2010CXCL1\u2010rtTA double transgenic mice (developed on the C57BL/6 background) were developed as previously described 21.", [["neutrophils", "ANATOMY", 43, 54], ["neurologic", "ANATOMY", 63, 73], ["neutrophil", "ANATOMY", 121, 131], ["CNS", "ANATOMY", 156, 159], ["neurologic disease", "DISEASE", 63, 81], ["neuroinflammatory diseases", "DISEASE", 211, 237], ["neutrophils", "CELL", 43, 54], ["neutrophil", "CELL", 121, 131], ["CNS", "ANATOMICAL_SYSTEM", 156, 159], ["Mice", "ORGANISM", 238, 242], ["methodspBI\u2010", "GENE_OR_GENE_PRODUCT", 261, 272], ["CXCL1\u2010rtTA", "GENE_OR_GENE_PRODUCT", 272, 282], ["mice", "ORGANISM", 301, 305], ["C57BL/6 background", "ORGANISM", 324, 342], ["neutrophils", "CELL_TYPE", 43, 54], ["Mice", "SPECIES", 238, 242], ["mice", "SPECIES", 301, 305], ["mice", "SPECIES", 301, 305], ["neutrophils augment neurologic disease", "PROBLEM", 43, 81], ["therapies", "TREATMENT", 101, 110], ["neutrophil accumulation", "PROBLEM", 121, 144], ["novel alternative therapies", "TREATMENT", 170, 197], ["treating neuroinflammatory diseases", "PROBLEM", 202, 237], ["Materials", "TEST", 247, 256], ["methodspBI\u2010CXCL1\u2010rtTA double transgenic mice", "TREATMENT", 261, 305], ["neutrophil accumulation", "OBSERVATION", 121, 144]]], ["In brief, pBI\u2010CXCL1 transgenic mice were generated by the University of California, Irvine transgenic mouse facility through DNA microinjection of fertilized C56BL/6 eggs using the linearized pBI\u2010CXCL1 construct 57.", [["pBI", "GENE_OR_GENE_PRODUCT", 10, 13], ["CXCL1", "GENE_OR_GENE_PRODUCT", 14, 19], ["mice", "ORGANISM", 31, 35], ["mouse", "ORGANISM", 102, 107], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["C56BL/6 eggs", "ORGANISM", 158, 170], ["CXCL1", "GENE_OR_GENE_PRODUCT", 196, 201], ["pBI", "PROTEIN", 10, 13], ["CXCL1", "PROTEIN", 14, 19], ["pBI", "DNA", 192, 195], ["CXCL1 construct 57", "DNA", 196, 214], ["mice", "SPECIES", 31, 35], ["mouse", "SPECIES", 102, 107], ["mice", "SPECIES", 31, 35], ["mouse", "SPECIES", 102, 107], ["pBI", "TEST", 10, 13], ["DNA microinjection", "TREATMENT", 125, 143], ["fertilized C56BL/6 eggs", "TREATMENT", 147, 170], ["the linearized pBI", "TREATMENT", 177, 195], ["CXCL1 construct", "TEST", 196, 211]]], ["The five resulting founder transgenic (tg) mice were mated to WT C57BL/6 mice to identify F1 offspring containing the transgene.", [["founder transgenic (tg) mice", "ORGANISM", 19, 47], ["WT C57BL/6 mice", "ORGANISM", 62, 77], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 73, 77]]], ["To generate double transgenic (tg) mice, hemizygous pBI\u2010CXCL1 transgenics were crossed to hemizygous GFAP\u2010rtTA*M2 mice (JAX), resulting in double transgenic mice (pBI\u2010CXCL1\u2010rtTA), single tg (rtTA\u2010GFAP or pBI\u2010CXCL1) or WT.", [["double transgenic (tg) mice", "ORGANISM", 12, 39], ["pBI", "GENE_OR_GENE_PRODUCT", 52, 55], ["CXCL1", "GENE_OR_GENE_PRODUCT", 56, 61], ["GFAP\u2010rtTA*M2 mice", "ORGANISM", 101, 118], ["JAX", "GENE_OR_GENE_PRODUCT", 120, 123], ["mice", "ORGANISM", 157, 161], ["pBI\u2010CXCL1\u2010rtTA", "GENE_OR_GENE_PRODUCT", 163, 177], ["rtTA\u2010GFAP", "GENE_OR_GENE_PRODUCT", 191, 200], ["pBI\u2010CXCL1", "GENE_OR_GENE_PRODUCT", 204, 213], ["hemizygous pBI", "DNA", 41, 55], ["CXCL1", "PROTEIN", 56, 61], ["pBI", "PROTEIN", 163, 166], ["CXCL1\u2010rtTA", "PROTEIN", 167, 177], ["rtTA", "PROTEIN", 191, 195], ["GFAP", "PROTEIN", 196, 200], ["pBI", "PROTEIN", 204, 207], ["CXCL1", "PROTEIN", 208, 213], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 157, 161], ["double transgenic (tg) mice", "TREATMENT", 12, 39], ["hemizygous pBI", "TEST", 41, 55], ["CXCL1 transgenics", "TEST", 56, 73], ["double transgenic mice (pBI\u2010CXCL1\u2010rtTA", "TREATMENT", 139, 177], ["single tg", "TREATMENT", 180, 189], ["double transgenic", "OBSERVATION", 12, 29]]], ["Dox administration to double tg results in elevated CXCL1 transgene expression within astrocytes corresponding with increased CXCL1 protein and neutrophil accumulation whereas Dox treatment of single tg had no effect on CXCL1 expression nor neutrophil accumulation within the CNS 21.MOG35\u201355 EAE immunization ::: Materials and methodsFor induction of EAE, experimental mice (aged 6\u20138 weeks old) were injected subcutaneously in the flanks with 200 \u03bcL of 1 mM MOG35\u201355 peptide (DNA/Peptide Synthesis Core Facility, University of Utah) emulsified with reconstituted complete Freund's adjuvant (Pierce Biotechnology, Waltham, MA, USA) containing Mycobacterium tuberculosis H37 Ra (2 mg/mL) (Difco Laboratories, Franklin Lakes, NJ, USA).", [["astrocytes", "ANATOMY", 86, 96], ["neutrophil", "ANATOMY", 144, 154], ["neutrophil", "ANATOMY", 241, 251], ["CNS", "ANATOMY", 276, 279], ["subcutaneously", "ANATOMY", 409, 423], ["flanks", "ANATOMY", 431, 437], ["Dox", "CHEMICAL", 0, 3], ["Dox", "CHEMICAL", 176, 179], ["EAE", "DISEASE", 292, 295], ["EAE", "DISEASE", 351, 354], ["MOG35\u201355 peptide", "CHEMICAL", 458, 474], ["H37 Ra", "CHEMICAL", 669, 675], ["Dox", "CHEMICAL", 0, 3], ["Dox", "CHEMICAL", 176, 179], ["MOG35\u201355 peptide", "CHEMICAL", 458, 474], ["Dox", "SIMPLE_CHEMICAL", 0, 3], ["CXCL1", "GENE_OR_GENE_PRODUCT", 52, 57], ["astrocytes", "CELL", 86, 96], ["CXCL1", "GENE_OR_GENE_PRODUCT", 126, 131], ["neutrophil", "CELL", 144, 154], ["Dox", "SIMPLE_CHEMICAL", 176, 179], ["CXCL1", "GENE_OR_GENE_PRODUCT", 220, 225], ["neutrophil", "CELL", 241, 251], ["mice", "ORGANISM", 369, 373], ["flanks", "ORGANISM_SUBDIVISION", 431, 437], ["DNA", "CELLULAR_COMPONENT", 476, 479], ["CXCL1", "PROTEIN", 52, 57], ["astrocytes", "CELL_TYPE", 86, 96], ["CXCL1 protein", "PROTEIN", 126, 139], ["CXCL1", "PROTEIN", 220, 225], ["mice", "SPECIES", 369, 373], ["Mycobacterium tuberculosis", "SPECIES", 642, 668], ["mice", "SPECIES", 369, 373], ["Mycobacterium tuberculosis", "SPECIES", 642, 668], ["Dox administration", "TREATMENT", 0, 18], ["double tg", "TEST", 22, 31], ["elevated CXCL1 transgene expression within astrocytes", "PROBLEM", 43, 96], ["increased CXCL1 protein", "PROBLEM", 116, 139], ["neutrophil accumulation", "PROBLEM", 144, 167], ["Dox treatment", "TREATMENT", 176, 189], ["single tg", "TEST", 193, 202], ["CXCL1 expression", "TEST", 220, 236], ["neutrophil accumulation", "PROBLEM", 241, 264], ["methods", "TREATMENT", 327, 334], ["induction of EAE", "TREATMENT", 338, 354], ["reconstituted complete Freund's adjuvant", "TREATMENT", 549, 589], ["Mycobacterium tuberculosis H37 Ra", "TREATMENT", 642, 675], ["CXCL1 protein", "OBSERVATION", 126, 139], ["neutrophil accumulation", "OBSERVATION", 144, 167], ["neutrophil accumulation", "OBSERVATION", 241, 264], ["flanks", "ANATOMY", 431, 437]]], ["Mice were injected intravenously with 100 \u03bcL Bordetella pertussis toxin (Ptx) (List Biological Laboratories Inc., Campbell, CA, USA) at 0.2 \u03bcg/mouse on days 0 and 2 following sensitization.", [["intravenously", "ANATOMY", 19, 32], ["Ptx", "CHEMICAL", 73, 76], ["Mice", "ORGANISM", 0, 4], ["Ptx", "SIMPLE_CHEMICAL", 73, 76], ["mouse", "ORGANISM", 143, 148], ["Mice", "SPECIES", 0, 4], ["Bordetella pertussis toxin", "SPECIES", 45, 71], ["mouse", "SPECIES", 143, 148], ["mouse", "SPECIES", 143, 148], ["100 \u03bcL Bordetella pertussis toxin", "TREATMENT", 38, 71]]], ["Double and single transgenic animals were injected with doxycycline (Dox) (50 mg/kg via i.p. injection) starting at day 9 following EAE induction and continuing through day 19 postimmunization (p.i.).", [["doxycycline", "CHEMICAL", 56, 67], ["Dox", "CHEMICAL", 69, 72], ["doxycycline", "CHEMICAL", 56, 67], ["Dox", "CHEMICAL", 69, 72], ["animals", "ORGANISM", 29, 36], ["doxycycline", "SIMPLE_CHEMICAL", 56, 67], ["Dox", "SIMPLE_CHEMICAL", 69, 72], ["Double and single transgenic animals", "TREATMENT", 0, 36], ["doxycycline (Dox)", "TREATMENT", 56, 73], ["EAE induction", "TREATMENT", 132, 145]]], ["Experimental mice injected with MOG35\u201355 were scored daily for clinical signs through day 21 following immunization using previously described methods 58.", [["mice", "ORGANISM", 13, 17], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["MOG35", "TREATMENT", 32, 37], ["clinical signs", "TEST", 63, 77], ["immunization", "TREATMENT", 103, 115]]], ["In brief, 0, normal mouse with no signs of disease; 1, limp tail or hind\u2010limb weakness; 2, limp tail and hind\u2010limb weakness; 3, partial hind\u2010limb paralysis; 4, complete hind\u2010limb paralysis; 5, moribund state/death.", [["limp tail", "ANATOMY", 55, 64], ["limp tail", "ANATOMY", 91, 100], ["hind\u2010limb weakness", "DISEASE", 68, 86], ["hind\u2010limb weakness", "DISEASE", 105, 123], ["paralysis", "DISEASE", 146, 155], ["paralysis", "DISEASE", 179, 188], ["death", "DISEASE", 208, 213], ["mouse", "ORGANISM", 20, 25], ["mouse", "SPECIES", 20, 25], ["mouse", "SPECIES", 20, 25], ["disease", "PROBLEM", 43, 50], ["limp tail", "PROBLEM", 55, 64], ["hind\u2010limb weakness", "PROBLEM", 68, 86], ["limp tail and hind\u2010limb weakness", "PROBLEM", 91, 123], ["partial hind\u2010limb paralysis", "PROBLEM", 128, 155], ["complete hind\u2010limb paralysis", "PROBLEM", 160, 188], ["no signs of", "UNCERTAINTY", 31, 42], ["disease", "OBSERVATION", 43, 50], ["limp tail", "ANATOMY", 55, 64], ["weakness", "OBSERVATION", 78, 86], ["limp tail", "ANATOMY", 91, 100], ["weakness", "OBSERVATION", 115, 123], ["paralysis", "OBSERVATION", 146, 155], ["paralysis", "OBSERVATION", 179, 188]]], ["All animal experiments were approved by the University of Utah Institutional Animal Care and Use Committee protocol 18\u201301005.Flow cytometry ::: Materials and methodsInflammatory leukocytes infiltrating into the CNS were isolated using an established protocol (3,4).", [["Inflammatory leukocytes", "ANATOMY", 165, 188], ["CNS", "ANATOMY", 211, 214], ["Inflammatory leukocytes", "CELL", 165, 188], ["CNS", "ANATOMICAL_SYSTEM", 211, 214], ["Inflammatory leukocytes", "CELL_TYPE", 165, 188], ["methodsInflammatory leukocytes", "PROBLEM", 158, 188], ["an established protocol", "TEST", 235, 258], ["Inflammatory", "OBSERVATION_MODIFIER", 165, 177], ["CNS", "ANATOMY", 211, 214]]], ["In short, CNS tissue was minced and leukocytes were isolated using a two\u2010step Percoll gradient (90% and 63%).", [["CNS tissue", "ANATOMY", 10, 20], ["leukocytes", "ANATOMY", 36, 46], ["CNS tissue", "TISSUE", 10, 20], ["leukocytes", "CELL", 36, 46], ["leukocytes", "CELL_TYPE", 36, 46], ["leukocytes", "TEST", 36, 46], ["a two\u2010step Percoll gradient", "TEST", 67, 94], ["short", "OBSERVATION_MODIFIER", 3, 8], ["CNS tissue", "ANATOMY", 10, 20]]], ["The isolated cells were collected and then washed prior to staining.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["The isolated cells", "PROBLEM", 0, 18], ["isolated cells", "OBSERVATION", 4, 18]]], ["Cells were incubated in an anti\u2010CD16/32 Fc Block (BD Biosciences, San Jose, CA) at a dilution of 1:200.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["CD16/32 Fc Block", "PROTEIN", 32, 48]]], ["Cells were stained with fluorescently tagged rat anti\u2010mouse IgG for the following cell surface antibodies, Ly6G FITC (1A8), CD11b PE (M1/70), CD45 BV510 (30\u2010F11), CD8 PE\u2010Cy7 (53\u20136.7), (BD Biosciences), Ly6C APC (HK1.4), CD4 BV785 (RM4\u20105), F4/80 FITC (BM8), I\u2010A/I\u2010E APC (M5/114.15.2), CD11c FITC (N418) (Biolegend, San Diego, CA), and CD4 FITC (RM4\u20105) or Armenian hamster anti\u2010mouse IgG for CD80 PerCP\u2010Cy5.5 (16\u201010A1) (BD Biosciences).", [["Cells", "ANATOMY", 0, 5], ["cell surface", "ANATOMY", 82, 94], ["FITC", "CHEMICAL", 112, 116], ["FITC", "CHEMICAL", 245, 249], ["FITC", "CHEMICAL", 290, 294], ["FITC", "CHEMICAL", 338, 342], ["Cells", "CELL", 0, 5], ["rat", "ORGANISM", 45, 48], ["IgG", "GENE_OR_GENE_PRODUCT", 60, 63], ["cell", "CELL", 82, 86], ["Ly6G FITC", "GENE_OR_GENE_PRODUCT", 107, 116], ["1A8", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD11b PE", "GENE_OR_GENE_PRODUCT", 124, 132], ["CD45", "GENE_OR_GENE_PRODUCT", 142, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 163, 166], ["Ly6C APC", "GENE_OR_GENE_PRODUCT", 202, 210], ["CD4", "GENE_OR_GENE_PRODUCT", 220, 223], ["FITC", "GENE_OR_GENE_PRODUCT", 245, 249], ["BM8", "GENE_OR_GENE_PRODUCT", 251, 254], ["APC", "GENE_OR_GENE_PRODUCT", 265, 268], ["CD11c FITC", "GENE_OR_GENE_PRODUCT", 284, 294], ["CD4 FITC", "GENE_OR_GENE_PRODUCT", 334, 342], ["hamster", "ORGANISM", 363, 370], ["CD80", "GENE_OR_GENE_PRODUCT", 390, 394], ["fluorescently tagged rat anti\u2010mouse IgG", "PROTEIN", 24, 63], ["cell surface antibodies", "PROTEIN", 82, 105], ["Ly6G FITC", "PROTEIN", 107, 116], ["1A8", "PROTEIN", 118, 121], ["CD11b PE", "PROTEIN", 124, 132], ["M1", "PROTEIN", 134, 136], ["70", "PROTEIN", 137, 139], ["CD45 BV510", "PROTEIN", 142, 152], ["F11", "PROTEIN", 157, 160], ["CD8", "PROTEIN", 163, 166], ["Cy7", "PROTEIN", 170, 173], ["BD Biosciences", "PROTEIN", 185, 199], ["Ly6C APC", "CELL_LINE", 202, 210], ["HK1.4", "PROTEIN", 212, 217], ["CD4 BV785", "PROTEIN", 220, 229], ["RM4", "PROTEIN", 231, 234], ["F4", "PROTEIN", 239, 241], ["BM8", "PROTEIN", 251, 254], ["I\u2010A", "CELL_LINE", 257, 260], ["I\u2010E APC", "CELL_LINE", 261, 268], ["M5", "PROTEIN", 270, 272], ["CD11c FITC", "PROTEIN", 284, 294], ["N418", "CELL_LINE", 296, 300], ["Biolegend", "PROTEIN", 303, 312], ["CA", "CELL_LINE", 325, 327], ["CD4 FITC", "PROTEIN", 334, 342], ["RM4\u20105", "CELL_LINE", 344, 349], ["Armenian hamster anti\u2010mouse IgG", "PROTEIN", 354, 385], ["CD80", "PROTEIN", 390, 394], ["Cy5.5", "PROTEIN", 401, 406], ["BD Biosciences", "PROTEIN", 418, 432], ["rat", "SPECIES", 45, 48], ["hamster", "SPECIES", 363, 370], ["rat", "SPECIES", 45, 48], ["hamster", "SPECIES", 363, 370], ["fluorescently tagged rat anti\u2010mouse IgG", "TEST", 24, 63], ["cell surface antibodies", "TEST", 82, 105], ["Ly6G FITC", "TEST", 107, 116], ["CD11b PE", "TEST", 124, 132], ["M1", "TEST", 134, 136], ["CD45 BV510", "TEST", 142, 152], ["CD8 PE", "TEST", 163, 169], ["Cy7", "TEST", 170, 173], ["BD Biosciences", "TEST", 185, 199], ["Ly6C APC", "TEST", 202, 210], ["HK1.4", "TEST", 212, 217], ["CD4", "TEST", 220, 223], ["F4", "TEST", 239, 241], ["FITC", "TEST", 245, 249], ["BM8", "TEST", 251, 254], ["I\u2010", "TEST", 257, 259], ["APC", "TEST", 265, 268], ["M5", "TEST", 270, 272], ["CD11c FITC", "TEST", 284, 294], ["Biolegend", "TEST", 303, 312], ["CA", "TEST", 325, 327], ["CD4 FITC", "TEST", 334, 342], ["Armenian hamster anti\u2010mouse IgG", "TEST", 354, 385], ["Cy5.5", "TEST", 401, 406], ["PE", "OBSERVATION", 130, 132], ["Ly6C", "ANATOMY", 202, 206]]], ["A full description of gating strategies for flow cytometric staining and intracellular cytokine staining is provided in the Supporting Information Figs.", [["intracellular", "ANATOMY", 73, 86], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 86], ["cytokine", "PROTEIN", 87, 95], ["flow cytometric staining", "TEST", 44, 68], ["intracellular cytokine staining", "TEST", 73, 104], ["cytokine staining", "OBSERVATION", 87, 104]]], ["S1\u2013S4.Ex vivo peptide restimulation ::: Materials and methodsSpinal Isolated spinal cord leukocytes that were isolated using a Percoll gradient as above, were stimulated with MOG35\u201355 peptide or 50 ng/mL PMA (Sigma, St. Louis, MO) with 2 ug/mL Ionomycin (Sigma, St. Louis, MO) and BD Cytofix/Cytoperm Plus Fixation/Permeabilization Kit (with BD GolgiPlug protein transport inhibitor containing brefeldin A) (BD Biosciences, San Jose, CA) and incubated at 37\u00b0C for 6 hours or 5 hours, respectively.", [["Spinal", "ANATOMY", 61, 67], ["spinal cord leukocytes", "ANATOMY", 77, 99], ["PMA", "CHEMICAL", 204, 207], ["Ionomycin", "CHEMICAL", 244, 253], ["brefeldin A", "CHEMICAL", 394, 405], ["PMA", "CHEMICAL", 204, 207], ["Ionomycin", "CHEMICAL", 244, 253], ["brefeldin A", "CHEMICAL", 394, 405], ["S1\u2013S4", "GENE_OR_GENE_PRODUCT", 0, 5], ["spinal cord leukocytes", "CELL", 77, 99], ["PMA", "SIMPLE_CHEMICAL", 204, 207], ["Sigma", "SIMPLE_CHEMICAL", 209, 214], ["Ionomycin", "SIMPLE_CHEMICAL", 244, 253], ["brefeldin A", "SIMPLE_CHEMICAL", 394, 405], ["S1", "PROTEIN", 0, 2], ["spinal cord leukocytes", "CELL_TYPE", 77, 99], ["methodsSpinal Isolated spinal cord leukocytes", "PROBLEM", 54, 99], ["a Percoll gradient", "TREATMENT", 125, 143], ["MOG35", "TREATMENT", 175, 180], ["BD Cytofix", "TREATMENT", 281, 291], ["Cytoperm", "TREATMENT", 292, 300], ["Fixation/Permeabilization Kit", "TREATMENT", 306, 335], ["BD GolgiPlug protein transport inhibitor", "TREATMENT", 342, 382], ["S4", "OBSERVATION", 3, 5], ["Spinal", "ANATOMY", 61, 67], ["spinal cord", "ANATOMY", 77, 88]]], ["Cells were stained the surface marker CD4 (eBiosciences, San Diego, CA) and for intracellular cytokines including Rat anti\u2010mouse IgG, IL\u201017A (eBiosciences, San Diego, CA) and IFN\u2010\u03b3 (BD Biosciences).Quantitative real\u2010time PCR ::: Materials and methodsTotal cDNA from brains and spinal cords of sham and EAE immunized mice at day 12 following disease induction was generated via Superscript III (Life Tech., Carlsbad, CA) following homogenization in Trizol (Life Tech., Carlsbad, CA).Quantitative real\u2010time PCR ::: Materials and methodsExpression of mRNA from defined mouse chemokine and cytokine genes including Cxcl1, Cxcl2, Cxcl10, Ccl2, Ccl5, IFN\u2010\u03b3, and IL\u201017A within the brain of experimental mice was determined by qPCR using SYBR Green I Master (Roche) on a LightCycler 480 (Roche) and normalized to \u03b2\u2010actin 59.Histology ::: Materials and methodsMice were euthanized according to IACUC guidelines and spinal cords were removed, fixed overnight in 4% paraformaldehyde (PFA) at 4\u00b0C and separated into eight 1.5 mm sections.", [["Cells", "ANATOMY", 0, 5], ["surface", "ANATOMY", 23, 30], ["intracellular", "ANATOMY", 80, 93], ["brains", "ANATOMY", 266, 272], ["spinal cords", "ANATOMY", 277, 289], ["brain", "ANATOMY", 674, 679], ["spinal cords", "ANATOMY", 906, 918], ["sections", "ANATOMY", 1017, 1025], ["paraformaldehyde", "CHEMICAL", 955, 971], ["PFA", "CHEMICAL", 973, 976], ["Cells", "CELL", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 38, 41], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["IL\u201017A", "GENE_OR_GENE_PRODUCT", 134, 140], ["CA", "GENE_OR_GENE_PRODUCT", 167, 169], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 175, 180], ["brains", "MULTI-TISSUE_STRUCTURE", 266, 272], ["spinal cords", "MULTI-TISSUE_STRUCTURE", 277, 289], ["mice", "ORGANISM", 316, 320], ["mouse", "ORGANISM", 566, 571], ["Cxcl1", "GENE_OR_GENE_PRODUCT", 611, 616], ["Cxcl2", "GENE_OR_GENE_PRODUCT", 618, 623], ["Cxcl10", "GENE_OR_GENE_PRODUCT", 625, 631], ["Ccl2", "GENE_OR_GENE_PRODUCT", 633, 637], ["Ccl5", "GENE_OR_GENE_PRODUCT", 639, 643], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 645, 650], ["IL\u201017A", "GENE_OR_GENE_PRODUCT", 656, 662], ["brain", "ORGAN", 674, 679], ["mice", "ORGANISM", 696, 700], ["\u03b2\u2010actin 59", "GENE_OR_GENE_PRODUCT", 805, 815], ["Mice", "ORGANISM", 851, 855], ["spinal cords", "ORGAN", 906, 918], ["paraformaldehyde", "SIMPLE_CHEMICAL", 955, 971], ["PFA", "SIMPLE_CHEMICAL", 973, 976], ["CD4", "PROTEIN", 38, 41], ["eBiosciences", "PROTEIN", 43, 55], ["CA", "PROTEIN", 68, 70], ["intracellular cytokines", "PROTEIN", 80, 103], ["Rat anti\u2010mouse IgG", "PROTEIN", 114, 132], ["IL\u201017A", "PROTEIN", 134, 140], ["eBiosciences", "PROTEIN", 142, 154], ["CA", "PROTEIN", 167, 169], ["IFN\u2010\u03b3", "PROTEIN", 175, 180], ["BD Biosciences", "PROTEIN", 182, 196], ["mRNA", "RNA", 548, 552], ["mouse chemokine", "PROTEIN", 566, 581], ["cytokine genes", "DNA", 586, 600], ["Cxcl1", "PROTEIN", 611, 616], ["Cxcl2", "DNA", 618, 623], ["Cxcl10", "DNA", 625, 631], ["Ccl2", "DNA", 633, 637], ["Ccl5", "DNA", 639, 643], ["IFN\u2010\u03b3", "DNA", 645, 650], ["IL\u201017A", "DNA", 656, 662], ["\u03b2\u2010actin 59", "PROTEIN", 805, 815], ["mice", "SPECIES", 316, 320], ["mouse", "SPECIES", 566, 571], ["mice", "SPECIES", 696, 700], ["Mice", "SPECIES", 851, 855], ["mice", "SPECIES", 316, 320], ["mouse", "SPECIES", 566, 571], ["mice", "SPECIES", 696, 700], ["eBiosciences", "TEST", 43, 55], ["CA", "TEST", 68, 70], ["intracellular cytokines", "TEST", 80, 103], ["Rat anti\u2010mouse IgG", "TEST", 114, 132], ["Quantitative real\u2010time PCR", "TEST", 198, 224], ["Total cDNA", "TEST", 250, 260], ["disease induction", "TREATMENT", 341, 358], ["Trizol", "TREATMENT", 448, 454], ["Quantitative real\u2010time PCR", "TEST", 482, 508], ["cytokine genes", "TEST", 586, 600], ["Cxcl1", "TEST", 611, 616], ["Cxcl2", "TEST", 618, 623], ["Cxcl10", "TEST", 625, 631], ["Ccl2", "TEST", 633, 637], ["Ccl5", "TEST", 639, 643], ["IFN\u2010\u03b3", "TEST", 645, 650], ["IL", "TEST", 656, 658], ["a LightCycler", "TEST", 761, 774], ["\u03b2\u2010actin", "TEST", 805, 812], ["4% paraformaldehyde (PFA)", "TREATMENT", 952, 977], ["spinal cords", "ANATOMY", 277, 289], ["sham", "ANATOMY", 293, 297], ["mouse chemokine", "OBSERVATION", 566, 581], ["cytokine genes", "OBSERVATION", 586, 600], ["brain", "ANATOMY", 674, 679], ["spinal cords", "ANATOMY", 906, 918]]], ["Each section was cryoprotected in 30% sucrose for five days before embedding in OCT; 8 \u03bcM thick coronal sections were cut and stained with luxol fast blue (LFB) combined with H&E. Pathology scoring of spinal cord sections was performed using previously described methods; a minimum number of three mice/group with 6\u20138 section/mouse assessed 60.", [["coronal sections", "ANATOMY", 96, 112], ["spinal cord sections", "ANATOMY", 201, 221], ["sucrose", "CHEMICAL", 38, 45], ["luxol fast blue", "CHEMICAL", 139, 154], ["sucrose", "CHEMICAL", 38, 45], ["sucrose", "SIMPLE_CHEMICAL", 38, 45], ["coronal sections", "MULTI-TISSUE_STRUCTURE", 96, 112], ["luxol fast blue", "SIMPLE_CHEMICAL", 139, 154], ["LFB", "SIMPLE_CHEMICAL", 156, 159], ["spinal cord sections", "MULTI-TISSUE_STRUCTURE", 201, 221], ["mice", "ORGANISM", 298, 302], ["mouse", "ORGANISM", 326, 331], ["mice", "SPECIES", 298, 302], ["mouse", "SPECIES", 326, 331], ["mice", "SPECIES", 298, 302], ["mouse", "SPECIES", 326, 331], ["OCT", "TEST", 80, 83], ["H&E", "TREATMENT", 175, 178], ["Pathology scoring of spinal cord sections", "TEST", 180, 221], ["spinal cord", "ANATOMY", 201, 212]]], ["In brief, for scoring of spinal cord section, each spinal cord section was divided into four quadrants (the ventral funiculus, the dorsal funiculus, and each lateral funiculus) 60; any quadrant containing demyelination, meningeal infiltration, or perivascular cuffing was given a score of 1 in that pathological class.", [["spinal cord section", "ANATOMY", 25, 44], ["spinal cord", "ANATOMY", 51, 62], ["ventral funiculus", "ANATOMY", 108, 125], ["dorsal funiculus", "ANATOMY", 131, 147], ["lateral funiculus", "ANATOMY", 158, 175], ["meningeal", "ANATOMY", 220, 229], ["perivascular", "ANATOMY", 247, 259], ["demyelination", "DISEASE", 205, 218], ["meningeal infiltration", "DISEASE", 220, 242], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 25, 36], ["spinal cord", "ORGAN", 51, 62], ["ventral funiculus", "MULTI-TISSUE_STRUCTURE", 108, 125], ["dorsal funiculus", "MULTI-TISSUE_STRUCTURE", 131, 147], ["lateral funiculus", "MULTI-TISSUE_STRUCTURE", 158, 175], ["scoring of spinal cord section", "TEST", 14, 44], ["each spinal cord section", "TREATMENT", 46, 70], ["any quadrant containing demyelination", "PROBLEM", 181, 218], ["meningeal infiltration", "PROBLEM", 220, 242], ["perivascular cuffing", "PROBLEM", 247, 267], ["spinal cord", "ANATOMY", 25, 36], ["spinal cord", "ANATOMY", 51, 62], ["ventral", "ANATOMY_MODIFIER", 108, 115], ["funiculus", "ANATOMY_MODIFIER", 116, 125], ["dorsal funiculus", "ANATOMY", 131, 147], ["quadrant", "ANATOMY", 185, 193], ["demyelination", "OBSERVATION", 205, 218], ["meningeal", "ANATOMY", 220, 229], ["infiltration", "OBSERVATION", 230, 242], ["perivascular", "ANATOMY_MODIFIER", 247, 259], ["cuffing", "OBSERVATION", 260, 267]]], ["The total number of positive quadrants for each pathological class was determined and then divided by the total number of quadrants present on the slide and multiplied by 100 to give the percent involvement for each pathological class.Immunofluorescence ::: Materials and methodsSpinal cord sections were processed as described above.", [["Spinal cord sections", "ANATOMY", 279, 299], ["Spinal cord sections", "MULTI-TISSUE_STRUCTURE", 279, 299], ["Spinal cord sections", "TEST", 279, 299], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["positive quadrants", "OBSERVATION_MODIFIER", 20, 38], ["Spinal cord", "ANATOMY", 279, 290]]], ["For immunofluorescence, slides were first desiccated for two hours and blocked with 5% Normal Donkey Serum with or without 0.3% Triton\u2010X 100.", [["Triton\u2010X", "CHEMICAL", 128, 136], ["Serum", "ORGANISM_SUBSTANCE", 101, 106], ["immunofluorescence", "TEST", 4, 22], ["slides", "TEST", 24, 30]]], ["Primary antibodies were incubated overnight at 4\u00b0C: goat anti\u2010CXCL1 1:50 (R&D Systems, Minneapolis, MN), rabbit anti\u2010GFAP 1:500 (Life Technologies, Carlsbad, CA), and rat anti\u2010Ly6B.2 1:100 (Serotec, Raleigh, NC).", [["goat", "ORGANISM", 52, 56], ["rabbit", "ORGANISM", 105, 111], ["GFAP", "GENE_OR_GENE_PRODUCT", 117, 121], ["rat", "ORGANISM", 167, 170], ["Serotec", "GENE_OR_GENE_PRODUCT", 190, 197], ["antibodies", "PROTEIN", 8, 18], ["GFAP 1:500", "PROTEIN", 117, 127], ["goat", "SPECIES", 52, 56], ["rabbit", "SPECIES", 105, 111], ["rat", "SPECIES", 167, 170], ["rabbit", "SPECIES", 105, 111], ["Primary antibodies", "TEST", 0, 18], ["GFAP", "TEST", 117, 121], ["Carlsbad", "TEST", 148, 156], ["CA", "TEST", 158, 160], ["NC", "ANATOMY", 208, 210]]], ["Images were analyzed using the Image J software (NIH) according to previously described methods 61, 62.", [["Images", "TEST", 0, 6]]], ["Quantification of Ly6B.2\u2010positive cells within spinal cords of experimental mice was determined by counting cells in a minimum of five spinal cord sections/per mouse with a minimum of three mice per group.Antibody administration ::: Materials and methodsRabbit polyclonal antiserum was generated to a 17\u2010amino acid portion of the amino\u2010terminus ligand\u2010binding domain of specific for mouse CXCR2 (MGEFKVDKFNIEDFFSG) (Cocalico Biologicals, Inc., Stevens, PA) and used to target neutrophils as previously described has been previously described 9, 32, 55.", [["Ly6B.2\u2010positive cells", "ANATOMY", 18, 39], ["spinal cords", "ANATOMY", 47, 59], ["cells", "ANATOMY", 108, 113], ["spinal cord sections", "ANATOMY", 135, 155], ["neutrophils", "ANATOMY", 476, 487], ["amino\u2010terminus", "CHEMICAL", 330, 344], ["Ly6B.2\u2010positive cells", "CELL", 18, 39], ["spinal cords", "ORGAN", 47, 59], ["mice", "ORGANISM", 76, 80], ["cells", "CELL", 108, 113], ["spinal cord sections", "MULTI-TISSUE_STRUCTURE", 135, 155], ["mouse", "ORGANISM", 160, 165], ["mice", "ORGANISM", 190, 194], ["Rabbit", "ORGANISM", 254, 260], ["mouse", "ORGANISM", 383, 388], ["CXCR2", "GENE_OR_GENE_PRODUCT", 389, 394], ["neutrophils", "CELL", 476, 487], ["Ly6B.2\u2010positive cells", "CELL_LINE", 18, 39], ["17\u2010amino acid portion", "PROTEIN", 301, 322], ["amino\u2010terminus ligand\u2010binding domain", "PROTEIN", 330, 366], ["mouse CXCR2", "PROTEIN", 383, 394], ["MGEFKVDKFNIEDFFSG", "PROTEIN", 396, 413], ["neutrophils", "CELL_TYPE", 476, 487], ["mice", "SPECIES", 76, 80], ["mouse", "SPECIES", 160, 165], ["mice", "SPECIES", 190, 194], ["Rabbit", "SPECIES", 254, 260], ["mouse", "SPECIES", 383, 388], ["mice", "SPECIES", 76, 80], ["mouse", "SPECIES", 160, 165], ["mice", "SPECIES", 190, 194], ["Rabbit", "SPECIES", 254, 260], ["mouse", "SPECIES", 383, 388], ["Quantification", "TEST", 0, 14], ["Ly6B.2\u2010positive cells", "PROBLEM", 18, 39], ["Antibody administration", "TREATMENT", 205, 228], ["methodsRabbit polyclonal antiserum", "TEST", 247, 281], ["Cocalico Biologicals", "TREATMENT", 416, 436], ["\u2010positive cells", "OBSERVATION", 24, 39], ["spinal cords", "ANATOMY", 47, 59], ["experimental mice", "OBSERVATION", 63, 80], ["spinal cord", "ANATOMY", 135, 146], ["neutrophils", "OBSERVATION", 476, 487]]], ["Normal rabbit serum (NRS) from preimmunized rabbits was used as controls.", [["serum", "ANATOMY", 14, 19], ["rabbit", "ORGANISM", 7, 13], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["NRS", "CELL", 21, 24], ["rabbits", "ORGANISM", 44, 51], ["rabbit", "SPECIES", 7, 13], ["rabbits", "SPECIES", 44, 51], ["rabbit", "SPECIES", 7, 13], ["rabbits", "SPECIES", 44, 51], ["preimmunized rabbits", "TREATMENT", 31, 51], ["rabbit", "OBSERVATION_MODIFIER", 7, 13], ["serum", "OBSERVATION_MODIFIER", 14, 19]]], ["Experimental mice were injected i.p. with 0.5 mL with either anti\u2010CXCR2 or NRS every 2\u20133 days starting on day 9 following EAE induction and ending on or before day 19.Statistical analysis ::: Materials and methodsFlow cytometric data were analyzed with FlowJo (Tree Star Inc.) and an unpaired Student's t\u2010test was used, with a p < 0.05 being considered as significant.Conflict of interestThe authors declare no commercial or financial conflict of interest.", [["mice", "ORGANISM", 13, 17], ["anti\u2010CXCR2", "SIMPLE_CHEMICAL", 61, 71], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["Experimental mice", "TREATMENT", 0, 17], ["anti\u2010CXCR2", "TREATMENT", 61, 71], ["NRS", "TREATMENT", 75, 78], ["EAE induction", "TREATMENT", 122, 135], ["Flow cytometric data", "TEST", 213, 233], ["an unpaired Student's t\u2010test", "TEST", 281, 309]]]], "PMC7254972": [["Until 2019, the changing EU stance towards China was rather low profile and indirect, but this has changed with the publication of the strong-worded Strategic Outlook and the implementation of an EU investment screening framework.IntroductionUntil the beginning of 2018, China\u2019s self-confident international posturing, which reached a temporary apex at the 2017 Chinese Communist Party congress, where the Chinese president and party leader Xi Jinping boasted China\u2019s world power status, had led to decreased willingness to compromise and refusal to seek out common positions with the EU.", [["posturing", "DISEASE", 308, 317]]], ["The 2016 and 2017 EU-China summit meetings did not produce a joint statement, due to disagreements over trade affairs and the question of China\u2019s market economy status.", [["joint", "ANATOMY", 61, 66]]], ["China realized it urgently needed to improve its relationship with the EU, in order to prevent a simultaneous deterioration of the relationships with its most important trading partners.IntroductionThe Chinese rapprochement is taking place during a time of a determined European China policy readjustment.", [["a simultaneous deterioration of the relationships", "PROBLEM", 95, 144], ["European China policy readjustment", "TREATMENT", 270, 304], ["simultaneous", "OBSERVATION_MODIFIER", 97, 109], ["deterioration", "OBSERVATION", 110, 123]]], ["Amid the outbreak of the COVID-19 pandemic, which has created new uncertainties and risks domestically as well as globally, how will this readjustment affect China\u2019s assessment of the relationship vis-\u00e0-vis key issues and the overall development trend after the EU leadership change?China\u2019s rapprochement amid EU\u2019s policy readjustment2018 was a year of rapprochement between China and the EU.", [["the COVID", "TEST", 21, 30], ["new", "OBSERVATION_MODIFIER", 62, 65], ["uncertainties", "OBSERVATION_MODIFIER", 66, 79]]], ["Against the background of Trump-infused uncertainties in international affairs, Chinese officials made several rhetorical efforts to demonstrate commonalities and alignments on global issues, such as climate protection, multilateralism and free trade.", [["global issues", "PROBLEM", 177, 190], ["climate protection", "TREATMENT", 200, 218], ["multilateralism", "TREATMENT", 220, 235]]], ["During a press conference at the National People\u2019s Congress in March 2018, China\u2019s foreign minister, Wang Yi, identified global governance as a promising field of cooperation between both actors with the aim to safeguard the global free trade system (Wang 2018).China\u2019s rapprochement amid EU\u2019s policy readjustmentDuring the EU-China summit in July 2018, both agreed on a joint statement in which the Europeans were able to include several key points regarding multilateralism and a reference to a rules-based order.", [["People", "SPECIES", 42, 48], ["joint", "ANATOMY", 371, 376]]], ["The policy paper put heavy emphasis on global interconnectedness and interdependence, which was seen to be challenged by the unholy alliance of \u201cunilateralism\u201d, \u201cprotectionism\u201d and \u201cde-globalization\u201d\u2014an indirect reference to Trump\u2019s foreign policy.", [["unilateralism", "DISEASE", 145, 158]]], ["It urged the EU and China to consider their \u201cextensive common interests\u201d and jointly promote multilateralism and an open, inclusive and balanced economic globalization (\u201cFull text of China\u2019s Policy Paper on the European Union\u201d 2018).China\u2019s rapprochement amid EU\u2019s policy readjustmentThe publication of the Strategic Outlook in March 2019, which defined China as a partner, competitor and rival and questioned the balance between challenges and opportunities presented by China, however, did not fit well into the Chinese narrative of the EU and China as \u201cdefenders of multilateralism\u201d or \u201canchors of stability\u201d, who together elevate the relationship and resist (US) \u201cunilateralism, protectionism and de-globalization\u201d.", [["unilateralism", "DISEASE", 668, 681], ["protectionism", "DISEASE", 683, 696]]], ["Already in 2017, a prominent think-tank expert identified the emergence of a new European stance towards China, which could \u201cimpose complications\u201d (Cui 2018).", [["prominent", "OBSERVATION_MODIFIER", 19, 28]]], ["The changing European attitude towards China is attributed to an unstable international environment, internal challenges to European unity, and a shifting balance within the EU-China relationship in economic competitiveness favouring China (Sun 2018).", [["an unstable international environment", "PROBLEM", 62, 99], ["unstable", "OBSERVATION", 65, 73]]], ["According to this assessment, the EU is entirely responsible for complicating the relationship and it is up to Brussels to decide how to go on with it.Chinese view of current key issuesWhile there are unresolved long-term disputes between the EU and China over a European arms embargo, human rights and China\u2019s trade practices and market economy status, the recent European readjustment of its relationship with China has created new disagreements and even tensions across a range of issues, particularly in areas like connectivity, investment screening and 5G.Chinese view of current key issuesThe European perception of the Chinese connectivity initiative, the Belt and Road Initiative (in short BRI), has changed from cautiously positive in the beginning to rather negative at the moment.", [["human", "ORGANISM", 286, 291], ["human", "SPECIES", 286, 291], ["human", "SPECIES", 286, 291], ["this assessment", "TEST", 13, 28], ["a European arms embargo", "TREATMENT", 261, 284], ["investment screening", "TEST", 533, 553], ["cautiously positive", "PROBLEM", 721, 740], ["unresolved", "OBSERVATION_MODIFIER", 201, 211], ["long-term", "OBSERVATION_MODIFIER", 212, 221], ["new", "OBSERVATION_MODIFIER", 430, 433], ["disagreements", "OBSERVATION", 434, 447]]], ["Chinese commentators explain the European hesitance to endorse the BRI by pointing out exaggerated worries about its geopolitical implications.", [["exaggerated worries", "PROBLEM", 87, 106]]], ["One researcher even suggests that framing BRI as a threat might contribute to European cohesion (Cui 2019a).Chinese view of current key issuesIn autumn 2018, the EU has announced its own connectivity initiative, which seeks to promote connectivity with \u201cEuropean characteristics\u201d, emphasizing sustainability, comprehensiveness and rules\u2014attributes often seen as missing in the BRI.", [["BRI", "PROTEIN", 42, 45], ["BRI", "DNA", 377, 380]]], ["China\u2019s reaction to the European connectivity initiative has been rather reserved.", [["China\u2019s reaction", "PROBLEM", 0, 16], ["the European connectivity initiative", "TREATMENT", 20, 56]]], ["The Chinese Foreign Ministry commented in cryptic words that it hopes the EU will \u201cplay a constructive role in advancing the Eurasian connectivity and send out the positive signal of promoting economic cooperation among the Eurasian countries\u201d (Ministry of Foreign Affairs of the People\u2019s Republic of China 2020).", [["People", "SPECIES", 280, 286], ["Foreign Ministry", "OBSERVATION", 12, 28]]], ["However, as two academics cautioned, should one side read too much into \u201cstrategic intentions\u201d or \u201cdeliberately distort\u201d the initiatives, bridging the two connectivity initiatives might become very difficult, and it could eventually become a new point of disagreement between the two actors (Fang and Yin 2019).Chinese view of current key issuesThe EU investment screening framework, which was implemented in March 2019, is often regarded as a reaction to a surge of Chinese investment and the take-over of several European high-tech companies.", [["a reaction", "PROBLEM", 442, 452], ["Chinese investment", "TREATMENT", 467, 485]]], ["After years of asking the Chinese side to grant more market access to European businesses and failed promises by the Chinese government to do so, the implementation of the screening framework is also an attempt to create more reciprocity by restricting access to the European market, while at the same time pushing China to open up its own.Chinese view of current key issuesThe Chinese government was, of course, not very happy about the European plan to better control foreign investments.", [["the screening framework", "TEST", 168, 191]]], ["These demands must have sounded very familiar to European ears, for it were EU representatives which used to present them to their Chinese interlocutors (and they still do).", [["ears", "ORGAN", 58, 62]]], ["Remarks by the Chinese envoy to the EU, who rejected \u201cabsolute reciprocity\u201d and vaguely stated that China will eventually open up, but according to its own initiative, further contributed to this rhetorical stalemate (Zhang 2019).Chinese view of current key issuesDespite these diplomatic antics, two studies by experts affiliated to the Chinese Academy of Social Sciences (CASS) about the investment screening framework show a different picture.", [["the investment screening framework", "TEST", 386, 420], ["a different picture", "PROBLEM", 426, 445]]], ["According to them, the framework itself seems not very threatening.", [["very threatening", "PROBLEM", 50, 66], ["seems not", "UNCERTAINTY", 40, 49]]], ["They point out the relative weakness of the framework compared with similar ones in the USA or Australia, and they expect Chinese investment into the EU to grow and to also flow into European high-tech sectors.", [["the relative weakness of the framework", "PROBLEM", 15, 53], ["weakness", "OBSERVATION", 28, 36]]], ["However, experts are wary of the implications the Europe-wide screening might have for Chinese investment, for it could trigger more restrictions and the establishment of screening mechanisms in more member states as well as increase the sensitivity of Chinese investments into the EU (Hu 2019).", [["wide screening", "TEST", 57, 71]]], ["More importantly, they see the investment screening as a part of a larger European policy readjustment, in which Europe choses \u201cselective trade protectionism\u201d instead of \u201cunilateral market openness\u201d (Ye 2019).Chinese view of current key issuesIn early 2019, US representatives have increased their efforts to convince European countries to exclude the Chinese telecommunication equipment producer Huawei from their future 5G infrastructure, due to security concerns, including Huawei\u2019s relationship with Chinese state security organs.", [["organs", "ANATOMY", 527, 533], ["organs", "ORGAN", 527, 533], ["the investment screening", "TEST", 27, 51], ["a larger European policy readjustment", "TREATMENT", 65, 102]]], ["Since then, the EU has published two reports on the possible risks and mitigation of risks regarding cybersecurity.", [["cybersecurity", "DISEASE", 101, 114], ["cybersecurity", "PROBLEM", 101, 114]]], ["Despite the clear China reference, the issue is far from settled and several member states are undecided whether or not to allow Huawei to participate in the public tender.", [["the public tender", "PROBLEM", 154, 171]]], ["Ironically, China has asked to refrain from politicizing cyber security, abusing and \u201cunilateralizing\u201d the concept of national security, and warns that arguing on these grounds could eventually create a precedent for future restrictions on other products (Ministry of Foreign Affairs of the People\u2019s Republic of China 2019a).", [["People", "SPECIES", 291, 297]]], ["To underline this point, Chinese ambassadors in several European countries have made public efforts to defend Huawei and even offered veiled threats, stating that in case European lawmakers decide to not allow Huawei to participate in building 5G networks in Europe, European countries might expect retaliation (Shi 2019).Chinese view of current key issuesChinese academics regard the issue surrounding Huawei as an indicator of persistent US influence in Europe.", [["Huawei", "CHEMICAL", 110, 116], ["5G networks", "MULTI-TISSUE_STRUCTURE", 244, 255], ["persistent", "OBSERVATION_MODIFIER", 429, 439]]], ["According to this view, the EU is facing US pressure to deny Huawei the participation in the build-up of the European 5G network.", [["5G network", "MULTI-TISSUE_STRUCTURE", 118, 128]]], ["In this context, some experts see Europe striving for strategic autonomy vis-\u00e0-vis the USA, while others warn about the consequences of siding with the Americans, for such an inclination could possibly be the beginning of a new Cold War (Cui 2019b).The impact of the COVID-19 crisis on EU-China relationsThe outbreak of the COVID-19 virus pandemic in Europe has altered the dynamic of the EU-China relationship.", [["COVID-19 virus", "CHEMICAL", 324, 338], ["COVID-19 virus", "ORGANISM", 324, 338], ["19 virus pandemic", "SPECIES", 330, 347], ["COVID-19 virus", "SPECIES", 324, 338], ["the COVID", "TREATMENT", 263, 272], ["the COVID", "TEST", 320, 329]]], ["Not only has it prevented a first meeting of the new European leadership with their Chinese counterparts in late March, it has also exposed a high dependence on Chinese produced medical equipment and highlighted China\u2019s diplomatic assertiveness.", [["high dependence", "OBSERVATION_MODIFIER", 142, 157]]], ["Initially, China\u2019s response was welcomed by the EU, despite it bypassing EU institutions, but its positive image as a generous partner was subsequently tainted, when some Chinese officials deliberately promoted conspiracy theories, aggressively spread disinformation and lobbied European politicians to publicly laud China\u2019s management of the crisis.The impact of the COVID-19 crisis on EU-China relationsChinese officials have put forward a narrative which highlights China\u2019s frontline role in combating the \u201cthreat to humanity\u201d, while at the same time calling for international solidarity and multilateralism.", [["multilateralism", "DISEASE", 595, 610], ["the crisis", "PROBLEM", 339, 349], ["the COVID", "TREATMENT", 364, 373]]], ["This tale also handily passes over questions regarding shortcomings in China\u2019s own handling of the crisis during the early stages of the outbreak.The impact of the COVID-19 crisis on EU-China relationsWhile the key issues in the relationship that existed at the start of the pandemic have not changed, the new crisis-driven dynamic might have solidified the negative perceptions of China in the EU, and the emerging trend towards a realistic assessment of the relationship appears to have been reinforced by China\u2019s capricious handling of the crisis and its diplomatic behaviour.", [["the crisis", "PROBLEM", 95, 105], ["the COVID", "TREATMENT", 160, 169], ["the new crisis", "PROBLEM", 302, 316], ["a realistic assessment", "TEST", 430, 452], ["the crisis", "PROBLEM", 539, 549], ["new", "OBSERVATION_MODIFIER", 306, 309], ["crisis", "OBSERVATION", 310, 316]]], ["Shortly after the outbreak of the virus, several EU and member state officials called for reducing reliance on China for medical supplies and for relocating production and supply chains.", [["medical supplies", "TREATMENT", 121, 137], ["relocating production and supply chains", "TREATMENT", 146, 185]]], ["At the same time, some member states have tightened investment screening regulations and the EU Competition Commissioner has recommended buying stakes in key companies, if necessary, to forestall possible takeovers by Chinese companies.The impact of the COVID-19 crisis on EU-China relationsChinese experts on the EU have recognized the shifting European perceptions due to China\u2019s \u201cpolitics of generosity\u201d and argued that China should be more sensitive about European unity and not create an impression that China is taking advantage of the situation (Feng 2020).", [["the COVID", "TREATMENT", 250, 259]]], ["A common concern among the expert community is the question surrounding the economic and trade relationship\u2014and particularly a possible relocation of production and supply chains.", [["production and supply chains", "PROBLEM", 150, 178], ["supply chains", "OBSERVATION", 165, 178]]], ["A prominent CASS researcher points out that a large-scale relocation seems unlikely, but the question ultimately depends on how both sides cooperate during the crisis (Zhou 2020).Looking forward: emerging trends in EU-China relationsThe global pandemic has hit EU-China relations at a sensitive time.", [["a large-scale relocation", "PROBLEM", 44, 68], ["prominent", "OBSERVATION_MODIFIER", 2, 11], ["CASS", "OBSERVATION", 12, 16], ["large", "OBSERVATION_MODIFIER", 46, 51], ["seems unlikely", "UNCERTAINTY", 69, 83], ["global", "OBSERVATION_MODIFIER", 237, 243], ["pandemic", "OBSERVATION_MODIFIER", 244, 252]]], ["The EU leadership change has ushered into a new period of difficult readjustment of the bloc\u2019s relationship with China.", [["the bloc", "TREATMENT", 84, 92], ["leadership change", "OBSERVATION", 7, 24], ["new", "OBSERVATION_MODIFIER", 44, 47]]], ["Furthermore, with high-level diplomatic arrangements in a state of limbo due to the impact of the global pandemic, it is doubtful whether the relationship will achieve the envisioned upgrade in (Ministry of Foreign Affairs of the People\u2019s Republic of China 2019b).Looking forward: emerging trends in EU-China relationsChinese experts are split about the future prospects of the EU-China relationship.", [["People", "SPECIES", 230, 236], ["high-level diplomatic arrangements", "PROBLEM", 18, 52], ["global", "OBSERVATION_MODIFIER", 98, 104], ["pandemic", "OBSERVATION", 105, 113]]], ["The possible extension of power by the EU institutions is identified by one expert as the biggest danger for a regression in the relationship (Yiwei 2019).", [["possible", "UNCERTAINTY", 4, 12], ["power", "OBSERVATION_MODIFIER", 26, 31]]], ["Striking a more optimistic note, another group claims that despite current problems, the bilateral trade will stabilize the relationship and converging interests on multilateralism and free trade will provide enough opportunities for cooperation.", [["current problems", "PROBLEM", 67, 83], ["bilateral", "ANATOMY_MODIFIER", 89, 98]]], ["Europe\u2019s quest for strategic autonomy is usually regarded as positive, since it could lead to a reduction in reliance on the USA\u2014which fits into China\u2019s long-held dream of Europe as an independent pole in a multipolar world.Looking forward: emerging trends in EU-China relationsAccording to the Chinese perspective, if the two sides really want to continue the development of the strategic partnership, they need to straighten out their \u201cmisperception\u201d, enhance \u201cstrategic mutual trust\u201d and the \u201cconsciousness of partnership\u201d.", [["reduction", "OBSERVATION_MODIFIER", 96, 105]]], ["However, one cannot help but notice the cognitive dissonance between what China says and China does, or promises to do.", [["the cognitive dissonance", "PROBLEM", 36, 60]]], ["Finally, it points out that a united Europe is in its interest, while bypassing the EU during its coronavirus \u201cmask diplomacy\u201d, threatening the said unity.Looking forward: emerging trends in EU-China relationsRegarding the biggest inhibiting factor for building mutual trust, the Chinese leadership has been very eager to signal to the new EU leadership right from the beginning that China\u2019s sovereignty and its internal affairs are off-limits for Europeans to comment on.", [["coronavirus", "ORGANISM", 98, 109], ["right", "ANATOMY_MODIFIER", 354, 359]]], ["Given the human rights violations in Xinjiang, the ever-shrinking space for China\u2019s civil society and the tense situation in Hong Kong, it\u2019s doubtful the Europeans will stop paying attention to these issues and unlikely that the two sides will overcome this mutual \u201ctrust deadlock\u201d any time soonLooking forward: emerging trends in EU-China relationsThe new EU leadership therefore should be aware that its relationship with a more confident China will grow more and more complex, selective and maybe even retaliatory.", [["human", "ORGANISM", 10, 15], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["new", "OBSERVATION_MODIFIER", 353, 356], ["more complex", "OBSERVATION_MODIFIER", 466, 478]]], ["Despite the ceasefire in the US-China trade war, the US-China relationship shows clear signs of further deterioration since the outbreak of the crisis.", [["the US", "TEST", 49, 55], ["further deterioration", "PROBLEM", 96, 117], ["the crisis", "PROBLEM", 140, 150], ["clear", "OBSERVATION", 81, 86], ["deterioration", "OBSERVATION", 104, 117]]], ["However, given the uncertainties about the overall damage to the European economy due to the virus and the divisions within the EU exposed by the crisis and exploited by China, the EU has to overcome its own internal inconsistencies and reevaluate a strategic hierarchy of policy goals it wants to achieve with China.", [["the overall damage", "PROBLEM", 39, 57], ["the virus", "PROBLEM", 89, 98], ["virus", "OBSERVATION", 93, 98], ["crisis", "OBSERVATION", 146, 152]]]], "a3728da499f468048be25b75d8c42a01b1ffbd73": [["BackgroundEnterococci are Gram-positive cocci which normally inhabit the intestinal tract of humans.", [["intestinal tract", "ANATOMY", 73, 89], ["intestinal tract", "ORGAN", 73, 89], ["humans", "ORGANISM", 93, 99], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99], ["BackgroundEnterococci", "PROBLEM", 0, 21], ["Gram-positive cocci", "PROBLEM", 26, 45], ["Enterococci", "OBSERVATION", 10, 21], ["Gram-positive cocci", "OBSERVATION", 26, 45], ["intestinal tract", "ANATOMY", 73, 89]]], ["E. faecalis and E. faecium are the most common strains.", [["E. faecalis", "ORGANISM", 0, 11], ["E. faecium", "ORGANISM", 16, 26], ["E. faecalis", "SPECIES", 0, 11], ["E. faecium", "SPECIES", 16, 26], ["E. faecalis", "SPECIES", 0, 11], ["E. faecium", "SPECIES", 16, 26], ["E. faecalis and E. faecium", "PROBLEM", 0, 26], ["faecalis", "OBSERVATION", 3, 11], ["E. faecium", "OBSERVATION_MODIFIER", 16, 26], ["most common", "OBSERVATION_MODIFIER", 35, 46]]], ["They started appearing as common pathogens in nosocomial infections in the 1970s.", [["nosocomial infections", "DISEASE", 46, 67], ["nosocomial infections", "PROBLEM", 46, 67], ["nosocomial", "OBSERVATION_MODIFIER", 46, 56], ["infections", "OBSERVATION", 57, 67]]], ["At the same time, antibiotic resistance among them started increasing [1] .", [["antibiotic resistance", "TREATMENT", 18, 39]]], ["Vancomycinresistant E. faecium (VRE-fm) are multi-drug resistant micro-organisms, and the treatment options and infection control measures are limited.", [["Vancomycinresistant", "CHEMICAL", 0, 19], ["VRE", "CHEMICAL", 32, 35], ["infection", "DISEASE", 112, 121], ["Vancomycinresistant", "ORGANISM", 0, 19], ["E. faecium", "ORGANISM", 20, 30], ["VRE-fm", "ORGANISM", 32, 38], ["E. faecium", "SPECIES", 20, 30], ["E. faecium", "SPECIES", 20, 30], ["Vancomycinresistant E. faecium (VRE-fm", "TEST", 0, 38], ["multi-drug resistant micro-organisms", "PROBLEM", 44, 80], ["the treatment options", "TREATMENT", 86, 107], ["infection control measures", "TREATMENT", 112, 138], ["faecium", "OBSERVATION", 23, 30]]], ["Additionally, there is a low clinical awareness.", [["a low clinical awareness", "PROBLEM", 23, 47], ["low", "OBSERVATION_MODIFIER", 25, 28]]], ["Therefore, infections caused by VRE-fm are a unique challenge to the clinician.", [["infections", "DISEASE", 11, 21], ["infections", "PROBLEM", 11, 21], ["VRE", "PROBLEM", 32, 35], ["infections", "OBSERVATION", 11, 21]]], ["Even though the most commonly reported Enterococcus infections are intra-abdominal infections, urinary tract infections, bacteremia and endocarditis, pneumonia is rarely described [2] .", [["intra-abdominal", "ANATOMY", 67, 82], ["urinary tract", "ANATOMY", 95, 108], ["Enterococcus infections", "DISEASE", 39, 62], ["intra-abdominal infections", "DISEASE", 67, 93], ["urinary tract infections", "DISEASE", 95, 119], ["bacteremia", "DISEASE", 121, 131], ["endocarditis", "DISEASE", 136, 148], ["pneumonia", "DISEASE", 150, 159], ["Enterococcus infections", "ORGANISM", 39, 62], ["intra-abdominal", "IMMATERIAL_ANATOMICAL_ENTITY", 67, 82], ["urinary tract", "ORGANISM_SUBDIVISION", 95, 108], ["Enterococcus infections", "PROBLEM", 39, 62], ["intra-abdominal infections", "PROBLEM", 67, 93], ["urinary tract infections", "PROBLEM", 95, 119], ["bacteremia", "PROBLEM", 121, 131], ["endocarditis", "PROBLEM", 136, 148], ["pneumonia", "PROBLEM", 150, 159], ["Enterococcus", "OBSERVATION_MODIFIER", 39, 51], ["infections", "OBSERVATION", 52, 62], ["intra-abdominal", "ANATOMY", 67, 82], ["infections", "OBSERVATION", 83, 93], ["urinary tract", "ANATOMY", 95, 108], ["infections", "OBSERVATION", 109, 119], ["bacteremia", "OBSERVATION", 121, 131], ["endocarditis", "OBSERVATION", 136, 148], ["pneumonia", "OBSERVATION", 150, 159]]], ["In this case report, we aimed to present a uremic patient with VRE-fm pneumonia, possibly related to epileptic seizures, being treated successfully with linezolid.Case presentationA 57-year old man with uremia on hemodialysis complicated by severe renal anemia, hypertension and heart failure, presented with a two-week history of recurrent fever and cough with purulent sputum.", [["renal", "ANATOMY", 248, 253], ["heart", "ANATOMY", 279, 284], ["purulent sputum", "ANATOMY", 362, 377], ["uremic", "DISEASE", 43, 49], ["VRE-fm pneumonia", "DISEASE", 63, 79], ["epileptic seizures", "DISEASE", 101, 119], ["linezolid", "CHEMICAL", 153, 162], ["uremia", "DISEASE", 203, 209], ["renal anemia", "DISEASE", 248, 260], ["hypertension", "DISEASE", 262, 274], ["heart failure", "DISEASE", 279, 292], ["fever", "DISEASE", 341, 346], ["cough", "DISEASE", 351, 356], ["purulent sputum", "DISEASE", 362, 377], ["linezolid", "CHEMICAL", 153, 162], ["patient", "ORGANISM", 50, 57], ["linezolid", "SIMPLE_CHEMICAL", 153, 162], ["man", "ORGANISM", 194, 197], ["renal", "ORGAN", 248, 253], ["heart", "ORGAN", 279, 284], ["patient", "SPECIES", 50, 57], ["man", "SPECIES", 194, 197], ["VRE", "PROBLEM", 63, 66], ["fm pneumonia", "PROBLEM", 67, 79], ["epileptic seizures", "PROBLEM", 101, 119], ["linezolid", "TREATMENT", 153, 162], ["uremia", "PROBLEM", 203, 209], ["hemodialysis", "TREATMENT", 213, 225], ["severe renal anemia", "PROBLEM", 241, 260], ["hypertension", "PROBLEM", 262, 274], ["heart failure", "PROBLEM", 279, 292], ["recurrent fever", "PROBLEM", 331, 346], ["cough", "PROBLEM", 351, 356], ["purulent sputum", "PROBLEM", 362, 377], ["uremic", "OBSERVATION", 43, 49], ["pneumonia", "OBSERVATION", 70, 79], ["possibly related to", "UNCERTAINTY", 81, 100], ["epileptic seizures", "OBSERVATION", 101, 119], ["uremia", "OBSERVATION", 203, 209], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["renal", "ANATOMY", 248, 253], ["anemia", "OBSERVATION", 254, 260], ["hypertension", "OBSERVATION", 262, 274], ["heart", "ANATOMY", 279, 284], ["failure", "OBSERVATION", 285, 292], ["recurrent", "OBSERVATION_MODIFIER", 331, 340], ["fever", "OBSERVATION", 341, 346], ["cough", "OBSERVATION", 351, 356], ["purulent", "OBSERVATION_MODIFIER", 362, 370], ["sputum", "OBSERVATION", 371, 377]]], ["Chest pain, nausea, vomiting, abdominal pain, diarrhea and night sweat was denied.", [["Chest", "ANATOMY", 0, 5], ["abdominal", "ANATOMY", 30, 39], ["Chest pain", "DISEASE", 0, 10], ["nausea", "DISEASE", 12, 18], ["vomiting", "DISEASE", 20, 28], ["abdominal pain", "DISEASE", 30, 44], ["diarrhea", "DISEASE", 46, 54], ["abdominal", "ORGANISM_SUBDIVISION", 30, 39], ["sweat", "ORGANISM_SUBDIVISION", 65, 70], ["Chest pain", "PROBLEM", 0, 10], ["nausea", "PROBLEM", 12, 18], ["vomiting", "PROBLEM", 20, 28], ["abdominal pain", "PROBLEM", 30, 44], ["diarrhea", "PROBLEM", 46, 54], ["night sweat", "PROBLEM", 59, 70], ["pain", "OBSERVATION", 6, 10], ["abdominal", "ANATOMY", 30, 39], ["pain", "OBSERVATION", 40, 44], ["diarrhea", "OBSERVATION", 46, 54]]], ["He had been diagnosed with end-stage renal disease (ESRD) nearly 2 months ago, and the etiology was primary glomerulonephritis.", [["renal", "ANATOMY", 37, 42], ["end-stage renal disease", "DISEASE", 27, 50], ["ESRD", "DISEASE", 52, 56], ["glomerulonephritis", "DISEASE", 108, 126], ["renal", "ORGAN", 37, 42], ["end-stage renal disease", "PROBLEM", 27, 50], ["ESRD", "PROBLEM", 52, 56], ["primary glomerulonephritis", "PROBLEM", 100, 126], ["stage", "OBSERVATION_MODIFIER", 31, 36], ["renal", "ANATOMY", 37, 42], ["disease", "OBSERVATION", 43, 50], ["primary", "OBSERVATION_MODIFIER", 100, 107], ["glomerulonephritis", "OBSERVATION", 108, 126]]], ["Hemodialysis with the central venous catheter started at that time.", [["venous", "ANATOMY", 30, 36], ["central venous", "MULTI-TISSUE_STRUCTURE", 22, 36], ["Hemodialysis", "TREATMENT", 0, 12], ["the central venous catheter", "TREATMENT", 18, 45], ["central", "ANATOMY_MODIFIER", 22, 29], ["venous", "ANATOMY", 30, 36], ["catheter", "OBSERVATION", 37, 45]]], ["Two weeks before admission, he suffered from recurrent epileptic seizures, characterized by convulsions of the whole body, unconsciousness and fecal incontinence in other hospital.", [["whole body", "ANATOMY", 111, 121], ["fecal", "ANATOMY", 143, 148], ["epileptic seizures", "DISEASE", 55, 73], ["convulsions", "DISEASE", 92, 103], ["unconsciousness", "DISEASE", 123, 138], ["fecal incontinence", "DISEASE", 143, 161], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["fecal", "ORGANISM_SUBDIVISION", 143, 148], ["recurrent epileptic seizures", "PROBLEM", 45, 73], ["convulsions of the whole body", "PROBLEM", 92, 121], ["unconsciousness", "PROBLEM", 123, 138], ["fecal incontinence", "PROBLEM", 143, 161], ["recurrent", "OBSERVATION_MODIFIER", 45, 54], ["epileptic seizures", "OBSERVATION", 55, 73], ["fecal", "ANATOMY", 143, 148], ["incontinence", "OBSERVATION", 149, 161]]], ["Shortly afterwards, fever and cough with yellow phlegm gradually appeared.", [["fever", "DISEASE", 20, 25], ["cough", "DISEASE", 30, 35], ["yellow phlegm", "DISEASE", 41, 54], ["fever", "PROBLEM", 20, 25], ["cough", "PROBLEM", 30, 35], ["yellow phlegm", "PROBLEM", 41, 54], ["fever", "OBSERVATION", 20, 25], ["cough", "OBSERVATION", 30, 35], ["yellow phlegm", "OBSERVATION", 41, 54]]], ["His labs were notable for white blood cell count (WBC) of 11.6 \u00d7 10 9 /L with 87% neutrophils, hemoglobin (Hb) 61 g/L, and C-reactive protein (CRP) 74.06 mg/L. Blood and sputum cultures were negative.", [["white blood cell", "ANATOMY", 26, 42], ["WBC", "ANATOMY", 50, 53], ["neutrophils", "ANATOMY", 82, 93], ["Blood", "ANATOMY", 160, 165], ["sputum cultures", "ANATOMY", 170, 185], ["white blood cell", "CELL", 26, 42], ["WBC", "CELL", 50, 53], ["neutrophils", "CELL", 82, 93], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 95, 105], ["Hb", "GENE_OR_GENE_PRODUCT", 107, 109], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 123, 141], ["CRP", "GENE_OR_GENE_PRODUCT", 143, 146], ["Blood", "ORGANISM_SUBSTANCE", 160, 165], ["sputum cultures", "CELL", 170, 185], ["neutrophils", "CELL_TYPE", 82, 93], ["hemoglobin", "PROTEIN", 95, 105], ["Hb", "PROTEIN", 107, 109], ["C-reactive protein", "PROTEIN", 123, 141], ["CRP", "PROTEIN", 143, 146], ["His labs", "TEST", 0, 8], ["white blood cell count", "TEST", 26, 48], ["WBC", "TEST", 50, 53], ["neutrophils", "TEST", 82, 93], ["hemoglobin", "TEST", 95, 105], ["Hb", "TEST", 107, 109], ["g/L", "TEST", 114, 117], ["C", "TEST", 123, 124], ["reactive protein", "TEST", 125, 141], ["CRP", "TEST", 143, 146], ["Blood", "TEST", 160, 165], ["sputum cultures", "TEST", 170, 185]]], ["Computed tomography (CT) scan of the chest revealed pneumonia.", [["chest", "ANATOMY", 37, 42], ["pneumonia", "DISEASE", 52, 61], ["chest", "ORGAN", 37, 42], ["Computed tomography (CT) scan of the chest", "TEST", 0, 42], ["pneumonia", "PROBLEM", 52, 61], ["chest", "ANATOMY", 37, 42], ["pneumonia", "OBSERVATION", 52, 61]]], ["Intravenous vancomycin (0.5 g three times a week) and meropenem (0.5 g Q8H) was administered empirically for suspected aspiration (given his lethargy after epileptic seizure).", [["vancomycin", "CHEMICAL", 12, 22], ["meropenem", "CHEMICAL", 54, 63], ["Q8H", "CHEMICAL", 71, 74], ["lethargy", "DISEASE", 141, 149], ["epileptic seizure", "DISEASE", 156, 173], ["vancomycin", "CHEMICAL", 12, 22], ["meropenem", "CHEMICAL", 54, 63], ["vancomycin", "SIMPLE_CHEMICAL", 12, 22], ["meropenem", "SIMPLE_CHEMICAL", 54, 63], ["Intravenous vancomycin", "TREATMENT", 0, 22], ["meropenem", "TREATMENT", 54, 63], ["aspiration", "PROBLEM", 119, 129], ["his lethargy", "PROBLEM", 137, 149], ["epileptic seizure)", "PROBLEM", 156, 174], ["aspiration", "OBSERVATION", 119, 129]]], ["Then the symptoms improved gradually and indicators of infection dropped to normal during 1 week.", [["infection", "DISEASE", 55, 64], ["the symptoms", "PROBLEM", 5, 17], ["infection", "PROBLEM", 55, 64], ["infection", "OBSERVATION", 55, 64]]], ["Unexpectedly, the patient had fever again on the day of admission, with a temperature of 38.8\u00b0C, accompanied by deteriorating general status.", [["fever", "DISEASE", 30, 35], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["fever", "PROBLEM", 30, 35], ["a temperature", "TEST", 72, 85]]], ["Therefore, he was transferred to our hospital for further treatment.Case presentationPhysical examination was significant for appearance of severe anemia, a temperature of 38.8\u00b0C, decreased breath sounds at the lung bases bilaterally, a diffuse moist rale on respiratory exam and a slight exudation around the right jugular hemodialysis catheter.", [["lung", "ANATOMY", 211, 215], ["respiratory", "ANATOMY", 259, 270], ["right jugular", "ANATOMY", 310, 323], ["anemia", "DISEASE", 147, 153], ["lung", "ORGAN", 211, 215], ["jugular", "MULTI-TISSUE_STRUCTURE", 316, 323], ["further treatment", "TREATMENT", 50, 67], ["Physical examination", "TEST", 85, 105], ["severe anemia", "PROBLEM", 140, 153], ["a temperature", "TEST", 155, 168], ["decreased breath sounds at the lung bases bilaterally", "PROBLEM", 180, 233], ["a diffuse moist rale", "PROBLEM", 235, 255], ["respiratory exam", "TEST", 259, 275], ["a slight exudation", "PROBLEM", 280, 298], ["the right jugular hemodialysis catheter", "TREATMENT", 306, 345], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["anemia", "OBSERVATION", 147, 153], ["decreased", "OBSERVATION_MODIFIER", 180, 189], ["breath sounds", "OBSERVATION", 190, 203], ["lung", "ANATOMY", 211, 215], ["bases", "ANATOMY_MODIFIER", 216, 221], ["bilaterally", "ANATOMY_MODIFIER", 222, 233], ["diffuse", "OBSERVATION_MODIFIER", 237, 244], ["moist", "OBSERVATION_MODIFIER", 245, 250], ["rale", "OBSERVATION_MODIFIER", 251, 255], ["slight", "OBSERVATION_MODIFIER", 282, 288], ["exudation", "OBSERVATION", 289, 298], ["right", "ANATOMY_MODIFIER", 310, 315], ["jugular", "ANATOMY", 316, 323], ["hemodialysis catheter", "OBSERVATION", 324, 345]]], ["Initial laboratory investigations revealed WBC of 7.0 \u00d7 10 9 /L with 74.2% neutrophils, Hb 55 g/L, CRP 25.29 mg/L, procalcitonin (PCT) 3.02 ng/ml, Scr 557.1umol/L and Btype natriuretic peptide (BNP) greater than 5000 pg/ml.", [["WBC", "ANATOMY", 43, 46], ["neutrophils", "ANATOMY", 75, 86], ["neutrophils", "CELL", 75, 86], ["CRP", "GENE_OR_GENE_PRODUCT", 99, 102], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 115, 128], ["Btype natriuretic peptide", "GENE_OR_GENE_PRODUCT", 167, 192], ["BNP", "GENE_OR_GENE_PRODUCT", 194, 197], ["neutrophils", "CELL_TYPE", 75, 86], ["Hb", "PROTEIN", 88, 90], ["CRP", "PROTEIN", 99, 102], ["procalcitonin", "PROTEIN", 115, 128], ["PCT", "PROTEIN", 130, 133], ["Initial laboratory investigations", "TEST", 0, 33], ["WBC", "TEST", 43, 46], ["neutrophils", "TEST", 75, 86], ["Hb", "TEST", 88, 90], ["g", "TEST", 94, 95], ["L", "TEST", 96, 97], ["CRP", "TEST", 99, 102], ["procalcitonin", "TEST", 115, 128], ["PCT", "TEST", 130, 133], ["Scr", "TEST", 147, 150], ["Btype natriuretic peptide", "TEST", 167, 192], ["BNP", "TEST", 194, 197]]], ["Chest CT demonstrated multiple exudation of both lungs, bilateral pleural effusion and atelectasis of both lower lobes (Fig. 1a) .", [["lungs", "ANATOMY", 49, 54], ["pleural", "ANATOMY", 66, 73], ["lower lobes", "ANATOMY", 107, 118], ["pleural effusion", "DISEASE", 66, 82], ["atelectasis", "DISEASE", 87, 98], ["lungs", "ORGAN", 49, 54], ["pleural effusion", "PATHOLOGICAL_FORMATION", 66, 82], ["Chest CT", "TEST", 0, 8], ["multiple exudation of both lungs", "PROBLEM", 22, 54], ["bilateral pleural effusion", "PROBLEM", 56, 82], ["atelectasis of both lower lobes", "PROBLEM", 87, 118], ["multiple", "OBSERVATION_MODIFIER", 22, 30], ["exudation", "OBSERVATION", 31, 40], ["both", "ANATOMY_MODIFIER", 44, 48], ["lungs", "ANATOMY", 49, 54], ["bilateral", "ANATOMY_MODIFIER", 56, 65], ["pleural", "ANATOMY", 66, 73], ["effusion", "OBSERVATION", 74, 82], ["atelectasis", "OBSERVATION", 87, 98], ["both", "ANATOMY_MODIFIER", 102, 106], ["lower lobes", "ANATOMY", 107, 118]]], ["No valvular vegetation was found in echocardiography, and left ventricular ejection fraction (LVEF) was 43%.", [["valvular", "ANATOMY", 3, 11], ["left ventricular", "ANATOMY", 58, 74], ["ventricular", "MULTI-TISSUE_STRUCTURE", 63, 74], ["valvular vegetation", "PROBLEM", 3, 22], ["echocardiography", "TEST", 36, 52], ["left ventricular ejection fraction", "TEST", 58, 92], ["LVEF", "TEST", 94, 98], ["valvular", "ANATOMY", 3, 11], ["vegetation", "OBSERVATION", 12, 22], ["left ventricular", "ANATOMY", 58, 74], ["ejection fraction", "OBSERVATION", 75, 92]]], ["Initial diagnosis of admission was ESRD with hemodialysis, sever renal anemia, community acquired pneumonia, heart failure and suspected catheter-related infection.", [["renal", "ANATOMY", 65, 70], ["heart", "ANATOMY", 109, 114], ["catheter", "ANATOMY", 137, 145], ["ESRD", "DISEASE", 35, 39], ["renal anemia", "DISEASE", 65, 77], ["pneumonia", "DISEASE", 98, 107], ["heart failure", "DISEASE", 109, 122], ["infection", "DISEASE", 154, 163], ["renal", "ORGAN", 65, 70], ["heart", "ORGAN", 109, 114], ["ESRD", "PROBLEM", 35, 39], ["hemodialysis", "TREATMENT", 45, 57], ["sever renal anemia", "PROBLEM", 59, 77], ["community acquired pneumonia", "PROBLEM", 79, 107], ["heart failure", "PROBLEM", 109, 122], ["suspected catheter-related infection", "PROBLEM", 127, 163], ["renal", "ANATOMY", 65, 70], ["anemia", "OBSERVATION", 71, 77], ["pneumonia", "OBSERVATION", 98, 107], ["heart", "ANATOMY", 109, 114], ["failure", "OBSERVATION", 115, 122], ["catheter", "OBSERVATION", 137, 145], ["infection", "OBSERVATION", 154, 163]]], ["Treatment with intravenous piperacillin / tazobactam (2.25 g Q12H) for pneumonia and correction of heart failure and anemia were commenced.", [["intravenous", "ANATOMY", 15, 26], ["heart", "ANATOMY", 99, 104], ["piperacillin / tazobactam", "CHEMICAL", 27, 52], ["Q12H", "CHEMICAL", 61, 65], ["pneumonia", "DISEASE", 71, 80], ["heart failure", "DISEASE", 99, 112], ["anemia", "DISEASE", 117, 123], ["piperacillin", "CHEMICAL", 27, 39], ["tazobactam", "CHEMICAL", 42, 52], ["Q12H", "CHEMICAL", 61, 65], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 26], ["piperacillin / tazobactam", "SIMPLE_CHEMICAL", 27, 52], ["heart", "ORGAN", 99, 104], ["intravenous piperacillin", "TREATMENT", 15, 39], ["tazobactam", "TREATMENT", 42, 52], ["pneumonia", "PROBLEM", 71, 80], ["heart failure", "PROBLEM", 99, 112], ["anemia", "PROBLEM", 117, 123], ["pneumonia", "OBSERVATION", 71, 80], ["heart", "ANATOMY", 99, 104], ["failure", "OBSERVATION", 105, 112], ["anemia", "OBSERVATION", 117, 123]]], ["The dialysis catheter and urinary catheter were removed and peripheral blood cultures were collected.", [["urinary", "ANATOMY", 26, 33], ["peripheral blood cultures", "ANATOMY", 60, 85], ["urinary", "ORGANISM_SUBSTANCE", 26, 33], ["peripheral blood cultures", "ORGANISM_SUBSTANCE", 60, 85], ["The dialysis catheter", "TREATMENT", 0, 21], ["urinary catheter", "TREATMENT", 26, 42], ["peripheral blood cultures", "TEST", 60, 85], ["dialysis", "OBSERVATION_MODIFIER", 4, 12], ["catheter", "OBSERVATION", 13, 21], ["urinary", "ANATOMY", 26, 33], ["catheter", "OBSERVATION", 34, 42], ["peripheral", "ANATOMY_MODIFIER", 60, 70], ["blood", "ANATOMY", 71, 76]]], ["But his fever with a maximum temperature of 40\u00b0C still persisted.", [["fever", "DISEASE", 8, 13], ["his fever", "PROBLEM", 4, 13], ["a maximum temperature", "TEST", 19, 40], ["fever", "OBSERVATION", 8, 13], ["persisted", "OBSERVATION_MODIFIER", 55, 64]]], ["Three consecutive blood, sputum culture and catheter cultures were negative.", [["blood", "ANATOMY", 18, 23], ["sputum", "ANATOMY", 25, 31], ["catheter cultures", "ANATOMY", 44, 61], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["sputum culture", "TEST", 25, 39], ["catheter cultures", "TEST", 44, 61]]], ["Additionally, thoracentesis and drainage were performed and hydrothorax culture was also negative.", [["hydrothorax", "DISEASE", 60, 71], ["thoracentesis", "TREATMENT", 14, 27], ["drainage", "TREATMENT", 32, 40], ["hydrothorax culture", "TEST", 60, 79], ["thoracentesis", "OBSERVATION", 14, 27], ["drainage", "OBSERVATION", 32, 40], ["hydrothorax", "ANATOMY", 60, 71]]], ["Laboratory detection of tuberculosis and fungi was all negative.", [["tuberculosis", "DISEASE", 24, 36], ["Laboratory detection", "TEST", 0, 20], ["tuberculosis", "PROBLEM", 24, 36], ["fungi", "TEST", 41, 46], ["tuberculosis", "OBSERVATION", 24, 36]]], ["Antibiotics were switched successively to cefoperazone sodium / sulbactam sodium (1.5 g Q12H) + moxifloxacin (0.4 g/day) + fluconazole (0.2 g/day), and vancomycin (0.5 g three times a week) + meropenem (0.5 g Q8H), according to consultation results of respiratory department.", [["cefoperazone sodium", "CHEMICAL", 42, 61], ["sulbactam sodium", "CHEMICAL", 64, 80], ["Q12H", "CHEMICAL", 88, 92], ["moxifloxacin", "CHEMICAL", 96, 108], ["fluconazole", "CHEMICAL", 123, 134], ["vancomycin", "CHEMICAL", 152, 162], ["meropenem", "CHEMICAL", 192, 201], ["cefoperazone sodium", "CHEMICAL", 42, 61], ["sulbactam sodium", "CHEMICAL", 64, 80], ["Q12H", "CHEMICAL", 88, 92], ["moxifloxacin", "CHEMICAL", 96, 108], ["fluconazole", "CHEMICAL", 123, 134], ["vancomycin", "CHEMICAL", 152, 162], ["meropenem", "CHEMICAL", 192, 201], ["cefoperazone", "SIMPLE_CHEMICAL", 42, 54], ["sodium", "SIMPLE_CHEMICAL", 55, 61], ["sulbactam sodium", "SIMPLE_CHEMICAL", 64, 80], ["Q12H", "SIMPLE_CHEMICAL", 88, 92], ["moxifloxacin", "SIMPLE_CHEMICAL", 96, 108], ["fluconazole", "SIMPLE_CHEMICAL", 123, 134], ["vancomycin", "SIMPLE_CHEMICAL", 152, 162], ["meropenem", "SIMPLE_CHEMICAL", 192, 201], ["Antibiotics", "TREATMENT", 0, 11], ["cefoperazone sodium / sulbactam sodium", "TREATMENT", 42, 80], ["moxifloxacin", "TREATMENT", 96, 108], ["fluconazole", "TREATMENT", 123, 134], ["vancomycin", "TREATMENT", 152, 162], ["meropenem", "TREATMENT", 192, 201], ["respiratory", "ANATOMY", 252, 263]]], ["However, no apparent improvement was noted, and his general condition deteriorated progressively.", [["no apparent", "UNCERTAINTY", 9, 20], ["improvement", "OBSERVATION", 21, 32], ["deteriorated", "OBSERVATION", 70, 82]]], ["Response of temperature and indicators of infection to antibiotic therapy was shown in Fig. 2 and Fig. 3 .", [["infection", "DISEASE", 42, 51], ["infection", "PROBLEM", 42, 51], ["antibiotic therapy", "TREATMENT", 55, 73], ["infection", "OBSERVATION", 42, 51]]], ["A repeated chest CT showed increased multiple exudation of both lungs (Fig. 1b) .", [["lungs", "ANATOMY", 64, 69], ["lungs", "ORGAN", 64, 69], ["A repeated chest CT", "TEST", 0, 19], ["increased multiple exudation of both lungs", "PROBLEM", 27, 69], ["chest", "ANATOMY", 11, 16], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["exudation", "OBSERVATION", 46, 55], ["both", "ANATOMY_MODIFIER", 59, 63], ["lungs", "ANATOMY", 64, 69]]], ["Finally, fourth blood culture became positive for E. faecium at>10 5 CFU/ml (vanA genotype) on hospital day 13.", [["blood culture", "ANATOMY", 16, 29], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["E. faecium", "ORGANISM", 50, 60], ["E. faecium", "SPECIES", 50, 60], ["E. faecium", "SPECIES", 50, 60], ["fourth blood culture", "TEST", 9, 29], ["E. faecium", "PROBLEM", 50, 60]]], ["At that point, antibiotic therapy was switched to intravenous linezolid (600 mg Q12H) based on the sensitivity pattern of isolates that were vancomycin, moxifloxacin, gentamicin, penicillin, rythromycin and ampicillin resistant, and linezolid, teicoplaninand and tegafycline sensitive.", [["intravenous", "ANATOMY", 50, 61], ["linezolid", "CHEMICAL", 62, 71], ["Q12H", "CHEMICAL", 80, 84], ["vancomycin", "CHEMICAL", 141, 151], ["moxifloxacin", "CHEMICAL", 153, 165], ["gentamicin", "CHEMICAL", 167, 177], ["penicillin", "CHEMICAL", 179, 189], ["rythromycin", "CHEMICAL", 191, 202], ["ampicillin", "CHEMICAL", 207, 217], ["linezolid", "CHEMICAL", 233, 242], ["teicoplaninand", "CHEMICAL", 244, 258], ["tegafycline", "CHEMICAL", 263, 274], ["linezolid", "CHEMICAL", 62, 71], ["Q12H", "CHEMICAL", 80, 84], ["vancomycin", "CHEMICAL", 141, 151], ["moxifloxacin", "CHEMICAL", 153, 165], ["gentamicin", "CHEMICAL", 167, 177], ["penicillin", "CHEMICAL", 179, 189], ["rythromycin", "CHEMICAL", 191, 202], ["ampicillin", "CHEMICAL", 207, 217], ["linezolid", "CHEMICAL", 233, 242], ["teicoplaninand", "CHEMICAL", 244, 258], ["tegafycline", "CHEMICAL", 263, 274], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 61], ["linezolid", "SIMPLE_CHEMICAL", 62, 71], ["vancomycin", "SIMPLE_CHEMICAL", 141, 151], ["moxifloxacin", "SIMPLE_CHEMICAL", 153, 165], ["gentamicin", "SIMPLE_CHEMICAL", 167, 177], ["penicillin", "SIMPLE_CHEMICAL", 179, 189], ["rythromycin", "SIMPLE_CHEMICAL", 191, 202], ["ampicillin", "SIMPLE_CHEMICAL", 207, 217], ["linezolid", "SIMPLE_CHEMICAL", 233, 242], ["teicoplaninand", "SIMPLE_CHEMICAL", 244, 258], ["tegafycline", "SIMPLE_CHEMICAL", 263, 274], ["antibiotic therapy", "TREATMENT", 15, 33], ["intravenous linezolid", "TREATMENT", 50, 71], ["isolates", "TREATMENT", 122, 130], ["vancomycin", "TREATMENT", 141, 151], ["moxifloxacin", "TREATMENT", 153, 165], ["gentamicin", "TREATMENT", 167, 177], ["penicillin", "TREATMENT", 179, 189], ["rythromycin", "TREATMENT", 191, 202], ["ampicillin", "TREATMENT", 207, 217], ["linezolid", "TREATMENT", 233, 242], ["teicoplaninand", "TREATMENT", 244, 258], ["tegafycline", "TREATMENT", 263, 274]]], ["In the following days, the fever subsided gradually (Fig. 2 ).", [["fever", "DISEASE", 27, 32], ["the fever", "PROBLEM", 23, 32], ["fever", "OBSERVATION", 27, 32]]], ["And the CRP and PCT levels decreased steadily (Fig. 3) .", [["CRP", "GENE_OR_GENE_PRODUCT", 8, 11], ["PCT", "GENE_OR_GENE_PRODUCT", 16, 19], ["CRP", "PROTEIN", 8, 11], ["PCT", "PROTEIN", 16, 19], ["the CRP", "TEST", 4, 11], ["PCT levels", "TEST", 16, 26]]], ["The patient completed a four-week course of linezolid with complete resolution of chest CT abnormalities (Fig. 1c ).Discussion and conclusionE. faecalis is more pathogenic than E. faecium, but the latter exhibits more resistance, taking up the majority of VRE infections [3] .", [["chest", "ANATOMY", 82, 87], ["linezolid", "CHEMICAL", 44, 53], ["chest CT abnormalities", "DISEASE", 82, 104], ["infections", "DISEASE", 260, 270], ["linezolid", "CHEMICAL", 44, 53], ["patient", "ORGANISM", 4, 11], ["linezolid", "SIMPLE_CHEMICAL", 44, 53], ["faecalis", "ORGANISM", 144, 152], ["E. faecium", "ORGANISM", 177, 187], ["patient", "SPECIES", 4, 11], ["faecalis", "SPECIES", 144, 152], ["E. faecium", "SPECIES", 177, 187], ["faecalis", "SPECIES", 144, 152], ["E. faecium", "SPECIES", 177, 187], ["linezolid", "TREATMENT", 44, 53], ["chest CT abnormalities", "TEST", 82, 104], ["faecalis", "PROBLEM", 144, 152], ["faecium", "PROBLEM", 180, 187], ["VRE infections", "PROBLEM", 256, 270], ["chest", "ANATOMY", 82, 87], ["more pathogenic", "OBSERVATION_MODIFIER", 156, 171], ["more resistance", "OBSERVATION_MODIFIER", 213, 228]]], ["VRE is an important nosocomial pathogen spreading in hospitals worldwide.", [["VRE", "DISEASE", 0, 3], ["VRE", "PROBLEM", 0, 3], ["an important nosocomial pathogen", "PROBLEM", 7, 39], ["important", "OBSERVATION_MODIFIER", 10, 19], ["nosocomial", "OBSERVATION_MODIFIER", 20, 30], ["pathogen", "OBSERVATION_MODIFIER", 31, 39], ["spreading", "OBSERVATION_MODIFIER", 40, 49]]], ["It was reported by the National Healthcare Safety Network (NHSN) that 35.5% of enterococcal hospital-associated infections were resistant to vancomycin from 2009 to 2010, which ranked as the second most common cause of nosocomial infections in the US [3] .", [["infections", "DISEASE", 112, 122], ["vancomycin", "CHEMICAL", 141, 151], ["infections", "DISEASE", 230, 240], ["vancomycin", "CHEMICAL", 141, 151], ["vancomycin", "SIMPLE_CHEMICAL", 141, 151], ["enterococcal hospital-associated infections", "PROBLEM", 79, 122], ["vancomycin", "TREATMENT", 141, 151], ["nosocomial infections", "PROBLEM", 219, 240], ["infections", "OBSERVATION", 112, 122], ["nosocomial", "OBSERVATION_MODIFIER", 219, 229], ["infections", "OBSERVATION", 230, 240]]], ["Additionally, Markwart et al. reported the proportion of VRE-fm was increasing from 11.2% in 2014 to 26.1% in 2017 in German hospitals, particularly in southern regions in Germany [4] .", [["VRE", "DISEASE", 57, 60], ["VRE", "PROBLEM", 57, 60], ["VRE", "OBSERVATION", 57, 60]]], ["In china, there was a rapid increase in vancomycin resistance from 12.4% in 2007 to 42.0% in 2016 among nosocomial enterococcal isolates in ICU, according to the Taiwan Nosocomial Infection Surveillance System [5] .", [["vancomycin", "CHEMICAL", 40, 50], ["Infection", "DISEASE", 180, 189], ["vancomycin", "CHEMICAL", 40, 50], ["vancomycin", "SIMPLE_CHEMICAL", 40, 50], ["a rapid increase", "PROBLEM", 20, 36], ["vancomycin resistance", "TREATMENT", 40, 61], ["nosocomial enterococcal isolates", "TREATMENT", 104, 136], ["rapid", "OBSERVATION_MODIFIER", 22, 27], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["vancomycin resistance", "OBSERVATION", 40, 61], ["Infection", "OBSERVATION", 180, 189]]], ["However, pulmonary infections due to enterococcus are distinctly unusual.", [["pulmonary", "ANATOMY", 9, 18], ["pulmonary infections", "DISEASE", 9, 29], ["enterococcus", "DISEASE", 37, 49], ["pulmonary", "ORGAN", 9, 18], ["enterococcus", "CANCER", 37, 49], ["pulmonary infections", "PROBLEM", 9, 29], ["enterococcus", "PROBLEM", 37, 49], ["pulmonary", "ANATOMY", 9, 18], ["infections", "OBSERVATION", 19, 29], ["enterococcus", "OBSERVATION", 37, 49]]], ["A prospective and observational study of 110 patients with serious infections due to Enterococcus across six hospitals found that there was 4% of those infections located in the respiratory tract over the course of 1 year [6] .", [["respiratory tract", "ANATOMY", 178, 195], ["infections", "DISEASE", 67, 77], ["infections", "DISEASE", 152, 162], ["patients", "ORGANISM", 45, 53], ["respiratory tract", "ORGANISM_SUBDIVISION", 178, 195], ["patients", "SPECIES", 45, 53], ["observational study", "TEST", 18, 37], ["serious infections", "PROBLEM", 59, 77], ["Enterococcus", "PROBLEM", 85, 97], ["those infections", "PROBLEM", 146, 162], ["Enterococcus", "OBSERVATION", 85, 97], ["infections", "OBSERVATION", 152, 162], ["respiratory tract", "ANATOMY", 178, 195]]], ["The best evidence that enterococcal pneumonia is rare has been reported by Richards et al. They found only two cases of enterococcal pneumonia among 181,993 patients evaluated for a total of 715,930 patient-days in American medical intensive care units [7] .", [["enterococcal pneumonia", "DISEASE", 23, 45], ["enterococcal pneumonia", "DISEASE", 120, 142], ["patients", "ORGANISM", 157, 165], ["patient", "ORGANISM", 199, 206], ["patients", "SPECIES", 157, 165], ["patient", "SPECIES", 199, 206], ["enterococcal pneumonia", "PROBLEM", 23, 45], ["enterococcal pneumonia", "PROBLEM", 120, 142], ["enterococcal", "OBSERVATION_MODIFIER", 23, 35], ["pneumonia", "OBSERVATION", 36, 45], ["enterococcal", "OBSERVATION_MODIFIER", 120, 132], ["pneumonia", "OBSERVATION", 133, 142]]], ["Recently, according to the National Healthcare Safety Network, only 1% of ventilator-associated pneumonias were caused by Enterococcus spp.", [["pneumonias", "DISEASE", 96, 106], ["Enterococcus spp", "ORGANISM", 122, 138], ["ventilator", "TREATMENT", 74, 84], ["pneumonias", "PROBLEM", 96, 106], ["Enterococcus spp", "PROBLEM", 122, 138], ["pneumonias", "OBSERVATION", 96, 106], ["Enterococcus spp", "OBSERVATION", 122, 138]]], ["[8] .Discussion and conclusionWe conducted a literature search based on PubMed in an attempt to identify all published cases of pleuropulmonary infection due to enterococcus, without time limits.", [["pleuropulmonary infection", "DISEASE", 128, 153], ["pleuropulmonary infection", "PROBLEM", 128, 153], ["enterococcus", "PROBLEM", 161, 173], ["pleuropulmonary", "ANATOMY", 128, 143], ["infection", "OBSERVATION", 144, 153], ["enterococcus", "OBSERVATION", 161, 173]]], ["Twenty-four cases of Enterococcus-associated pleuropulmonary infection previously published in the literature were eventually summarized in Table 1 [6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .", [["Enterococcus", "CHEMICAL", 21, 33], ["pleuropulmonary infection", "DISEASE", 45, 70], ["Enterococcus", "ORGANISM", 21, 33], ["[9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26]", "SIMPLE_CHEMICAL", 152, 240], ["Enterococcus", "PROBLEM", 21, 33], ["pleuropulmonary infection", "PROBLEM", 45, 70], ["Enterococcus", "OBSERVATION", 21, 33], ["pleuropulmonary", "ANATOMY", 45, 60], ["infection", "OBSERVATION", 61, 70]]], ["The enterococcal pneumonia cases previously described in the literature mainly occurred in elderly patients with immunosuppression, organ transplantation, hematological malignancies, solid cancer, renal failure, cardiocerebrovascular disease and chronic obstructive pulmonary disease.", [["organ", "ANATOMY", 132, 137], ["hematological malignancies", "ANATOMY", 155, 181], ["solid cancer", "ANATOMY", 183, 195], ["renal", "ANATOMY", 197, 202], ["cardiocerebrovascular", "ANATOMY", 212, 233], ["pulmonary", "ANATOMY", 266, 275], ["enterococcal pneumonia", "DISEASE", 4, 26], ["hematological malignancies", "DISEASE", 155, 181], ["solid cancer", "DISEASE", 183, 195], ["renal failure", "DISEASE", 197, 210], ["cardiocerebrovascular disease", "DISEASE", 212, 241], ["chronic obstructive pulmonary disease", "DISEASE", 246, 283], ["patients", "ORGANISM", 99, 107], ["organ", "ORGAN", 132, 137], ["hematological malignancies", "CANCER", 155, 181], ["solid cancer", "CANCER", 183, 195], ["renal", "ORGAN", 197, 202], ["pulmonary", "ORGAN", 266, 275], ["patients", "SPECIES", 99, 107], ["The enterococcal pneumonia cases", "PROBLEM", 0, 32], ["immunosuppression", "TREATMENT", 113, 130], ["organ transplantation", "TREATMENT", 132, 153], ["hematological malignancies", "PROBLEM", 155, 181], ["solid cancer", "PROBLEM", 183, 195], ["renal failure", "PROBLEM", 197, 210], ["cardiocerebrovascular disease", "PROBLEM", 212, 241], ["chronic obstructive pulmonary disease", "PROBLEM", 246, 283], ["enterococcal", "OBSERVATION_MODIFIER", 4, 16], ["pneumonia", "OBSERVATION", 17, 26], ["hematological malignancies", "OBSERVATION", 155, 181], ["solid cancer", "OBSERVATION", 183, 195], ["renal", "ANATOMY", 197, 202], ["failure", "OBSERVATION", 203, 210], ["cardiocerebrovascular disease", "OBSERVATION", 212, 241], ["chronic", "OBSERVATION_MODIFIER", 246, 253], ["obstructive", "OBSERVATION_MODIFIER", 254, 265], ["pulmonary", "ANATOMY", 266, 275], ["disease", "OBSERVATION", 276, 283]]], ["Ten of the 24 cases of Enterococcus pneumonia were complicated by lung abscess and empyema requiring drainage.", [["lung abscess", "ANATOMY", 66, 78], ["Enterococcus pneumonia", "DISEASE", 23, 45], ["lung abscess", "DISEASE", 66, 78], ["empyema", "DISEASE", 83, 90], ["lung", "ORGAN", 66, 70], ["Enterococcus pneumonia", "PROBLEM", 23, 45], ["lung abscess", "PROBLEM", 66, 78], ["empyema", "PROBLEM", 83, 90], ["drainage", "TREATMENT", 101, 109], ["Enterococcus", "OBSERVATION_MODIFIER", 23, 35], ["pneumonia", "OBSERVATION", 36, 45], ["lung", "ANATOMY", 66, 70], ["abscess", "OBSERVATION", 71, 78], ["empyema", "OBSERVATION", 83, 90], ["drainage", "OBSERVATION", 101, 109]]], ["There were 8 cases of pneumonia due to E. faecium of which 3 were vancomycin-resistant.", [["pneumonia", "DISEASE", 22, 31], ["vancomycin", "CHEMICAL", 66, 76], ["vancomycin", "CHEMICAL", 66, 76], ["E. faecium", "ORGANISM", 39, 49], ["vancomycin", "SIMPLE_CHEMICAL", 66, 76], ["E. faecium", "SPECIES", 39, 49], ["E. faecium", "SPECIES", 39, 49], ["pneumonia", "PROBLEM", 22, 31], ["E. faecium", "PROBLEM", 39, 49], ["vancomycin", "TREATMENT", 66, 76], ["pneumonia", "OBSERVATION", 22, 31], ["faecium", "OBSERVATION", 42, 49]]], ["To our knowledge, ours is the first VRE-fm pneumonia after epileptic seizure in a patient with ESRD on hemodialysis.", [["pneumonia", "DISEASE", 43, 52], ["epileptic seizure", "DISEASE", 59, 76], ["ESRD", "DISEASE", 95, 99], ["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["pneumonia", "PROBLEM", 43, 52], ["epileptic seizure", "PROBLEM", 59, 76], ["ESRD", "PROBLEM", 95, 99], ["hemodialysis", "TREATMENT", 103, 115], ["pneumonia", "OBSERVATION", 43, 52], ["epileptic seizure", "OBSERVATION", 59, 76]]], ["Interestingly, the patient had recurrent epilepsy before he developed pneumonia, which raised the likelihood that aspiration of gastrointestinal content induced by epilepsy (given his altered mental status and lethargy) occurred at some point.", [["gastrointestinal", "ANATOMY", 128, 144], ["epilepsy", "DISEASE", 41, 49], ["pneumonia", "DISEASE", 70, 79], ["aspiration of gastrointestinal content", "DISEASE", 114, 152], ["epilepsy", "DISEASE", 164, 172], ["lethargy", "DISEASE", 210, 218], ["patient", "ORGANISM", 19, 26], ["gastrointestinal", "ORGAN", 128, 144], ["patient", "SPECIES", 19, 26], ["recurrent epilepsy", "PROBLEM", 31, 49], ["pneumonia", "PROBLEM", 70, 79], ["aspiration of gastrointestinal content", "PROBLEM", 114, 152], ["epilepsy", "PROBLEM", 164, 172], ["his altered mental status", "PROBLEM", 180, 205], ["lethargy", "PROBLEM", 210, 218], ["recurrent", "OBSERVATION_MODIFIER", 31, 40], ["epilepsy", "OBSERVATION", 41, 49], ["pneumonia", "OBSERVATION", 70, 79], ["aspiration", "OBSERVATION", 114, 124], ["gastrointestinal", "ANATOMY", 128, 144], ["epilepsy", "OBSERVATION", 164, 172]]], ["And his pulmonary infiltrates involved the middle and lower parts of two lungs, which were typical for aspiration mechanism.", [["pulmonary infiltrates", "ANATOMY", 8, 29], ["lower parts", "ANATOMY", 54, 65], ["lungs", "ANATOMY", 73, 78], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 8, 29], ["lungs", "ORGAN", 73, 78], ["his pulmonary infiltrates", "PROBLEM", 4, 29], ["aspiration mechanism", "PROBLEM", 103, 123], ["pulmonary", "ANATOMY", 8, 17], ["infiltrates", "OBSERVATION", 18, 29], ["middle", "ANATOMY_MODIFIER", 43, 49], ["lower", "ANATOMY_MODIFIER", 54, 59], ["parts", "ANATOMY_MODIFIER", 60, 65], ["two", "ANATOMY_MODIFIER", 69, 72], ["lungs", "ANATOMY", 73, 78], ["typical for", "UNCERTAINTY", 91, 102], ["aspiration", "OBSERVATION", 103, 113]]], ["According to previous reports, Enterococcal-associated aspiration pneumonia also occurred in patients fed by Dobb-Hofftube and experiencing near drowning [23, 26] .", [["aspiration pneumonia", "DISEASE", 55, 75], ["drowning", "DISEASE", 145, 153], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["Enterococcal-associated aspiration pneumonia", "PROBLEM", 31, 75], ["near drowning", "PROBLEM", 140, 153], ["Enterococcal", "OBSERVATION", 31, 43], ["aspiration", "OBSERVATION", 55, 65], ["pneumonia", "OBSERVATION", 66, 75]]], ["Since our patient was admitted with a hemodialysis catheter accompanied by purulent exudation at the outlet of the catheter, recurrent fever, heart failure and positive blood culture, another possible mechanism that pneumonia secondary to a septic embolus originated from the dialysis catheter or the heart was suggested.", [["heart", "ANATOMY", 142, 147], ["blood", "ANATOMY", 169, 174], ["septic embolus", "ANATOMY", 241, 255], ["heart", "ANATOMY", 301, 306], ["fever", "DISEASE", 135, 140], ["heart failure", "DISEASE", 142, 155], ["pneumonia", "DISEASE", 216, 225], ["septic embolus", "DISEASE", 241, 255], ["patient", "ORGANISM", 10, 17], ["heart", "ORGAN", 142, 147], ["blood", "ORGANISM_SUBSTANCE", 169, 174], ["heart", "ORGAN", 301, 306], ["patient", "SPECIES", 10, 17], ["a hemodialysis catheter", "TREATMENT", 36, 59], ["purulent exudation", "PROBLEM", 75, 93], ["the catheter", "TREATMENT", 111, 123], ["recurrent fever", "PROBLEM", 125, 140], ["heart failure", "PROBLEM", 142, 155], ["positive blood culture", "PROBLEM", 160, 182], ["pneumonia", "PROBLEM", 216, 225], ["a septic embolus", "PROBLEM", 239, 255], ["the dialysis catheter", "TREATMENT", 272, 293], ["catheter", "OBSERVATION", 51, 59], ["purulent", "OBSERVATION_MODIFIER", 75, 83], ["exudation", "OBSERVATION", 84, 93], ["outlet", "OBSERVATION_MODIFIER", 101, 107], ["catheter", "OBSERVATION", 115, 123], ["recurrent", "OBSERVATION_MODIFIER", 125, 134], ["fever", "OBSERVATION", 135, 140], ["heart", "ANATOMY", 142, 147], ["failure", "OBSERVATION", 148, 155], ["possible", "UNCERTAINTY", 192, 200], ["pneumonia", "OBSERVATION", 216, 225], ["septic", "OBSERVATION_MODIFIER", 241, 247], ["embolus", "OBSERVATION", 248, 255], ["dialysis catheter", "OBSERVATION", 276, 293], ["heart", "ANATOMY", 301, 306]]], ["However, imaging of vessels at the catheter and an echocardiography showed no embolism and the catheter culture was negative in the current case.", [["vessels", "ANATOMY", 20, 27], ["embolism", "DISEASE", 78, 86], ["vessels", "MULTI-TISSUE_STRUCTURE", 20, 27], ["imaging", "TEST", 9, 16], ["an echocardiography", "TEST", 48, 67], ["embolism", "PROBLEM", 78, 86], ["the catheter culture", "TEST", 91, 111], ["vessels", "ANATOMY", 20, 27], ["catheter", "OBSERVATION", 35, 43], ["no", "UNCERTAINTY", 75, 77], ["embolism", "OBSERVATION", 78, 86], ["catheter", "OBSERVATION", 95, 103]]], ["From the cases summarized in Table 1 , it is notable that only 2 cases of Enterococcal pneumonia were associated with endocarditis [11, 13] .", [["Enterococcal pneumonia", "DISEASE", 74, 96], ["endocarditis", "DISEASE", 118, 130], ["Enterococcal pneumonia", "PROBLEM", 74, 96], ["endocarditis", "PROBLEM", 118, 130], ["Enterococcal", "OBSERVATION_MODIFIER", 74, 86], ["pneumonia", "OBSERVATION", 87, 96], ["endocarditis", "OBSERVATION", 118, 130]]], ["Furthermore, previous literature data reported 3 cases of VRE-fm pneumonia were treated with linezolid, of which 2 survived and 1 died.", [["VRE", "DISEASE", 58, 61], ["pneumonia", "DISEASE", 65, 74], ["linezolid", "CHEMICAL", 93, 102], ["linezolid", "CHEMICAL", 93, 102], ["linezolid", "SIMPLE_CHEMICAL", 93, 102], ["VRE", "PROBLEM", 58, 61], ["fm pneumonia", "PROBLEM", 62, 74], ["linezolid", "TREATMENT", 93, 102], ["pneumonia", "OBSERVATION", 65, 74]]], ["In contrast, the isolate recovered from our patient was sensitive to linezolid according to the drug sensitivity test, and his infection indicators and body temperature showed good response to the treatment of linezolid, and the chest CT abnormalities completely resolved after a four-week course of linezolid.", [["body", "ANATOMY", 152, 156], ["chest", "ANATOMY", 229, 234], ["linezolid", "CHEMICAL", 69, 78], ["infection", "DISEASE", 127, 136], ["linezolid", "CHEMICAL", 210, 219], ["linezolid", "CHEMICAL", 300, 309], ["linezolid", "CHEMICAL", 69, 78], ["linezolid", "CHEMICAL", 210, 219], ["linezolid", "CHEMICAL", 300, 309], ["patient", "ORGANISM", 44, 51], ["linezolid", "SIMPLE_CHEMICAL", 69, 78], ["body", "ORGANISM_SUBDIVISION", 152, 156], ["linezolid", "SIMPLE_CHEMICAL", 210, 219], ["linezolid", "SIMPLE_CHEMICAL", 300, 309], ["patient", "SPECIES", 44, 51], ["linezolid", "TREATMENT", 69, 78], ["the drug sensitivity test", "TEST", 92, 117], ["his infection", "PROBLEM", 123, 136], ["body temperature", "TEST", 152, 168], ["linezolid", "TREATMENT", 210, 219], ["the chest CT abnormalities", "TEST", 225, 251], ["linezolid", "TREATMENT", 300, 309], ["good response", "OBSERVATION", 176, 189], ["chest", "ANATOMY", 229, 234]]], ["Previous case reports of enterococcal pneumonia were based on clinical findings and infiltrate on chest X ray or CT in combination with the isolation of enterococci in cultures from a transtracheal aspirate, protected brush (PS), bronchoalveolar lavage (BAL), sputum or lung tissue.", [["transtracheal aspirate", "ANATOMY", 184, 206], ["brush", "ANATOMY", 218, 223], ["bronchoalveolar lavage", "ANATOMY", 230, 252], ["BAL", "ANATOMY", 254, 257], ["sputum", "ANATOMY", 260, 266], ["lung tissue", "ANATOMY", 270, 281], ["enterococcal pneumonia", "DISEASE", 25, 47], ["brush", "TISSUE", 218, 223], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 230, 252], ["BAL", "MULTI-TISSUE_STRUCTURE", 254, 257], ["lung tissue", "TISSUE", 270, 281], ["enterococcal pneumonia", "PROBLEM", 25, 47], ["clinical findings", "TEST", 62, 79], ["infiltrate", "PROBLEM", 84, 94], ["chest X ray", "TEST", 98, 109], ["CT", "TEST", 113, 115], ["enterococci", "PROBLEM", 153, 164], ["cultures", "TEST", 168, 176], ["a transtracheal aspirate", "TEST", 182, 206], ["bronchoalveolar lavage (BAL)", "TEST", 230, 258], ["sputum or lung tissue", "PROBLEM", 260, 281], ["enterococcal", "OBSERVATION_MODIFIER", 25, 37], ["pneumonia", "OBSERVATION", 38, 47], ["infiltrate", "OBSERVATION", 84, 94], ["chest", "ANATOMY", 98, 103], ["enterococci", "OBSERVATION", 153, 164], ["transtracheal", "ANATOMY", 184, 197], ["aspirate", "OBSERVATION", 198, 206], ["bronchoalveolar lavage", "OBSERVATION", 230, 252], ["lung", "ANATOMY", 270, 274], ["tissue", "OBSERVATION", 275, 281]]], ["Since isolation of Enterococcus from respiratory secretions usually represents colonization, lung tissue, PS or BAL culture may identify true infection of the lower respiratory tract more accurately than the sputum or endotracheal aspirate cultures.", [["respiratory secretions", "ANATOMY", 37, 59], ["lung tissue", "ANATOMY", 93, 104], ["BAL culture", "ANATOMY", 112, 123], ["lower respiratory tract", "ANATOMY", 159, 182], ["sputum", "ANATOMY", 208, 214], ["endotracheal aspirate cultures", "ANATOMY", 218, 248], ["Enterococcus", "CHEMICAL", 19, 31], ["infection of the lower respiratory tract", "DISEASE", 142, 182], ["lung tissue", "TISSUE", 93, 104], ["lower respiratory", "ORGANISM_SUBDIVISION", 159, 176], ["tract", "ORGANISM_SUBDIVISION", 177, 182], ["Enterococcus", "PROBLEM", 19, 31], ["respiratory secretions", "PROBLEM", 37, 59], ["colonization", "PROBLEM", 79, 91], ["lung tissue, PS", "TEST", 93, 108], ["BAL culture", "TEST", 112, 123], ["true infection of the lower respiratory tract", "PROBLEM", 137, 182], ["the sputum", "TEST", 204, 214], ["endotracheal aspirate cultures", "TEST", 218, 248], ["Enterococcus", "OBSERVATION", 19, 31], ["respiratory secretions", "OBSERVATION", 37, 59], ["colonization", "OBSERVATION", 79, 91], ["lung", "ANATOMY", 93, 97], ["tissue", "OBSERVATION", 98, 104], ["infection", "OBSERVATION", 142, 151], ["lower", "ANATOMY_MODIFIER", 159, 164], ["respiratory tract", "ANATOMY", 165, 182], ["endotracheal", "ANATOMY", 218, 230]]], ["However, in our case, bronchoscopy and lung needle biopsy was not performed to obtain lung tissue, PS or BAL specimens, because the patient was seriously ill at that time.", [["lung", "ANATOMY", 39, 43], ["lung tissue", "ANATOMY", 86, 97], ["BAL specimens", "ANATOMY", 105, 118], ["lung needle biopsy", "MULTI-TISSUE_STRUCTURE", 39, 57], ["lung tissue", "TISSUE", 86, 97], ["BAL specimens", "TISSUE", 105, 118], ["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 132, 139], ["bronchoscopy", "TEST", 22, 34], ["lung needle biopsy", "TEST", 39, 57], ["lung tissue", "TEST", 86, 97], ["PS", "TEST", 99, 101], ["BAL specimens", "TEST", 105, 118], ["seriously ill", "PROBLEM", 144, 157], ["lung", "ANATOMY", 39, 43], ["lung", "ANATOMY", 86, 90]]], ["Evidence supporting a diagnosis of VRE-fm pneumonia in our patient included persistent respiratory symptoms, multiple infiltration on chest CT, bacteremia with VRE-fm and good response to linezolid based on susceptibility testing.Discussion and conclusionCurrently, nine phenotypes of vancomycin resistance described are van A, van B, van C, van D, van E, van G, van L, van M and van N [27] .", [["respiratory", "ANATOMY", 87, 98], ["chest", "ANATOMY", 134, 139], ["VRE", "DISEASE", 35, 38], ["pneumonia", "DISEASE", 42, 51], ["bacteremia", "DISEASE", 144, 154], ["linezolid", "CHEMICAL", 188, 197], ["vancomycin", "CHEMICAL", 285, 295], ["linezolid", "CHEMICAL", 188, 197], ["vancomycin", "CHEMICAL", 285, 295], ["patient", "ORGANISM", 59, 66], ["linezolid", "SIMPLE_CHEMICAL", 188, 197], ["vancomycin", "SIMPLE_CHEMICAL", 285, 295], ["patient", "SPECIES", 59, 66], ["VRE", "PROBLEM", 35, 38], ["fm pneumonia", "PROBLEM", 39, 51], ["persistent respiratory symptoms", "PROBLEM", 76, 107], ["multiple infiltration", "PROBLEM", 109, 130], ["chest CT", "TEST", 134, 142], ["bacteremia", "PROBLEM", 144, 154], ["VRE-fm", "PROBLEM", 160, 166], ["linezolid", "TREATMENT", 188, 197], ["susceptibility testing", "TEST", 207, 229], ["vancomycin resistance", "TREATMENT", 285, 306], ["VRE", "OBSERVATION", 35, 38], ["fm", "ANATOMY", 39, 41], ["pneumonia", "OBSERVATION", 42, 51], ["persistent", "OBSERVATION_MODIFIER", 76, 86], ["respiratory", "ANATOMY", 87, 98], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["infiltration", "OBSERVATION", 118, 130], ["chest", "ANATOMY", 134, 139], ["bacteremia", "OBSERVATION", 144, 154], ["good response to linezolid", "OBSERVATION", 171, 197]]], ["Van A contributes to most of the human cases of VRE around the world, and is mostly carried by E. faecium.", [["VRE", "DISEASE", 48, 51], ["human", "ORGANISM", 33, 38], ["E. faecium", "ORGANISM", 95, 105], ["human", "SPECIES", 33, 38], ["E. faecium", "SPECIES", 95, 105], ["human", "SPECIES", 33, 38], ["E. faecium", "SPECIES", 95, 105], ["VRE", "PROBLEM", 48, 51], ["VRE", "OBSERVATION", 48, 51], ["faecium", "OBSERVATION", 98, 105]]], ["Moreover, a study by Bocanegra-Ibarias et al., which involved phenotypic and genotypic characterization of VRE-fm clinical isolates from two hospitals in Mexico, first detected VanB phenotype-vanA genotype [28] .", [["a study", "TEST", 10, 17], ["VRE", "PROBLEM", 107, 110]]], ["Hypermutability, increased mobile genetic elements, metabolic alterations and hypermutability confer drug resistance to E. faecium.", [["Hypermutability", "DISEASE", 0, 15], ["metabolic alterations", "DISEASE", 52, 73], ["hypermutability", "DISEASE", 78, 93], ["E. faecium", "ORGANISM", 120, 130], ["E. faecium", "SPECIES", 120, 130], ["E. faecium", "SPECIES", 120, 130], ["Hypermutability", "PROBLEM", 0, 15], ["increased mobile genetic elements", "PROBLEM", 17, 50], ["metabolic alterations", "PROBLEM", 52, 73], ["hypermutability", "PROBLEM", 78, 93], ["E. faecium", "PROBLEM", 120, 130], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["mobile genetic elements", "OBSERVATION", 27, 50], ["metabolic alterations", "OBSERVATION", 52, 73]]], ["Our patient was found to be infected by E. faecium with Van A gene, so he was clinically unresponsive to vancomycin.", [["vancomycin", "CHEMICAL", 105, 115], ["vancomycin", "CHEMICAL", 105, 115], ["patient", "ORGANISM", 4, 11], ["E. faecium", "ORGANISM", 40, 50], ["Van A", "GENE_OR_GENE_PRODUCT", 56, 61], ["vancomycin", "SIMPLE_CHEMICAL", 105, 115], ["patient", "SPECIES", 4, 11], ["E. faecium", "SPECIES", 40, 50], ["E. faecium", "SPECIES", 40, 50], ["vancomycin", "TREATMENT", 105, 115], ["infected", "OBSERVATION", 28, 36], ["faecium", "OBSERVATION", 43, 50]]], ["The main causes for emergence of VREfm in our patient may be his immunocompromised conditions due to ESRD, repeated hospitalizations, mechanical instrumentation (invasive hemodialysis catheter) and exposure to multiple antibiotics (specifically vancomycin).", [["VREfm", "DISEASE", 33, 38], ["ESRD", "DISEASE", 101, 105], ["vancomycin", "CHEMICAL", 245, 255], ["vancomycin", "CHEMICAL", 245, 255], ["VREfm", "GENE_OR_GENE_PRODUCT", 33, 38], ["patient", "ORGANISM", 46, 53], ["vancomycin", "SIMPLE_CHEMICAL", 245, 255], ["patient", "SPECIES", 46, 53], ["VREfm", "TREATMENT", 33, 38], ["his immunocompromised conditions", "PROBLEM", 61, 93], ["ESRD", "PROBLEM", 101, 105], ["mechanical instrumentation (invasive hemodialysis catheter", "TREATMENT", 134, 192], ["multiple antibiotics", "TREATMENT", 210, 230], ["vancomycin", "TREATMENT", 245, 255], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Therefore, clinicians should minimize unnecessary invasive procedures and vancomycin abuse.", [["vancomycin", "CHEMICAL", 74, 84], ["vancomycin", "CHEMICAL", 74, 84], ["vancomycin", "SIMPLE_CHEMICAL", 74, 84], ["unnecessary invasive procedures", "TREATMENT", 38, 69], ["vancomycin abuse", "TREATMENT", 74, 90]]], ["Deescalation from initial broad-spectrum antibiotics to narrow spectrum antibiotics immediately after receiving the antibiotic sensitivity report is necessary.", [["initial broad-spectrum antibiotics", "TREATMENT", 18, 52], ["narrow spectrum antibiotics", "TREATMENT", 56, 83], ["the antibiotic sensitivity", "TEST", 112, 138]]], ["Additionally, strict adherence to infection control practices can prevent further emergence and spread of drug resistance.Discussion and conclusionIn conclusion, VRE pneumonia is rarely reported.", [["infection", "DISEASE", 34, 43], ["pneumonia", "DISEASE", 166, 175], ["infection control practices", "TREATMENT", 34, 61], ["drug resistance", "PROBLEM", 106, 121], ["VRE pneumonia", "PROBLEM", 162, 175], ["drug resistance", "OBSERVATION", 106, 121], ["pneumonia", "OBSERVATION", 166, 175]]], ["Physicians should consider multi-drug resistant organisms such as VRE in uremic patients with pneumonia that fails to resolve with broad-spectrum antibiotics, especially in the cases with aspiration induced by epilepsy, immunocompromised conditions, and repeated or prolonged hospitalizations.", [["VRE", "DISEASE", 66, 69], ["uremic", "DISEASE", 73, 79], ["pneumonia", "DISEASE", 94, 103], ["epilepsy", "DISEASE", 210, 218], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["multi-drug resistant organisms", "PROBLEM", 27, 57], ["VRE", "PROBLEM", 66, 69], ["uremic patients", "PROBLEM", 73, 88], ["pneumonia", "PROBLEM", 94, 103], ["broad-spectrum antibiotics", "TREATMENT", 131, 157], ["aspiration", "PROBLEM", 188, 198], ["epilepsy", "PROBLEM", 210, 218], ["immunocompromised conditions", "PROBLEM", 220, 248], ["uremic", "OBSERVATION_MODIFIER", 73, 79], ["pneumonia", "OBSERVATION", 94, 103], ["aspiration", "OBSERVATION", 188, 198], ["epilepsy", "OBSERVATION", 210, 218]]], ["Better clinical outcomes can be expected if the empirical antibiotic treatment covers VRE and early adjustment of sensitive antibiotics based on susceptibility testing.Availability of data and materialsThe datasets used and/or analyzed during the case report are available from the corresponding author on reasonable request.Availability of data and materialsEthics approval and consent to participate Not applicable.Consent for publicationWritten informed consent for publication of his clinical details and/or clinical images was obtained from the patient.", [["patient", "ORGANISM", 550, 557], ["patient", "SPECIES", 550, 557], ["the empirical antibiotic treatment", "TREATMENT", 44, 78], ["VRE", "PROBLEM", 86, 89], ["sensitive antibiotics", "TREATMENT", 114, 135], ["susceptibility testing", "TEST", 145, 167], ["clinical images", "TEST", 512, 527]]]], "08a22278486e12768ce186677a6a89663d24586f": [["25In this study, we reported for the first time the existence of complemented palindrome small RNAs 26 (cpsRNAs) and proposed cpsRNAs and palindrome small RNAs (psRNAs) as a novel class of small RNAs.", [["cpsRNAs", "GENE_OR_GENE_PRODUCT", 104, 111], ["cpsRNAs", "GENE_OR_GENE_PRODUCT", 126, 133], ["palindrome small RNAs", "GENE_OR_GENE_PRODUCT", 138, 159], ["psRNAs", "GENE_OR_GENE_PRODUCT", 161, 167], ["palindrome small RNAs 26", "RNA", 78, 102], ["cpsRNAs", "DNA", 104, 111], ["cpsRNAs and palindrome small RNAs", "RNA", 126, 159], ["psRNAs", "DNA", 161, 167], ["small RNAs", "RNA", 189, 199], ["this study", "TEST", 5, 15], ["complemented palindrome small RNAs", "PROBLEM", 65, 99], ["palindrome small RNAs (psRNAs)", "PROBLEM", 138, 168], ["small RNAs", "PROBLEM", 189, 199], ["small RNAs", "OBSERVATION", 149, 159], ["small RNAs", "OBSERVATION", 189, 199]]], ["2725The first discovered cpsRNA UCUUUAACAAGCUUGUUAAAGA from SARS coronavirus named CoV-cpsR-22 contained 22 nucleotides perfectly matching its reverse complementary sequence.", [["SARS coronavirus", "DISEASE", 60, 76], ["nucleotides", "CHEMICAL", 108, 119], ["SARS coronavirus", "ORGANISM", 60, 76], ["CoV", "ORGANISM", 83, 86], ["cpsRNA", "DNA", 25, 31], ["SARS coronavirus named CoV-cpsR-22", "DNA", 60, 94], ["reverse complementary sequence", "DNA", 143, 173], ["coronavirus", "SPECIES", 65, 76], ["SARS coronavirus", "SPECIES", 60, 76], ["CoV-cpsR-22", "SPECIES", 83, 94], ["SARS coronavirus", "TEST", 60, 76], ["CoV", "TEST", 83, 86], ["cpsR", "TEST", 87, 91], ["22 nucleotides", "TREATMENT", 105, 119]]], ["Small RNA sequencing (small RNA-seq or sRNA-seq) is used to acquire thousands of short RNA 58 sequences with lengths of usually less than 50 bp.", [["seq", "DNA", 44, 47], ["short RNA 58 sequences", "DNA", 81, 103], ["Small RNA sequencing", "PROBLEM", 0, 20], ["small RNA", "TEST", 22, 31], ["short RNA", "TEST", 81, 90], ["lengths", "TEST", 109, 116], ["bp", "TEST", 141, 143], ["RNA", "OBSERVATION", 6, 9], ["small", "OBSERVATION_MODIFIER", 22, 27]]], ["With sRNA-seq, many novel non-coding RNAs (ncRNAs) 59 have been discovered.", [["sRNA-seq", "DNA", 5, 13], ["non-coding RNAs", "RNA", 26, 41], ["ncRNAs", "DNA", 43, 49], ["many novel non-coding RNAs", "PROBLEM", 15, 41]]], ["For example, two featured series of rRNA-derived RNA fragments (rRFs) constitute a 60 novel class of small RNAs [1] .", [["rRFs", "GENE_OR_GENE_PRODUCT", 64, 68], ["rRNA-derived RNA fragments", "DNA", 36, 62], ["rRFs", "DNA", 64, 68], ["small RNAs", "RNA", 101, 111], ["rRNA-derived RNA fragments", "PROBLEM", 36, 62], ["small RNAs", "PROBLEM", 101, 111], ["RNA fragments", "OBSERVATION", 49, 62], ["small RNAs", "OBSERVATION", 101, 111]]], ["Small RNA-seq has also been used for virus detection in plants [2] [3] [4] and 6125invertebrates [5] .", [["Small RNA-seq", "PROBLEM", 0, 13], ["virus detection", "TEST", 37, 52], ["RNA", "OBSERVATION", 6, 9]]], ["In 2016, Wang et al. first used sRNA-seq data from the NCBI SRA database to prove that 62 sRNA-seq can be used to detect and identify human viruses [6] , but the detection results were not as good as 63 those of plant or invertebrate viruses.", [["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["human viruses", "SPECIES", 134, 147], ["human viruses", "PROBLEM", 134, 147], ["the detection", "TEST", 158, 171], ["invertebrate viruses", "PROBLEM", 221, 241], ["viruses", "OBSERVATION", 234, 241]]], ["To improve virus detection in mammals, our strategy was to detect and 64 compare featured RNA fragments in plants, invertebrates and mammals using sRNA-seq data.", [["featured RNA fragments", "DNA", 81, 103], ["virus detection", "TEST", 11, 26], ["featured RNA fragments in plants", "PROBLEM", 81, 113], ["virus", "OBSERVATION", 11, 16], ["RNA fragments", "OBSERVATION", 90, 103]]], ["In one 65 previous study [7] , we detected siRNA duplexes induced by plant viruses and analyzed these siRNA 66 duplexes as an important class of featured RNA fragments.", [["featured RNA fragments", "DNA", 145, 167], ["previous study", "TEST", 10, 24], ["siRNA duplexes", "TREATMENT", 43, 57], ["plant viruses", "PROBLEM", 69, 82], ["these siRNA 66 duplexes", "TREATMENT", 96, 119], ["featured RNA fragments", "PROBLEM", 145, 167], ["siRNA duplexes", "OBSERVATION", 43, 57], ["plant viruses", "OBSERVATION", 69, 82], ["RNA fragments", "OBSERVATION", 154, 167]]], ["In this study, we detected siRNA duplexes 67 induced by invertebrate and mammal viruses a n d unexpectedly discovered another important class of 68 featured RNA fragments, which were complemented palindrome small RNAs (cpsRNAs).", [["fragments", "ANATOMY", 161, 170], ["mammal viruses", "ORGANISM", 73, 87], ["68 featured RNA fragments", "RNA", 145, 170], ["palindrome small RNAs", "RNA", 196, 217], ["cpsRNAs", "DNA", 219, 226], ["this study", "TEST", 3, 13], ["siRNA duplexes", "TREATMENT", 27, 41], ["68 featured RNA fragments", "PROBLEM", 145, 170], ["palindrome small RNAs", "PROBLEM", 196, 217], ["siRNA duplexes", "OBSERVATION", 27, 41], ["mammal viruses", "OBSERVATION", 73, 87], ["68 featured", "OBSERVATION_MODIFIER", 145, 156], ["RNA fragments", "OBSERVATION", 157, 170], ["palindrome", "OBSERVATION_MODIFIER", 196, 206], ["small RNAs", "OBSERVATION", 207, 217]]], ["Among all the 69 detected cpsRNAs, we found a typical 22-nt cpsRNA UCUUUAACAAGCUUGUUAAAGA from SARS 70 coronavirus (SARS-CoV) strain MA15, which deserved further studies because mice infected with SARS-7125CoV MA15 died from an overwhelming viral infection with virally mediated destruction of pneumocytes 72 and ciliated epithelial cells [8] .", [["pneumocytes 72", "ANATOMY", 294, 308], ["ciliated epithelial cells", "ANATOMY", 313, 338], ["SARS 70 coronavirus", "DISEASE", 95, 114], ["SARS-7125CoV MA15", "CHEMICAL", 197, 214], ["viral infection", "DISEASE", 241, 256], ["cpsRNAs", "GENE_OR_GENE_PRODUCT", 26, 33], ["SARS 70 coronavirus", "ORGANISM", 95, 114], ["SARS-CoV", "ORGANISM", 116, 124], ["mice", "ORGANISM", 178, 182], ["SARS-7125CoV MA15", "ORGANISM", 197, 214], ["pneumocytes 72", "CELL", 294, 308], ["ciliated epithelial cells", "CELL", 313, 338], ["cpsRNAs", "PROTEIN", 26, 33], ["22-nt cpsRNA", "DNA", 54, 66], ["pneumocytes 72", "CELL_TYPE", 294, 308], ["ciliated epithelial cells", "CELL_TYPE", 313, 338], ["mice", "SPECIES", 178, 182], ["SARS 70 coronavirus", "SPECIES", 95, 114], ["SARS-CoV", "SPECIES", 116, 124], ["mice", "SPECIES", 178, 182], ["SARS-7125CoV MA15", "SPECIES", 197, 214], ["SARS 70 coronavirus (SARS-CoV) strain MA15", "PROBLEM", 95, 137], ["further studies", "TEST", 154, 169], ["SARS", "PROBLEM", 197, 201], ["an overwhelming viral infection", "PROBLEM", 225, 256], ["virally mediated destruction of pneumocytes", "PROBLEM", 262, 305], ["ciliated epithelial cells", "PROBLEM", 313, 338], ["overwhelming", "OBSERVATION_MODIFIER", 228, 240], ["viral", "OBSERVATION_MODIFIER", 241, 246], ["infection", "OBSERVATION", 247, 256], ["epithelial cells", "OBSERVATION", 322, 338]]], ["Although the palindromic motif TCTTTAACAAGCTTGTTAAAGA was 73 already observed in a previous study [9] , it never be considered to be transcribed as cpsRNAs before our 74 studies.", [["palindromic motif", "DNA", 13, 30], ["the palindromic motif TCTTTAACAAGCTTGTTAAAGA", "TEST", 9, 53], ["a previous study", "TEST", 81, 97]]], ["7525The first discovered cpsRNA named SARS-CoV-cpsR-22 contained 22 nucleotides perfectly 76 matching its reverse complementary sequence.", [["nucleotides", "CHEMICAL", 68, 79], ["SARS-CoV", "ORGANISM", 38, 46], ["cpsRNA", "DNA", 25, 31], ["SARS-CoV-cpsR-22", "DNA", 38, 54], ["22 nucleotides perfectly 76", "DNA", 65, 92], ["reverse complementary sequence", "DNA", 106, 136], ["SARS-CoV-cpsR-22", "SPECIES", 38, 54], ["cpsRNA", "TEST", 25, 31], ["SARS", "TEST", 38, 42], ["CoV", "TEST", 43, 46], ["cpsR", "TEST", 47, 51]]], ["In our previous study of mitochondrial genomes, we had 77 reported for the first time a 20-nt palindrome small RNA (psRNA) named hsa-tiR-MDL1-20 [10].", [["mitochondrial genomes", "ANATOMY", 25, 46], ["mitochondrial", "CELLULAR_COMPONENT", 25, 38], ["mitochondrial genomes", "DNA", 25, 46], ["20-nt palindrome small RNA", "DNA", 88, 114], ["psRNA", "DNA", 116, 121], ["hsa", "DNA", 129, 132], ["MDL1", "DNA", 137, 141], ["nt palindrome small RNA", "TREATMENT", 91, 114], ["MDL1", "TEST", 137, 141]]], ["The 78 biological functions of hsa-tiR-MDL1-20 had been preliminarily studied in our previous study, while the 79 biological functions of SARS-CoV-cpsR-22 were still unknown.", [["hsa-tiR-MDL1-20", "CHEMICAL", 31, 46], ["hsa-tiR-MDL1-20", "GENE_OR_GENE_PRODUCT", 31, 46], ["SARS-CoV", "ORGANISM", 138, 146], ["cpsR-22", "GENE_OR_GENE_PRODUCT", 147, 154], ["hsa-tiR", "PROTEIN", 31, 38], ["MDL1", "PROTEIN", 39, 43], ["SARS-CoV-cpsR-22", "DNA", 138, 154], ["SARS-CoV", "SPECIES", 138, 146], ["hsa-tiR", "TEST", 31, 38], ["MDL1", "TEST", 39, 43], ["our previous study", "TEST", 81, 99], ["SARS", "TEST", 138, 142], ["CoV", "TEST", 143, 146], ["cpsR", "TEST", 147, 151]]], ["In this study, we compared the features of 80 siRNA duplexes induced by mammal viruses with those induced by plant and invertebrate viruses and found 81 that siRNA duplexes induced by mammal viruses had significantly lower percentages of total sequenced 82 reads and it seemed that they were only produced from a few sites on the virus genomes.", [["mammal viruses", "ORGANISM", 184, 198], ["virus genomes", "DNA", 330, 343], ["this study", "TEST", 3, 13], ["80 siRNA duplexes", "PROBLEM", 43, 60], ["mammal viruses", "PROBLEM", 72, 86], ["invertebrate viruses", "PROBLEM", 119, 139], ["siRNA duplexes", "PROBLEM", 158, 172], ["mammal viruses", "PROBLEM", 184, 198], ["siRNA duplexes", "OBSERVATION", 46, 60], ["mammal viruses", "OBSERVATION", 72, 86], ["viruses", "OBSERVATION", 132, 139], ["siRNA duplexes", "OBSERVATION", 158, 172], ["mammal viruses", "OBSERVATION", 184, 198], ["virus genomes", "OBSERVATION", 330, 343]]], ["One possible 83 reason could be a large proportion of sRNA-seq data is from other small RNA fragments caused by the 84 presence of a number of dsRNA-triggered nonspecific responses such as the type I interferon (IFN) 85 synthesis [11] .", [["type I interferon (IFN) 85", "GENE_OR_GENE_PRODUCT", 193, 219], ["type I interferon (IFN) 85", "PROTEIN", 193, 219], ["other small RNA fragments", "PROBLEM", 76, 101], ["dsRNA", "PROBLEM", 143, 148], ["the type I interferon (IFN)", "TREATMENT", 189, 216], ["large", "OBSERVATION_MODIFIER", 34, 39], ["sRNA", "OBSERVATION", 54, 58], ["small", "OBSERVATION_MODIFIER", 82, 87], ["RNA fragments", "OBSERVATION", 88, 101]]], ["Another possible reason could be the missing siRNA duplexes or siRNA fragments functions 86 in cells by interaction with host RNAs or proteins.", [["cells", "ANATOMY", 95, 100], ["cells", "CELL", 95, 100], ["siRNA fragments", "DNA", 63, 78], ["host RNAs", "RNA", 121, 130], ["the missing siRNA duplexes", "PROBLEM", 33, 59], ["siRNA fragments functions", "PROBLEM", 63, 88], ["possible reason could be", "UNCERTAINTY", 8, 32], ["siRNA duplexes", "OBSERVATION", 45, 59], ["siRNA fragments", "OBSERVATION", 63, 78]]], ["Based on this idea, we suspected that SARS-CoV-cpsR-87 22 could play a role in SARS-CoV infection or pathogenicity.", [["SARS-CoV-cpsR-87 22", "CHEMICAL", 38, 57], ["SARS-CoV infection", "DISEASE", 79, 97], ["SARS-CoV-cpsR-87 22", "GENE_OR_GENE_PRODUCT", 38, 57], ["SARS-CoV", "ORGANISM", 79, 87], ["SARS-CoV", "SPECIES", 79, 87], ["SARS", "TEST", 38, 42], ["CoV-cpsR", "TEST", 43, 51], ["SARS", "PROBLEM", 79, 83], ["CoV infection", "PROBLEM", 84, 97], ["pathogenicity", "PROBLEM", 101, 114], ["infection", "OBSERVATION", 88, 97]]], ["Then, we performed RNAi experiments to test 88 the cellular effects induced by SARS-CoV-cpsR-22 and its segments.", [["cellular", "ANATOMY", 51, 59], ["cellular", "CELL", 51, 59], ["SARS-CoV-cpsR-22", "DNA", 79, 95], ["SARS-CoV", "SPECIES", 79, 87], ["RNAi experiments", "TEST", 19, 35], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["cpsR", "TEST", 88, 92], ["segments", "ANATOMY_MODIFIER", 104, 112]]], ["8925In this study, we reported for the first time the existence of cpsRNAs.", [["cpsRNAs", "GENE_OR_GENE_PRODUCT", 67, 74], ["cpsRNAs", "PROTEIN", 67, 74], ["this study", "TEST", 7, 17]]], ["Further sequence analysis 90 supported that SARS-CoV-cpsR-22 could originate from bat betacoronaviruses.", [["SARS-CoV", "ORGANISM", 44, 52], ["cpsR-22", "GENE_OR_GENE_PRODUCT", 53, 60], ["bat betacoronaviruses", "ORGANISM", 82, 103], ["SARS-CoV-cpsR-22", "DNA", 44, 60], ["Further sequence analysis", "TEST", 0, 25], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["cpsR", "TEST", 53, 57]]], ["The results of RNAi 91 .", [["RNAi", "TEST", 15, 19]]], ["CC-BY-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It . https://doi.org/10.1101/185876 doi: bioRxiv preprint experiments showed that one 19-nt segment of SARS-CoV-cpsR-22 significantly induced cell apoptosis.", [["cell", "ANATOMY", 142, 146], ["SARS-CoV-cpsR-22", "CHEMICAL", 103, 119], ["https://doi.org/10.1101/185876", "CHEMICAL", 5, 35], ["cpsR-22", "SIMPLE_CHEMICAL", 112, 119], ["cell", "CELL", 142, 146], ["19-nt segment", "DNA", 86, 99], ["SARS-CoV-cpsR-22", "DNA", 103, 119], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["cpsR", "TEST", 112, 116], ["significantly induced cell apoptosis", "PROBLEM", 120, 156], ["CoV", "ANATOMY", 108, 111], ["significantly induced", "OBSERVATION_MODIFIER", 120, 141], ["cell apoptosis", "OBSERVATION", 142, 156]]], ["9225This study aims to provide useful information for a better understanding of psRNAs and cpsRNAs, which 93 constitute a novel class of small RNAs.", [["psRNAs", "GENE_OR_GENE_PRODUCT", 80, 86], ["cpsRNAs", "GENE_OR_GENE_PRODUCT", 91, 98], ["psRNAs", "DNA", 80, 86], ["cpsRNAs", "DNA", 91, 98], ["small RNAs", "RNA", 137, 147], ["This study", "TEST", 4, 14], ["small RNAs", "PROBLEM", 137, 147], ["small RNAs", "OBSERVATION", 137, 147]]], ["The discovery of psRNAs and cpsRNAs paved the way to find new 94 markers for pathogen detection and reveal the mechanisms in the infection or pathogenicity from a different 95 point of view.", [["infection", "DISEASE", 129, 138], ["psRNAs", "GENE_OR_GENE_PRODUCT", 17, 23], ["cpsRNAs", "GENE_OR_GENE_PRODUCT", 28, 35], ["psRNAs", "PROTEIN", 17, 23], ["cpsRNAs", "PROTEIN", 28, 35], ["pathogen detection", "TEST", 77, 95], ["the infection", "PROBLEM", 125, 138], ["pathogenicity", "PROBLEM", 142, 155], ["infection", "OBSERVATION", 129, 138]]], ["96 97Comparison of siRNA-duplexes induced by plant, invertebrate and mammal viruses 99In this study, 11 invertebrate viruses were detected using 51 runs of sRNA-seq data (Supplementary 100 file 1) and two mammal viruses (H1N1 and SARS-CoV) were detected using 12 runs of sRNA-seq data.", [["mammal viruses 99In", "ORGANISM", 69, 88], ["mammal viruses", "ORGANISM", 205, 219], ["H1N1", "ORGANISM", 221, 225], ["SARS-CoV", "ORGANISM", 230, 238], ["SARS-CoV", "SPECIES", 230, 238], ["siRNA-duplexes", "TREATMENT", 19, 33], ["this study", "TEST", 89, 99], ["11 invertebrate viruses", "PROBLEM", 101, 124], ["sRNA-seq data", "TEST", 156, 169], ["H1N1", "PROBLEM", 221, 225], ["mammal viruses", "OBSERVATION", 69, 83], ["viruses", "OBSERVATION", 212, 219]]], ["In 101 our previous study, six mammal viruses were detected using 36 runs of sRNA-seq data [6] .", [["our previous study", "TEST", 7, 25], ["six mammal viruses", "PROBLEM", 27, 45], ["sRNA-seq data", "TEST", 77, 90]]], ["The detection of 102 siRNA-duplexes by 11 invertebrate and eight mammal viruses was performed using a published program in 103 our previous study [7] .", [["The detection", "TEST", 0, 13], ["duplexes", "TEST", 27, 35], ["eight mammal viruses", "PROBLEM", 59, 79], ["our previous study", "TEST", 127, 145], ["viruses", "OBSERVATION", 72, 79]]], ["Then, we compared the features of siRNA duplexes induced by invertebrate viruses 104 ( Figure 1A ) with those induced by plant viruses ( Figure 1B) .", [["siRNA duplexes", "PROBLEM", 34, 48], ["invertebrate viruses", "PROBLEM", 60, 80], ["plant viruses", "PROBLEM", 121, 134], ["siRNA duplexes", "OBSERVATION", 34, 48], ["plant viruses", "OBSERVATION", 121, 134]]], ["The results showed that the duplex length was 105 the principal factor to determine the read count in both plants and invertebrates.", [["the duplex length", "TEST", 24, 41], ["the read count", "TEST", 84, 98]]], ["21-nt siRNA duplexes were 106 the most abundant duplexes in both plants and invertebrates, followed by 22-nt siRNA duplexes in plants 107 but 20-nt siRNA duplexes in invertebrates.", [["22-nt siRNA duplexes", "DNA", 103, 123], ["nt siRNA duplexes", "TREATMENT", 3, 20], ["nt siRNA duplexes", "TREATMENT", 106, 123], ["nt siRNA duplexes", "TREATMENT", 145, 162], ["abundant", "OBSERVATION_MODIFIER", 39, 47], ["duplexes", "OBSERVATION", 48, 56]]], ["21-nt siRNA duplexes with 2-nt overhangs were the most 108 abundant 21-nt duplexes in plants, while 21-nt siRNA duplexes with 1-nt overhangs were the most abundant 109 21-nt duplexes in invertebrates but they had a very close read count to that of 21-nt siRNA duplexes with 2-110 nt overhangs.", [["2-nt overhangs", "DNA", 26, 40], ["21-nt duplexes", "DNA", 68, 82], ["21-nt siRNA duplexes", "DNA", 100, 120], ["1-nt overhangs", "DNA", 126, 140], ["109 21-nt duplexes", "DNA", 164, 182], ["21-nt siRNA duplexes", "DNA", 248, 268], ["2-110 nt overhangs", "DNA", 274, 292], ["nt siRNA duplexes", "TREATMENT", 3, 20], ["2-nt overhangs", "TREATMENT", 26, 40], ["nt duplexes in plants", "PROBLEM", 71, 92], ["nt siRNA duplexes", "TREATMENT", 103, 120], ["1-nt overhangs", "TREATMENT", 126, 140], ["nt duplexes in invertebrates", "PROBLEM", 171, 199], ["nt siRNA duplexes", "TREATMENT", 251, 268]]], ["18-nt, 19-nt, 20-nt and 22-nt siRNA duplexes in invertebrates had much higher percentages of 111 total sequenced reads that those in plants.", [["18-nt, 19-nt, 20-nt and 22-nt siRNA duplexes", "DNA", 0, 44], ["nt siRNA duplexes", "TREATMENT", 27, 44]]], ["In addition, 18-nt and 19-nt siRNA duplexes had very close read 112 counts and 20-nt and 22-nt siRNA duplexes had very close read counts in invertebrates.", [["18-nt and 19-nt siRNA duplexes", "DNA", 13, 43], ["nt siRNA duplexes", "TREATMENT", 26, 43], ["nt siRNA duplexes", "TREATMENT", 92, 109]]], ["Since siRNA 113 duplexes induced by mammal viruses had significantly lower percentages of total sequenced reads, the 114 comparison of siRNA-duplex features between mammals and invertebrates/or plants could not provide 115 meaningful results using the existing public data with standard sequencing depth.", [["mammal viruses", "ORGANISM", 36, 50], ["siRNA 113 duplexes", "TREATMENT", 6, 24], ["mammal viruses", "PROBLEM", 36, 50], ["siRNA", "TEST", 135, 140], ["duplex features", "TEST", 141, 156], ["viruses", "OBSERVATION", 43, 50]]], ["However, as an 116 unexpected result from siRNA-duplex analysis, we discovered cpsRNAs from invertebrate and mammal 117 viruses.", [["cpsRNAs", "GENE_OR_GENE_PRODUCT", 79, 86], ["mammal 117 viruses", "ORGANISM", 109, 127], ["cpsRNAs", "PROTEIN", 79, 86], ["siRNA-duplex analysis", "TEST", 42, 63], ["cpsRNAs", "TEST", 79, 86], ["117 viruses", "OBSERVATION", 116, 127]]], ["118Comparison of siRNA-duplexes induced by plant, invertebrate and mammal viruses 99One typical cpsRNA UCUUUAACAAGCUUGUUAAAGA (DQ497008: 25962-25983) located in the 119 orf3b gene on the SARS-CoV strain MA15 genome was detected in four runs of sRNA-seq data (SRA: 120 SRR452404, SRR452406, SRR452408 and SRR452410).", [["DQ497008: 25962-25983", "CHEMICAL", 127, 148], ["mammal viruses 99One", "ORGANISM", 67, 87], ["orf3b", "GENE_OR_GENE_PRODUCT", 169, 174], ["SARS-CoV", "ORGANISM", 187, 195], ["MA15", "ORGANISM", 203, 207], ["119 orf3b gene", "DNA", 165, 179], ["SARS-CoV strain MA15 genome", "DNA", 187, 214], ["SARS-CoV", "SPECIES", 187, 195], ["siRNA-duplexes", "TREATMENT", 17, 31], ["the SARS", "PROBLEM", 183, 191], ["CoV strain MA15 genome", "PROBLEM", 192, 214], ["SRA", "TEST", 259, 262], ["mammal viruses", "OBSERVATION", 67, 81]]], ["This cpsRNA was named SARS-CoV-cpsR-22, 121 which contained 22 nucleotides perfectly matching its reverse complementary sequence (Figure 2A) .", [["nucleotides", "CHEMICAL", 63, 74], ["cpsRNA", "GENE_OR_GENE_PRODUCT", 5, 11], ["cpsRNA", "DNA", 5, 11], ["SARS-CoV-cpsR-22", "DNA", 22, 38], ["reverse complementary sequence", "DNA", 98, 128], ["This cpsRNA", "TEST", 0, 11], ["SARS", "TEST", 22, 26], ["CoV", "TEST", 27, 30], ["cpsR", "TEST", 31, 35]]], ["We 122 also detected one 18-nt and one 19-nt segment of SARS-CoV-cpsR-22, which could also be derived from 123 siRNA duplexes ( Figure 2B ) but their strands (positive or negative) could not be determined.", [["19-nt segment", "DNA", 39, 52], ["SARS-CoV-cpsR-22", "DNA", 56, 72], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["cpsR", "TEST", 65, 69], ["siRNA duplexes", "TEST", 111, 125]]], ["Among 124 SARS-CoV-cpsR-22 and its two segments, the 19-nt segment was the most abundant and the 22-nt SARS-125Comparison of siRNA-duplexes induced by plant, invertebrate and mammal viruses 99CoV-cpsR-22 was the least abundant.", [["SARS", "DISEASE", 10, 14], ["mammal viruses", "ORGANISM", 175, 189], ["cpsR-22", "GENE_OR_GENE_PRODUCT", 196, 203], ["124 SARS-CoV-cpsR-22", "DNA", 6, 26], ["19-nt segment", "DNA", 53, 66], ["22-nt SARS-125Comparison of siRNA-duplexes", "DNA", 97, 139], ["SARS", "TEST", 10, 14], ["CoV-", "TEST", 15, 19], ["cpsR", "TEST", 19, 23], ["siRNA-duplexes", "TREATMENT", 125, 139], ["mammal viruses", "TEST", 175, 189], ["cpsR", "TEST", 196, 200], ["segments", "ANATOMY_MODIFIER", 39, 47], ["mammal viruses", "OBSERVATION", 175, 189], ["abundant", "OBSERVATION_MODIFIER", 218, 226]]], ["CC-BY-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It . https://doi.org/10.1101/185876 doi: bioRxiv preprintDiscovery of psRNAs and cpsRNAs 128Palindromic motifs are found in published genomes of most species and play important roles in 129 biological processes.", [["https://doi.org/10.1101/185876", "CHEMICAL", 5, 35], ["psRNAs", "GENE_OR_GENE_PRODUCT", 70, 76], ["psRNAs and cpsRNAs 128Palindromic motifs", "DNA", 70, 110], ["psRNAs", "TREATMENT", 70, 76], ["cpsRNAs", "TREATMENT", 81, 88]]], ["The well-known samples of palindromic DNA motifs include restriction enzyme sites, 130 methylation sites and palindromic motifs in T cell receptors [12] .", [["T cell", "ANATOMY", 131, 137], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["T cell receptors", "GENE_OR_GENE_PRODUCT", 131, 147], ["palindromic DNA motifs", "DNA", 26, 48], ["restriction enzyme sites", "DNA", 57, 81], ["130 methylation sites", "DNA", 83, 104], ["palindromic motifs", "DNA", 109, 127], ["T cell receptors", "PROTEIN", 131, 147], ["palindromic DNA motifs", "TREATMENT", 26, 48], ["restriction enzyme sites", "PROBLEM", 57, 81], ["methylation sites", "TREATMENT", 87, 104], ["palindromic motifs in T cell receptors", "TREATMENT", 109, 147]]], ["In this study, we found that palindromic or 131 complemented palindrome small RNAs motifs existed ubiquitously in animal virus genomes, but not all of 132 them were detected to be transcribed and processed into cpsRNAs probably due to inadequate sequencing 133 depth of the sRNA-seq data.", [["animal virus", "ORGANISM", 114, 126], ["cpsRNAs", "GENE_OR_GENE_PRODUCT", 211, 218], ["palindromic or 131 complemented palindrome small RNAs motifs", "DNA", 29, 89], ["cpsRNAs", "DNA", 211, 218], ["this study", "TEST", 3, 13], ["palindromic or 131 complemented palindrome small RNAs motifs", "PROBLEM", 29, 89], ["animal virus genomes", "PROBLEM", 114, 134], ["the sRNA", "TEST", 270, 278], ["virus genomes", "OBSERVATION", 121, 134]]], ["For example, we only found two psRNAs ( The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["psRNAs", "PROTEIN", 31, 37]]], ["It . https://doi.org/10.1101/185876 doi: bioRxiv preprintDatasets and data analysis 200All sRNA-seq data were downloaded from the NCBI SRA database.", [["https://doi.org/10.1101/185876", "CHEMICAL", 5, 35], ["NCBI SRA database", "DNA", 130, 147], ["bioRxiv preprintDatasets", "TREATMENT", 41, 65], ["data analysis", "TEST", 70, 83], ["All sRNA", "TEST", 87, 95]]], ["The invertebrate and mammal 201 viruses were detected from sRNA-seq data using VirusDetect [4] and their genome sequences were 202 downloaed from the NCBI GenBank database.", [["mammal 201 viruses", "ORGANISM", 21, 39], ["genome sequences", "DNA", 105, 121], ["NCBI GenBank database", "DNA", 150, 171], ["The invertebrate and mammal 201 viruses", "PROBLEM", 0, 39], ["VirusDetect", "TEST", 79, 90], ["their genome sequences", "TEST", 99, 121]]], ["The description of sRNA-seq data and virus genomes is 203 presented in Supplementary file 1.", [["sRNA", "DNA", 19, 23], ["virus genomes", "DNA", 37, 50], ["sRNA-seq data", "TEST", 19, 32], ["virus genomes", "PROBLEM", 37, 50]]], ["The cleaning and quality control of sRNA-seq data were performed 204 using the pipeline Fastq_clean [15] that was optimized to clean the raw reads from Illumina platforms.", [["sRNA", "DNA", 36, 40], ["The cleaning", "TREATMENT", 0, 12], ["sRNA-seq data", "TEST", 36, 49], ["the pipeline Fastq_clean", "TREATMENT", 75, 99], ["Illumina platforms", "TEST", 152, 170]]], ["205Datasets and data analysis 200Using the software bowtie v0.12.7 with one mismatch, we aligned all the cleaned sRNA-seq reads to viral 206 genome sequences and obtained alignment results in SAM format for detection of siRNA duplexes using the 207 program duplexfinder [7] .", [["sRNA-seq reads", "DNA", 113, 127], ["viral 206 genome sequences", "DNA", 131, 157], ["data analysis", "TEST", 16, 29], ["the software bowtie", "TEST", 39, 58], ["viral 206 genome sequences", "TEST", 131, 157], ["siRNA duplexes", "TREATMENT", 220, 234]]], ["Statistical computation and plotting were performed using the software R v2.15.3 208 with the Bioconductor packages [16] .", [["Statistical computation", "TEST", 0, 23], ["plotting", "TEST", 28, 36], ["the software R v", "TEST", 58, 74], ["the Bioconductor packages", "TREATMENT", 90, 115]]], ["The orf3b gene from human betacoronavirus (GenBank: 209 DQ497008.1), its 20 homologous sequences from bat betacoronavirus and nine homologous sequences from 210 civet betacoronavirus were aligned using ClustalW2 (Supplementary file 2) .", [["orf3b", "GENE_OR_GENE_PRODUCT", 4, 9], ["human", "ORGANISM", 20, 25], ["bat betacoronavirus", "ORGANISM", 102, 121], ["orf3b gene", "DNA", 4, 14], ["20 homologous sequences", "DNA", 73, 96], ["bat betacoronavirus and nine homologous sequences", "DNA", 102, 151], ["human", "SPECIES", 20, 25], ["human betacoronavirus (GenBank: 209 DQ497008.1", "SPECIES", 20, 66], ["bat betacoronavirus", "SPECIES", 102, 121], ["its 20 homologous sequences", "TREATMENT", 69, 96], ["bat betacoronavirus", "TEST", 102, 121], ["nine homologous sequences", "TEST", 126, 151]]], ["After removal of identical 211 sequences, the orf3b gene from human betacoronavirus, eight homologous sequences from bat 212 betacoronavirus and two homologous sequences from civet betacoronavirus were used for phylogenetic 213 analysis.", [["orf3b", "GENE_OR_GENE_PRODUCT", 46, 51], ["human", "ORGANISM", 62, 67], ["betacoronavirus", "CANCER", 68, 83], ["bat 212 betacoronavirus", "ORGANISM", 117, 140], ["211 sequences", "DNA", 27, 40], ["orf3b gene", "DNA", 46, 56], ["human betacoronavirus", "DNA", 62, 83], ["bat 212 betacoronavirus", "DNA", 117, 140], ["civet betacoronavirus", "DNA", 175, 196], ["human", "SPECIES", 62, 67], ["human betacoronavirus", "SPECIES", 62, 83], ["civet betacoronavirus", "SPECIES", 175, 196], ["removal", "TREATMENT", 6, 13], ["identical 211 sequences", "TEST", 17, 40], ["civet betacoronavirus", "TREATMENT", 175, 196], ["phylogenetic 213 analysis", "TEST", 211, 236]]], ["Since these homologous sequences had high identities (from 85.16% to 99.78%) to the orf3b gene 214 from DQ497008, the Neighbor Joining (NJ) method was used for phylogenetic analysis.", [["orf3b gene 214", "DNA", 84, 98], ["DQ497008", "DNA", 104, 112], ["these homologous sequences", "TEST", 6, 32], ["the Neighbor Joining (NJ) method", "TREATMENT", 114, 146], ["phylogenetic analysis", "TEST", 160, 181]]], ["215 216RNAi and cellular experiments 217Based on the shRNA design protocol [1], the sequences of SARS-CoV-cpsR-22, its 16-nt, 18-nt, 19-nt 218 20-nt segments ( Figure 2B ) and their control \"CGTACGCGGAATACTTCGA\" were selected to use as 219 target sequences for pSIREN-RetroQ vector construction (Clontech, USA), respectively.", [["cellular", "ANATOMY", 16, 24], ["cellular", "CELL", 16, 24], ["SARS-CoV", "ORGANISM", 97, 105], ["SARS-CoV-cpsR-22", "DNA", 97, 113], ["16-nt, 18-nt, 19-nt 218 20-nt segments", "DNA", 119, 157], ["Figure 2B", "DNA", 160, 169], ["CGTACGCGGAATACTTCGA", "DNA", 191, 210], ["219 target sequences", "DNA", 236, 256], ["pSIREN", "DNA", 261, 267], ["SARS-CoV", "SPECIES", 97, 105], ["RNAi", "TEST", 7, 11], ["cellular experiments", "TEST", 16, 36], ["the shRNA design protocol", "TREATMENT", 49, 74], ["the sequences", "TEST", 80, 93], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105], ["cpsR", "TEST", 106, 110], ["nt", "TEST", 122, 124], ["nt", "TEST", 129, 131], ["nt", "TEST", 136, 138], ["pSIREN-RetroQ vector construction", "TREATMENT", 261, 294]]], ["PC-9 cells were 220 divided into six groups named 22, 16, 18, 19, 20 and control for transfection using plasmids containing 221 20 -nt segments and control sequences.", [["PC-9 cells", "ANATOMY", 0, 10], ["plasmids", "ANATOMY", 104, 112], ["PC-9 cells", "CELL", 0, 10], ["PC-9 cells", "CELL_LINE", 0, 10], ["plasmids", "DNA", 104, 112], ["221 20 -nt segments", "DNA", 124, 143], ["control sequences", "DNA", 148, 165], ["PC", "TEST", 0, 2], ["transfection using plasmids", "TREATMENT", 85, 112]]], ["Each group had three 222 replicate samples for plasmid transfection and cell apoptosis measurement.", [["samples", "ANATOMY", 35, 42], ["plasmid", "ANATOMY", 47, 54], ["cell", "ANATOMY", 72, 76], ["cell", "CELL", 72, 76], ["plasmid transfection", "TREATMENT", 47, 67], ["cell apoptosis measurement", "TEST", 72, 98], ["cell apoptosis", "OBSERVATION", 72, 86]]], ["Each sample was processed 223 following the same procedure described below.", [["sample", "ANATOMY", 5, 11], ["the same procedure", "TREATMENT", 40, 58]]], ["At 12 h prior to transfection, the PC-9 cells were washed 224 with PBS and trypsinized.", [["PC-9 cells", "ANATOMY", 35, 45], ["PC-9 cells", "CELL", 35, 45], ["PC-9 cells", "CELL_LINE", 35, 45], ["transfection", "TEST", 17, 29], ["the PC", "TEST", 31, 37], ["PBS", "TREATMENT", 67, 70]]], ["Gbico RPMI-1640 medium was added into the cells, which were then centrifuged 225 at 1000 rpm for 10 min at 4\u00b0C to remove the supernatant.", [["cells", "ANATOMY", 42, 47], ["supernatant", "ANATOMY", 125, 136], ["Gbico", "CHEMICAL", 0, 5], ["RPMI-1640", "CHEMICAL", 6, 15], ["cells", "CELL", 42, 47], ["Gbico RPMI", "TEST", 0, 10]]], ["Gbico RPMI-1640 medium (Thermo Fisher 226 Scientific, USA) containing 10% fetal bovine serum was added to adjust the solvent to reach a volume of 2 227 \u03bc L and contain 2 \u2573 10 5 cells.", [["fetal bovine serum", "ANATOMY", 74, 92], ["cells", "ANATOMY", 177, 182], ["Gbico RPMI-1640", "CHEMICAL", 0, 15], ["bovine", "ORGANISM", 80, 86], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["cells", "CELL", 177, 182], ["bovine", "SPECIES", 80, 86], ["bovine", "SPECIES", 80, 86], ["Gbico RPMI", "TEST", 0, 10], ["10% fetal bovine serum", "TREATMENT", 70, 92], ["the solvent", "TREATMENT", 113, 124], ["a volume", "TEST", 134, 142]]], ["These cells were seeded in one well of a 6-well plate for plasmid transfection.Comparison of siRNA-duplexes induced by plant and invertebrate viruses 309All the cleaned sRNA-seq reads were aligned to viral genome sequences using the software bowtie v0.12.7 310 with one mismatch.", [["cells", "ANATOMY", 6, 11], ["plasmid", "ANATOMY", 58, 65], ["cells", "CELL", 6, 11], ["cleaned sRNA-seq reads", "DNA", 161, 183], ["viral genome sequences", "DNA", 200, 222], ["These cells", "PROBLEM", 0, 11], ["plasmid transfection", "TREATMENT", 58, 78], ["siRNA-duplexes", "TREATMENT", 93, 107], ["the software bowtie", "TEST", 229, 248], ["transfection", "OBSERVATION", 66, 78], ["siRNA", "OBSERVATION", 93, 98], ["mismatch", "OBSERVATION", 270, 278]]], ["The detection of siRNA duplexes was performed using the program duplexfinder [7] .", [["siRNA duplexes", "TREATMENT", 17, 31], ["siRNA duplexes", "OBSERVATION", 17, 31]]], ["A. 311Comparison of siRNA-duplexes induced by plant and invertebrate viruses 309The read count of siRNA duplexes varies with the duplex length and the overhang length, using data from 312 11 invertebrate viral genomes.", [["invertebrate viral genomes", "DNA", 191, 217], ["A. 311Comparison", "SPECIES", 0, 16], ["siRNA-duplexes", "TREATMENT", 20, 34], ["invertebrate viruses", "PROBLEM", 56, 76], ["The read count", "TEST", 80, 94], ["siRNA duplexes", "PROBLEM", 98, 112], ["the duplex length", "TEST", 125, 142], ["the overhang length", "TEST", 147, 166], ["data", "TEST", 174, 178], ["siRNA duplexes", "OBSERVATION", 98, 112], ["overhang", "OBSERVATION_MODIFIER", 151, 159], ["length", "OBSERVATION_MODIFIER", 160, 166], ["viral genomes", "OBSERVATION", 204, 217]]], ["The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["The copyright holder", "TREATMENT", 0, 20]]], ["It . https://doi.org/10.1101/185876 doi: bioRxiv preprint All the genome sequences are represented by their GenBank accession numbers (e.g. DQ497008).", [["https://doi.org/10.1101/185876", "CHEMICAL", 5, 35], ["genome sequences", "DNA", 66, 82], ["bioRxiv", "TREATMENT", 41, 48]]], ["A. 16-nt, 318 18-nt, 19-nt, 20-nt and 22-nt siRNA duplexes were used for RNAi experiments. *16-nt and 20-nt had not 319 been detected in this study.", [["16-nt, 318 18-nt, 19-nt, 20-nt and 22-nt siRNA duplexes", "DNA", 3, 58], ["16-nt and 20-nt", "DNA", 92, 107], ["nt", "TEST", 17, 19], ["nt", "TEST", 24, 26], ["nt and 22-nt siRNA duplexes", "TREATMENT", 31, 58], ["RNAi experiments", "TREATMENT", 73, 89], ["this study", "TEST", 137, 147]]], ["B. All the homologous sequences at the 22-nt locus on civet betacoronavirus 320 genomes were identical to SARS-CoV-cpsR-22, while one of four genotypes at the 22-nt locus on bat 321 betacoronavirus genomes was identical to SARS-CoV-cpsR-22.", [["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["SARS-CoV", "ORGANISM", 106, 114], ["22-nt locus", "DNA", 39, 50], ["civet betacoronavirus 320 genomes", "DNA", 54, 87], ["SARS-CoV-cpsR-22", "DNA", 106, 122], ["22-nt locus", "DNA", 159, 170], ["bat 321 betacoronavirus genomes", "DNA", 174, 205], ["SARS-CoV-cpsR-22", "DNA", 223, 239], ["SARS-CoV-cpsR-22", "SPECIES", 106, 122], ["SARS-CoV-cpsR-22", "SPECIES", 223, 239], ["All the homologous sequences", "TEST", 3, 31], ["civet betacoronavirus", "TREATMENT", 54, 75], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["cpsR", "TEST", 115, 119], ["four genotypes", "TEST", 137, 151], ["SARS", "TEST", 223, 227], ["CoV", "TEST", 228, 231], ["cpsR", "TEST", 232, 236]]], ["C. The psRNA (heteropalindromic) hsa-tiR-322 MDL1 and cpsRNA SARS-CoV-cpsR-22 can form hairpins.", [["psRNA", "GENE_OR_GENE_PRODUCT", 7, 12], ["MDL1", "GENE_OR_GENE_PRODUCT", 45, 49], ["cpsRNA", "GENE_OR_GENE_PRODUCT", 54, 60], ["cpsR-22", "GENE_OR_GENE_PRODUCT", 70, 77], ["psRNA (heteropalindromic) hsa-tiR-322 MDL1 and cpsRNA SARS-CoV-cpsR-22", "DNA", 7, 77], ["The psRNA", "TEST", 3, 12], ["heteropalindromic", "TEST", 14, 31], ["hsa-tiR", "TEST", 33, 40], ["MDL1", "TEST", 45, 49], ["cpsRNA SARS", "TEST", 54, 65], ["CoV", "TEST", 66, 69], ["cpsR", "TEST", 70, 74]]], ["D. The phylogenetic tree was built by the 323Comparison of siRNA-duplexes induced by plant and invertebrate viruses 309Neighbor Joining (NJ) method using the orf3b gene from human betacoronavirus, eight homologous 324 sequences from bat betacoronavirus and two homologous sequences from civet betacoronavirus.", [["orf3b", "GENE_OR_GENE_PRODUCT", 158, 163], ["human", "ORGANISM", 174, 179], ["betacoronavirus", "CANCER", 180, 195], ["bat betacoronavirus", "ORGANISM", 233, 252], ["orf3b gene", "DNA", 158, 168], ["human betacoronavirus", "DNA", 174, 195], ["homologous 324 sequences", "DNA", 203, 227], ["bat betacoronavirus", "DNA", 233, 252], ["human", "SPECIES", 174, 179], ["human betacoronavirus", "SPECIES", 174, 195], ["bat betacoronavirus", "SPECIES", 233, 252], ["civet betacoronavirus", "SPECIES", 287, 308], ["siRNA-duplexes", "TREATMENT", 59, 73], ["invertebrate viruses", "PROBLEM", 95, 115], ["phylogenetic tree", "OBSERVATION", 7, 24]]], ["The 325Comparison of siRNA-duplexes induced by plant and invertebrate viruses 309branch's length corresponds to an average number of nucleotide changes per 100 nucleotides.", [["nucleotide", "CHEMICAL", 133, 143], ["nucleotide", "CHEMICAL", 133, 143], ["nucleotides", "CHEMICAL", 160, 171], ["siRNA-duplexes", "TREATMENT", 21, 35], ["nucleotide changes", "PROBLEM", 133, 151], ["siRNA", "OBSERVATION", 21, 26], ["viruses", "OBSERVATION", 70, 77], ["branch", "OBSERVATION_MODIFIER", 81, 87], ["length", "OBSERVATION_MODIFIER", 90, 96], ["average", "OBSERVATION_MODIFIER", 115, 122], ["number", "OBSERVATION_MODIFIER", 123, 129]]], ["326 327 Figure 3 .Comparison of siRNA-duplexes induced by plant and invertebrate viruses 309SARS-CoV-cpsR-22 induced cell apoptosis 328 PC-9 cells were divided into six groups named 22, 16, 18, 19, 20 and control for transfection using plasmids 329Comparison of siRNA-duplexes induced by plant and invertebrate viruses 309containing SARS-CoV-cpsR-22, its 16-nt, 18-nt, 19-nt, 20-nt segments.", [["cell", "ANATOMY", 117, 121], ["PC-9 cells", "ANATOMY", 136, 146], ["invertebrate viruses", "ORGANISM", 68, 88], ["309SARS-CoV", "ORGANISM", 89, 100], ["cpsR-22", "CELL", 101, 108], ["cell", "CELL", 117, 121], ["PC-9 cells", "CELL", 136, 146], ["SARS-CoV", "ORGANISM", 333, 341], ["309SARS-CoV-cpsR-22", "DNA", 89, 108], ["plasmids 329Comparison", "DNA", 236, 258], ["SARS-CoV-cpsR-22", "DNA", 333, 349], ["16-nt, 18-nt, 19-nt, 20-nt segments", "DNA", 355, 390], ["SARS-CoV-cpsR-22", "SPECIES", 333, 349], ["siRNA", "TEST", 32, 37], ["invertebrate viruses", "TEST", 68, 88], ["CoV", "TEST", 97, 100], ["cpsR", "TEST", 101, 105], ["cell apoptosis", "TEST", 117, 131], ["PC", "TEST", 136, 138], ["cells", "TEST", 141, 146], ["transfection using plasmids", "TREATMENT", 217, 244], ["siRNA-duplexes", "TREATMENT", 262, 276], ["invertebrate viruses", "TEST", 298, 318], ["SARS", "TEST", 333, 337], ["CoV", "TEST", 338, 341], ["cpsR", "TEST", 342, 346], ["nt", "TEST", 365, 367], ["segments", "ANATOMY_MODIFIER", 382, 390]]], ["Each group had three replicate 330 samples for plasmid transfection and cell apoptosis measurement.", [["samples", "ANATOMY", 35, 42], ["plasmid", "ANATOMY", 47, 54], ["cell", "ANATOMY", 72, 76], ["cell", "CELL", 72, 76], ["plasmid transfection", "TREATMENT", 47, 67], ["cell apoptosis measurement", "TEST", 72, 98], ["cell apoptosis", "OBSERVATION", 72, 86]]], ["Each sample was processed following the 331 same procedure.", [["sample", "ANATOMY", 5, 11], ["same procedure", "TREATMENT", 44, 58]]], ["Cell apoptosis was measured at 72 h after transfection.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell apoptosis", "PROBLEM", 0, 14]]], ["The samples in this figure were 332 selected randomly from their corresponding groups.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["CC-BY-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It . https://doi.org/10.1101/185876 doi: bioRxiv preprint", [["https://doi.org/10.1101/185876", "CHEMICAL", 5, 35], ["bioRxiv", "TREATMENT", 41, 48]]]], "PMC7206178": [["Due to the benefits of online learning, more and more universities combine traditional place-based courses with online education to achieve better teaching results.", [["online learning", "TREATMENT", 23, 38], ["online education", "TREATMENT", 112, 128]]], ["In this study, two types of data are collected from 505 anonymous students to predict at-risk students in a university project-based course.", [["this study", "TEST", 3, 13]]], ["One dataset records the students\u2019 online learning activities of the course which provides a learning platform for self-study.", [["self-study", "TEST", 114, 124]]], ["Section 4 presents the proposed SPDN model.", [["SPDN", "CANCER", 32, 36]]], ["6 concludes this work and discusses future avenues of research.Related Methods of Education Data Mining ::: Related WorkThere has been a large amount of relevant work about the student performance prediction.", [["large", "OBSERVATION_MODIFIER", 137, 142], ["amount", "OBSERVATION_MODIFIER", 143, 149]]], ["In [1, 3, 4, 13], each machine learning model considers different types of predictive features extracted from raw online learning activity records to predict whether students can graduate on time.", [["predictive features", "PROBLEM", 75, 94]]], ["Also generalized linear model is used to predict students\u2019 dropout by extracting features from the original learning website log files such as page click rate, forums and so on [2, 10].", [["generalized", "OBSERVATION_MODIFIER", 5, 16], ["linear", "OBSERVATION_MODIFIER", 17, 23]]], ["The second emerging approach involves the exploration of neural networks (NN).", [["neural networks", "ANATOMY", 57, 72], ["neural networks", "MULTI-TISSUE_STRUCTURE", 57, 72], ["NN", "MULTI-TISSUE_STRUCTURE", 74, 76], ["NN", "CELL_TYPE", 74, 76], ["neural networks", "OBSERVATION", 57, 72]]], ["Because deep learning achieves better performance than traditional machine learning in many respects, work has been done to predict students\u2019 dropout in MOOC through deep neural network (DNN) models [10] and recurrent neural network (RNN) models [6].", [["neural network", "MULTI-TISSUE_STRUCTURE", 171, 185], ["neural network", "MULTI-TISSUE_STRUCTURE", 218, 232], ["traditional machine", "TREATMENT", 55, 74], ["deep", "ANATOMY_MODIFIER", 166, 170], ["neural", "ANATOMY", 171, 177], ["neural network", "ANATOMY", 218, 232]]], ["Different from all current methods which still rely on feature engineering to reduce the input dimension and limit the development of larger NN models, Kim et al. [11] propose GritNet which extracts the original learning behavior sequence from network log as raw input of the RNN model.", [["all current methods", "TREATMENT", 15, 34]]], ["It outperforms the standard logistic-regression based method without complex feature engineering.CNN for Behavioral Feature Learning of Time Series ::: Related WorkThe method of learning a time series feature is to represent a sequence of behaviors within a time window as a low-dimensional vector.", [["a low-dimensional vector", "TREATMENT", 273, 297]]], ["KimCNN [12] is a typical CNN structure, which applies the convolution operation with several different size kernels on every possible location of the activity vector matrix, and use max-pooling to get the most prominent feature.", [["matrix", "CELLULAR_COMPONENT", 166, 172], ["KimCNN", "TEST", 0, 6], ["a typical CNN structure", "PROBLEM", 15, 38], ["the convolution operation", "TREATMENT", 54, 79], ["several different size kernels", "TREATMENT", 85, 115], ["max-pooling", "TREATMENT", 182, 193], ["size", "OBSERVATION_MODIFIER", 103, 107], ["most prominent", "OBSERVATION_MODIFIER", 205, 219]]], ["KimCNN has been used in news recommendation to fuse semantic-level and knowledge-level representations of news [17].", [["KimCNN", "CHEMICAL", 0, 6], ["KimCNN", "PROTEIN", 0, 6], ["KimCNN", "TREATMENT", 0, 6]]], ["Wang et al. proposed knowledge-aware CNN (KCNN) to treat words and entities as multiple channels instead of simple concatenating, and explicitly keeps their alignment relationship during convolution.", [["KCNN", "PROTEIN", 42, 46]]], ["In this paper, we implement this structure to fuse student Internet access activities and learning activities and learning student behavioral representation in MFCNN component.Online Learning Activity ::: Dataset Description and InsightStudents\u2019 online learning activities are extracted from the online learning website log of a university project-based course which spans over 13 weeks from 2018.9.28 to 2018.12.27.", [["MFCNN", "CANCER", 160, 165], ["learning activities", "TREATMENT", 90, 109]]]], "fedd928db5fbfa07819caacf01debbccca353a19": [["I. INTRODUCTIONC ORONAVIRUS disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become global pandemic in less than four months since it was first reported, reaching a 3.3 million confirmed cases and 238,000 death as of May 2nd, 2020.", [["acute respiratory syndrome coronavirus", "DISEASE", 60, 98], ["death", "DISEASE", 247, 252], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 53, 100], ["SARS-CoV-2", "ORGANISM", 102, 112], ["severe acute respiratory syndrome coronavirus", "SPECIES", 53, 98], ["SARS-CoV-2", "SPECIES", 102, 112], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 53, 98], ["SARS-CoV", "TEST", 102, 110], ["global pandemic", "PROBLEM", 126, 141], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86], ["global", "OBSERVATION_MODIFIER", 126, 132], ["pandemic", "OBSERVATION", 133, 141]]], ["Due to its highly contagious nature and lack of appropriate treatment and vaccines, early detection of COVID-19 becomes increasingly important to prevent further spreading and to flatten the curve for proper allocation of limited medical resources.I. INTRODUCTIONCurrently, reverse transcription polymerase chain reaction (RT-PCR), which detects viral nucleic acid, is the golden standard for COVID-19 diagnosis, but RT-PCR results using nasopharyngeal and throat swabs can be affected by sampling errors and low viral load [1] .", [["nasopharyngeal", "ANATOMY", 438, 452], ["throat swabs", "ANATOMY", 457, 469], ["nucleic acid", "CHEMICAL", 352, 364], ["nasopharyngeal", "CANCER", 438, 452], ["throat", "ORGANISM", 457, 463], ["appropriate treatment", "TREATMENT", 48, 69], ["vaccines", "TREATMENT", 74, 82], ["COVID", "TEST", 103, 108], ["further spreading", "PROBLEM", 154, 171], ["limited medical resources", "TREATMENT", 222, 247], ["reverse transcription polymerase chain reaction", "PROBLEM", 274, 321], ["RT-PCR", "TEST", 323, 329], ["viral nucleic acid", "TEST", 346, 364], ["COVID", "TEST", 393, 398], ["RT-PCR", "TEST", 417, 423], ["nasopharyngeal and throat swabs", "PROBLEM", 438, 469], ["sampling errors", "TEST", 489, 504], ["low viral load", "PROBLEM", 509, 523], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["contagious", "OBSERVATION", 18, 28], ["nasopharyngeal", "ANATOMY", 438, 452], ["throat", "ANATOMY", 457, 463]]], ["Antigen tests may be fast, but have poor sensitivity.I. INTRODUCTIONSince most COVID-19 infected patients were diagnosed with pneumonia, radiological examinations may be useful for diagnosis and assessment of disease progress.", [["pneumonia", "DISEASE", 126, 135], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["Antigen tests", "TEST", 0, 13], ["poor sensitivity", "PROBLEM", 36, 52], ["pneumonia", "PROBLEM", 126, 135], ["radiological examinations", "TEST", 137, 162], ["assessment", "TEST", 195, 205], ["pneumonia", "OBSERVATION", 126, 135]]], ["Chest computed tomography (CT) screening on initial patient presentation showed outperforming sensitivity to RT-PCR [2] and even confirmed COVID-19 infection on negative or weakly-positive RT-PCR cases [1] .", [["infection", "DISEASE", 148, 157], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Chest computed tomography (CT) screening", "TEST", 0, 40], ["RT", "TEST", 109, 111], ["PCR", "TEST", 112, 115], ["COVID", "TEST", 139, 144], ["infection", "PROBLEM", 148, 157], ["PCR cases", "TEST", 192, 201], ["infection", "OBSERVATION", 148, 157]]], ["Accordingly, recent COVID-19 radiological literature primarily focused on CT findings [2] , [3] .", [["recent COVID", "TEST", 13, 25], ["radiological literature", "TEST", 29, 52], ["CT findings", "TEST", 74, 85]]], ["However, as the prevalence of COVID-19 increases, the routine use of CT places a huge burden on radiology departments and potential infection of the CT suites; so the need to recognize COVID-19 features on chest X-ray (CXR) is increasing.I. INTRODUCTIONCommon chest X-ray findings reflect those described by CT such as bilateral, peripheral consolidation and/or ground glass opacities [2] , [3] .", [["infection", "DISEASE", 132, 141], ["COVID", "PROTEIN", 185, 190], ["COVID", "TEST", 30, 35], ["CT", "TEST", 69, 71], ["the CT suites", "TEST", 145, 158], ["COVID", "TEST", 185, 190], ["chest X-ray", "TEST", 206, 217], ["CXR", "TEST", 219, 222], ["INTRODUCTIONCommon chest X-ray", "TEST", 241, 271], ["CT", "TEST", 308, 310], ["bilateral, peripheral consolidation", "PROBLEM", 319, 354], ["ground glass opacities", "PROBLEM", 362, 384], ["infection", "OBSERVATION", 132, 141], ["chest", "ANATOMY", 206, 211], ["increasing", "OBSERVATION_MODIFIER", 227, 237], ["chest", "ANATOMY", 260, 265], ["bilateral", "ANATOMY_MODIFIER", 319, 328], ["peripheral", "ANATOMY_MODIFIER", 330, 340], ["consolidation", "OBSERVATION", 341, 354], ["ground glass opacities", "OBSERVATION", 362, 384]]], ["Specifically, Wong et al [4] described frequent chest X-ray (CXR) appearances on COVID-19.", [["frequent chest X-ray", "TEST", 39, 59], ["CXR", "TEST", 61, 64], ["COVID", "TEST", 81, 86], ["chest", "ANATOMY", 48, 53]]], ["Unfortunately, it is reported that chest X-ray findings have a lower sensitivity than initial RT-PCR testing (69% versus 91%, respectively) [4] .", [["chest", "ANATOMY", 35, 40], ["chest X-ray", "TEST", 35, 46], ["a lower sensitivity", "PROBLEM", 61, 80], ["initial RT", "TEST", 86, 96], ["PCR testing", "TEST", 97, 108], ["chest", "ANATOMY", 35, 40]]], ["Despite this low sensitivity, CXR abnormalities were detectable in 9% of patients whose initial RT-PCR was negative.I. INTRODUCTIONAs the COVID-19 pandemic threatens to overwhelm healthcare systems worldwide, CXR may be considered as a tool for identifying COVID-19 if the diagnostic performance with CXR is improved.", [["patients", "ORGANISM", 73, 81], ["CXR", "PROTEIN", 30, 33], ["CXR", "PROTEIN", 301, 304], ["patients", "SPECIES", 73, 81], ["this low sensitivity", "PROBLEM", 8, 28], ["CXR abnormalities", "TEST", 30, 47], ["initial RT-PCR", "TEST", 88, 102], ["CXR", "TEST", 209, 212], ["COVID", "TEST", 257, 262], ["CXR", "TEST", 301, 304]]], ["Even if CXR cannot completely replace the RT-PCR, the indication of pneumonia is a clinical manifestation of patient at higher risk requiring hospitalization, so CXR can be used for patient triage, determining the priority of patients' treatments to help saturated healthcare system in the pandemic situation.", [["pneumonia", "DISEASE", 68, 77], ["patient", "ORGANISM", 109, 116], ["patient", "ORGANISM", 182, 189], ["patients", "ORGANISM", 226, 234], ["CXR", "PROTEIN", 8, 11], ["CXR", "PROTEIN", 162, 165], ["patient", "SPECIES", 109, 116], ["patient", "SPECIES", 182, 189], ["patients", "SPECIES", 226, 234], ["CXR", "TEST", 8, 11], ["the RT-PCR", "TEST", 38, 48], ["pneumonia", "PROBLEM", 68, 77], ["CXR", "TEST", 162, 165], ["patient triage", "TEST", 182, 196], ["patients' treatments", "TREATMENT", 226, 246], ["pneumonia", "OBSERVATION", 68, 77]]], ["This is especially important, since the most frequent known etiology of community acquired pneumonia is bacterial infection in general [5] .", [["pneumonia", "DISEASE", 91, 100], ["bacterial infection", "DISEASE", 104, 123], ["community acquired pneumonia", "PROBLEM", 72, 100], ["bacterial infection", "PROBLEM", 104, 123], ["pneumonia", "OBSERVATION", 91, 100], ["bacterial", "OBSERVATION_MODIFIER", 104, 113], ["infection", "OBSERVATION", 114, 123]]], ["By excluding these population by triage, limited medical resource can be spared substantially.I. INTRODUCTIONAccordingly, deep learning (DL) approaches on chest Xray for COVID-19 classification have been actively explored [6] - [12] .", [["chest", "ANATOMY", 155, 160], ["[6] - [12]", "SIMPLE_CHEMICAL", 222, 232], ["triage", "TEST", 33, 39], ["chest Xray", "TEST", 155, 165], ["COVID", "TEST", 170, 175], ["deep", "ANATOMY_MODIFIER", 122, 126], ["chest", "ANATOMY", 155, 160]]], ["Especially, Wang et al [6] proposed an open source deep convolutional neural network platform called COVID-Net that is tailored for the detection of COVID-19 cases from chest radiography images.", [["chest", "ANATOMY", 169, 174], ["neural network", "MULTI-TISSUE_STRUCTURE", 70, 84], ["COVID", "DNA", 101, 106], ["COVID", "TEST", 149, 154], ["chest radiography images", "TEST", 169, 193], ["chest", "ANATOMY", 169, 174]]], ["They claimed that COVID-Net can achieve good sensitivity for COVID-19 cases with 80% sensitivity.", [["COVID", "TEST", 61, 66]]], ["Inspired by this early success, in this paper we aim to further investigate deep convolutional neural network and evaluate its feasibility for COVID-19 diagnosis.", [["convolutional neural network", "ANATOMY", 81, 109], ["neural network", "MULTI-TISSUE_STRUCTURE", 95, 109], ["deep convolutional neural network", "PROBLEM", 76, 109], ["COVID", "TEST", 143, 148]]], ["Unfortunately, under the current public health emergency, it is difficult to collect large set of well-curated data for training neural networks.", [["neural networks", "ANATOMY", 129, 144], ["neural networks", "MULTI-TISSUE_STRUCTURE", 129, 144], ["training neural networks", "TREATMENT", 120, 144]]], ["Therefore, one of the main focuses of this paper is to develop a neural network architecture that is suitable for training with limited training data set, which can still produce radiologically interpretable results.", [["neural network", "ANATOMY", 65, 79], ["limited training data", "TEST", 128, 149], ["main", "OBSERVATION_MODIFIER", 22, 26], ["neural network", "OBSERVATION", 65, 79]]], ["Since most frequently observed distribution patterns of COVID-19 in CXR are bilateral involvement, peripheral distribution and ground-glass opacification (GGO) [13] , a properly designed neural network should reflect such radiological findings.I. INTRODUCTIONTo achieve this goal, we first investigate several imaging biomarkers that are often used in CXR analysis, such as lung area intensity distribution, the cardio-thoracic ratio, etc. Our analysis found that there are statistically significant differences in the patch-wise intensity distribution, which is well-correlated with the radiological findings of the localized intensity variations in COVID-19 CXR.", [["neural network", "ANATOMY", 187, 201], ["lung area", "ANATOMY", 374, 383], ["thoracic", "ANATOMY", 419, 427], ["GGO", "DISEASE", 155, 158], ["COVID-19", "GENE_OR_GENE_PRODUCT", 56, 64], ["CXR", "CANCER", 68, 71], ["neural network", "MULTI-TISSUE_STRUCTURE", 187, 201], ["lung", "ORGAN", 374, 378], ["COVID-19", "DNA", 56, 64], ["CXR", "DNA", 68, 71], ["COVID-19 CXR", "DNA", 651, 663], ["COVID", "TEST", 56, 61], ["CXR", "TEST", 68, 71], ["bilateral involvement", "PROBLEM", 76, 97], ["peripheral distribution and ground-glass opacification (GGO)", "PROBLEM", 99, 159], ["a properly designed neural network", "PROBLEM", 167, 201], ["several imaging biomarkers", "TEST", 302, 328], ["CXR analysis", "TEST", 352, 364], ["the cardio-thoracic ratio", "TEST", 408, 433], ["Our analysis", "TEST", 440, 452], ["the localized intensity variations", "PROBLEM", 613, 647], ["COVID", "TEST", 651, 656], ["CXR", "TEST", 660, 663], ["bilateral", "ANATOMY_MODIFIER", 76, 85], ["involvement", "OBSERVATION", 86, 97], ["peripheral", "ANATOMY_MODIFIER", 99, 109], ["distribution", "OBSERVATION_MODIFIER", 110, 122], ["ground-glass opacification", "OBSERVATION", 127, 153], ["lung", "ANATOMY", 374, 378], ["area", "ANATOMY_MODIFIER", 379, 383], ["cardio", "ANATOMY", 412, 418], ["thoracic ratio", "ANATOMY", 419, 433], ["statistically", "OBSERVATION_MODIFIER", 474, 487], ["significant", "OBSERVATION_MODIFIER", 488, 499], ["differences", "OBSERVATION_MODIFIER", 500, 511], ["localized", "OBSERVATION_MODIFIER", 617, 626], ["intensity", "OBSERVATION_MODIFIER", 627, 636]]], ["This findings lead us to propose a novel patch-based deep neural network architecture with random patch cropping, from which the final classification result are obtained by majority voting from inference results at multiple patch locations.", [["neural network", "ANATOMY", 58, 72], ["neural network", "MULTI-TISSUE_STRUCTURE", 58, 72], ["a novel patch", "TREATMENT", 33, 46], ["random patch cropping", "TREATMENT", 91, 112], ["deep", "ANATOMY_MODIFIER", 53, 57], ["neural network", "ANATOMY", 58, 72]]], ["One of the important advantages of the proposed method is that due to the patch training the network complexity is relative small and multiple patches in each image can be used to augment training data set, so that even with the limited data set the neural network can be trained efficiently without overfitting.", [["neural network", "ANATOMY", 250, 264], ["network", "MULTI-TISSUE_STRUCTURE", 93, 100], ["neural network", "MULTI-TISSUE_STRUCTURE", 250, 264], ["the patch training", "TREATMENT", 70, 88], ["training data", "TEST", 188, 201], ["overfitting", "PROBLEM", 300, 311], ["small", "OBSERVATION_MODIFIER", 124, 129], ["multiple", "OBSERVATION_MODIFIER", 134, 142], ["patches", "OBSERVATION_MODIFIER", 143, 150]]], ["By combining with our novel preprocessing step to normalize the data heterogeneities and bias, we demonstrate that the proposed network architecture provides better sensitivity and interpretability, compared to the existing COVID-Net [6] with the same data set.I. INTRODUCTIONFurthermore, by extending the idea of the gradient-weighted class activation map (Grad-CAM) [14] , yet another important contribution of this paper is a novel probabilistic Grad-CAM that takes into account of patch-wise disease probability in generating global saliency map.", [["COVID", "DNA", 224, 229], ["the gradient", "TEST", 314, 326], ["wise disease probability", "PROBLEM", 491, 515]]], ["The resulting class activation map clearly show the interpretable results that are well correlated with radiological findings.II. PROPOSED NETWORK ARCHITECTUREThe overall algorithmic framework is given in Fig. 1 .", [["II", "CHEMICAL", 126, 128], ["radiological findings", "TEST", 104, 125], ["ARCHITECTURE", "OBSERVATION_MODIFIER", 147, 159]]], ["The CXR images are first pre-processed for data normalization, after which the pre-processed data are fed into a segmentation network, from which lung areas can be extracted as shown in Fig. 1(a) .", [["lung areas", "ANATOMY", 146, 156], ["lung", "ORGAN", 146, 150], ["The CXR images", "TEST", 0, 14], ["the pre-processed data", "TEST", 75, 97], ["a segmentation network", "TEST", 111, 133], ["lung", "ANATOMY", 146, 150]]], ["From the segmented lung area, classification network is used to classify the corresponding diseases using a patch-by-patch training and inference, after which the final decision is made based on the majority voting as shown in Fig. 1(b) .", [["lung area", "ANATOMY", 19, 28], ["lung area", "MULTI-TISSUE_STRUCTURE", 19, 28], ["the corresponding diseases", "PROBLEM", 73, 99], ["a patch-by-patch training", "TREATMENT", 106, 131], ["segmented", "ANATOMY_MODIFIER", 9, 18], ["lung", "ANATOMY", 19, 23], ["area", "ANATOMY_MODIFIER", 24, 28]]], ["Additionally, a probabilistic Grad-CAM saliency map is calculated to provide an interpretable result.", [["a probabilistic Grad-CAM saliency map", "TEST", 14, 51]]], ["In the following, each network is described in detail.A. Segmentation networkOur segmentation network aims to extract lung and heart contour from the chest radiography images.", [["lung", "ANATOMY", 118, 122], ["heart", "ANATOMY", 127, 132], ["chest", "ANATOMY", 150, 155], ["lung", "ORGAN", 118, 122], ["heart", "ORGAN", 127, 132], ["the chest radiography images", "TEST", 146, 174], ["lung", "ANATOMY", 118, 122], ["heart", "ANATOMY", 127, 132], ["contour", "ANATOMY_MODIFIER", 133, 140], ["chest", "ANATOMY", 150, 155]]], ["We adopted an extended fully convolutional (FC)-DenseNet103 to perform semantic segmentation [15] .", [["DenseNet103", "DNA", 48, 59], ["semantic segmentation", "TEST", 71, 92]]], ["Segmentation networkwhere L(\u0398) is the cross entropy loss of multi-categorical semantic segmentation and \u0398 denotes the network parameter set, which is composed of filter kernel weights and biases.", [["Segmentation", "TEST", 0, 12], ["the cross entropy loss of multi-categorical semantic segmentation", "PROBLEM", 34, 99], ["semantic segmentation", "OBSERVATION", 78, 99], ["filter kernel", "OBSERVATION", 162, 175]]], ["Specifically, L(\u0398) is defined asA.", [["L(\u0398)", "GENE_OR_GENE_PRODUCT", 14, 18], ["asA", "GENE_OR_GENE_PRODUCT", 30, 33], ["L(\u0398)", "PROTEIN", 14, 18], ["asA", "PROTEIN", 30, 33], ["asA", "TREATMENT", 30, 33], ["asA", "OBSERVATION", 30, 33]]], ["Segmentation networkwhere 1(\u00b7) is the indicator function, p \u0398 (x j ) denotes the softmax probability of the j-th pixel in a CXR image x, and y j denotes the corresponding ground truth label. s denotes class category, i.e., s \u2208 {background, heart, left lung, right lung}. \u03bb s denotes weights given to each class category.A. Segmentation networkCXR images from different dataset resources may induce heterogeneity in their bits depth, compression type, image size, acquisition condition, scanning protocol, postprocessing, etc. Therefore, we develop a universal preprocessing step for data normalization to ensure uniform intensity histogram throughout the entire dataset.", [["heart", "ANATOMY", 240, 245], ["left lung", "ANATOMY", 247, 256], ["right lung}", "ANATOMY", 258, 269], ["heart", "ORGAN", 240, 245], ["lung", "ORGAN", 252, 256], ["a CXR image", "TEST", 122, 133], ["heart, left lung, right lung}", "PROBLEM", 240, 269], ["A. Segmentation networkCXR images", "TEST", 320, 353], ["scanning protocol", "TEST", 486, 503], ["data normalization", "TEST", 583, 601], ["uniform intensity histogram", "TEST", 612, 639], ["heart", "ANATOMY", 240, 245], ["left", "ANATOMY_MODIFIER", 247, 251], ["lung", "ANATOMY", 252, 256], ["right", "ANATOMY_MODIFIER", 258, 263], ["compression", "OBSERVATION", 433, 444], ["size", "OBSERVATION_MODIFIER", 457, 461]]], ["The detailed preprocessing steps are as follows:A. Segmentation network1) Data type casting (from uint8/uint16 to float32) 2) Histogram equalization (gray level = [0, 255.0]) 3) Gamma correction (\u03b3 = 0.5) 4) Image resize (height, width = [256, 256]) Using the preprocessed data, we trained FC-DenseNet103 [15] as our backbone segmentation network architecture.", [["network architecture", "MULTI-TISSUE_STRUCTURE", 339, 359], ["type casting", "TEST", 79, 91], ["Histogram equalization", "TEST", 126, 148], ["gray level", "TEST", 150, 160], ["Gamma correction (\u03b3", "TEST", 178, 197], ["Image resize (height, width", "TEST", 208, 235]]], ["We applied Adam optimizer [16] with an initial learning rate of 0.0001.", [["an initial learning rate", "TEST", 36, 60]]], ["Whenever training loss did not improve by certain criterion, the learning rate was reduced by factor 10.", [["training loss", "PROBLEM", 9, 22]]], ["We adopted early stopping strategy based on validation performance.", [["early stopping strategy", "TREATMENT", 11, 34], ["validation performance", "TEST", 44, 66]]], ["Batch size was optimized to 2.", [["Batch size", "TEST", 0, 10], ["size", "OBSERVATION_MODIFIER", 6, 10]]], ["We implemented the network using PyTorch library [17] .B. Classification networkThe classification network aims to classify the chest X-ray images according to the types of disease.", [["the chest X-ray images", "TEST", 124, 146], ["disease", "PROBLEM", 173, 180], ["chest", "ANATOMY", 128, 133], ["disease", "OBSERVATION", 173, 180]]], ["The first is to prevent from overfitting, since it is known that overfitting can occur when using an overly complex model for small number of data.", [["overfitting", "PROBLEM", 29, 40], ["overfitting", "OBSERVATION", 29, 40]]], ["Secondly, we intended to do transfer learning with pre-trained weights from ImageNet to compensate for the small training data set.", [["the small training data", "TEST", 103, 126]]], ["We found that these strategy make the training stable even when the dataset size is small.B. Classification networkThe labels were divided into four classes: normal, bacterial pneumonia, tuberculosis (TB), and viral pneumonia which includes the pneumonia caused by COVID-19 infection.", [["bacterial pneumonia", "DISEASE", 166, 185], ["tuberculosis", "DISEASE", 187, 199], ["TB", "DISEASE", 201, 203], ["viral pneumonia", "DISEASE", 210, 225], ["pneumonia", "DISEASE", 245, 254], ["COVID-19", "CHEMICAL", 265, 273], ["infection", "DISEASE", 274, 283], ["COVID-19", "SPECIES", 265, 273], ["bacterial pneumonia", "PROBLEM", 166, 185], ["tuberculosis (TB)", "PROBLEM", 187, 204], ["viral pneumonia", "PROBLEM", 210, 225], ["the pneumonia", "PROBLEM", 241, 254], ["COVID-19 infection", "PROBLEM", 265, 283], ["stable", "OBSERVATION_MODIFIER", 47, 53], ["size", "OBSERVATION_MODIFIER", 76, 80], ["small", "OBSERVATION_MODIFIER", 84, 89], ["normal", "OBSERVATION", 158, 164], ["bacterial", "OBSERVATION_MODIFIER", 166, 175], ["pneumonia", "OBSERVATION", 176, 185], ["tuberculosis", "OBSERVATION", 187, 199], ["viral", "OBSERVATION_MODIFIER", 210, 215], ["pneumonia", "OBSERVATION", 216, 225], ["pneumonia", "OBSERVATION", 245, 254], ["infection", "OBSERVATION", 274, 283]]], ["We assigned the same class for viral pneumonia from other viruses (e.g. SARS-cov or MERS-cov) with COVID-19, since it is reported that they have similar radiologic features even challenging for the experienced radiologists [18] .", [["pneumonia", "DISEASE", 37, 46], ["SARS", "DISEASE", 72, 76], ["COVID-19", "DNA", 99, 107], ["viral pneumonia", "PROBLEM", 31, 46], ["other viruses", "PROBLEM", 52, 65], ["COVID", "TEST", 99, 104], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["pneumonia", "OBSERVATION", 37, 46]]], ["Rather, we concentrated on more feasible work such as distinguishing bacterial pneumonia or tuberculosis from viral pneumonia, which show considerable differences in the radiologic features and are still useful for patient triage.B. Classification networkThe pre-processed images were first masked with the lung masks from the segmentation networks, which are then fed into a classification network.", [["lung", "ANATOMY", 307, 311], ["pneumonia", "DISEASE", 79, 88], ["tuberculosis", "DISEASE", 92, 104], ["viral pneumonia", "DISEASE", 110, 125], ["patient", "ORGANISM", 215, 222], ["lung", "ORGAN", 307, 311], ["patient", "SPECIES", 215, 222], ["bacterial pneumonia", "PROBLEM", 69, 88], ["tuberculosis", "PROBLEM", 92, 104], ["viral pneumonia", "PROBLEM", 110, 125], ["patient triage", "TEST", 215, 229], ["The pre-processed images", "TEST", 255, 279], ["the lung masks", "TREATMENT", 303, 317], ["bacterial", "OBSERVATION_MODIFIER", 69, 78], ["pneumonia", "OBSERVATION", 79, 88], ["tuberculosis", "OBSERVATION", 92, 104], ["viral", "OBSERVATION_MODIFIER", 110, 115], ["pneumonia", "OBSERVATION", 116, 125], ["considerable", "OBSERVATION_MODIFIER", 138, 150], ["differences", "OBSERVATION_MODIFIER", 151, 162], ["lung", "ANATOMY", 307, 311], ["masks", "OBSERVATION", 312, 317]]], ["In the global approach, the masked images were resized to 224 \u00d7 224, which were fed into the network.", [["the masked images", "TEST", 24, 41]]], ["This approach is focusing on the global appearance of the CXR data, and was used as a baseline network for comparison.", [["CXR", "PROTEIN", 58, 61], ["the CXR data", "TEST", 54, 66]]], ["In fact, many of the existing researches employs similar procedure [6] - [9] .B. Classification networkIn the local patch-based approach, which is our proposed method, the masked images were cropped randomly with a size of 224 \u00d7 224, and resulting patches were used as the network inputs as shown in Fig. 1(b) .", [["similar procedure", "TREATMENT", 49, 66], ["the masked images", "TEST", 168, 185], ["size", "OBSERVATION_MODIFIER", 215, 219]]], ["In contrast to the global approach, various CXR images are resized to a much bigger 1024\u00d71024 image for our classification network to reflect the original pixel distribution better.", [["various CXR images", "TEST", 36, 54], ["pixel distribution", "OBSERVATION", 155, 173]]], ["Therefore, the segmentation mask from Fig. 1 (a) are upsampled to match the 1024 \u00d7 1024 image size.", [["the segmentation mask", "TREATMENT", 11, 32], ["size", "OBSERVATION_MODIFIER", 94, 98]]], ["To avoid cropping the patch from the empty area of the masked image, the centers of patches were randomly selected within the lung areas.", [["lung areas", "ANATOMY", 126, 136], ["lung", "ORGAN", 126, 130], ["cropping the patch", "TREATMENT", 9, 27], ["lung", "ANATOMY", 126, 130], ["areas", "ANATOMY_MODIFIER", 131, 136]]], ["The number K was chosen to sufficiently cover all lung pixels multiple times.", [["lung pixels", "ANATOMY", 50, 61], ["lung", "ORGAN", 50, 54], ["The number K", "TREATMENT", 0, 12], ["lung", "ANATOMY", 50, 54], ["pixels", "OBSERVATION", 55, 61]]], ["Then, each patch was fed into the network to generate network output, and among K network output the final decision was made based on majority voting, i.e. the most frequently declared class were regarded as final output as depicted in Fig. 1(b) .", [["K network", "MULTI-TISSUE_STRUCTURE", 80, 89], ["each patch", "TREATMENT", 6, 16], ["among K network output", "TEST", 74, 96]]], ["In this experiments, the number of random patches K was set to 100, which means that 100 patches were generated randomly from one whole image for majority voting.B. Classification networkFor network training, pre-trained parameters from ImageNet are used for network weight initialization, after which the network was trained using the CXR data.", [["random patches K", "TEST", 35, 51], ["network training", "TREATMENT", 191, 207], ["network weight initialization", "TREATMENT", 259, 288], ["the CXR data", "TEST", 332, 344]]], ["As for optimization algorithm, Adam optimizer [16] with learning rate of 0.00001 was applied.", [["optimization algorithm", "TEST", 7, 29], ["learning rate", "TREATMENT", 56, 69]]], ["The network were trained for 100 epochs, but we adopted early stopping strategy based on validation performance metrics.", [["early stopping strategy", "TREATMENT", 56, 79]]], ["The batch size of 16 was used.", [["The batch size", "TEST", 0, 14], ["size", "OBSERVATION_MODIFIER", 10, 14]]], ["We applied weight decay and L 1 regularization to prevent overfitting problem.", [["weight decay", "TREATMENT", 11, 23], ["L 1 regularization", "TREATMENT", 28, 46], ["overfitting problem", "PROBLEM", 58, 77], ["overfitting", "OBSERVATION", 58, 69]]], ["The classification network was also implemented by Pytorch library.C. Probabilistic Grad-CAM saliency map visualizationWe investigate the interpretability of our approach by visualizing a saliency map.", [["Pytorch library", "DNA", 51, 66], ["a saliency map", "TEST", 186, 200]]], ["One of the most widely used saliency map visualization methods is so-called gradient weighted class activation map (Grad-CAM) [14] .", [["saliency map visualization methods", "TREATMENT", 28, 62], ["most widely", "OBSERVATION_MODIFIER", 11, 22]]], ["Probabilistic Grad-CAM saliency map visualizationwhere f k (x) \u2208 R u\u00d7v is the k-th feature channel at the last convolution layer (which corresponds to the layer 4 of ResNet-18 in our case), UP(\u00b7) denotes the upsampling operator from a u\u00d7v feature map to the m\u00d7n image, \u03c3(\u00b7) is the rectified linear unit (ReLU) [14] .", [["R u\u00d7v", "GENE_OR_GENE_PRODUCT", 65, 70], ["k-th feature channel", "PROTEIN", 78, 98], ["ResNet", "PROTEIN", 166, 172], ["upsampling operator", "DNA", 208, 227], ["Probabilistic Grad-CAM saliency map", "TEST", 0, 35], ["ResNet", "TEST", 166, 172], ["convolution", "OBSERVATION_MODIFIER", 111, 122], ["layer", "OBSERVATION_MODIFIER", 123, 128], ["layer", "OBSERVATION_MODIFIER", 155, 160]]], ["Here, \u03b1 c k is the feature weighted parameter for the class c, which can be obtained byC.", [["\u03b1 c k", "GENE_OR_GENE_PRODUCT", 6, 11], ["\u03b1 c k", "DNA", 6, 11]]], ["Probabilistic Grad-CAM saliency map visualizationfor some scaling parameter Z, where y c is the score for the class c before the softmax layer and f k i denotes the i-th pixel value of f k (x).", [["Probabilistic Grad-CAM saliency map", "TREATMENT", 0, 35]]], ["The Grad-CAM map l c is then normalized to have value in [0, 1].", [["The Grad-CAM map l c", "TEST", 0, 20], ["value", "TEST", 48, 53]]], ["The Grad-CAM for the global approach is used as a baseline saliency map.C. Probabilistic Grad-CAM saliency map visualizationHowever, care should be taken in applying Grad-CAM to our local patch-based approach, since each patch has different score for the COVID-19 class.", [["Grad-CAM", "MULTI-TISSUE_STRUCTURE", 4, 12], ["Grad-CAM", "DNA", 4, 12], ["a baseline saliency map", "TEST", 48, 71], ["our local patch", "TREATMENT", 178, 193]]], ["Therefore, to obtain the global saliency map, patch-wise Grad-CAM saliency maps should be weighted with the estimated probability of the class, and their average value should be computed.", [["CAM", "MULTI-TISSUE_STRUCTURE", 62, 65], ["the global saliency map", "TEST", 21, 44], ["patch", "TREATMENT", 46, 51], ["Grad-CAM saliency maps", "TREATMENT", 57, 79]]], ["More specifically, our probabilistic Grad-CAM with respect to the input image x \u2208 R m\u00d7n has the following value at the i-th pixel location:C. Probabilistic Grad-CAM saliency map visualizationwhere x k \u2208 R p\u00d7q denotes the k-th input patch, Q k : R p\u00d7q \u2192 R m\u00d7n refers to the operator that copies the p \u00d7 q-size k-th patch into the appropriate location of a zero-padded image in R m\u00d7n , and l c (x k ) \u2208 R p\u00d7q denotes the Grad-CAM computed by (3) with respect to the input patch x k \u2208 R p\u00d7q , and K i denotes the number of the frequency of the i-th pixel in the total K patches.", [["K", "CHEMICAL", 565, 566], ["R p\u00d7q", "GENE_OR_GENE_PRODUCT", 401, 406], ["R p\u00d7q", "DNA", 203, 208], ["R p\u00d7q \u2192 R m\u00d7n", "DNA", 245, 258], ["p \u00d7 q", "DNA", 298, 303], ["R p\u00d7q", "PROTEIN", 401, 406], ["Grad-CAM", "PROTEIN", 419, 427], ["the input image", "TEST", 62, 77], ["visualizationwhere", "TEST", 178, 196], ["k", "TEST", 199, 200], ["the p \u00d7 q-size k-th patch", "TREATMENT", 294, 319], ["a zero-padded image", "TREATMENT", 353, 372], ["the input patch", "TREATMENT", 460, 475], ["the i-th pixel", "TREATMENT", 537, 551], ["the total K patches", "TREATMENT", 555, 574]]], ["Additionally, the class probability r c (x k ) for the k-th patch can be readily calculated after the softmax layer.", [["the k-th patch", "TREATMENT", 51, 65]]], ["(5) when constructing a global saliency map.III. METHOD A. DatasetWe used public CXR datasets, whose characteristics are summarized in Table I and Table II .", [["a global saliency map", "TEST", 22, 43], ["public CXR datasets", "TEST", 74, 93]]], ["In particular, the data in Table I are used for training and validation of the segmentation networks, since the ground-truth segmentation masks are available.", [["training", "TREATMENT", 48, 56], ["the segmentation networks", "TEST", 75, 100]]], ["The curated data in Table II are from some of the data in Table I as well as other COVID-19 resources, which were used for training, validation, and test for the classification network.", [["validation", "TEST", 133, 143]]], ["More detailed descriptions of the dataset are follows.III. METHOD A. Dataset1) Segmentation network dataset: The JSRT dataset was released by the Japanese Society of Radiological Technology (JSRT) [19] .", [["The JSRT dataset", "TREATMENT", 109, 125]]], ["Total 247 chest posteroanterior (PA) radiographs were collected from 14 institutions including normal and lung nodule cases.", [["chest", "ANATOMY", 10, 15], ["lung nodule", "ANATOMY", 106, 117], ["chest posteroanterior", "MULTI-TISSUE_STRUCTURE", 10, 31], ["lung nodule", "CANCER", 106, 117], ["Total 247 chest posteroanterior (PA) radiographs", "TEST", 0, 48], ["chest", "ANATOMY", 10, 15], ["normal", "OBSERVATION", 95, 101], ["lung", "ANATOMY", 106, 110], ["nodule", "OBSERVATION", 111, 117]]], ["Corresponding segmentation masks were collected from the SCR database [20] .", [["Corresponding segmentation masks", "PROBLEM", 0, 32], ["the SCR database", "TEST", 53, 69], ["segmentation masks", "OBSERVATION", 14, 32]]], ["The JSRT/SCR dataset were randomly split into training (80%) and validation (20%).", [["JSRT/SCR dataset", "DNA", 4, 20], ["The JSRT/SCR dataset", "TREATMENT", 0, 20], ["validation", "TEST", 65, 75]]], ["Total 138 chest PA radiographs were collected including normal, tuberculosis cases and corresponding lung segmentation masks.", [["chest", "ANATOMY", 10, 15], ["lung", "ANATOMY", 101, 105], ["tuberculosis", "DISEASE", 64, 76], ["lung", "ORGAN", 101, 105], ["Total 138 chest PA radiographs", "TEST", 0, 30], ["chest", "ANATOMY", 10, 15], ["normal", "OBSERVATION", 56, 62], ["tuberculosis", "OBSERVATION", 64, 76], ["lung", "ANATOMY", 101, 105], ["segmentation masks", "OBSERVATION", 106, 124]]], ["Specifically, for normal cases, the JSRT dataset and the NLM dataset from the segmentation validation dataset were included.", [["JSRT dataset", "DNA", 36, 48], ["the segmentation validation dataset", "TEST", 74, 109]]], ["For comparing COVID-19 from normal and different lung diseases, data were also collected from different sources [22] , [23] , including additional normal cases.", [["lung", "ANATOMY", 49, 53], ["lung diseases", "DISEASE", 49, 62], ["COVID-19", "CANCER", 14, 22], ["lung", "ORGAN", 49, 53], ["COVID-19", "DNA", 14, 22], ["COVID", "TEST", 14, 19], ["different lung diseases", "PROBLEM", 39, 62], ["lung", "ANATOMY", 49, 53], ["diseases", "OBSERVATION", 54, 62]]], ["These datasets were selected because they are fully accessible to any research group, and they provide the labels with detailed diagnosis of disease.", [["disease", "PROBLEM", 141, 148], ["disease", "OBSERVATION", 141, 148]]], ["This enables more specific classification of pneumonia into bacterial and viral pneumonia, which should be classified separately because of their distinct clinical and radiologic differences.III. METHOD A. DatasetIn the collected data from the public dataset [22] , over 80% was pediatric CXR from Guangzhou Women and Childrens Medical Center [24] .", [["pneumonia", "DISEASE", 45, 54], ["pneumonia", "DISEASE", 80, 89], ["Women", "SPECIES", 308, 313], ["pneumonia into bacterial and viral pneumonia", "PROBLEM", 45, 89], ["pediatric CXR", "TEST", 279, 292], ["pneumonia", "OBSERVATION", 45, 54], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["viral", "OBSERVATION_MODIFIER", 74, 79], ["pneumonia", "OBSERVATION", 80, 89]]], ["Therefore, to avoid the network from learning biased features from age-related characteristics, we excluded pediatric CXR images.", [["pediatric CXR images", "TEST", 108, 128]]], ["This is because we aim to utilize CXR radiography with unbiased age distribution for more accurate evaluation of deep neural networks for COVID-19 classification.", [["neural networks", "ANATOMY", 118, 133], ["neural networks", "MULTI-TISSUE_STRUCTURE", 118, 133], ["CXR radiography", "TEST", 34, 49], ["accurate evaluation", "TEST", 90, 109], ["COVID", "TEST", 138, 143], ["deep", "ANATOMY_MODIFIER", 113, 117], ["neural", "ANATOMY", 118, 124]]], ["Total dataset was curated into five classes; normal, tuberculosis, bacterial pneumoia, viral pneumonia, COVID-19 pneumonia.", [["tuberculosis", "DISEASE", 53, 65], ["bacterial pneumoia", "DISEASE", 67, 85], ["viral pneumonia", "DISEASE", 87, 102], ["pneumonia", "DISEASE", 113, 122], ["Total dataset", "TREATMENT", 0, 13], ["tuberculosis", "PROBLEM", 53, 65], ["bacterial pneumoia", "PROBLEM", 67, 85], ["viral pneumonia", "PROBLEM", 87, 102], ["COVID", "PROBLEM", 104, 109], ["pneumonia", "PROBLEM", 113, 122], ["normal", "OBSERVATION", 45, 51], ["tuberculosis", "OBSERVATION", 53, 65], ["bacterial pneumoia", "OBSERVATION", 67, 85], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["pneumonia", "OBSERVATION", 93, 102], ["pneumonia", "OBSERVATION", 113, 122]]], ["The numbers of each disease class from the data set are summarized in Table III .", [["numbers", "OBSERVATION_MODIFIER", 4, 11], ["each", "OBSERVATION_MODIFIER", 15, 19], ["disease", "OBSERVATION", 20, 27]]], ["Specifically, a total of 180 radiography images of 118 subjects from COVID-19 image data collection were included.", [["180 radiography images", "TEST", 25, 47], ["COVID", "TEST", 69, 74], ["image data collection", "TEST", 78, 99]]], ["Moreover, a total of 322 chest radiography images from different subjects were used, which include 191, 54, and 20 images for normal, bacterial pneumonia, and viral pneumonia (not including COVID-19), respectively.", [["pneumonia", "DISEASE", 144, 153], ["viral pneumonia", "DISEASE", 159, 174], ["322 chest radiography images", "TEST", 21, 49], ["bacterial pneumonia", "PROBLEM", 134, 153], ["viral pneumonia", "PROBLEM", 159, 174], ["COVID", "TEST", 190, 195], ["chest", "ANATOMY", 25, 30], ["bacterial", "OBSERVATION_MODIFIER", 134, 143], ["pneumonia", "OBSERVATION", 144, 153], ["viral", "OBSERVATION_MODIFIER", 159, 164], ["pneumonia", "OBSERVATION", 165, 174]]], ["The combined dataset were randomly split into train, validation, and test sets with the ratio of 0.7, 0.1, and 0.2.III. METHOD A. Dataset3) Dataset for comparison with COVID-Net: We prepared a separate dataset to compare our method with existing stateof-the art (SOTA) algorithm called COVID-Net [6] .", [["test sets", "TEST", 69, 78], ["the ratio", "TEST", 84, 93]]], ["COVID-19 image data collection was combined with RSNA Pneumonia Detection Challenge dataset as described in [6] for a fair comparison between our method and COVID-Net.", [["Pneumonia", "DISEASE", 54, 63], ["COVID", "DNA", 0, 5], ["COVID", "TEST", 0, 5], ["image data collection", "TEST", 9, 30], ["RSNA Pneumonia", "PROBLEM", 49, 63], ["Pneumonia", "OBSERVATION", 54, 63]]], ["The reason we separately train our network with the COVID-Net data set is that RSNA Pneumonia Detection Challenge dataset provide only the information regarding the presence of pneumonia, rather than the detailed diagnosis of disease, so that the labels were divided into only three categories including normal, pneumonia, and COVID-19 as in Table IV .", [["Pneumonia", "DISEASE", 84, 93], ["pneumonia", "DISEASE", 177, 186], ["pneumonia", "DISEASE", 312, 321], ["COVID", "DNA", 52, 57], ["RSNA Pneumonia", "PROBLEM", 79, 93], ["pneumonia", "PROBLEM", 177, 186], ["disease", "PROBLEM", 226, 233], ["pneumonia", "PROBLEM", 312, 321], ["COVID", "TEST", 327, 332], ["Pneumonia", "OBSERVATION", 84, 93], ["pneumonia", "OBSERVATION", 177, 186], ["disease", "OBSERVATION", 226, 233], ["normal", "OBSERVATION", 304, 310], ["pneumonia", "OBSERVATION", 312, 321]]], ["More specifically, there were 8,851 normal and 6,012 pneumonia chest radiography images from 13,645 patients in RSNA Pneumonia Detection Challenge dataset, and these images were combined with COVID-19 image data collection to compose a total dataset.", [["pneumonia", "DISEASE", 53, 62], ["Pneumonia", "DISEASE", 117, 126], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["pneumonia chest radiography images", "TEST", 53, 87], ["RSNA Pneumonia", "PROBLEM", 112, 126], ["these images", "TEST", 160, 172], ["COVID", "TEST", 192, 197], ["chest", "ANATOMY", 63, 68], ["RSNA", "ANATOMY", 112, 116], ["Pneumonia", "OBSERVATION", 117, 126]]], ["Among these, 100 normal, 100 pneumonia, and 10 COVID-19 images were randomly selected for validation and test set, respecitvely as in [6] .", [["pneumonia", "DISEASE", 29, 38], ["pneumonia", "PROBLEM", 29, 38], ["COVID", "TEST", 47, 52], ["images", "TEST", 56, 62], ["validation and test set", "TEST", 90, 113], ["pneumonia", "OBSERVATION", 29, 38]]], ["Although we believe our categorization into normal, bacterial, TB, and viral+COVID-19 cases is more correlated with the radiological findings and practically useful in clinical environment [18] , we conducted this additional comparison experiments with the data set in Table IV to demonstrate that our algorithm provides competitive performance compared to COVID-Net in the same experiment set-up.B. Statistical Analysis of Potential CXR COVID-19 markersThe following standard biomarkers from CXR image analysis are investigated.B. Statistical Analysis of Potential CXR COVID-19 markers\u2022 Lung morphology: Morphological structures of the segmented lung area as illustrated in Fig. 2 (b) was evaluated throughout different classes. \u2022 Mean lung intensity: From the segmented lung area, we calculated mean value of the pixel intensity within the lung area as shown in Fig. 2 (c). \u2022 Standard deviation of lung intensity: From the intensity histogram of lung area pixels, we calculated one standard deviation which is indicated as the black double-headed arrow in Fig. 2 (c). \u2022 Cardiothoracic Ratio (CTR): CTR can be calculated by dividing the maximal transverse cardiac diameter by the maximal internal thoracic diameter annotated repectively as red and blue double-headed arrows in Fig. 2 (a).", [["Lung", "ANATOMY", 588, 592], ["lung area", "ANATOMY", 647, 656], ["lung", "ANATOMY", 737, 741], ["lung area", "ANATOMY", 772, 781], ["lung area", "ANATOMY", 842, 851], ["lung", "ANATOMY", 900, 904], ["lung area pixels", "ANATOMY", 948, 964], ["cardiac", "ANATOMY", 1157, 1164], ["thoracic", "ANATOMY", 1198, 1206], ["TB", "DISEASE", 63, 65], ["Lung", "ORGAN", 588, 592], ["lung", "ORGAN", 647, 651], ["lung", "ORGAN", 737, 741], ["lung", "ORGAN", 772, 776], ["lung", "ORGAN", 842, 846], ["lung", "ORGAN", 900, 904], ["lung", "ORGAN", 948, 952], ["cardiac", "ORGAN", 1157, 1164], ["thoracic", "ORGAN", 1198, 1206], ["COVID", "DNA", 357, 362], ["Potential CXR COVID-19 markers", "DNA", 424, 454], ["CXR COVID-19 markers", "DNA", 566, 586], ["red and blue double-headed arrows", "CELL_TYPE", 1241, 1274], ["our categorization", "TEST", 20, 38], ["bacterial", "PROBLEM", 52, 61], ["TB", "PROBLEM", 63, 65], ["viral+COVID", "TEST", 71, 82], ["COVID", "TEST", 357, 362], ["Potential CXR COVID", "TEST", 424, 443], ["standard biomarkers", "TEST", 468, 487], ["CXR image analysis", "TEST", 493, 511], ["Potential CXR COVID", "TEST", 556, 575], ["Mean lung intensity", "PROBLEM", 732, 751], ["Standard deviation of lung intensity", "PROBLEM", 878, 914], ["the intensity histogram", "TEST", 921, 944], ["bacterial", "OBSERVATION_MODIFIER", 52, 61], ["morphology", "OBSERVATION", 593, 603], ["Morphological structures", "OBSERVATION", 605, 629], ["segmented", "ANATOMY_MODIFIER", 637, 646], ["lung", "ANATOMY", 647, 651], ["area", "ANATOMY_MODIFIER", 652, 656], ["lung", "ANATOMY", 737, 741], ["intensity", "OBSERVATION", 742, 751], ["segmented", "ANATOMY_MODIFIER", 762, 771], ["lung", "ANATOMY", 772, 776], ["area", "ANATOMY_MODIFIER", 777, 781], ["mean value", "OBSERVATION", 797, 807], ["pixel intensity", "OBSERVATION", 815, 830], ["lung", "ANATOMY", 842, 846], ["area", "ANATOMY_MODIFIER", 847, 851], ["deviation", "OBSERVATION", 887, 896], ["lung", "ANATOMY", 900, 904], ["intensity", "OBSERVATION_MODIFIER", 905, 914], ["lung", "ANATOMY", 948, 952], ["area", "ANATOMY_MODIFIER", 953, 957], ["one", "OBSERVATION_MODIFIER", 980, 983], ["standard deviation", "OBSERVATION", 984, 1002], ["diameter", "OBSERVATION_MODIFIER", 1165, 1173], ["internal thoracic", "ANATOMY", 1189, 1206], ["diameter", "OBSERVATION_MODIFIER", 1207, 1215]]], ["Cardiothoracic Ratio (CTR) is a widely used marker to diagnosis cardiomegaly [25] , [26] .", [["cardiomegaly", "DISEASE", 64, 76], ["cardiomegaly", "PROBLEM", 64, 76]]], ["We hypothesized that if cardiothoracic boundary become blurred by rounded opacities or consolidation in COVID-19 CXR [2]- [4] , distinct off-average CTR value can be utilized as an abnormality alarm.", [["opacities", "DISEASE", 74, 83], ["blurred", "PROBLEM", 55, 62], ["rounded opacities", "PROBLEM", 66, 83], ["consolidation", "PROBLEM", 87, 100], ["COVID", "TEST", 104, 109], ["CXR", "TEST", 113, 116], ["an abnormality alarm", "PROBLEM", 178, 198], ["rounded", "OBSERVATION_MODIFIER", 66, 73], ["opacities", "OBSERVATION", 74, 83], ["consolidation", "OBSERVATION", 87, 100], ["abnormality", "OBSERVATION", 181, 192]]], ["Statistical analysis for the potential biomarkers was performed using MATLAB 2015a (Mathworks, Natick).", [["Statistical analysis", "TEST", 0, 20], ["the potential biomarkers", "TEST", 25, 49]]], ["Kolmogorov Smirnov test was used to evaluate the normal distribution of marker candidates.", [["Kolmogorov Smirnov test", "TEST", 0, 23], ["normal", "OBSERVATION", 49, 55]]], ["For non-normally distributed variables, Wilcoxon signed rank test was used to compare segmentation performance with identical data size, and Wilcoxon rank sum test was used to compare COVID-19 marker candidates to those of other classes with different data sizes.", [["COVID-19 marker candidates", "DNA", 184, 210], ["Wilcoxon signed rank test", "TEST", 40, 65], ["segmentation performance", "TEST", 86, 110], ["Wilcoxon rank sum test", "TEST", 141, 163], ["COVID", "TEST", 184, 189], ["size", "OBSERVATION_MODIFIER", 131, 135], ["sizes", "OBSERVATION_MODIFIER", 257, 262]]], ["Statistical significance (SS) levels were indicated as asterisks; * for p <0.05, ** for p <0.01 and *** for p <0.001.C. Classification performance metricsThe performance of the classification methods was evaluated using the confusion matrix.", [["confusion", "DISEASE", 224, 233], ["matrix", "CELLULAR_COMPONENT", 234, 240], ["the confusion matrix", "TREATMENT", 220, 240]]], ["From the confusion matrix,IV.", [["confusion", "DISEASE", 9, 18], ["matrix", "CELLULAR_COMPONENT", 19, 25]]], ["Segmentation performance on cross-database Segmentation performance of anatomical structure was evaluated using Jaccard similarity coefficient.", [["Segmentation performance", "TEST", 0, 24], ["anatomical structure", "OBSERVATION", 71, 91]]], ["Table V presents the Jaccard similarity coefficient of each contour on the validation dataset.", [["Jaccard", "DNA", 21, 28], ["contour", "OBSERVATION_MODIFIER", 60, 67]]], ["The results confirmed our method provides comparable accuracy to previous works using the JSRT dataset and the NLM(MC) dataset [27] , [28] .", [["the JSRT dataset", "TREATMENT", 86, 102]]], ["To evaluate segmentation performance on cross-database, we tested either original or preprocessed images of the NLM dataset as inputs.", [["segmentation performance", "TEST", 12, 36]]], ["The result shows that our universal preprocessing step for data normalization contributes to the processing of cross-database with statistically significant improvement on segmentation accuracy (Jaccard similarity coefficients from 0.932 to 0.943, p < 0.001).", [["segmentation accuracy", "TEST", 172, 193], ["Jaccard similarity coefficients", "TEST", 195, 226], ["significant", "OBSERVATION_MODIFIER", 145, 156], ["improvement", "OBSERVATION_MODIFIER", 157, 168]]], ["This result indicates that preprocessing is crucial factor to ensure segmentation performance in cross-database.B. Morphological analysis of lung areaTo analyze morphological characteristics in the segmented lung area, a representative CXR radiograph for each class was selected for visual evaluation.", [["lung", "ANATOMY", 141, 145], ["lung area", "ANATOMY", 208, 217], ["lung", "ORGAN", 141, 145], ["lung", "ORGAN", 208, 212], ["crucial factor", "PROBLEM", 44, 58], ["Morphological analysis", "TEST", 115, 137], ["a representative CXR radiograph", "TEST", 219, 250], ["visual evaluation", "TEST", 283, 300], ["lung", "ANATOMY", 141, 145], ["segmented", "ANATOMY_MODIFIER", 198, 207], ["lung", "ANATOMY", 208, 212], ["area", "ANATOMY_MODIFIER", 213, 217]]], ["Lung contour of each class showed differentiable features and showed mild tendency.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["differentiable features", "PROBLEM", 34, 57], ["mild tendency", "PROBLEM", 69, 82], ["contour", "OBSERVATION_MODIFIER", 5, 12], ["mild", "OBSERVATION_MODIFIER", 69, 73], ["tendency", "OBSERVATION", 74, 82]]], ["In normal and tuberculosis cases (the first and the second row of Fig. 3, respectively) , overall lung and heart contour were wellsegmented.", [["lung", "ANATOMY", 98, 102], ["heart", "ANATOMY", 107, 112], ["tuberculosis", "DISEASE", 14, 26], ["lung", "ORGAN", 98, 102], ["heart", "ORGAN", 107, 112], ["normal", "OBSERVATION", 3, 9], ["tuberculosis", "OBSERVATION", 14, 26], ["lung", "ANATOMY", 98, 102], ["heart", "ANATOMY", 107, 112], ["contour", "ANATOMY_MODIFIER", 113, 120]]], ["In the bacterial case, however, the segmented lung area was deformed due to wide spread opacity of bacterial pneumonia as shown in the third row of Fig. 3 , and both the right cardiac and thoracic borders were lost.", [["lung area", "ANATOMY", 46, 55], ["right cardiac", "ANATOMY", 170, 183], ["thoracic borders", "ANATOMY", 188, 204], ["pneumonia", "DISEASE", 109, 118], ["lung", "ORGAN", 46, 50], ["cardiac", "ORGAN", 176, 183], ["the segmented lung area", "PROBLEM", 32, 55], ["wide spread opacity", "PROBLEM", 76, 95], ["bacterial pneumonia", "PROBLEM", 99, 118], ["bacterial case", "OBSERVATION", 7, 21], ["segmented", "ANATOMY_MODIFIER", 36, 45], ["lung", "ANATOMY", 46, 50], ["deformed", "OBSERVATION", 60, 68], ["wide", "OBSERVATION_MODIFIER", 76, 80], ["spread", "OBSERVATION_MODIFIER", 81, 87], ["opacity", "OBSERVATION", 88, 95], ["bacterial", "OBSERVATION_MODIFIER", 99, 108], ["pneumonia", "OBSERVATION", 109, 118], ["both", "ANATOMY_MODIFIER", 161, 165], ["right", "ANATOMY_MODIFIER", 170, 175], ["cardiac", "ANATOMY", 176, 183], ["thoracic", "ANATOMY", 188, 196], ["borders", "ANATOMY_MODIFIER", 197, 204]]], ["In overall bacterial infection cases, similar findings were occasionally observed which caused degraded segmentation performance.", [["bacterial infection", "DISEASE", 11, 30], ["overall bacterial infection cases", "PROBLEM", 3, 36], ["overall", "OBSERVATION_MODIFIER", 3, 10], ["bacterial infection", "OBSERVATION", 11, 30]]], ["This suggests that abnormal morphology of the segmentation masks may be a useful biomarker to differentiate the severe infections.", [["infections", "DISEASE", 119, 129], ["abnormal morphology of the segmentation masks", "PROBLEM", 19, 64], ["a useful biomarker", "TEST", 72, 90], ["the severe infections", "PROBLEM", 108, 129], ["abnormal", "OBSERVATION_MODIFIER", 19, 27], ["morphology", "OBSERVATION_MODIFIER", 28, 38], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["infections", "OBSERVATION", 119, 129]]], ["In the fourth row of Fig. 3 , viral infection caused bilateral consolidations [29] , thus partial deformation of lung area was observed.", [["lung area", "ANATOMY", 113, 122], ["viral infection", "DISEASE", 30, 45], ["lung", "ORGAN", 113, 117], ["viral infection", "PROBLEM", 30, 45], ["bilateral consolidations", "PROBLEM", 53, 77], ["partial deformation of lung area", "PROBLEM", 90, 122], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["infection", "OBSERVATION", 36, 45], ["bilateral", "ANATOMY_MODIFIER", 53, 62], ["consolidations", "OBSERVATION", 63, 77], ["partial", "OBSERVATION_MODIFIER", 90, 97], ["deformation", "OBSERVATION_MODIFIER", 98, 109], ["lung", "ANATOMY", 113, 117], ["area", "ANATOMY_MODIFIER", 118, 122]]], ["In the COVID-19 case of the fifth row of Fig. 3 , despite the bi-basal infiltrations [30] , lung area was fully segmented.", [["lung area", "ANATOMY", 92, 101], ["lung", "ORGAN", 92, 96], ["the bi-basal infiltrations", "PROBLEM", 58, 84], ["bi-basal", "OBSERVATION_MODIFIER", 62, 70], ["infiltrations", "OBSERVATION", 71, 84], ["lung", "ANATOMY", 92, 96], ["area", "ANATOMY_MODIFIER", 97, 101], ["segmented", "OBSERVATION_MODIFIER", 112, 121]]], ["In overall cases of the viral and the COVID-19 classes, lung areas were either normally or partiallyimcompletely segmented, so morphological features of the segmentation masks may not be sufficiently discriminatory markers for viral and COVID-19 classes.", [["lung areas", "ANATOMY", 56, 66], ["lung", "ORGAN", 56, 60], ["COVID-19 classes", "DNA", 38, 54], ["the viral", "TEST", 20, 29], ["the COVID", "TEST", 34, 43], ["lung areas", "PROBLEM", 56, 66], ["the segmentation masks", "PROBLEM", 153, 175], ["viral", "TEST", 227, 232], ["COVID", "TEST", 237, 242], ["viral", "OBSERVATION", 24, 29], ["lung", "ANATOMY", 56, 60], ["may not be", "UNCERTAINTY", 176, 186]]], ["Based on these morphological findings in segmented lung area, we further investigated other potential COVID-19 biomarkers.C. Statistical significancy of potential COVID-19 bio-markersWe hypothesized that CXR appearance influenced by consolidations or infiltration of COVID-19 may be reflected in intensity of the radiograph.", [["lung area", "ANATOMY", 51, 60], ["lung area", "MULTI-TISSUE_STRUCTURE", 51, 60], ["C", "GENE_OR_GENE_PRODUCT", 122, 123], ["COVID", "PROTEIN", 102, 107], ["COVID-19 bio-markers", "DNA", 163, 183], ["CXR", "PROTEIN", 204, 207], ["potential COVID", "TEST", 92, 107], ["COVID", "TEST", 163, 168], ["bio-markers", "TEST", 172, 183], ["CXR", "TEST", 204, 207], ["consolidations", "PROBLEM", 233, 247], ["infiltration", "PROBLEM", 251, 263], ["COVID", "TEST", 267, 272], ["the radiograph", "TEST", 309, 323], ["segmented", "ANATOMY_MODIFIER", 41, 50], ["lung", "ANATOMY", 51, 55], ["area", "ANATOMY_MODIFIER", 56, 60], ["consolidations", "OBSERVATION", 233, 247], ["infiltration", "OBSERVATION", 251, 263]]], ["Thus, intensity-related COVID-19 marker candidates were extracted and compared.C. Statistical significancy of potential COVID-19 bio-markers1) Lung areas intensity: Mean pixel intensity of each lung area is shown in the scatter plot of Fig. 4(a) .", [["Lung", "ANATOMY", 143, 147], ["lung area", "ANATOMY", 194, 203], ["Lung", "ORGAN", 143, 147], ["lung", "ORGAN", 194, 198], ["COVID-19 marker candidates", "DNA", 24, 50], ["COVID", "PROTEIN", 120, 125], ["COVID", "TEST", 24, 29], ["COVID", "TEST", 120, 125], ["Lung areas intensity", "PROBLEM", 143, 163], ["Mean pixel intensity of each lung area", "PROBLEM", 165, 203], ["areas", "OBSERVATION_MODIFIER", 148, 153], ["intensity", "OBSERVATION_MODIFIER", 154, 163], ["Mean pixel", "OBSERVATION", 165, 175], ["intensity", "OBSERVATION_MODIFIER", 176, 185], ["each", "ANATOMY_MODIFIER", 189, 193], ["lung", "ANATOMY", 194, 198], ["area", "ANATOMY_MODIFIER", 199, 203], ["scatter plot", "OBSERVATION", 220, 232]]], ["COVID-19 cases showed lower mean intensity compared to other cases with statistical significance level (p <0.001 for normal and bacterial, p <0.01 for TB).", [["TB", "DISEASE", 151, 153], ["COVID", "TEST", 0, 5], ["lower mean intensity", "PROBLEM", 22, 42], ["bacterial", "TEST", 128, 137], ["TB", "PROBLEM", 151, 153], ["lower", "OBSERVATION_MODIFIER", 22, 27], ["mean intensity", "OBSERVATION_MODIFIER", 28, 42]]], ["Despite the statistical significance, the scatter plot showed broad overlap between several classes.", [["the scatter plot", "TEST", 38, 54], ["broad overlap between several classes", "PROBLEM", 62, 99], ["broad overlap", "OBSERVATION", 62, 75]]], ["2) Lung areas intensity variance: Standard deviation of pixel intensity of each lung area are scattered in plot in Fig. 4(b) .", [["Lung", "ANATOMY", 3, 7], ["lung area", "ANATOMY", 80, 89], ["Lung", "ORGAN", 3, 7], ["lung", "ORGAN", 80, 84], ["Lung areas intensity variance", "PROBLEM", 3, 32], ["Standard deviation of pixel intensity of each lung area", "PROBLEM", 34, 89], ["Lung", "ANATOMY", 3, 7], ["areas", "OBSERVATION_MODIFIER", 8, 13], ["intensity", "OBSERVATION_MODIFIER", 14, 23], ["Standard deviation", "OBSERVATION", 34, 52], ["pixel", "OBSERVATION_MODIFIER", 56, 61], ["intensity", "OBSERVATION_MODIFIER", 62, 71], ["each", "ANATOMY_MODIFIER", 75, 79], ["lung", "ANATOMY", 80, 84], ["area", "ANATOMY_MODIFIER", 85, 89], ["scattered", "OBSERVATION_MODIFIER", 94, 103], ["plot", "OBSERVATION_MODIFIER", 107, 111]]], ["For both the COVID-19 and the viral cases, the variance values were higher than other classes with statistical significance (p <0.001 for all).", [["COVID-19", "DNA", 13, 21], ["the COVID", "TEST", 9, 18], ["the viral cases", "TEST", 26, 41], ["the variance values", "TEST", 43, 62]]], ["Table VII describes the corresponding statistical result.C. Statistical significancy of potential COVID-19 bio-markersTo investigate the effect of scanning protocol on statistics, we performed additional study by excluding AP Supine radiographs from entire dataset with documented patient information.", [["patient", "ORGANISM", 281, 288], ["COVID-19 bio-markers", "DNA", 98, 118], ["patient", "SPECIES", 281, 288], ["COVID", "TEST", 98, 103], ["scanning protocol", "TEST", 147, 164], ["additional study", "TEST", 193, 209], ["AP Supine radiographs", "TEST", 223, 244]]], ["Recall that AP Supine protocol is an alternative to standard PA or AP protocol depending on patient condition.", [["PA", "GENE_OR_GENE_PRODUCT", 61, 63], ["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["AP Supine protocol", "TREATMENT", 12, 30], ["AP protocol", "TEST", 67, 78]]], ["Since AP Supine protocol is not common in normal cases, potential for considerable heterogeneity in data distribution, causing biased results in statistical analysis, so we investigated this issue.", [["AP Supine protocol", "TEST", 6, 24], ["considerable heterogeneity in data distribution", "PROBLEM", 70, 117], ["statistical analysis", "TEST", 145, 165], ["considerable", "OBSERVATION_MODIFIER", 70, 82], ["heterogeneity", "OBSERVATION", 83, 96]]], ["The result shown in Table VIII compared to Table VII showed minor difference in both the COVID-19 and the viral and cases.", [["Table VIII", "GENE_OR_GENE_PRODUCT", 20, 30], ["Table VII", "GENE_OR_GENE_PRODUCT", 43, 52], ["Table VIII", "PROTEIN", 20, 30], ["Table VII", "TEST", 43, 52], ["minor difference", "PROBLEM", 60, 76], ["the COVID", "TEST", 85, 94], ["minor", "OBSERVATION_MODIFIER", 60, 65], ["difference", "OBSERVATION", 66, 76]]], ["The result indicates that for both the COVID-19 and viral classes, the highly intensity-variable characteristic in the lung area is invariant to scaning protocol.C. Statistical significancy of potential COVID-19 bio-markers3) Cardiothoracic ratio: CTR values of each lung area is scattered in Fig. 4(c) .", [["lung area", "ANATOMY", 119, 128], ["lung area", "ANATOMY", 267, 276], ["lung", "ORGAN", 119, 123], ["lung", "ORGAN", 267, 271], ["COVID", "PROTEIN", 203, 208], ["C.", "SPECIES", 162, 164], ["C.", "SPECIES", 162, 164], ["the COVID", "TEST", 35, 44], ["viral classes", "PROBLEM", 52, 65], ["scaning protocol", "TREATMENT", 145, 161], ["COVID", "TEST", 203, 208], ["bio-markers", "TEST", 212, 223], ["Cardiothoracic ratio", "TEST", 226, 246], ["CTR values", "TEST", 248, 258], ["highly", "OBSERVATION_MODIFIER", 71, 77], ["intensity", "OBSERVATION_MODIFIER", 78, 87], ["variable", "OBSERVATION_MODIFIER", 88, 96], ["characteristic", "OBSERVATION_MODIFIER", 97, 111], ["lung", "ANATOMY", 119, 123], ["area", "ANATOMY_MODIFIER", 124, 128], ["lung", "ANATOMY", 267, 271], ["area", "ANATOMY_MODIFIER", 272, 276], ["scattered", "OBSERVATION_MODIFIER", 280, 289]]], ["Despite there exist statistical differences between the COVID-19 cases to other classes (p <0.001 for normal and TB, p <0.05 for Bacteria), the scatter plot showed broad overlap between several classes.", [["the COVID", "TEST", 52, 61], ["TB", "TEST", 113, 115], ["Bacteria", "PROBLEM", 129, 137], ["the scatter plot", "TEST", 140, 156], ["broad overlap between several classes", "PROBLEM", 164, 201], ["broad overlap", "OBSERVATION", 164, 177]]], ["Table IX describes the corresponding statistical result.", [["Table IX", "GENE_OR_GENE_PRODUCT", 0, 8], ["IX", "PROTEIN", 6, 8]]], ["Based on the statistical analysis of potential bio-marker 0.499 0.086 *** *** * candidates, we found that intensity distribution pattern within the lung area may be most effective in the diagnosis, which highly reflects the reported chest X-ray (CXR) appearances of COVID-19, i.e., multi-focally distributed consolidation and GGO in specific region such as peripheral and lower zone [2] - [4] .", [["lung area", "ANATOMY", 148, 157], ["GGO", "DISEASE", 326, 329], ["lung", "ORGAN", 148, 152], ["potential bio-marker", "TEST", 37, 57], ["the reported chest X-ray", "TEST", 220, 244], ["CXR", "TEST", 246, 249], ["COVID", "TEST", 266, 271], ["multi-focally distributed consolidation", "PROBLEM", 282, 321], ["GGO in specific region", "PROBLEM", 326, 348], ["intensity", "OBSERVATION_MODIFIER", 106, 115], ["lung", "ANATOMY", 148, 152], ["area", "ANATOMY_MODIFIER", 153, 157], ["may be", "UNCERTAINTY", 158, 164], ["most effective", "OBSERVATION_MODIFIER", 165, 179], ["chest", "ANATOMY", 233, 238], ["multi-", "OBSERVATION_MODIFIER", 282, 288], ["focally", "OBSERVATION_MODIFIER", 288, 295], ["distributed", "OBSERVATION_MODIFIER", 296, 307], ["consolidation", "OBSERVATION", 308, 321], ["GGO", "OBSERVATION", 326, 329], ["region", "ANATOMY_MODIFIER", 342, 348], ["peripheral", "ANATOMY_MODIFIER", 357, 367], ["lower", "ANATOMY_MODIFIER", 372, 377], ["zone", "ANATOMY_MODIFIER", 378, 382]]], ["However, care should be taken, since not only the locally concentrated multiple opacities can cause uneven intensity distribution throughout entire lung area, but also different texture distribution within CXR may cause the similar intensity variations.", [["lung area", "ANATOMY", 148, 157], ["opacities", "DISEASE", 80, 89], ["lung", "ORGAN", 148, 152], ["CXR", "PROTEIN", 206, 209], ["the locally concentrated multiple opacities", "PROBLEM", 46, 89], ["uneven intensity distribution throughout entire lung area", "PROBLEM", 100, 157], ["CXR", "TEST", 206, 209], ["the similar intensity variations", "PROBLEM", 220, 252], ["multiple", "OBSERVATION_MODIFIER", 71, 79], ["opacities", "OBSERVATION", 80, 89], ["uneven", "OBSERVATION_MODIFIER", 100, 106], ["intensity", "OBSERVATION_MODIFIER", 107, 116], ["distribution", "OBSERVATION_MODIFIER", 117, 129], ["entire", "ANATOMY_MODIFIER", 141, 147], ["lung", "ANATOMY", 148, 152], ["area", "ANATOMY_MODIFIER", 153, 157], ["different", "OBSERVATION_MODIFIER", 168, 177], ["texture", "OBSERVATION_MODIFIER", 178, 185], ["distribution", "OBSERVATION_MODIFIER", 186, 198], ["may cause", "UNCERTAINTY", 210, 219], ["similar", "OBSERVATION_MODIFIER", 224, 231], ["intensity", "OBSERVATION_MODIFIER", 232, 241]]], ["For example, multi-focally distributed consolidation from COVID-19 could make the intensity variance differentiating factor from other classes, but also bacterial pneumonia generates opacity as well, whose feature may lead to the similar intensity distributions as results of different characteristics of opacity spreading pattern.C. Statistical significancy of potential COVID-19 bio-markersTo decouple these compounding effects, we further investigated the local and global intensity distribution.", [["pneumonia", "DISEASE", 163, 172], ["opacity", "DISEASE", 305, 312], ["COVID-19", "DNA", 58, 66], ["COVID-19 bio-markers", "DNA", 372, 392], ["multi-focally distributed consolidation", "PROBLEM", 13, 52], ["COVID", "TEST", 58, 63], ["bacterial pneumonia", "PROBLEM", 153, 172], ["opacity", "PROBLEM", 183, 190], ["opacity spreading pattern", "PROBLEM", 305, 330], ["COVID", "TEST", 372, 377], ["multi", "OBSERVATION_MODIFIER", 13, 18], ["focally", "OBSERVATION_MODIFIER", 19, 26], ["distributed", "OBSERVATION_MODIFIER", 27, 38], ["consolidation", "OBSERVATION", 39, 52], ["bacterial", "OBSERVATION_MODIFIER", 153, 162], ["pneumonia", "OBSERVATION", 163, 172], ["opacity", "OBSERVATION", 183, 190], ["similar", "OBSERVATION_MODIFIER", 230, 237], ["intensity", "OBSERVATION_MODIFIER", 238, 247], ["different characteristics", "OBSERVATION_MODIFIER", 276, 301], ["opacity", "OBSERVATION", 305, 312], ["spreading", "OBSERVATION_MODIFIER", 313, 322], ["pattern", "OBSERVATION_MODIFIER", 323, 330], ["local", "OBSERVATION_MODIFIER", 459, 464], ["global", "OBSERVATION_MODIFIER", 469, 475], ["intensity", "OBSERVATION_MODIFIER", 476, 485]]], ["For the correctly classified patches from our classification network, we computed their mean intensity and standard deviation (STD) values.", [["standard deviation (STD) values", "PROBLEM", 107, 138], ["mean intensity", "OBSERVATION_MODIFIER", 88, 102]]], ["We refer to the distribution of mean intensity of each patch as the inter-patch intensity distribution (Fig. 5(a) ) and the STD of each patch as intra-patch intensity distribution ( Fig. 5(b) ).", [["each patch", "TREATMENT", 50, 60], ["the STD of each patch", "TREATMENT", 120, 141]]], ["As shown in Fig. 5(a) , the inter-patch intensity distribution of the unified COVID-19 and viral class showed distict lower intensity values (p <0.001 for all) to other classes and highly intensity-variant characteristics which can be represented as the large error bar.", [["COVID-19", "DNA", 78, 86], ["the unified COVID", "TEST", 66, 83], ["viral class", "TEST", 91, 102], ["distict lower intensity values", "PROBLEM", 110, 140], ["lower intensity", "OBSERVATION_MODIFIER", 118, 133], ["highly intensity", "OBSERVATION_MODIFIER", 181, 197], ["large", "OBSERVATION_MODIFIER", 254, 259], ["error bar", "OBSERVATION", 260, 269]]], ["This result is in accordance with the result of lung area intensity and intensity variance ( Fig. 4(a), (b) ).", [["lung area", "ANATOMY", 48, 57], ["lung", "ORGAN", 48, 52], ["intensity variance", "TEST", 72, 90], ["lung", "ANATOMY", 48, 52]]], ["Intra-patch intensity distribution, however, showed no difference compared to the normal class (p >0.05).", [["Intra-patch intensity distribution", "PROBLEM", 0, 34], ["intensity", "OBSERVATION_MODIFIER", 12, 21]]], ["From these intra-and inter-patch intensity distribution results, we can infer that intra-patch variance, which represents local texture information, was not crucially informative, whereas the globally distributed multi-focal intensity change may be an important discriminating feature for COVID-19 diagnosis, which is strongly correlated with the radiological findings.C. Statistical significancy of potential COVID-19 bio-markersOne common finding among the marker candidates was no difference between the COVID-19 and the viral case (p >0.05 for all the markers), which is also correlated with radiological findings [18] .", [["COVID-19 bio-markers", "DNA", 410, 430], ["COVID-19", "DNA", 507, 515], ["the globally distributed multi-focal intensity change", "PROBLEM", 188, 241], ["the radiological findings", "TEST", 343, 368], ["COVID", "TEST", 410, 415], ["bio-markers", "TEST", 419, 430], ["the COVID", "TEST", 503, 512], ["local texture", "OBSERVATION", 122, 135], ["globally", "OBSERVATION_MODIFIER", 192, 200], ["distributed", "OBSERVATION_MODIFIER", 201, 212], ["multi-focal", "OBSERVATION_MODIFIER", 213, 224]]], ["Therefore, in the classification network, the COVID-19 and viral classes were integrated into one class.D. Classification performanceThe classification performances of the proposed method are provided in Table X .", [["COVID-19", "DNA", 46, 54], ["the COVID", "TEST", 42, 51]]], ["The confusion matrices for the (a) global method and the (b) local patch-based method are shown in Fig. 6 .", [["confusion", "DISEASE", 4, 13], ["The confusion matrices", "PROBLEM", 0, 22], ["the (b) local patch-based method", "TREATMENT", 53, 85]]], ["The proposed local patch-based approach showed consistently better performance than global approach in all metrics.", [["The proposed local patch", "TREATMENT", 0, 24], ["local patch", "OBSERVATION", 13, 24]]], ["In particular, as depicted in Table XI , our method showed the sensitivity of 92.5% for COVID-19 and viruses, which was acceptable performance as a screening method, considering the fact that the sensitivity of COVID-19 diagnosis by X-ray image is known to be 69% even for clinical experts and that the current gold standard, RT-PCR, has sensitivity of 91% [4] .", [["XI", "GENE_OR_GENE_PRODUCT", 36, 38], ["COVID-19", "CELL", 88, 96], ["COVID-19", "SPECIES", 88, 96], ["our method", "TEST", 41, 51], ["the sensitivity", "TEST", 59, 74], ["COVID", "TEST", 88, 93], ["viruses", "PROBLEM", 101, 108], ["a screening method", "TEST", 146, 164], ["COVID", "TEST", 211, 216], ["X-ray image", "TEST", 233, 244], ["RT-PCR", "TEST", 326, 332], ["sensitivity", "TEST", 338, 349]]], ["Moreover, compared to the global approach, the sensitivity of other classes are significantly high, which confirms the efficacy of our method.", [["our method", "TEST", 131, 141]]], ["E. Interpretability using saliency map Fig. 7 and Fig. 8 illustrate the examples of visualization of saliency map.", [["saliency map Fig.", "TEST", 26, 43], ["visualization of saliency map", "TEST", 84, 113]]], ["As shown in Fig. 7(a) , the existing Grad- CAM method for global approach showed the limitation that it only focuses on the broad main lesion so that it cannot properly differentiate multifocal lesions within the image.", [["lesion", "ANATOMY", 135, 141], ["lesions", "ANATOMY", 194, 201], ["lesion", "CANCER", 135, 141], ["multifocal lesions", "CANCER", 183, 201], ["global approach", "TEST", 58, 73], ["the broad main lesion", "PROBLEM", 120, 141], ["multifocal lesions within the image", "PROBLEM", 183, 218], ["broad", "OBSERVATION_MODIFIER", 124, 129], ["main", "OBSERVATION_MODIFIER", 130, 134], ["lesion", "OBSERVATION", 135, 141], ["multifocal", "OBSERVATION_MODIFIER", 183, 193], ["lesions", "OBSERVATION", 194, 201]]], ["On the other hand, with the probabilistic Grad-CAM, multifocal GGOs and consolidations were visualized effectively by our local patch-based approach as shown in Fig. 7(c) , which was in consistent with the findings reported by clinical experts.", [["GGOs", "ANATOMY", 63, 67], ["GGOs", "CANCER", 63, 67], ["multifocal GGOs", "PROBLEM", 52, 67], ["consolidations", "PROBLEM", 72, 86], ["our local patch-based approach", "TREATMENT", 118, 148], ["multifocal", "OBSERVATION_MODIFIER", 52, 62], ["GGOs", "OBSERVATION", 63, 67], ["consolidations", "OBSERVATION", 72, 86], ["consistent with", "UNCERTAINTY", 186, 201]]], ["In particular, when we compute the probabilistic Grad-CAM for the COVID-19 class using patient images from various classes (i.e., normal, bacterial, TB, and COVID-19), a noticeable activation map was observed only in the COVID-19 patient data set, whereas almost no activations were observed in patients with other diseases and conditions as shown in Fig. 8 .", [["TB", "DISEASE", 149, 151], ["patient", "ORGANISM", 87, 94], ["patient", "ORGANISM", 230, 237], ["patients", "ORGANISM", 295, 303], ["COVID-19 class", "DNA", 66, 80], ["patient", "SPECIES", 87, 94], ["patient", "SPECIES", 230, 237], ["patients", "SPECIES", 295, 303], ["patient images", "TEST", 87, 101], ["TB", "TEST", 149, 151], ["COVID", "TEST", 157, 162], ["a noticeable activation map", "PROBLEM", 168, 195], ["the COVID", "TEST", 217, 226], ["other diseases and conditions", "PROBLEM", 309, 338]]], ["These results strongly support our claim that the probabilistic Grad-CAM saliency map from our local patch-based approach is more intuitive and interpretable compared to the existing methods.A. COVID-19 Features on CXRIn the diagnosis of COVID-19, other diseases mimicking COVID-19 pneumonia should be differentiated, including community-acquired pneumonia such as streptococcus pneumonia, mycoplasma and chlamydia related pneumonia, and other coronavirus infections.A. COVID-19 Features on CXRIn radiological literature, most frequently observed distribution patterns of COVID-19 are bilateral involvement, peripheral distribution and ground-glass opacification (GGO) [13] .", [["pneumonia", "DISEASE", 282, 291], ["pneumonia", "DISEASE", 347, 356], ["streptococcus pneumonia", "DISEASE", 365, 388], ["mycoplasma and chlamydia", "DISEASE", 390, 414], ["pneumonia", "DISEASE", 423, 432], ["coronavirus infections", "DISEASE", 444, 466], ["GGO", "DISEASE", 664, 667], ["coronavirus", "ORGANISM", 444, 455], ["COVID-19", "GENE_OR_GENE_PRODUCT", 572, 580], ["COVID-19", "DNA", 572, 580], ["the probabilistic Grad-CAM saliency map", "TEST", 46, 85], ["our local patch-based approach", "TREATMENT", 91, 121], ["COVID", "TEST", 238, 243], ["other diseases mimicking COVID", "PROBLEM", 248, 278], ["pneumonia", "PROBLEM", 282, 291], ["community-acquired pneumonia", "PROBLEM", 328, 356], ["streptococcus pneumonia", "PROBLEM", 365, 388], ["mycoplasma", "PROBLEM", 390, 400], ["chlamydia", "PROBLEM", 405, 414], ["pneumonia", "PROBLEM", 423, 432], ["other coronavirus infections", "PROBLEM", 438, 466], ["COVID", "TEST", 572, 577], ["bilateral involvement", "PROBLEM", 585, 606], ["peripheral distribution and ground-glass opacification (GGO)", "PROBLEM", 608, 668], ["pneumonia", "OBSERVATION", 282, 291], ["pneumonia", "OBSERVATION", 347, 356], ["streptococcus pneumonia", "OBSERVATION", 365, 388], ["pneumonia", "OBSERVATION", 423, 432], ["coronavirus", "OBSERVATION_MODIFIER", 444, 455], ["infections", "OBSERVATION", 456, 466], ["19 Features", "OBSERVATION_MODIFIER", 476, 487], ["bilateral", "ANATOMY_MODIFIER", 585, 594], ["involvement", "OBSERVATION", 595, 606], ["peripheral", "ANATOMY_MODIFIER", 608, 618], ["distribution", "OBSERVATION_MODIFIER", 619, 631], ["ground-glass opacification", "OBSERVATION", 636, 662]]], ["Wong et al [4] found that consolidation was the most common finding (30/64, 47%), followed by GGO (21/64, 33%).", [["GGO", "DISEASE", 94, 97], ["consolidation", "PROBLEM", 26, 39], ["GGO", "TEST", 94, 97], ["consolidation", "OBSERVATION", 26, 39]]], ["CXR abnormalities had a peripheral (26/64, 41%) and lower zone distribution (32/64, 50%) with bilateral involvement (32/64, 50%), whereas pleural effusion was uncommon (2/64, 3%).A. COVID-19 Features on CXROur statistical analysis of the intensity distribution clearly showed that the globally distributed localized intensity vari-ation is a discriminatory factor for COVID-19 CXR images, which was also confirmed with our saliency map.", [["lower zone", "ANATOMY", 52, 62], ["pleural", "ANATOMY", 138, 145], ["pleural effusion", "DISEASE", 138, 154], ["pleural", "ORGAN", 138, 145], ["CXR", "PROTEIN", 0, 3], ["COVID-19", "DNA", 182, 190], ["CXROur", "DNA", 203, 209], ["COVID", "DNA", 368, 373], ["CXR abnormalities", "TEST", 0, 17], ["bilateral involvement", "PROBLEM", 94, 115], ["pleural effusion", "PROBLEM", 138, 154], ["CXROur statistical analysis", "TEST", 203, 230], ["COVID", "TEST", 368, 373], ["CXR images", "TEST", 377, 387], ["our saliency map", "TEST", 419, 435], ["peripheral", "ANATOMY_MODIFIER", 24, 34], ["lower", "ANATOMY_MODIFIER", 52, 57], ["zone", "ANATOMY_MODIFIER", 58, 62], ["bilateral", "ANATOMY_MODIFIER", 94, 103], ["pleural", "ANATOMY", 138, 145], ["effusion", "OBSERVATION", 146, 154], ["globally", "OBSERVATION_MODIFIER", 285, 293], ["distributed", "OBSERVATION_MODIFIER", 294, 305], ["localized", "OBSERVATION_MODIFIER", 306, 315], ["intensity", "OBSERVATION_MODIFIER", 316, 325]]], ["This clearly confirmed that the proposed method clearly reflects the radiological findings.B. Feasibility as a 'triage' for COVID-19In pandemic situation of infectious disease, the distribution of medical resources is a matter of the greatest importance.", [["infectious disease", "DISEASE", 157, 175], ["COVID", "TEST", 124, 129], ["infectious disease", "PROBLEM", 157, 175], ["infectious", "OBSERVATION", 157, 167]]], ["As COVID-19 is spreading rapidly and surpassing the capacity of medical system in many countries, it is necessary to make reasonable decision to distribute the limited resources based on the 'triage', which determine the needs and urgency for each patient.", [["patient", "ORGANISM", 248, 255], ["COVID-19", "DNA", 3, 11], ["patient", "SPECIES", 248, 255], ["COVID", "TEST", 3, 8], ["urgency", "PROBLEM", 231, 238], ["spreading", "OBSERVATION_MODIFIER", 15, 24], ["rapidly", "OBSERVATION_MODIFIER", 25, 32]]], ["In general, the most common cause of community acquired pneumonia is bacterial infection [5] .", [["pneumonia", "DISEASE", 56, 65], ["bacterial infection", "DISEASE", 69, 88], ["community acquired pneumonia", "PROBLEM", 37, 65], ["bacterial infection", "PROBLEM", 69, 88], ["pneumonia", "OBSERVATION", 56, 65], ["bacterial", "OBSERVATION_MODIFIER", 69, 78], ["infection", "OBSERVATION", 79, 88]]], ["Specifically, most studies reported that S. pneumoniae is the most frequent causative strain (15 \u2212 42%), after which H. influenza (11 \u2212 12%) and viral pneumonia follow as the second and the third most common causes of pneumonia, respectively [5] .", [["S. pneumoniae", "DISEASE", 41, 54], ["H. influenza", "DISEASE", 117, 129], ["viral pneumonia", "DISEASE", 145, 160], ["pneumonia", "DISEASE", 218, 227], ["S. pneumoniae", "ORGANISM", 41, 54], ["H. influenza", "ORGANISM", 117, 129], ["S. pneumoniae", "SPECIES", 41, 54], ["H. influenza", "SPECIES", 117, 129], ["S. pneumoniae", "SPECIES", 41, 54], ["S. pneumoniae", "PROBLEM", 41, 54], ["H. influenza", "PROBLEM", 117, 129], ["viral pneumonia", "PROBLEM", 145, 160], ["pneumonia", "PROBLEM", 218, 227], ["pneumoniae", "OBSERVATION", 44, 54], ["viral", "OBSERVATION_MODIFIER", 145, 150], ["pneumonia", "OBSERVATION", 151, 160], ["pneumonia", "OBSERVATION", 218, 227]]], ["In addition, depending on the geological region, substantial proportion of pneumonia may be diagnosed as tuberculosis (up to 10%) [5] .", [["pneumonia", "DISEASE", 75, 84], ["tuberculosis", "DISEASE", 105, 117], ["pneumonia", "PROBLEM", 75, 84], ["tuberculosis", "PROBLEM", 105, 117], ["substantial", "OBSERVATION_MODIFIER", 49, 60], ["proportion", "OBSERVATION_MODIFIER", 61, 71], ["pneumonia", "OBSERVATION", 75, 84], ["may be", "UNCERTAINTY", 85, 91], ["tuberculosis", "OBSERVATION", 105, 117]]], ["Summing these up, the proportion of bacterial pneumonia and tuberculosis is suspected to be still large even in this pandemic situation of COVID-19.", [["pneumonia", "DISEASE", 46, 55], ["tuberculosis", "DISEASE", 60, 72], ["bacterial pneumonia", "PROBLEM", 36, 55], ["tuberculosis", "PROBLEM", 60, 72], ["COVID", "TEST", 139, 144], ["bacterial", "OBSERVATION_MODIFIER", 36, 45], ["pneumonia", "OBSERVATION", 46, 55], ["tuberculosis", "OBSERVATION", 60, 72], ["large", "OBSERVATION_MODIFIER", 98, 103]]], ["In this respect, the disease such as bacterial pneumonia or tuberculosis as well as normal condition can be excluded primarily, to preserve limited medical resources such as RT-PCR or CT only for those who suspected to be infected with COVID-19.B. Feasibility as a 'triage' for COVID-19The detailed triage workflow that utilizes the proposed algorithm is described in Fig. 9 .", [["bacterial pneumonia", "DISEASE", 37, 56], ["tuberculosis", "DISEASE", 60, 72], ["the disease", "PROBLEM", 17, 28], ["bacterial pneumonia", "PROBLEM", 37, 56], ["tuberculosis", "PROBLEM", 60, 72], ["RT-PCR", "TEST", 174, 180], ["CT", "TEST", 184, 186], ["COVID", "TEST", 236, 241], ["COVID", "TEST", 278, 283], ["disease", "OBSERVATION", 21, 28], ["bacterial", "OBSERVATION_MODIFIER", 37, 46], ["pneumonia", "OBSERVATION", 47, 56], ["tuberculosis", "OBSERVATION", 60, 72], ["infected", "OBSERVATION", 222, 230]]], ["Specifically, our neural network is trained to classify other viral and COVID-19 in the same class.", [["neural network", "ANATOMY", 18, 32], ["neural network", "MULTI-TISSUE_STRUCTURE", 18, 32], ["viral and COVID-19", "DNA", 62, 80], ["COVID", "TEST", 72, 77]]], ["This is not only because it is strongly correlated with the radiological findings [18] , but also useful as a triage.", [["a triage", "TEST", 108, 116]]], ["More specifically, by excluding normal, bacterial pneumonia, and TB at the early stage, we can use RT-PCR or CT for only those patients classified as other virus and COVID-19 cases for final diagnosis.", [["pneumonia", "DISEASE", 50, 59], ["TB", "DISEASE", 65, 67], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["bacterial pneumonia", "PROBLEM", 40, 59], ["TB", "PROBLEM", 65, 67], ["RT-PCR", "TEST", 99, 105], ["CT", "TEST", 109, 111], ["other virus", "TEST", 150, 161], ["COVID", "TEST", 166, 171], ["bacterial", "OBSERVATION_MODIFIER", 40, 49], ["pneumonia", "OBSERVATION", 50, 59]]], ["By doing this procedure, we can save limited medical resources such as RT-PCR or CT to those patients whose diagnosis by CXR is difficult even by radiologists.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["this procedure", "TREATMENT", 9, 23], ["RT-PCR", "TEST", 71, 77], ["CT", "TEST", 81, 83], ["CXR", "TEST", 121, 124]]], ["Fig. 9 : Potential triage workflow that utilizes the proposed algorithm in the diagnosis of COVID-19 patient.C. Training stabilityIn order to investigate the origin of the apparent advantages of using local patch-based training over the global approach, we investigate the training dynamics to investigate the presence of overfitting.", [["patient", "ORGANISM", 101, 108], ["C", "GENE_OR_GENE_PRODUCT", 109, 110], ["patient", "SPECIES", 101, 108], ["COVID", "TEST", 92, 97], ["local patch-based training", "TREATMENT", 201, 227], ["the global approach", "TREATMENT", 233, 252], ["the training dynamics", "TEST", 269, 290], ["overfitting", "PROBLEM", 322, 333], ["stability", "OBSERVATION_MODIFIER", 121, 130], ["overfitting", "OBSERVATION", 322, 333]]], ["This is especially important, given that the training data is limited due to the difficulty of systematic CXR data collection for COVID-19 cases under current public health emergency.", [["the training data", "TEST", 41, 58], ["systematic CXR data collection", "TEST", 95, 125], ["COVID", "TEST", 130, 135]]], ["Fig. 10 shows the curves for accuracy and F1 score of (a) the global approach and (b) the proposed local patchbased approach for each epoch.", [["the curves", "TEST", 14, 24], ["accuracy", "TEST", 29, 37], ["the proposed local patchbased approach", "TREATMENT", 86, 124]]], ["Note that both approaches use the same number of weight parameters.", [["weight parameters", "TEST", 49, 66]]], ["Still, thanks to the increasing training data set from the random patch cropping across all image area, our local patch-based algorithm did not showed any sign of overfitting even with the small numbers of training data, while the global approach showed significant overfitting problem.", [["the random patch cropping", "TREATMENT", 55, 80], ["overfitting", "PROBLEM", 163, 174], ["training data", "TEST", 206, 219], ["the global approach", "TEST", 227, 246], ["significant overfitting problem", "PROBLEM", 254, 285], ["overfitting", "OBSERVATION", 163, 174], ["significant", "OBSERVATION_MODIFIER", 254, 265], ["overfitting", "OBSERVATION", 266, 277]]], ["This clearly indicates that with the limited data set the patch-based neural network training may be a promising direction.D. Comparison with COVID-NetSince the proposed patch-based neural network architecture is designed by considering limited training data set, we investigated any potential performance loss in comparison with other state-of-the art (SOTA) deep learning approach that has been developed without such consideration.", [["neural", "ANATOMY", 70, 76], ["neural network", "ANATOMY", 182, 196], ["neural network", "MULTI-TISSUE_STRUCTURE", 70, 84], ["neural network", "MULTI-TISSUE_STRUCTURE", 182, 196], ["COVID", "DNA", 142, 147], ["NetSince", "DNA", 148, 156], ["the patch-based neural network training", "TREATMENT", 54, 93], ["the proposed patch", "TREATMENT", 157, 175], ["limited training data", "TEST", 237, 258], ["the art (SOTA) deep learning approach", "TREATMENT", 345, 382], ["neural network", "OBSERVATION", 182, 196]]], ["Specifically, COVID-Net [6] is one of the most successful approaches in COVID-19 diagnosis, so we chose it as the SOTA method.D. Comparison with COVID-NetThe comparison between our method and COVID-Net is shown in Table XII .", [["COVID", "DNA", 192, 197]]], ["With the same dataset, our method showed overall accuracy of 91.9 % which is comparable to that of 92.4 % for COVID-Net.", [["our method", "TEST", 23, 33], ["overall accuracy", "TEST", 41, 57]]], ["Furthermore, our method provided significantly improved sensitivity to COVID-19 cases compared to the COVID-Net.", [["COVID", "DNA", 102, 107], ["COVID", "TEST", 71, 76]]], ["In addition, it is also remarkable that our method uses only about 10% number of parameters (11.6 M) compared to that of COVID-Net (116.6 M), because the proposed algorithm is developed based on less complex network architecture without increasing the complexity of the model.", [["network architecture", "MULTI-TISSUE_STRUCTURE", 208, 228]]], ["This may bring the advantages not only in the aspect of computational time but also in the aspect of performance and stability with small-sized dataset.", [["small-sized dataset", "PROBLEM", 132, 151], ["stability", "OBSERVATION_MODIFIER", 117, 126], ["small", "OBSERVATION_MODIFIER", 132, 137], ["sized", "OBSERVATION_MODIFIER", 138, 143]]], ["Comparison with COVID-NetWe are aware that the current study has limitations due to the lack of well-curated pneumonia CXR dataset.", [["pneumonia", "DISEASE", 109, 118], ["the current study", "TEST", 43, 60], ["well-curated pneumonia", "PROBLEM", 96, 118], ["CXR dataset", "TEST", 119, 130], ["pneumonia", "OBSERVATION", 109, 118]]], ["Specifically, our CXR data set come from a single or at most two sources (see Table II ).", [["CXR", "PROTEIN", 18, 21], ["our CXR data", "TEST", 14, 26]]], ["Moreover, publicly available COVID-19 dataset [23] are largely extracted from online publications, website, etc, so they are not collected in a rigorous manner.D. Comparison with COVID-NetTo mitigate the issue of potential bias from the limitation of the database, we employed a universal preprocessing step for data normalization for the entire dataset as discussed before.", [["COVID", "TEST", 29, 34]]], ["We investigated the effects of our preprocessing step on cross-database generalization by investigating the COVID-19 dataset, which poses the most severe intra-dataset heterogeneity.", [["COVID-19 dataset", "DNA", 108, 124], ["the COVID", "TEST", 104, 113], ["the most severe intra-dataset heterogeneity", "PROBLEM", 138, 181], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["intra-dataset", "OBSERVATION_MODIFIER", 154, 167], ["heterogeneity", "OBSERVATION", 168, 181]]], ["As shown in Fig. 11(b) , each original CXRs of the COVID-19 class showed highly-varying intensity characteristics among each segmented anatomies.", [["COVID-19 class", "DNA", 51, 65], ["each original CXRs", "TEST", 25, 43], ["the COVID", "TEST", 47, 56], ["varying intensity", "OBSERVATION_MODIFIER", 80, 97], ["segmented anatomies", "OBSERVATION", 125, 144]]], ["Thanks to our preprocessing step, the mean pixel intensity distribution between lung and heart regions of the preprocessed COVID-19 dataset (see Fig. 11 (c)) became similar to the normal class in Fig. 11(a) .", [["lung", "ANATOMY", 80, 84], ["heart", "ANATOMY", 89, 94], ["lung", "ORGAN", 80, 84], ["heart", "ORGAN", 89, 94], ["COVID-19 dataset", "DNA", 123, 139], ["the mean pixel intensity distribution between lung and heart regions", "PROBLEM", 34, 102], ["the preprocessed COVID", "TEST", 106, 128], ["mean pixel", "OBSERVATION_MODIFIER", 38, 48], ["intensity", "OBSERVATION_MODIFIER", 49, 58], ["lung", "ANATOMY", 80, 84], ["heart", "ANATOMY", 89, 94], ["regions", "ANATOMY_MODIFIER", 95, 102]]], ["The problem of heterogeneity can be also mitigated as shown in the intensity histograms (see Fig. 11 (d)-(f)).", [["the intensity histograms", "TEST", 63, 87]]], ["The results confirmed that the original COVID-19 data could be well preprocessed to have comparable intensity distribution to that of well-curated normal data.", [["COVID", "DNA", 40, 45], ["the original COVID", "TEST", 27, 45]]], ["F. Segmentation network analysis 1) Comparison with U-Net: Recall that we chose FC-DenseNet103 as a backbone segmentation network architecture thanks to its higher segmentation performance with smaller number of parameters (9.4 M) [31] .", [["network architecture", "MULTI-TISSUE_STRUCTURE", 122, 142], ["DenseNet103", "DNA", 83, 94], ["FC", "TEST", 80, 82], ["smaller", "OBSERVATION_MODIFIER", 194, 201]]], ["To demonstrate the effectiveness of CXR segmentation by the FC-Densenet103, we trained U-Net [32] under identical training conditions and compared the results.", [["CXR", "DNA", 36, 39], ["Densenet103", "CELL_LINE", 63, 74], ["CXR segmentation", "TEST", 36, 52], ["the FC", "TEST", 56, 62], ["identical training conditions", "TREATMENT", 104, 133]]], ["There was no significant difference between the networks result.", [["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35]]], ["The proposed segmentation method with the FC-DenseNet103 resulted consistently better classification performance in all metrics than the U-Net.", [["DenseNet103", "DNA", 45, 56]]], ["When compared with the FC-DenseNet67, which has smaller number of parameters (3.5 M) [15] , the performance improvement by our method is significant.", [["FC", "PROTEIN", 23, 25], ["our method", "TEST", 123, 133], ["smaller", "OBSERVATION_MODIFIER", 48, 55], ["number", "OBSERVATION_MODIFIER", 56, 62], ["significant", "OBSERVATION_MODIFIER", 137, 148]]], ["Given the better trade-off between the complexity versus performance, we adopted FC-DenseNet103 as our segmentation network.", [["FC", "PROTEIN", 81, 83], ["DenseNet103", "DNA", 84, 95]]], ["2) Effect of trainset size: To demonstrate the robustness of the proposed segmentation network with limited training dataset, we performed the ablation study by reducing training dataset size.", [["the ablation study", "TEST", 139, 157], ["size", "OBSERVATION_MODIFIER", 22, 26], ["size", "OBSERVATION_MODIFIER", 187, 191]]], ["Lung segmentation performance was evaluated on the cross-database NLM(MC) dataset.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["Lung segmentation performance", "TEST", 0, 29]]], ["For the preprocessed NLM(MC) dataset, Jaccard similarity coefficients remain stable until 50% of trainset was used for training as shown in Table XV ; however, in the original NLM(MC) dataset without preprocessing step, segmentation performance decreased steeply as the size of trainsets decreased.", [["Jaccard similarity coefficients", "TEST", 38, 69], ["preprocessing step", "TEST", 200, 218], ["segmentation performance", "TEST", 220, 244], ["stable", "OBSERVATION_MODIFIER", 77, 83], ["size", "OBSERVATION_MODIFIER", 270, 274], ["trainsets", "OBSERVATION_MODIFIER", 278, 287], ["decreased", "OBSERVATION_MODIFIER", 288, 297]]], ["This results support that proposed segmentation network endures limited training dataset size by matching intensity distribution of cross-database CXRs thanks to our preprocessing step.", [["cross-database CXRs", "TEST", 132, 151], ["size", "OBSERVATION_MODIFIER", 89, 93]]], ["3) Segmentation effects on marker analysis and classification: The proposed segmentation network was trained with normal subject set that have segmentation mask as shown Table V , XV, and showed comparable performance with the state-of-the-art for the normal subjects.", [["XV", "PROTEIN", 180, 182], ["marker analysis", "TEST", 27, 42], ["segmentation mask", "TREATMENT", 143, 160], ["normal", "OBSERVATION", 252, 258]]], ["However, when CXR images with severe consolidation are used, segmentation performance degradation is unavoidable, since such images have been never observed during the training.D. Comparison with COVID-NetFor example, the radiograph from a bacterial pneumonia case in Fig. 3 was under-segmented due to widely spread severe opacity.", [["pneumonia", "DISEASE", 250, 259], ["opacity", "DISEASE", 323, 330], ["CXR", "PROTEIN", 14, 17], ["CXR images", "TEST", 14, 24], ["severe consolidation", "PROBLEM", 30, 50], ["segmentation performance degradation", "TEST", 61, 97], ["such images", "TEST", 120, 131], ["the radiograph", "TEST", 218, 232], ["a bacterial pneumonia case", "PROBLEM", 238, 264], ["widely spread severe opacity", "PROBLEM", 302, 330], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["consolidation", "OBSERVATION", 37, 50], ["bacterial", "OBSERVATION_MODIFIER", 240, 249], ["pneumonia", "OBSERVATION", 250, 259], ["-segmented", "OBSERVATION_MODIFIER", 284, 294], ["widely", "OBSERVATION_MODIFIER", 302, 308], ["spread", "OBSERVATION_MODIFIER", 309, 315], ["severe", "OBSERVATION_MODIFIER", 316, 322], ["opacity", "OBSERVATION", 323, 330]]], ["To further investigate this issue, we examined all cases of under-segmentation by defining the undersegmentation as a segmentation mask in which over 1/4 of the entire lung region is deformed.", [["lung", "ANATOMY", 168, 172], ["lung", "ORGAN", 168, 172], ["a segmentation mask", "TREATMENT", 116, 135], ["entire", "ANATOMY_MODIFIER", 161, 167], ["lung", "ANATOMY", 168, 172], ["region", "ANATOMY_MODIFIER", 173, 179], ["deformed", "OBSERVATION", 183, 191]]], ["Our investigation showed that the under-segmentations are only outliers that are observed in some patient data set (7 of 54 bacterials cases (13%,), 2 of 57 cases for TB (3.5%), and 5 of 200 cases for COVID-19 and viral pneumonia (2.5%)), whereas no under segmentation were observed from 191 healthy subjects.D. Comparison with COVID-NetTo confirm that the difference in the segmentation results can be a morphological marker for classification, we evaluated whether it is possible to distinguish normal and abnormal images (including bacterial pneumonia, tuberculosis, COVID-19 and other viruses) using only binary segmentation masks (not X-ray images).", [["TB", "DISEASE", 167, 169], ["viral pneumonia", "DISEASE", 214, 229], ["pneumonia", "DISEASE", 545, 554], ["tuberculosis", "DISEASE", 556, 568], ["patient", "ORGANISM", 98, 105], ["COVID-NetTo", "GENE_OR_GENE_PRODUCT", 328, 339], ["COVID", "DNA", 328, 333], ["NetTo", "DNA", 334, 339], ["patient", "SPECIES", 98, 105], ["COVID-19", "SPECIES", 201, 209], ["Our investigation", "TEST", 0, 17], ["bacterials cases", "TEST", 124, 140], ["TB", "TEST", 167, 169], ["COVID", "TEST", 201, 206], ["viral pneumonia", "PROBLEM", 214, 229], ["abnormal images", "PROBLEM", 508, 523], ["bacterial pneumonia", "PROBLEM", 535, 554], ["tuberculosis", "PROBLEM", 556, 568], ["COVID", "TEST", 570, 575], ["X-ray images", "TEST", 640, 652], ["viral", "OBSERVATION_MODIFIER", 214, 219], ["pneumonia", "OBSERVATION", 220, 229], ["bacterial", "OBSERVATION_MODIFIER", 535, 544], ["pneumonia", "OBSERVATION", 545, 554], ["tuberculosis", "OBSERVATION", 556, 568]]], ["With a separately trained neural network using only binary masks, it was possible to distinguish between normal and abnormal images with 86.9% sensitivity.", [["neural network", "ANATOMY", 26, 40], ["neural network", "MULTI-TISSUE_STRUCTURE", 26, 40]]], ["This confirms that the morphology of the segmentation mask is a discriminatory biomarker between normal and the patient groups.", [["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119], ["a discriminatory biomarker", "TEST", 62, 88], ["segmentation mask", "OBSERVATION", 41, 58], ["normal", "OBSERVATION", 97, 103]]], ["Although the differences in other labels were not significant, the overall sensitivity for bacterial were better when the under-segmented subjects were excluded.", [["subjects", "ORGANISM", 138, 146], ["bacterial", "PROBLEM", 91, 100], ["significant", "OBSERVATION_MODIFIER", 50, 61]]], ["Therefore, the under-segmentation still has some effects on the classification between the diseases.D. Comparison with COVID-NetFinally, we performed an additional experiment for the comparison of classification with and without segmentation masks.", [["COVID", "DNA", 119, 124], ["the diseases", "PROBLEM", 87, 99], ["segmentation masks", "TREATMENT", 229, 247], ["diseases", "OBSERVATION", 91, 99]]], ["The results in Table XVI clearly confirmed that despite the under-segmented outliers the use of segmentation mask significantly improved the classification performance on the whole.", [["Table XVI", "TEST", 15, 24], ["segmentation mask", "TREATMENT", 96, 113]]], ["This suggests that there are rooms to improve the performance of the proposed method, if the segmentation network could be further trained using patient cases with correct segmentation labels.", [["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152]]], ["G. Classification network analysis 1) Effect of patch size on the performance: To evaluate the effect of the patch size on the performance of the classification algorithm, we tested various patch sizes, such as 112 \u00d7 112, and 448\u00d7448.", [["the patch size", "TREATMENT", 105, 119], ["the classification algorithm", "TEST", 142, 170], ["size", "OBSERVATION_MODIFIER", 54, 58], ["size", "OBSERVATION_MODIFIER", 115, 119], ["sizes", "OBSERVATION_MODIFIER", 196, 201]]], ["With double-sized (448\u00d7 448) patches, the results were not better than those with patch size of 224 \u00d7 224, as depicted in Table XVII .", [["patch size", "TEST", 82, 92], ["sized", "OBSERVATION_MODIFIER", 12, 17]]], ["In summary, there seems to be a clear drawback in reducing the patch size, and there was also no benefit with increasing the patch size.", [["increasing the patch size", "TREATMENT", 110, 135], ["size", "OBSERVATION_MODIFIER", 69, 73], ["no", "UNCERTAINTY", 94, 96], ["patch", "OBSERVATION_MODIFIER", 125, 130], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["2) Effects of trainset size: We analyzed the effect of dataset size in terms of classification performance, since we aimed to develop the method that has the advantage of maintaining robustness even when only limited data are available.", [["trainset size", "PROBLEM", 14, 27], ["size", "OBSERVATION_MODIFIER", 23, 27], ["size", "OBSERVATION_MODIFIER", 63, 67]]], ["The classification performances with decreasing dataset sizes are provided in Fig. 12 .", [["decreasing dataset sizes", "PROBLEM", 37, 61], ["decreasing", "OBSERVATION_MODIFIER", 37, 47], ["sizes", "OBSERVATION_MODIFIER", 56, 61]]], ["The global approach using whole image, which is similar to most classification methods, showed prominent decrease in accuracy with decreasing dataset size, but the proposed local patch-based method showed less compromised performance, showing the robustness to the reduced dataset size as shown in Fig. 12(a) .", [["whole image", "TEST", 26, 37], ["decreasing dataset size", "PROBLEM", 131, 154], ["the reduced dataset size", "PROBLEM", 261, 285], ["global", "OBSERVATION_MODIFIER", 4, 10], ["prominent", "OBSERVATION_MODIFIER", 95, 104], ["decrease", "OBSERVATION_MODIFIER", 105, 113], ["decreasing", "OBSERVATION_MODIFIER", 131, 141], ["size", "OBSERVATION_MODIFIER", 150, 154], ["size", "OBSERVATION_MODIFIER", 281, 285]]], ["These results were more prominent when comparing them by relative scale as shown in Fig. 12(b) .VI. CONCLUSIONIn the rapidly evolving global pandemic of COVID-19, the use of CXR for COVID-19 diagnosis or triage for patient management has become an important issue to preserve limited medical resources and prevent further spreading of the virus.", [["COVID-19", "CELL", 153, 161], ["patient", "ORGANISM", 215, 222], ["patient", "SPECIES", 215, 222], ["COVID", "TEST", 153, 158], ["CXR", "TEST", 174, 177], ["COVID", "TEST", 182, 187], ["triage", "TEST", 204, 210], ["patient management", "TREATMENT", 215, 233], ["the virus", "PROBLEM", 335, 344], ["more prominent", "OBSERVATION_MODIFIER", 19, 33], ["global", "OBSERVATION_MODIFIER", 134, 140], ["pandemic", "OBSERVATION", 141, 149], ["virus", "OBSERVATION", 339, 344]]], ["However, the current diagnostic performance with CXR is not sufficient for routine clinical use, so the need of artificial intelligence to improve diagnostic performance of CXR is increasing.", [["CXR", "PROTEIN", 49, 52], ["CXR", "PROTEIN", 173, 176], ["CXR", "TEST", 49, 52], ["artificial intelligence", "TREATMENT", 112, 135], ["diagnostic performance", "TEST", 147, 169], ["CXR", "TEST", 173, 176], ["increasing", "OBSERVATION_MODIFIER", 180, 190]]], ["Unfortunately, due to the emergent nature of COVID-19 global pandemic, systematic collection of the large data set for deep neural network training is difficult.VI. CONCLUSIONTo address this problem, we investigated potential biomarkers in the CXR and found the globally distributed localized intensity variation can be an discrimatory feature for the COVID-19.", [["neural network", "ANATOMY", 124, 138], ["neural network", "MULTI-TISSUE_STRUCTURE", 124, 138], ["CXR", "PROTEIN", 244, 247], ["COVID-19", "DNA", 352, 360], ["COVID", "TEST", 45, 50], ["global pandemic", "PROBLEM", 54, 69], ["the large data", "TEST", 96, 110], ["deep neural network training", "TREATMENT", 119, 147], ["potential biomarkers", "TEST", 216, 236], ["the CXR", "TEST", 240, 247], ["the globally distributed localized intensity variation", "PROBLEM", 258, 312], ["the COVID", "TEST", 348, 357], ["large", "OBSERVATION_MODIFIER", 100, 105], ["globally", "OBSERVATION_MODIFIER", 262, 270], ["distributed", "OBSERVATION_MODIFIER", 271, 282], ["localized", "OBSERVATION_MODIFIER", 283, 292], ["intensity variation", "OBSERVATION", 293, 312]]], ["Based on this finding, we propose a patch-based deep neural network architecture that can be stably trained with small data set.", [["neural network", "ANATOMY", 53, 67], ["neural network", "MULTI-TISSUE_STRUCTURE", 53, 67], ["a patch", "TREATMENT", 34, 41], ["deep", "ANATOMY_MODIFIER", 48, 52], ["neural network", "OBSERVATION", 53, 67]]], ["Once the neural network was trained, the final decision was made based on the majority voting from multiple patches at random locations within lungs.", [["neural network", "ANATOMY", 9, 23], ["lungs", "ANATOMY", 143, 148], ["neural network", "MULTI-TISSUE_STRUCTURE", 9, 23], ["lungs", "ORGAN", 143, 148], ["multiple", "OBSERVATION_MODIFIER", 99, 107], ["patches", "OBSERVATION", 108, 115], ["lungs", "ANATOMY", 143, 148]]], ["We also proposed a novel probabilistic Grad-CAM saliency map that is tailored to the local patch-based approach.", [["a novel probabilistic Grad-CAM saliency map", "TREATMENT", 17, 60], ["the local patch-based approach", "TREATMENT", 81, 111]]], ["Our experimental results demonstrated that the proposed network was trained stably with small data set, provided comparative results with the SOTA method, and generated interpretable saliency maps that are strongly correlated with the radiological findings.", [["the SOTA method", "TEST", 138, 153], ["the radiological findings", "TEST", 231, 256]]]], "PMC7308021": [["Ethical ApprovalNot required.Funding sourcesNo funding was received to conduct the research shown in the manuscript.", [["Ethical Approval", "TREATMENT", 0, 16], ["funding", "OBSERVATION", 47, 54]]]], "PMC7380230": [["In three dimensions, the Sierpinski Gasket [2] and the Menger Sponge [3] have a analogous properties, with finite volume and infinite surface area.", [["surface area", "ANATOMY", 134, 146], ["the Sierpinski Gasket", "TEST", 21, 42], ["the Menger Sponge", "TREATMENT", 51, 68], ["a analogous properties", "TREATMENT", 78, 100], ["finite volume and infinite surface area", "TREATMENT", 107, 146], ["three dimensions", "OBSERVATION_MODIFIER", 3, 19], ["surface", "OBSERVATION_MODIFIER", 134, 141]]], ["These features are perfectly consistent with the isoperimetric theorems that relate surface area, A, with enclosed volume, V, for a 3-dimensional body by the inequality A3\u226536\u03c0V2, with equality for the sphere.", [["surface area", "ANATOMY", 84, 96], ["the isoperimetric theorems", "PROBLEM", 45, 71], ["consistent with", "UNCERTAINTY", 29, 44], ["surface", "OBSERVATION_MODIFIER", 84, 91], ["area", "OBSERVATION_MODIFIER", 92, 96], ["volume", "OBSERVATION_MODIFIER", 115, 121]]], ["Since we are being bombarded with animations and pictures of the Covid-19 virus as a sphere with a number of attachments leading off its surface to increase its surface area and provide links to latch on to other cells, we question whether, at the quantum gravitational level, space and black hole surfaces might be like that, with intricate structure down to arbitrarily small scales (or to a cut-off scale of order the Planck length), leading to an increase over the expected surface area.", [["surface", "ANATOMY", 137, 144], ["surface area", "ANATOMY", 161, 173], ["cells", "ANATOMY", 213, 218], ["surface area", "ANATOMY", 478, 490], ["Covid-19 virus", "ORGANISM", 65, 79], ["surface", "CELLULAR_COMPONENT", 137, 144], ["cells", "CELL", 213, 218], ["Covid-19 virus", "SPECIES", 65, 79], ["space and black hole surfaces", "TREATMENT", 277, 306], ["black hole", "OBSERVATION", 287, 297], ["increase", "OBSERVATION_MODIFIER", 451, 459], ["surface", "OBSERVATION_MODIFIER", 478, 485]]], ["The surface area of a black hole is a key feature that gives its entropy and information content.", [["surface area", "ANATOMY", 4, 16], ["a black hole", "PROBLEM", 20, 32], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["area", "OBSERVATION_MODIFIER", 12, 16], ["black hole", "OBSERVATION", 22, 32]]], ["Bekenstein [4] and Hawking [5] discovered many of these crucial classical properties whose significance for physics is wider than the study of black holes.", [["Bekenstein", "CHEMICAL", 0, 10], ["the study", "TEST", 130, 139]]], ["Hawking [6] showed that they are not mere coincidences or analogies with thermodynamic laws, as was once thought, but deep consequences of the quantum structure of a black hole: black holes are black bodies.IntroductionIn section 2, we outline a fractal extension of the surface structure of the static, spherically symmetric Schwarzschild black hole and determine conditions needed for the volume to remain finite while the surface area tends to infinity in the limit of increasing intricacy on arbitrarily small scales.", [["surface", "ANATOMY", 271, 278], ["surface area", "ANATOMY", 425, 437], ["black holes", "PROBLEM", 178, 189], ["black bodies", "PROBLEM", 194, 206], ["IntroductionIn section", "TREATMENT", 207, 229], ["spherically symmetric Schwarzschild black hole", "PROBLEM", 304, 350], ["increasing intricacy on arbitrarily small scales", "PROBLEM", 472, 520], ["black hole", "OBSERVATION", 166, 176], ["black holes", "OBSERVATION", 178, 189], ["black bodies", "OBSERVATION", 194, 206], ["fractal", "OBSERVATION_MODIFIER", 246, 253], ["surface", "OBSERVATION_MODIFIER", 271, 278], ["spherically", "OBSERVATION_MODIFIER", 304, 315], ["symmetric", "OBSERVATION_MODIFIER", 316, 325], ["Schwarzschild", "OBSERVATION_MODIFIER", 326, 339], ["black hole", "OBSERVATION", 340, 350], ["increasing", "OBSERVATION_MODIFIER", 472, 482], ["intricacy", "OBSERVATION", 483, 492], ["small", "OBSERVATION_MODIFIER", 508, 513], ["scales", "OBSERVATION_MODIFIER", 514, 520]]], ["We highlight a number of consequences for the entropy and Hawking lifetime of black holes and for assessments of the entropy of the observable universe.", [["the entropy", "TREATMENT", 42, 53], ["black holes", "TREATMENT", 78, 89], ["assessments", "TEST", 98, 109]]], ["In section 3 we discuss the physical bases for this type of horizon structure and in section 4 we discuss our results and their limitations.Black hole with an intricate surfaceWe will construct a fractal horizon surface starting from a Schwarzschild black hole of mass M and radius Rg=2GM/c2 by attaching some number of smaller spheres to touch its outer surface with yet smaller spheres touching the surfaces of those spheres, and so on.", [["outer surface", "ANATOMY", 349, 362], ["Black hole", "PROBLEM", 140, 150], ["an intricate surfaceWe", "TREATMENT", 156, 178], ["a fractal horizon surface", "TREATMENT", 194, 219], ["mass M", "PROBLEM", 264, 270], ["radius Rg", "TEST", 275, 284], ["hole", "OBSERVATION", 146, 150], ["mass", "OBSERVATION", 264, 268], ["smaller", "OBSERVATION_MODIFIER", 320, 327], ["spheres", "OBSERVATION", 328, 335], ["outer", "OBSERVATION_MODIFIER", 349, 354], ["surface", "OBSERVATION_MODIFIER", 355, 362], ["smaller", "OBSERVATION_MODIFIER", 372, 379], ["spheres", "OBSERVATION", 380, 387], ["surfaces", "OBSERVATION_MODIFIER", 401, 409]]], ["The original Koch snowflake boundary in 2-dimensions is made of a crenellated structure of increasingly small triangles whose sides have the middle third converted into the base of a new equilateral triangle with sides that are three times smaller: our boundary will be composed of surfaces of hierarchically smaller, touching, spheres.", [["a crenellated structure", "PROBLEM", 64, 87], ["Koch snowflake", "OBSERVATION", 13, 27], ["boundary", "OBSERVATION_MODIFIER", 28, 36], ["crenellated", "OBSERVATION_MODIFIER", 66, 77], ["structure", "OBSERVATION", 78, 87], ["increasingly", "OBSERVATION_MODIFIER", 91, 103], ["small", "OBSERVATION_MODIFIER", 104, 109], ["triangles", "OBSERVATION_MODIFIER", 110, 119], ["middle", "ANATOMY_MODIFIER", 141, 147], ["base", "ANATOMY_MODIFIER", 173, 177], ["new", "OBSERVATION_MODIFIER", 183, 186], ["equilateral", "OBSERVATION_MODIFIER", 187, 198], ["triangle", "OBSERVATION_MODIFIER", 199, 207], ["sides", "ANATOMY_MODIFIER", 213, 218], ["three times", "OBSERVATION_MODIFIER", 228, 239], ["smaller", "OBSERVATION_MODIFIER", 240, 247], ["hierarchically", "OBSERVATION_MODIFIER", 294, 308], ["smaller", "OBSERVATION_MODIFIER", 309, 316]]], ["An animation of the construction for this \u2018sphereflake\u2019 can be see in ref.", [["the construction", "TREATMENT", 16, 32], ["this \u2018sphereflake\u2019", "TREATMENT", 37, 55]]], ["Suppose that each step to smaller scale intricacy leads to the attachment of N spheres of radius \u03bb times smaller than the sphere to the sphere to which they are attached tangentially.", [["N", "CHEMICAL", 77, 78], ["radius", "ANATOMY_MODIFIER", 90, 96], ["smaller", "OBSERVATION_MODIFIER", 105, 112]]], ["Therefore, the hierarchy of radii is just rn+1=\u03bbrn over N steps, where r0=Rg, is the Schwarzschild radius.Black hole with an intricate surfaceIf we allow this process of adding smaller spheres to touch the surface, then the total volume of the black hole after an infinite number of steps, V\u221e, will be(1)V\u221e=\u2211n=0\u221eNn4\u03c03(\u03bbnRg)3=4\u03c0Rg33\u2211n=0\u221e(N\u03bb3)n.This is a finite convergent so long as N\u03bb3<1.", [["surface", "ANATOMY", 135, 142], ["surface", "ANATOMY", 206, 213], ["V\u221e", "CHEMICAL", 290, 292], ["Nn4\u03c03(\u03bbnRg)3=4\u03c0Rg33\u2211n", "CHEMICAL", 312, 333], ["surface", "CELLULAR_COMPONENT", 206, 213], ["the Schwarzschild radius", "PROBLEM", 81, 105], ["Black hole", "PROBLEM", 106, 116], ["the total volume of the black hole", "TREATMENT", 220, 254], ["V\u221e", "TEST", 290, 292], ["V\u221e", "TEST", 304, 306], ["\u2211n", "TEST", 307, 309], ["\u03bbnRg", "TEST", 318, 322], ["Rg33\u2211n", "TEST", 327, 333], ["\u221e", "TEST", 335, 336], ["N\u03bb", "TEST", 337, 339], ["radii", "ANATOMY_MODIFIER", 28, 33], ["radius", "ANATOMY_MODIFIER", 99, 105], ["hole", "OBSERVATION", 112, 116], ["surface", "OBSERVATION_MODIFIER", 135, 142]]], ["This ensures the geometric series on the right-hand side of eq.", [["right-hand", "ANATOMY", 41, 51], ["the geometric series", "TEST", 13, 33], ["right", "ANATOMY_MODIFIER", 41, 46], ["eq", "OBSERVATION", 60, 62]]], ["In that case, the N\u2192\u221e limit is(2)V\u221e=4\u03c0Rg33(1\u2212N\u03bb3)>4\u03c0Rg33Therefore, the volume of the extended fractal black hole is finite under these conditions.Black hole with an intricate surfaceSimilarly, the total surface area after an infinite number steps, A\u221e, is(3)A\u221e=\u2211n=0\u221eNn4\u03c0(\u03bbnRg)2=4\u03c0Rg2\u2211n=0\u221e(N\u03bb2)n>4\u03c0Rg2.Since we want the surface area to diverge in the limit we require N\u03bb2>1.", [["surface area", "ANATOMY", 203, 215], ["surface area", "ANATOMY", 318, 330], ["N\u2192\u221e", "CHEMICAL", 18, 21], ["Rg33", "CHEMICAL", 38, 42], ["Nn4", "CHEMICAL", 265, 268], ["Rg2", "CHEMICAL", 296, 299], ["4\u03c0Rg33Therefore", "SIMPLE_CHEMICAL", 50, 65], ["\u03c0Rg2", "SIMPLE_CHEMICAL", 295, 299], ["Rg2", "PROTEIN", 296, 299], ["V", "TEST", 33, 34], ["Rg33", "TEST", 38, 42], ["Rg33Therefore", "TEST", 52, 65], ["the extended fractal black hole", "TREATMENT", 81, 112], ["Black hole", "PROBLEM", 146, 156], ["an intricate surfaceSimilarly", "TREATMENT", 162, 191], ["an infinite number steps", "TEST", 222, 246], ["A\u221e", "TEST", 248, 250], ["A\u221e", "TEST", 257, 259], ["\u2211n", "TEST", 260, 262], ["Nn4", "TEST", 265, 268], ["\u03bbnRg", "TEST", 270, 274], ["\u03c0Rg2", "TEST", 278, 282], ["n", "TEST", 283, 284], ["\u221e", "TEST", 286, 287], ["N\u03bb", "TEST", 288, 290], ["n", "TEST", 292, 293], ["Rg2", "TEST", 296, 299], ["the surface area", "TREATMENT", 314, 330], ["fractal", "OBSERVATION_MODIFIER", 94, 101], ["black hole", "OBSERVATION", 102, 112], ["hole", "OBSERVATION", 152, 156]]], ["When N\u03bb2<1, the area converges to(4)A\u221e=4\u03c0Rg21\u2212N\u03bb2.", [["Rg21\u2212N\u03bb2", "CHEMICAL", 41, 49], ["Rg21\u2212N\u03bb2", "SIMPLE_CHEMICAL", 41, 49], ["Rg21", "PROTEIN", 41, 45], ["N\u03bb2", "PROTEIN", 46, 49]]]], "PMC7334145": [["Persistence is defined as the ability to maintain an action or complete a task regardless of the person\u2019s inclination towards the task [5, 7].", [["person", "SPECIES", 97, 103]]], ["Recent studies have shown that persistence in educational settings is associated with academic achievement [3, 19], creativity [20] and long-term academic outcomes such as later schooling and future earnings [6, 19].", [["Recent studies", "TEST", 0, 14], ["persistence", "OBSERVATION_MODIFIER", 31, 42]]], ["However, not all persistence is positive.", [["positive", "OBSERVATION", 32, 40]]], ["[2] have argued that some persistence may be unproductive, or wheel-spinning, defined as spending too much time struggling without achieving mastery.", [["may be", "UNCERTAINTY", 38, 44], ["unproductive", "OBSERVATION", 45, 57]]], ["[2] defined wheel-spinning as not achieving mastery even after attempting 10 or more problems within a problem set; [14] involved two human raters to code wheel-spinning behaviors qualitatively based on a coding manual, with a Cohen\u2019s Kappa of 0.9.", [["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["a Cohen\u2019s Kappa", "TEST", 225, 240]]], ["In the learning system ASSISTments, [4] looked at non-persistent behaviors in which students quit the problem set without reaching mastery of a skill, differentiating between quitting immediately and quitting after attempting a few problems.", [["a few problems", "PROBLEM", 226, 240]]], ["Within the same learning system, [10] defined non-persistence as attempting fewer than ten problems for a skill, but did not consider non-persistence detection in their work.Detection of Persistence in Learning ::: IntroductionDetection of wheel-spinning behaviors is important in identifying students who may need additional support during a learning task.", [["additional support", "TREATMENT", 315, 333], ["a learning task", "TREATMENT", 341, 356], ["Persistence", "OBSERVATION_MODIFIER", 187, 198]]], ["A follow-up study further refined this model and was able to detect wheel-spinning on the seventh practice opportunities [8].", [["A follow-up study", "TEST", 0, 17]]], ["Other machine learning methods such as neural networks [14], gradient boosting [17] and random forest [22] have also been used to enable wheel-spinning detection at earlier stages in practice.", [["neural networks", "ANATOMY", 39, 54], ["Other machine learning methods", "TREATMENT", 0, 30], ["gradient boosting", "TREATMENT", 61, 78]]], ["Most notably, [4] was able to identify wheel-spinning students at their third opportunity, applying Long Short Term Memory Recurrent Neural Networks.", [["Neural Networks", "OBSERVATION", 133, 148]]], ["While these studies all take place in an ITS environment, there has also been work on wheel-spinning detection in educational games.", [["these studies", "TEST", 6, 19]]], ["[16] constructed a model to detect wheel-spinning based on the features engineered within the first 5 min, first 10 min, and first 15 min of game playing, and [15] constructed a model to differentiate wheel-spinning from productive persistence in a sequence of mathematics games.Detection of Persistence in Learning ::: IntroductionIn reviewing these prior works, we note that for a wheel-spinning detector to be practical for real-time usage, there are two important criteria to consider.", [["Persistence", "OBSERVATION_MODIFIER", 292, 303]]], ["At the same time, recent efforts to improve prediction of wheel-spinning using gradient boosting or neural networks have improved speed and quality of prediction at the cost of interpretability, posing a challenge for educational researchers to uncover and understand the impact of learning behaviors on wheel-spinning.Detection of Persistence in Learning ::: IntroductionIn this paper, we attempt to address each of these limitations.", [["neural networks", "ANATOMY", 100, 115], ["neural networks", "MULTI-TISSUE_STRUCTURE", 100, 115], ["gradient boosting", "TREATMENT", 79, 96], ["educational researchers", "TREATMENT", 218, 241], ["Persistence", "OBSERVATION_MODIFIER", 332, 343]]], ["We 1) construct multi-class detectors distinguishing the three categories discussed above states\u2014non-persistence, productive persistence, and unproductive persistence (wheel-spinning)\u2014so as to capture and compare specific behaviors that differentiate both between persistent vs. non-persistent students, and productively persistent vs. wheel-spinning students; 2) explore the minimum number of practice opportunities that could be used with reasonable accuracy to detect the various persistence states under these conditions, and derive specific features that may be translated into practical interventions.", [["productive persistence", "PROBLEM", 114, 136], ["persistent vs", "PROBLEM", 264, 277], ["productively persistent vs", "PROBLEM", 308, 334], ["practice opportunities", "TREATMENT", 394, 416], ["practical interventions", "TREATMENT", 583, 606], ["productive", "OBSERVATION_MODIFIER", 114, 124], ["persistence", "OBSERVATION_MODIFIER", 125, 136], ["unproductive", "OBSERVATION_MODIFIER", 142, 154], ["persistence", "OBSERVATION_MODIFIER", 155, 166], ["persistent", "OBSERVATION_MODIFIER", 264, 274], ["productively", "OBSERVATION_MODIFIER", 308, 320], ["persistent", "OBSERVATION_MODIFIER", 321, 331]]], ["We conclude by discussing the possible impact of the features on persistence and unproductive persistence in learning.ASSISTments ::: MethodsASSISTments is a free online learning platform that provides immediate feedback to students and formative assessment of student performance to teachers [9].", [["formative assessment", "TEST", 237, 257], ["unproductive", "OBSERVATION_MODIFIER", 81, 93], ["persistence", "OBSERVATION_MODIFIER", 94, 105]]], ["Within the ASSISTments system, Skill Builders are a type of math problem set where students practice randomly generated problems that are based on existing templates and correspond to the same skill [9].", [["existing templates", "TREATMENT", 147, 165]]], ["This test comprises one randomly selected item from a template in the completed problem set, and is delivered through the Automatic Reassessment and Relearning System (ARRS) [21].", [["This test", "TEST", 0, 9], ["a template", "TREATMENT", 52, 62]]], ["The main objective of ARRS is to assess a student\u2019s retention of a skill over time.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["If the student does not answer this item correctly, and therefore fails in skill retention, they will be assigned the corresponding Skill Builder problem set to re-learn the materials.Data Collection and Label Generation ::: MethodsOur research dataset is the publicly available ASSISTments Skill Builders data set from the 2014\u20132015 school year, which consists of 26,522 students who attempted 1,088 Skill Builder problem sets over a year.", [["Methods", "TREATMENT", 225, 232]]], ["This data set was chosen due to its use in past research on wheel-spinning and persistence (i.e. [10]).", [["This data", "TEST", 0, 9]]]], "PMC7090697": [["IntroductionRabies virus (RABV) is a prototypical neurotropic virus causing acute, fatal encephalitis in humans and other animals worldwide.", [["neurotropic virus", "DISEASE", 50, 67], ["encephalitis", "DISEASE", 89, 101], ["IntroductionRabies virus", "ORGANISM", 0, 24], ["RABV", "ORGANISM", 26, 30], ["neurotropic virus", "ORGANISM", 50, 67], ["humans", "ORGANISM", 105, 111], ["IntroductionRabies virus", "SPECIES", 0, 24], ["humans", "SPECIES", 105, 111], ["IntroductionRabies virus", "SPECIES", 0, 24], ["RABV", "SPECIES", 26, 30], ["humans", "SPECIES", 105, 111], ["IntroductionRabies virus (RABV", "PROBLEM", 0, 30], ["a prototypical neurotropic virus", "PROBLEM", 35, 67], ["acute, fatal encephalitis in humans", "PROBLEM", 76, 111], ["neurotropic virus", "OBSERVATION", 50, 67], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["fatal", "OBSERVATION_MODIFIER", 83, 88], ["encephalitis", "OBSERVATION", 89, 101]]], ["Although rabies can be prevented by appropriate post-exposure prophylaxis (PEP) administration, more than 59,000 people die of this incurable disease annually in the world (Brunker and Mollentze 2018), emerging the significant demand to further investigate the mechanism of RABV life cycle and develop efficient therapeutics.", [["rabies", "DISEASE", 9, 15], ["rabies", "ORGANISM", 9, 15], ["people", "ORGANISM", 113, 119], ["RABV", "ORGANISM", 274, 278], ["people", "SPECIES", 113, 119], ["rabies", "SPECIES", 9, 15], ["RABV", "SPECIES", 274, 278], ["rabies", "PROBLEM", 9, 15], ["appropriate post-exposure prophylaxis", "TREATMENT", 36, 73], ["PEP) administration", "TREATMENT", 75, 94], ["this incurable disease", "PROBLEM", 127, 149], ["RABV life cycle", "TREATMENT", 274, 289]]], ["RABV has a non-segmented, single stranded negative RNA genome of about 12 kb, encoding five viral proteins including nucleoprotein (N), matrix protein (M), phosphoprotein (P), RNA-dependent RNA polymerase (L) and glycoprotein (G) (Davis et al.2015).", [["RABV", "ORGANISM", 0, 4], ["nucleoprotein (N)", "GENE_OR_GENE_PRODUCT", 117, 134], ["matrix protein", "GENE_OR_GENE_PRODUCT", 136, 150], ["RNA-dependent RNA polymerase (L)", "GENE_OR_GENE_PRODUCT", 176, 208], ["glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 213, 229], ["non-segmented, single stranded negative RNA genome", "DNA", 11, 61], ["viral proteins", "PROTEIN", 92, 106], ["nucleoprotein (N)", "PROTEIN", 117, 134], ["matrix protein", "PROTEIN", 136, 150], ["M", "PROTEIN", 152, 153], ["phosphoprotein (P)", "PROTEIN", 156, 174], ["RNA-dependent RNA polymerase", "PROTEIN", 176, 204], ["L", "PROTEIN", 206, 207], ["glycoprotein", "PROTEIN", 213, 225], ["RABV", "SPECIES", 0, 4], ["five viral proteins", "TEST", 87, 106], ["nucleoprotein", "TEST", 117, 130], ["matrix protein", "TEST", 136, 150], ["phosphoprotein", "TEST", 156, 170], ["RNA", "TEST", 176, 179], ["negative", "OBSERVATION", 42, 50], ["RNA genome", "OBSERVATION", 51, 61]]], ["To facilitate the efficient infection and replication, RABV has developed multiple strategies including interaction with host proteins to gain essential functions in viral replicative cycle.", [["infection", "DISEASE", 28, 37], ["RABV", "ORGANISM", 55, 59], ["host proteins", "PROTEIN", 121, 134], ["RABV", "SPECIES", 55, 59], ["the efficient infection", "PROBLEM", 14, 37], ["RABV", "TREATMENT", 55, 59], ["host proteins", "TREATMENT", 121, 134], ["efficient", "OBSERVATION_MODIFIER", 18, 27], ["infection", "OBSERVATION", 28, 37], ["viral replicative cycle", "OBSERVATION", 166, 189]]], ["An example is that the heat shock proteins 70 (HSP70) was shown to interact with the N protein of RABV and to be present in both the nucleocapsid and purified virions, while down regulation of HSP70, using an inhibitor or RNA interference, results in a significant decrease in the production of viral mRNAs, viral proteins, and virions (Lahaye et al.2012).", [["virions", "ANATOMY", 159, 166], ["heat shock proteins 70", "GENE_OR_GENE_PRODUCT", 23, 45], ["HSP70", "GENE_OR_GENE_PRODUCT", 47, 52], ["RABV", "ORGANISM", 98, 102], ["nucleocapsid", "CELLULAR_COMPONENT", 133, 145], ["HSP70", "GENE_OR_GENE_PRODUCT", 193, 198], ["heat shock proteins 70", "PROTEIN", 23, 45], ["HSP70", "PROTEIN", 47, 52], ["N protein", "PROTEIN", 85, 94], ["RABV", "PROTEIN", 98, 102], ["HSP70", "PROTEIN", 193, 198], ["viral mRNAs", "RNA", 295, 306], ["viral proteins", "PROTEIN", 308, 322], ["RABV", "SPECIES", 98, 102], ["the heat shock proteins", "TEST", 19, 42], ["the N protein of RABV", "TREATMENT", 81, 102], ["HSP70", "TEST", 193, 198], ["an inhibitor", "TREATMENT", 206, 218], ["RNA interference", "PROBLEM", 222, 238], ["a significant decrease", "PROBLEM", 251, 273], ["viral mRNAs", "PROBLEM", 295, 306], ["viral proteins", "PROBLEM", 308, 322], ["significant", "OBSERVATION_MODIFIER", 253, 264], ["decrease", "OBSERVATION_MODIFIER", 265, 273], ["viral mRNAs", "OBSERVATION", 295, 306], ["viral proteins", "OBSERVATION", 308, 322]]], ["However, the knowledge on the host protein assembled into RABV virions is limited.IntroductionMany viruses hijack the cellular machineries by interaction with a considerable number of host factors for efficient replication.", [["cellular", "ANATOMY", 118, 126], ["RABV virions", "ORGANISM", 58, 70], ["cellular", "CELL", 118, 126], ["host protein", "PROTEIN", 30, 42], ["host factors", "PROTEIN", 184, 196], ["RABV", "SPECIES", 58, 62], ["efficient replication", "TREATMENT", 201, 222], ["RABV virions", "OBSERVATION", 58, 70]]], ["For example, retroviruses, rhabdoviruses, filoviruses, arenaviruses, and paramyxoviruses bud via host endosomal sorting complex required for transport (ESCRT) machinery (Chen and Lamb 2008; Votteler and Sundquist 2013).", [["bud", "ANATOMY", 89, 92], ["endosomal", "ANATOMY", 102, 111], ["arenaviruses", "DISEASE", 55, 67], ["retroviruses", "ORGANISM", 13, 25], ["rhabdoviruses", "GENE_OR_GENE_PRODUCT", 27, 40], ["filoviruses", "GENE_OR_GENE_PRODUCT", 42, 53], ["host endosomal sorting complex", "GENE_OR_GENE_PRODUCT", 97, 127], ["host endosomal sorting complex", "PROTEIN", 97, 127], ["ESCRT", "PROTEIN", 152, 157], ["retroviruses", "PROBLEM", 13, 25], ["rhabdoviruses", "PROBLEM", 27, 40], ["filoviruses", "PROBLEM", 42, 53], ["arenaviruses", "PROBLEM", 55, 67], ["paramyxoviruses bud", "PROBLEM", 73, 92], ["retroviruses", "OBSERVATION", 13, 25], ["rhabdoviruses", "OBSERVATION", 27, 40]]], ["Human immunodeficiency virus (HIV) is one of the best understood viruses in this respect.", [["Human immunodeficiency virus (HIV)", "DISEASE", 0, 34], ["Human immunodeficiency virus", "ORGANISM", 0, 28], ["HIV", "ORGANISM", 30, 33], ["Human immunodeficiency virus (HIV", "SPECIES", 0, 33], ["Human immunodeficiency virus", "SPECIES", 0, 28], ["HIV", "SPECIES", 30, 33], ["Human immunodeficiency virus (HIV)", "PROBLEM", 0, 34], ["immunodeficiency virus", "OBSERVATION", 6, 28], ["viruses", "OBSERVATION", 65, 72]]], ["ESCRT subunits are recruited at HIV assembly sites and have been detected in the released HIV particles by three dimensional super resolution microscopy (Van Engelenburg et al.2014).", [["ESCRT", "GENE_OR_GENE_PRODUCT", 0, 5], ["HIV", "ORGANISM", 90, 93], ["ESCRT subunits", "PROTEIN", 0, 14], ["HIV assembly sites", "DNA", 32, 50], ["HIV", "SPECIES", 90, 93], ["HIV", "SPECIES", 32, 35], ["HIV", "SPECIES", 90, 93], ["ESCRT subunits", "TREATMENT", 0, 14]]], ["ESCRT machinery were also found to be associated with RABV life cycle (Okumura and Harty 2011), but what kind of ESCRT subunits participate in RABV budding has been not investigated.IntroductionSensitive mass spectrometry enables the identification of host proteins incorporated into virions with high accuracy and sensitivity.", [["virions", "ANATOMY", 284, 291], ["ESCRT", "GENE_OR_GENE_PRODUCT", 0, 5], ["ESCRT", "GENE_OR_GENE_PRODUCT", 113, 118], ["RABV", "ORGANISM", 143, 147], ["ESCRT", "PROTEIN", 0, 5], ["ESCRT subunits", "PROTEIN", 113, 127], ["host proteins", "PROTEIN", 252, 265], ["RABV", "SPECIES", 54, 58], ["RABV", "SPECIES", 143, 147], ["ESCRT subunits", "TREATMENT", 113, 127], ["IntroductionSensitive mass spectrometry", "PROBLEM", 182, 221], ["host proteins", "PROBLEM", 252, 265]]], ["So far, proteomic studies have been performed on a number of purified virus preparations, including DNA viruses (Stegen et al.2013; Alejo et al.2018) and a broad range of RNA viruses (Shaw et al.2008; Radhakrishnan et al.2010; Nuss et al.2014; Lussignol et al.2016; McKnight et al.2017; Ziegler et al.2018), as well as virus-like particles (Vera-Velasco et al.2018).", [["DNA", "CELLULAR_COMPONENT", 100, 103], ["proteomic studies", "TEST", 8, 25], ["purified virus preparations", "TREATMENT", 61, 88], ["DNA viruses", "PROBLEM", 100, 111], ["RNA viruses", "PROBLEM", 171, 182], ["virus", "TEST", 319, 324], ["RNA viruses", "OBSERVATION", 171, 182]]], ["These studies have revealed substantial host proteins incorporated into viral particles, with several highlighting the utility of proteomics in understanding the mechanisms of virus-host interaction and identification of the essential role of cellular proteins in viral assembly or morphogenesis.", [["cellular", "ANATOMY", 243, 251], ["cellular", "CELL", 243, 251], ["cellular proteins", "PROTEIN", 243, 260], ["These studies", "TEST", 0, 13], ["substantial host proteins", "PROBLEM", 28, 53], ["viral particles", "PROBLEM", 72, 87], ["virus", "PROBLEM", 176, 181], ["cellular proteins", "PROBLEM", 243, 260], ["substantial", "OBSERVATION_MODIFIER", 28, 39], ["host proteins", "OBSERVATION", 40, 53], ["viral particles", "OBSERVATION", 72, 87], ["cellular proteins", "OBSERVATION", 243, 260]]], ["For an instance, the proteomic analysis of hepatitis C virions (HCV) has identified the participation of host proteins in viral infection and revealed the interaction of HCV capsid protein with nucleoporin Nup98, a host protein important for viral propagation and morphogenesis (Lussignol et al.2016).", [["hepatitis C", "DISEASE", 43, 54], ["viral infection", "DISEASE", 122, 137], ["hepatitis C virions", "ORGANISM", 43, 62], ["HCV", "ORGANISM", 64, 67], ["HCV", "ORGANISM", 170, 173], ["nucleoporin", "GENE_OR_GENE_PRODUCT", 194, 205], ["Nup98", "GENE_OR_GENE_PRODUCT", 206, 211], ["host proteins", "PROTEIN", 105, 118], ["HCV capsid protein", "PROTEIN", 170, 188], ["nucleoporin Nup98", "PROTEIN", 194, 211], ["HCV", "SPECIES", 64, 67], ["HCV", "SPECIES", 170, 173], ["the proteomic analysis", "TEST", 17, 39], ["hepatitis C virions (HCV)", "PROBLEM", 43, 68], ["host proteins", "PROBLEM", 105, 118], ["viral infection", "PROBLEM", 122, 137], ["HCV capsid protein", "TREATMENT", 170, 188], ["nucleoporin Nup98", "TREATMENT", 194, 211], ["a host protein", "TREATMENT", 213, 227], ["viral propagation", "TREATMENT", 242, 259], ["morphogenesis (Lussignol et al", "TREATMENT", 264, 294], ["hepatitis", "OBSERVATION", 43, 52], ["viral infection", "OBSERVATION", 122, 137]]], ["Proteomic analysis has also shown the engagement of host proteins in the assembly of respiratory syncytial virus (RSV), with one, heat shock protein 90, playing an important role in the assembly and maturation of the virus particles (Radhakrishnan et al.2010).", [["respiratory syncytial virus", "DISEASE", 85, 112], ["respiratory syncytial virus", "ORGANISM", 85, 112], ["RSV", "ORGANISM", 114, 117], ["heat shock protein 90", "GENE_OR_GENE_PRODUCT", 130, 151], ["host proteins", "PROTEIN", 52, 65], ["heat shock protein 90", "PROTEIN", 130, 151], ["respiratory syncytial virus", "SPECIES", 85, 112], ["respiratory syncytial virus", "SPECIES", 85, 112], ["RSV", "SPECIES", 114, 117], ["Proteomic analysis", "TEST", 0, 18], ["host proteins", "PROBLEM", 52, 65], ["respiratory syncytial virus", "PROBLEM", 85, 112], ["heat shock protein", "TEST", 130, 148], ["the virus particles", "PROBLEM", 213, 232], ["respiratory syncytial", "ANATOMY", 85, 106]]], ["However, until the present work, the host protein constituents of rabies virions had remained largely unknown, although their identification could significantly enhance our understanding of the pathways of viral budding and entry, and the mechanisms of virus-host interactions required for RABV propagation.IntroductionHere, the protein contents of purified RABV were identified by the nano-scale liquid chromatography tandem mass spectrometry (nano LC\u2013MS/MS) approach, revealing 49 virions-associated host proteins with some validated by Western blotting or immunogold labeling.", [["rabies virions", "ORGANISM", 66, 80], ["RABV", "ORGANISM", 290, 294], ["RABV", "ORGANISM", 358, 362], ["host proteins", "PROTEIN", 502, 515], ["rabies", "SPECIES", 66, 72], ["RABV", "SPECIES", 290, 294], ["RABV", "SPECIES", 358, 362], ["the host protein constituents", "TEST", 33, 62], ["rabies virions", "PROBLEM", 66, 80], ["viral budding", "PROBLEM", 206, 219], ["virus", "PROBLEM", 253, 258], ["RABV propagation", "TREATMENT", 290, 306], ["purified RABV", "PROBLEM", 349, 362], ["tandem mass spectrometry", "TEST", 419, 443], ["nano LC\u2013MS/MS) approach", "TREATMENT", 445, 468], ["49 virions", "PROBLEM", 480, 490], ["host proteins", "PROBLEM", 502, 515], ["immunogold labeling", "TEST", 559, 578], ["host proteins", "OBSERVATION_MODIFIER", 502, 515]]], ["In addition, the potential functional implications of these cellular proteins in the RABV replicative cycle were extrapolated.Viruses and Cells ::: Materials and MethodsRABV, CVS-11 strain was propagated in mouse Neuro-2A (N2a) cells in DMEM/F12 (Corning, New York, USA) and Opti-MEM (Gibco, Carlsbad, California, USA) at a 1:1 ratio, supplemented with 2% (V/V) fetal bovine serum (FBS; Biological Industries, Kibbutz Beit Haemek, Israel), penicillin G (100 U/mL) and streptomycin (100 \u00b5g/mL).", [["cellular", "ANATOMY", 60, 68], ["Cells", "ANATOMY", 138, 143], ["Neuro-2A (N2a) cells", "ANATOMY", 213, 233], ["fetal bovine serum", "ANATOMY", 362, 380], ["FBS", "ANATOMY", 382, 385], ["penicillin", "CHEMICAL", 440, 450], ["streptomycin", "CHEMICAL", 468, 480], ["penicillin G", "CHEMICAL", 440, 452], ["streptomycin", "CHEMICAL", 468, 480], ["cellular", "CELL", 60, 68], ["RABV", "ORGANISM", 85, 89], ["Cells", "CELL", 138, 143], ["CVS-11 strain", "ORGANISM", 175, 188], ["mouse", "ORGANISM", 207, 212], ["Neuro-2A (N2a) cells", "CELL", 213, 233], ["DMEM/F12", "CELL", 237, 245], ["bovine", "ORGANISM", 368, 374], ["serum", "ORGANISM_SUBSTANCE", 375, 380], ["FBS", "ORGANISM_SUBSTANCE", 382, 385], ["penicillin G", "SIMPLE_CHEMICAL", 440, 452], ["streptomycin", "SIMPLE_CHEMICAL", 468, 480], ["cellular proteins", "PROTEIN", 60, 77], ["mouse Neuro-2A (N2a) cells", "CELL_LINE", 207, 233], ["mouse", "SPECIES", 207, 212], ["bovine", "SPECIES", 368, 374], ["RABV", "SPECIES", 85, 89], ["mouse", "SPECIES", 207, 212], ["bovine", "SPECIES", 368, 374], ["these cellular proteins", "PROBLEM", 54, 77], ["Materials", "TEST", 148, 157], ["MethodsRABV", "TEST", 162, 173], ["CVS", "TEST", 175, 178], ["fetal bovine serum", "TEST", 362, 380], ["FBS", "TEST", 382, 385], ["Biological Industries", "TREATMENT", 387, 408], ["penicillin G", "TREATMENT", 440, 452], ["streptomycin", "TREATMENT", 468, 480], ["cellular proteins", "OBSERVATION", 60, 77], ["RABV", "OBSERVATION", 85, 89], ["replicative cycle", "OBSERVATION", 90, 107]]], ["The virus titer was determined as TCID50 according to the Spearman\u2013K\u00e4rber method (Dean and Abelseth 1973).Purification of RABV Particles ::: Materials and MethodsN2a cells at 70% confluence were infected with CVS-11 virus at a multiplicity of infection (MOI) of 0.01.", [["MethodsN2a cells", "ANATOMY", 155, 171], ["multiplicity of infection", "DISEASE", 227, 252], ["RABV", "ORGANISM", 122, 126], ["MethodsN2a cells", "CELL", 155, 171], ["CVS-11 virus", "ORGANISM", 209, 221], ["MethodsN2a cells", "CELL_LINE", 155, 171], ["RABV", "SPECIES", 122, 126], ["CVS-11 virus", "SPECIES", 209, 221], ["The virus titer", "TEST", 0, 15], ["RABV Particles", "TEST", 122, 136], ["MethodsN2a cells", "TEST", 155, 171], ["CVS", "TEST", 209, 212], ["virus", "PROBLEM", 216, 221], ["infection", "PROBLEM", 243, 252], ["virus", "OBSERVATION", 4, 9], ["RABV Particles", "OBSERVATION", 122, 136], ["infection", "OBSERVATION", 243, 252]]], ["The virus-containing supernatant were harvested at 72 h post-infection and clarified by differential centrifugation, first at 3000 \u00d7g for 15 min, then at 10,000 \u00d7g for 30 min, and the supernatants were used in the next step.", [["supernatant", "ANATOMY", 21, 32], ["supernatants", "ANATOMY", 184, 196], ["The virus", "PROBLEM", 0, 9], ["infection", "PROBLEM", 61, 70], ["the supernatants", "TREATMENT", 180, 196], ["virus", "OBSERVATION", 4, 9], ["infection", "OBSERVATION", 61, 70]]], ["All clarification and purification processes were carried out at 4 \u00b0C to avoid inactivation and maintain stability of virion structure.", [["purification processes", "TEST", 22, 44], ["virion structure", "OBSERVATION", 118, 134]]], ["A 10% iodixanol cushion was prepared by diluting a stock solution of OptiPrep\u00ae (60% w/v aqueous iodixanol, Sigma, St Louis, USA) with TNE buffer (50 mmol/L Tris\u2013HCl, 100 mmol/L NaCl, 1 mmol/L EDTA, pH 7.4) and used for pelleting RABV virions by ultracentrifugation at 70,000 \u00d7g for 1 h in a type 45Ti rotor (Beckman Coulter, California, USA) at 4 \u00b0C. The pellets were dispersed in 0.5 mL TNE buffer and then overlaid on the top of a discontinuous iodixanol density gradient (10%, 15%, 20%, 25% and 30%).", [["iodixanol", "CHEMICAL", 6, 15], ["OptiPrep\u00ae", "CHEMICAL", 69, 78], ["iodixanol", "CHEMICAL", 96, 105], ["TNE", "CHEMICAL", 134, 137], ["Tris\u2013HCl", "CHEMICAL", 156, 164], ["NaCl", "CHEMICAL", 177, 181], ["iodixanol", "CHEMICAL", 447, 456], ["iodixanol", "CHEMICAL", 6, 15], ["OptiPrep\u00ae", "CHEMICAL", 69, 78], ["iodixanol", "CHEMICAL", 96, 105], ["Tris\u2013HCl", "CHEMICAL", 156, 164], ["NaCl", "CHEMICAL", 177, 181], ["EDTA", "CHEMICAL", 192, 196], ["iodixanol", "CHEMICAL", 447, 456], ["iodixanol", "SIMPLE_CHEMICAL", 6, 15], ["OptiPrep\u00ae", "SIMPLE_CHEMICAL", 69, 78], ["iodixanol", "SIMPLE_CHEMICAL", 96, 105], ["TNE", "SIMPLE_CHEMICAL", 134, 137], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 156, 164], ["EDTA", "SIMPLE_CHEMICAL", 192, 196], ["RABV", "ORGANISM", 229, 233], ["iodixanol", "SIMPLE_CHEMICAL", 447, 456], ["RABV", "SPECIES", 229, 233], ["A 10% iodixanol cushion", "TREATMENT", 0, 23], ["OptiPrep\u00ae", "TREATMENT", 69, 78], ["v aqueous iodixanol", "TREATMENT", 86, 105], ["TNE buffer", "TREATMENT", 134, 144], ["Tris\u2013HCl", "TREATMENT", 156, 164], ["NaCl", "TREATMENT", 177, 181], ["L EDTA", "TREATMENT", 190, 196], ["pH", "TEST", 198, 200], ["pelleting RABV virions", "TREATMENT", 219, 241], ["The pellets", "TREATMENT", 351, 362], ["a discontinuous iodixanol density gradient", "TREATMENT", 431, 473], ["pellets", "OBSERVATION_MODIFIER", 355, 362], ["discontinuous", "OBSERVATION_MODIFIER", 433, 446], ["iodixanol density", "OBSERVATION", 447, 464]]], ["After ultracentrifugation at 100,000 \u00d7g for 1 h in an SW41 rotor (Beckman Coulter), visible virus bands were removed by suction and checked by electron microscopy.", [["ultracentrifugation", "TREATMENT", 6, 25], ["an SW41 rotor (Beckman Coulter", "TREATMENT", 51, 81], ["visible virus bands", "PROBLEM", 84, 103], ["electron microscopy", "TEST", 143, 162], ["virus bands", "OBSERVATION", 92, 103]]], ["In order to obtain higher purity, virus preparations containing bullet shaped particles were subjected to centrifugation at 100,000 \u00d7g in a discontinuous iodixanol density gradient (15%, 20% and 25%) for further purification.Electron Microscopy of Purified RABV Particles ::: Materials and MethodsThe resulting RABV preparations were examined by transmission electron microscopy (TEM) and then by cryo-electron microscopy (cryo-EM) to observe their purity and morphology as follows.", [["iodixanol", "CHEMICAL", 154, 163], ["iodixanol", "CHEMICAL", 154, 163], ["iodixanol", "SIMPLE_CHEMICAL", 154, 163], ["RABV", "ORGANISM", 257, 261], ["RABV", "ORGANISM", 311, 315], ["RABV", "SPECIES", 257, 261], ["RABV", "SPECIES", 311, 315], ["virus preparations", "TREATMENT", 34, 52], ["bullet shaped particles", "PROBLEM", 64, 87], ["centrifugation", "TEST", 106, 120], ["a discontinuous iodixanol density gradient", "TREATMENT", 138, 180], ["further purification", "TEST", 204, 224], ["Electron Microscopy", "TEST", 225, 244], ["Methods", "TREATMENT", 290, 297], ["cryo-electron microscopy", "TEST", 397, 421]]], ["The purified preparations were adsorbed onto fresh glow-discharged 300 mesh carbon-coated copper grids for 5 min at 20 \u00b0C to 25 \u00b0C, then negatively stained with 2% phosphotungstic acid (pH 7.0), and imaged using a H-7650 electron microscope (Hitachi, Japan) operating at 80 kV.", [["copper", "CHEMICAL", 90, 96], ["phosphotungstic acid", "CHEMICAL", 164, 184], ["carbon", "CHEMICAL", 76, 82], ["copper", "CHEMICAL", 90, 96], ["phosphotungstic acid", "CHEMICAL", 164, 184], ["H-7650", "CHEMICAL", 214, 220], ["copper grids", "SIMPLE_CHEMICAL", 90, 102], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 164, 184], ["The purified preparations", "TREATMENT", 0, 25], ["fresh glow", "TREATMENT", 45, 55], ["mesh carbon-coated copper grids", "TREATMENT", 71, 102], ["2% phosphotungstic acid", "TREATMENT", 161, 184], ["pH", "TEST", 186, 188]]], ["For cryo-EM, purified virions (3 \u00b5L) were frozen onto 200 mesh C-Flat cooper grids (Protochips, USA) by plunging into liquid ethane, using a Vitrobot mark IV specimen preparation unit (FEI, Eindhoven, Netherlands) with settings at 4 \u00b0C, 100% humidity and 1.5 s blot time.", [["virions", "ANATOMY", 22, 29], ["ethane", "CHEMICAL", 125, 131], ["ethane", "CHEMICAL", 125, 131], ["ethane", "SIMPLE_CHEMICAL", 125, 131], ["purified virions", "TREATMENT", 13, 29], ["a Vitrobot mark IV specimen preparation", "TREATMENT", 139, 178], ["settings", "TREATMENT", 219, 227], ["100% humidity", "TREATMENT", 237, 250]]], ["Cryo-EM images were recorded at a magnification of 96,000 \u00d7 in an FEI Tecnai Arctica electron microscope (FEI, Hillsboro, USA) at 200 kV, equipped with an FEI 4096 \u00d7 4096 CCD camera.Deglycosylation, SDS-PAGE and Western Blot Analysis ::: Materials and MethodsPrior to proteomic analysis, purified virion preps were deglycosylated to increase the sensitivity of detection of peptides containing glycosylation sites, as described previously (Shaw et al.2008; Vera-Velasco et al.2018).", [["glycosylation sites", "PROTEIN", 394, 413], ["proteomic analysis", "TEST", 268, 286], ["purified virion preps", "TREATMENT", 288, 309], ["peptides containing glycosylation sites", "PROBLEM", 374, 413], ["glycosylation sites", "OBSERVATION", 394, 413]]], ["Aliquots of purified virus containing 100 \u00b5g protein were deglycosylated with PNGase F (New England Biolabs, Ipswich, Mass., USA) as recommended by the manufacturer.", [["Aliquots", "ANATOMY", 0, 8], ["purified virus", "PROBLEM", 12, 26]]], ["Proteins (8 \u00b5g) from either purified or deglycosylated virions were separated by 10% SDS-PAGE.", [["Proteins", "TEST", 0, 8], ["deglycosylated virions", "PROBLEM", 40, 62]]], ["For Western blot analysis the proteins were transferred to a nitrocellulose membrane which was then probed with specific RABV glycoprotein polyclonal antibody (made in our laboratory) and Alexa Fluor 680-labeled secondary antibody (Invitrogen, Carlsbad, Cal., USA).", [["membrane", "ANATOMY", 76, 84], ["nitrocellulose", "CHEMICAL", 61, 75], ["Alexa Fluor 680", "CHEMICAL", 188, 203], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["RABV", "ORGANISM", 121, 125], ["Alexa Fluor 680", "SIMPLE_CHEMICAL", 188, 203], ["RABV glycoprotein polyclonal antibody", "PROTEIN", 121, 158], ["Alexa Fluor 680-labeled secondary antibody", "PROTEIN", 188, 230], ["RABV", "SPECIES", 121, 125], ["Western blot analysis", "TEST", 4, 25], ["a nitrocellulose membrane", "TREATMENT", 59, 84], ["specific RABV glycoprotein polyclonal antibody", "TEST", 112, 158], ["Alexa Fluor", "TEST", 188, 199], ["secondary antibody", "TEST", 212, 230], ["Invitrogen", "TEST", 232, 242]]], ["Protein bands were observed using an Odyssey infrared imaging system (LI-COR).Proteomics Analysis ::: Materials and MethodsDeglycosylated protein samples were digested in solution with sequencing grade trypsin (Promega, USA) at 37 \u00b0C for 15 h with an enzyme: protein ratio of 1:50 (w/w) followed by protein alkylation in 0.1 mol/L iodoacetamide.", [["samples", "ANATOMY", 146, 153], ["iodoacetamide", "CHEMICAL", 331, 344], ["iodoacetamide", "CHEMICAL", 331, 344], ["0.1 mol/L iodoacetamide", "SIMPLE_CHEMICAL", 321, 344], ["trypsin", "PROTEIN", 202, 209], ["Protein bands", "TEST", 0, 13], ["an Odyssey infrared imaging system", "TEST", 34, 68], ["Proteomics Analysis", "TEST", 78, 97], ["MethodsDeglycosylated protein samples", "TEST", 116, 153], ["sequencing grade trypsin", "PROBLEM", 185, 209], ["an enzyme", "TEST", 248, 257], ["protein ratio", "TEST", 259, 272], ["protein alkylation", "TREATMENT", 299, 317], ["L iodoacetamide", "TREATMENT", 329, 344]]], ["The resulting peptide mixtures were extracted, desalted with C18 cartridges (Empore\u2122 SPE Cartridges C18, 7 mm bed inner diameter, 3 ml volume, Sigma, USA), dried by vacuum centrifugation, re-solubilized in 0.1% (v/v) formic acid.", [["formic acid", "CHEMICAL", 217, 228], ["formic acid", "CHEMICAL", 217, 228], ["v/v) formic acid", "SIMPLE_CHEMICAL", 212, 228], ["The resulting peptide mixtures", "PROBLEM", 0, 30], ["C18 cartridges", "TREATMENT", 61, 75], ["Empore\u2122 SPE Cartridges C18", "TREATMENT", 77, 103], ["7 mm bed inner diameter", "TREATMENT", 105, 128], ["vacuum centrifugation", "TREATMENT", 165, 186], ["formic acid", "TREATMENT", 217, 228], ["vacuum centrifugation", "OBSERVATION", 165, 186]]], ["Proteomic analysis was conducted by nano LC\u2013MS/MS as described previously (Huang et al.2016).", [["Proteomic analysis", "TEST", 0, 18]]], ["Briefly, 2 \u00b5g digested peptides from three different preparations were individually separated using C18-reversed phase analytical EASY columns (Thermo Fisher Scientific, USA) at a flow rate of 300 nL/min.", [["2 \u00b5g digested peptides", "TREATMENT", 9, 31], ["a flow rate", "TEST", 178, 189]]], ["Peptides were gradient-eluted into a Q Exactive mass spectrometer (Thermo Fisher Scientific, USA) acquiring fragmentation spectra generated by collision-induced dissociation (CID).", [["Peptides", "TEST", 0, 8], ["gradient", "TEST", 14, 22], ["a Q Exactive mass spectrometer", "PROBLEM", 35, 65], ["mass", "OBSERVATION", 48, 52]]], ["Resolution was 70,000 and 17,500 respectively for MS and MS/MS scans at m/z 200.", [["Resolution", "TEST", 0, 10], ["MS", "PROBLEM", 50, 52], ["MS/MS scans", "TEST", 57, 68]]], ["Dynamic exclusion was set to 60 s.Proteomics Analysis ::: Materials and MethodsAll MS/MS spectral data were searched using the Andromeda search engine and MaxQuant software version 1.3.0.5 (Cox and Mann 2008) against the UniProtKB mouse sequence database (uniprot_Mouse_83482_20170627.) coupled with RABV (CVS-11) protein sequences downloaded from GenBank (https://www.ncbi.nlm.nih.gov/nuccore/GQ918139.1).", [["mouse", "ORGANISM", 231, 236], ["RABV", "ORGANISM", 300, 304], ["RABV (CVS-11) protein sequences", "DNA", 300, 331], ["mouse", "SPECIES", 231, 236], ["mouse", "SPECIES", 231, 236], ["RABV", "SPECIES", 300, 304], ["Dynamic exclusion", "TEST", 0, 17], ["MS spectral data", "TEST", 86, 102], ["RABV", "TEST", 300, 304], ["CVS", "TEST", 306, 309], ["protein sequences", "TEST", 314, 331]]], ["In MaxQuant, the abundance of protein was expressed by intensity based absolute quantification (iBAQ), calculated as the sum of all peptide peak intensities divided by the number of theoretically observable tryptic peptides.", [["absolute quantification", "OBSERVATION", 71, 94], ["peak intensities", "OBSERVATION", 140, 156], ["tryptic peptides", "OBSERVATION", 207, 223]]], ["Compared with the Top3 approach this provided a more reliable way to obtain absolute protein abundances at a proteome-wide scale, especially in detecting short proteins of MW < 25 kDa (Ahrne et al.2013).", [["MW", "PROTEIN", 172, 174], ["absolute protein abundances", "PROBLEM", 76, 103]]], ["A protein was identified to have high-confidence when its iBAQ > 106 and unique peptides \u2265 2.", [["A protein", "TEST", 0, 9], ["its iBAQ", "TEST", 54, 62]]], ["To increase the confidence, proteins identified in three separate assays were included in the candidate list.Protease K Treatment and Western Blot Analysis ::: Materials and MethodsIn order to justify the incorporation of host proteins, the purified virions were first subjected to protease K (ProK; Thermo, USA) treatment.", [["virions", "ANATOMY", 250, 257], ["K", "CHEMICAL", 118, 119], ["K", "CHEMICAL", 291, 292], ["Protease K", "GENE_OR_GENE_PRODUCT", 109, 119], ["host proteins", "PROTEIN", 222, 235], ["Methods", "TREATMENT", 174, 181], ["host proteins", "TREATMENT", 222, 235], ["the purified virions", "TREATMENT", 237, 257], ["Thermo, USA) treatment", "TREATMENT", 300, 322]]], ["After stopping the reaction with phenylmethanesulfonyl fluoride (PMSF; Sigma, USA) and protease inhibitor (Thermo, USA) the treated virions were pelleted through a 10% iodixanol cushion to remove any cleaved peptide.", [["virions", "ANATOMY", 132, 139], ["phenylmethanesulfonyl fluoride", "CHEMICAL", 33, 63], ["iodixanol", "CHEMICAL", 168, 177], ["phenylmethanesulfonyl fluoride", "CHEMICAL", 33, 63], ["PMSF", "CHEMICAL", 65, 69], ["iodixanol", "CHEMICAL", 168, 177], ["phenylmethanesulfonyl fluoride", "SIMPLE_CHEMICAL", 33, 63], ["PMSF", "SIMPLE_CHEMICAL", 65, 69], ["iodixanol", "SIMPLE_CHEMICAL", 168, 177], ["the reaction", "PROBLEM", 15, 27], ["phenylmethanesulfonyl fluoride (PMSF", "TREATMENT", 33, 69], ["protease inhibitor", "TREATMENT", 87, 105], ["the treated virions", "TREATMENT", 120, 139], ["a 10% iodixanol cushion", "TREATMENT", 162, 185], ["any cleaved peptide", "PROBLEM", 196, 215]]], ["N2a cells were mock infected or infected with CVS-11 for 72 h at an MOI of 0.1.", [["N2a cells", "ANATOMY", 0, 9], ["CVS-11", "CHEMICAL", 46, 52], ["N2a cells", "CELL", 0, 9], ["N2a cells", "CELL_LINE", 0, 9], ["N2a cells", "PROBLEM", 0, 9], ["CVS", "TEST", 46, 49], ["an MOI", "TEST", 65, 71], ["infected", "OBSERVATION_MODIFIER", 32, 40]]], ["Supernatants of cell extracts were collected following incubation in cell lysis buffer (Cell Signaling Technology, USA) with added protease inhibitor (Thermo, USA) on ice for 20 min, and centrifugation at 14,000 \u00d7g for 15 min.", [["Supernatants", "ANATOMY", 0, 12], ["cell extracts", "ANATOMY", 16, 29], ["cell", "ANATOMY", 69, 73], ["Cell", "ANATOMY", 88, 92], ["cell extracts", "ORGANISM_SUBSTANCE", 16, 29], ["cell", "CELL", 69, 73], ["Cell", "CELL", 88, 92], ["cell extracts", "PROBLEM", 16, 29], ["incubation in cell lysis buffer", "TREATMENT", 55, 86], ["added protease inhibitor", "TREATMENT", 125, 149], ["ice", "TREATMENT", 167, 170], ["centrifugation", "TREATMENT", 187, 201], ["cell extracts", "OBSERVATION", 16, 29]]], ["Both cell extracts (25 \u00b5g) and untreated or protease-treated virion preparations (10 \u00b5g) were analyzed by Western blotting with antibodies against the indicated proteins.", [["cell extracts", "ANATOMY", 5, 18], ["cell extracts", "ORGANISM_SUBSTANCE", 5, 18], ["protease", "PROTEIN", 44, 52], ["antibodies", "PROTEIN", 128, 138], ["Both cell extracts", "TREATMENT", 0, 18], ["protease", "TREATMENT", 44, 52], ["virion preparations", "TREATMENT", 61, 80], ["antibodies", "TREATMENT", 128, 138]]], ["The virion glycoprotein (G), nucleoprotein (N) and matrix protein (M) were probed by their specific mouse polyclonal antibodies (made in our laboratory).", [["virion glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 4, 27], ["nucleoprotein (N)", "GENE_OR_GENE_PRODUCT", 29, 46], ["matrix protein", "GENE_OR_GENE_PRODUCT", 51, 65], ["mouse", "ORGANISM", 100, 105], ["virion glycoprotein", "PROTEIN", 4, 23], ["G", "PROTEIN", 25, 26], ["nucleoprotein (N)", "PROTEIN", 29, 46], ["matrix protein", "PROTEIN", 51, 65], ["mouse polyclonal antibodies", "PROTEIN", 100, 127], ["mouse", "SPECIES", 100, 105], ["mouse", "SPECIES", 100, 105], ["The virion glycoprotein (G), nucleoprotein (N) and matrix protein (M)", "TREATMENT", 0, 69]]], ["Rabbit polyclonal antibody against HSC70 (ab137808), cofilin (ab11062), CHMP4B (ab105767), HSP40 (ab69402), VPS37B (ab122450) and mouse polyclonal antibody against CHMP2A (ab67064), mouse monoclonal antibody against \u03b2-actin (ab 6276) were obtained from Abcam (Cambridge, UK).", [["Rabbit", "ORGANISM", 0, 6], ["HSC70", "GENE_OR_GENE_PRODUCT", 35, 40], ["ab137808", "GENE_OR_GENE_PRODUCT", 42, 50], ["cofilin", "GENE_OR_GENE_PRODUCT", 53, 60], ["ab11062", "GENE_OR_GENE_PRODUCT", 62, 69], ["CHMP4B (ab105767)", "GENE_OR_GENE_PRODUCT", 72, 89], ["HSP40 (ab69402)", "GENE_OR_GENE_PRODUCT", 91, 106], ["VPS37B", "GENE_OR_GENE_PRODUCT", 108, 114], ["mouse", "ORGANISM", 130, 135], ["polyclonal antibody against CHMP2A (ab67064)", "GENE_OR_GENE_PRODUCT", 136, 180], ["mouse", "ORGANISM", 182, 187], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 216, 223], ["Abcam", "GENE_OR_GENE_PRODUCT", 253, 258], ["UK", "GENE_OR_GENE_PRODUCT", 271, 273], ["Rabbit polyclonal antibody", "PROTEIN", 0, 26], ["HSC70", "PROTEIN", 35, 40], ["ab137808", "PROTEIN", 42, 50], ["cofilin", "PROTEIN", 53, 60], ["ab11062", "PROTEIN", 62, 69], ["CHMP4B", "PROTEIN", 72, 78], ["ab105767", "PROTEIN", 80, 88], ["HSP40", "PROTEIN", 91, 96], ["ab69402", "PROTEIN", 98, 105], ["VPS37B", "PROTEIN", 108, 114], ["ab122450", "PROTEIN", 116, 124], ["mouse polyclonal antibody", "PROTEIN", 130, 155], ["CHMP2A", "PROTEIN", 164, 170], ["ab67064", "PROTEIN", 172, 179], ["mouse monoclonal antibody", "PROTEIN", 182, 207], ["\u03b2-actin", "PROTEIN", 216, 223], ["ab 6276", "PROTEIN", 225, 232], ["Rabbit", "SPECIES", 0, 6], ["mouse", "SPECIES", 130, 135], ["mouse", "SPECIES", 182, 187], ["Rabbit", "SPECIES", 0, 6], ["mouse", "SPECIES", 130, 135], ["mouse", "SPECIES", 182, 187], ["Rabbit polyclonal antibody", "TEST", 0, 26], ["HSC70", "TEST", 35, 40], ["cofilin", "TEST", 53, 60], ["CHMP4B", "TEST", 72, 78], ["HSP40", "TEST", 91, 96], ["VPS37B", "TEST", 108, 114], ["mouse polyclonal antibody", "TEST", 130, 155], ["CHMP2A", "TEST", 164, 170], ["mouse monoclonal antibody", "TEST", 182, 207], ["\u03b2-actin (ab", "TEST", 216, 227]]], ["Monoclonal antibodies against CD9 (sc-13118), VPS4B (sc-377162) were obtained from Santa Cruz Biotechnology (Santa Cruz, Cal., USA).", [["sc-13118", "CHEMICAL", 35, 43], ["sc-377162", "CHEMICAL", 53, 62], ["CD9", "GENE_OR_GENE_PRODUCT", 30, 33], ["Monoclonal antibodies", "PROTEIN", 0, 21], ["CD9", "PROTEIN", 30, 33], ["Monoclonal antibodies", "TEST", 0, 21], ["CD9", "TEST", 30, 33], ["sc", "TEST", 35, 37], ["VPS4B", "TEST", 46, 51]]], ["Rabbit polyclonal antibody against TSG 101 (T5701) was obtained from Sigma (St. Louis, Missouri, USA).", [["TSG 101", "CHEMICAL", 35, 42], ["Rabbit", "ORGANISM", 0, 6], ["polyclonal antibody against TSG 101", "GENE_OR_GENE_PRODUCT", 7, 42], ["T5701", "CANCER", 44, 49], ["St. Louis", "ORGANISM", 76, 85], ["Rabbit polyclonal antibody", "PROTEIN", 0, 26], ["TSG 101", "PROTEIN", 35, 42], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit polyclonal antibody", "TEST", 0, 26], ["TSG", "TEST", 35, 38]]], ["Mouse polyclonal antibody against ALIX (#2171) was obtained from Cell Signaling Technology (Danvers, Mass., USA).", [["Cell", "ANATOMY", 65, 69], ["Mouse", "ORGANISM", 0, 5], ["Cell", "CELL", 65, 69], ["Mouse polyclonal antibody", "PROTEIN", 0, 25], ["ALIX", "PROTEIN", 34, 38], ["#2171", "PROTEIN", 40, 45], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse polyclonal antibody", "TEST", 0, 25]]], ["Detection was performed using species-specific highly cross-adsorbed secondary antibody, Alexa Fluor 680 (A10038 for mouse and A10043 for rabbit (Invitrogen, Carlsbad, Cal., USA) and imaged by LI-COR.Immunogold Labeling and Electron Microscopy ::: Materials and MethodsTo localize incorporated proteins on the viral surface, the purified virions were adsorbed onto 300-mesh formvar/carbon-coated nickel grids (PolySciences, Philadelphia, USA) at 20 \u00b0C to 25 \u00b0C. After 5 min, excess buffer was removed by blotting and the preparations were blocked with 3% BSA in phosphate-buffered saline (PBS, pH 7.4) for 45 min at 20 \u00b0C to 25 \u00b0C. The blocked virions were incubated with primary antibodies (20 \u00b5g/mL in 1% BSA/PBS) for 1.5 h, followed by 10 nm colloidal gold particle-conjugated secondary antibody (ab27241, Abcam, Cambridge, UK) for 40 min at room temperature.", [["surface", "ANATOMY", 316, 323], ["virions", "ANATOMY", 338, 345], ["virions", "ANATOMY", 644, 651], ["Alexa Fluor 680", "CHEMICAL", 89, 104], ["nickel", "CHEMICAL", 396, 402], ["BSA", "CHEMICAL", 555, 558], ["phosphate", "CHEMICAL", 562, 571], ["Alexa Fluor 680", "CHEMICAL", 89, 104], ["carbon", "CHEMICAL", 382, 388], ["nickel", "CHEMICAL", 396, 402], ["phosphate", "CHEMICAL", 562, 571], ["Alexa Fluor 680", "SIMPLE_CHEMICAL", 89, 104], ["mouse", "ORGANISM", 117, 122], ["rabbit", "ORGANISM", 138, 144], ["nickel grids", "SIMPLE_CHEMICAL", 396, 408], ["BSA", "SIMPLE_CHEMICAL", 555, 558], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 562, 587], ["BSA", "SIMPLE_CHEMICAL", 707, 710], ["ab27241", "SIMPLE_CHEMICAL", 800, 807], ["cross-adsorbed secondary antibody", "PROTEIN", 54, 87], ["Alexa Fluor 680", "PROTEIN", 89, 104], ["primary antibodies", "PROTEIN", 672, 690], ["conjugated secondary antibody", "PROTEIN", 769, 798], ["ab27241", "PROTEIN", 800, 807], ["mouse", "SPECIES", 117, 122], ["rabbit", "SPECIES", 138, 144], ["Alexa Fluor 680", "SPECIES", 89, 104], ["mouse", "SPECIES", 117, 122], ["rabbit", "SPECIES", 138, 144], ["species", "TEST", 30, 37], ["Alexa Fluor", "TEST", 89, 100], ["rabbit", "TEST", 138, 144], ["the viral surface", "TREATMENT", 306, 323], ["the purified virions", "TREATMENT", 325, 345], ["mesh formvar/carbon-coated nickel grids", "TREATMENT", 369, 408], ["excess buffer", "TREATMENT", 475, 488], ["3% BSA in phosphate", "TREATMENT", 552, 571], ["buffered saline (PBS", "TREATMENT", 572, 592], ["pH", "TEST", 594, 596], ["The blocked virions", "TREATMENT", 632, 651], ["primary antibodies", "TREATMENT", 672, 690], ["1% BSA/PBS", "TREATMENT", 704, 714], ["nm colloidal gold particle", "TEST", 742, 768], ["conjugated secondary antibody", "TEST", 769, 798], ["COR", "ANATOMY", 196, 199], ["viral surface", "OBSERVATION_MODIFIER", 310, 323]]], ["The grids were washed thoroughly but gently with PBS, then washed with water before negative staining.", [["PBS", "TREATMENT", 49, 52], ["staining", "OBSERVATION", 93, 101]]], ["Images of virions labeled by colloidal gold particles were captured by TEM as described above.Virus Cultivation, Purification and Morphology ::: ResultsProteomic analysis of RABV requires purified virions with high purity and an intact structure of typical bullet-shaped morphology.", [["virions", "ANATOMY", 10, 17], ["virions", "ANATOMY", 197, 204], ["RABV", "ORGANISM", 174, 178], ["RABV", "SPECIES", 174, 178], ["Virus Cultivation", "TEST", 94, 111], ["ResultsProteomic analysis", "TEST", 145, 170], ["purified virions", "TREATMENT", 188, 204], ["high purity", "OBSERVATION_MODIFIER", 210, 221], ["intact structure", "OBSERVATION_MODIFIER", 229, 245], ["typical", "OBSERVATION_MODIFIER", 249, 256], ["bullet", "OBSERVATION", 257, 263], ["shaped", "OBSERVATION_MODIFIER", 264, 270], ["morphology", "OBSERVATION_MODIFIER", 271, 281]]], ["Supernatants of large-scale cultures of CVS-11 with a titer of 108.05 TCID50/mL, were harvested and the virus was purified by ultracentrifugation, resulting in five visible fractions in the iodixanol density gradient (F0-F4) as shown in Fig. 1A.", [["Supernatants", "ANATOMY", 0, 12], ["iodixanol", "CHEMICAL", 190, 199], ["1A.", "CHEMICAL", 242, 245], ["iodixanol", "CHEMICAL", 190, 199], ["CVS-11", "CELL", 40, 46], ["iodixanol", "SIMPLE_CHEMICAL", 190, 199], ["large-scale cultures", "TEST", 16, 36], ["CVS", "TEST", 40, 43], ["a titer", "TEST", 52, 59], ["the virus", "PROBLEM", 100, 109], ["five visible fractions", "PROBLEM", 160, 182], ["the iodixanol density gradient", "TEST", 186, 216], ["large", "OBSERVATION_MODIFIER", 16, 21], ["visible", "OBSERVATION_MODIFIER", 165, 172], ["fractions", "OBSERVATION_MODIFIER", 173, 182], ["iodixanol density", "OBSERVATION", 190, 207], ["Fig", "OBSERVATION", 237, 240]]], ["Observation by TEM showed that most particles are in well-defined bullet-shaped with a length of 120\u2013180 nm in the F3 band (20%\u201325% iodixanol).", [["iodixanol", "CHEMICAL", 132, 141], ["iodixanol", "CHEMICAL", 132, 141], ["iodixanol", "SIMPLE_CHEMICAL", 132, 141], ["a length", "TEST", 85, 93], ["the F3 band", "TEST", 111, 122], ["25% iodixanol", "TREATMENT", 128, 141], ["most particles", "OBSERVATION_MODIFIER", 31, 45], ["bullet", "OBSERVATION", 66, 72], ["shaped", "OBSERVATION_MODIFIER", 73, 79]]], ["The truncated or crescent defective interfering (DI) particals with length of 50\u201370 nm can also be found in the F1 (10%\u201315% iodixanol) and F2 (15%\u201320% iodixanol) bands.", [["iodixanol", "CHEMICAL", 124, 133], ["iodixanol", "CHEMICAL", 151, 160], ["iodixanol", "CHEMICAL", 124, 133], ["iodixanol", "CHEMICAL", 151, 160], ["iodixanol", "SIMPLE_CHEMICAL", 124, 133], ["iodixanol", "SIMPLE_CHEMICAL", 151, 160], ["The truncated", "PROBLEM", 0, 13], ["crescent defective interfering (DI) particals", "PROBLEM", 17, 62], ["length", "TEST", 68, 74], ["iodixanol", "TEST", 124, 133], ["F2", "TEST", 139, 141], ["crescent", "OBSERVATION_MODIFIER", 17, 25], ["defective", "OBSERVATION_MODIFIER", 26, 35], ["interfering", "OBSERVATION_MODIFIER", 36, 47]]], ["No virus particles were apparent in the F0 and F4 bands (Supplementary Figure S1).", [["virus particles", "PROBLEM", 3, 18], ["virus particles", "OBSERVATION", 3, 18]]], ["Following further sedimentation through a 15%\u201325% iodixanol density gradient, the purity and integrity of the virions of three independent purifications were checked by electron microscopy prior to the following proteomic analysis.", [["iodixanol", "CHEMICAL", 50, 59], ["iodixanol", "CHEMICAL", 50, 59], ["iodixanol", "SIMPLE_CHEMICAL", 50, 59], ["further sedimentation", "PROBLEM", 10, 31], ["a 15%\u201325% iodixanol density gradient", "TREATMENT", 40, 76], ["electron microscopy", "TEST", 169, 188], ["proteomic analysis", "TEST", 212, 230], ["sedimentation", "OBSERVATION_MODIFIER", 18, 31]]], ["As shown in Fig. 1B, the purified virus particles were free of cellular debris or vesicles with most having intact, typical bullet shapes of length 120\u2013180 nm.", [["cellular debris", "ANATOMY", 63, 78], ["vesicles", "ANATOMY", 82, 90], ["1B", "GENE_OR_GENE_PRODUCT", 17, 19], ["cellular", "CELL", 63, 71], ["vesicles", "CELLULAR_COMPONENT", 82, 90], ["the purified virus particles", "PROBLEM", 21, 49], ["cellular debris", "PROBLEM", 63, 78], ["vesicles", "PROBLEM", 82, 90], ["length", "TEST", 141, 147], ["Fig", "OBSERVATION", 12, 15], ["virus particles", "OBSERVATION", 34, 49], ["free", "OBSERVATION_MODIFIER", 55, 59], ["cellular debris", "OBSERVATION", 63, 78], ["typical", "OBSERVATION_MODIFIER", 116, 123], ["bullet", "OBSERVATION", 124, 130], ["shapes", "OBSERVATION_MODIFIER", 131, 137], ["length", "OBSERVATION_MODIFIER", 141, 147]]], ["Small numbers of ruptured and DI particles were observed (Fig. 1B).", [["ruptured and DI particles", "PROBLEM", 17, 42], ["numbers", "OBSERVATION_MODIFIER", 6, 13], ["ruptured", "OBSERVATION", 17, 25], ["DI particles", "OBSERVATION", 30, 42]]], ["Higher magnification highlighted the characteristic bullet-shaped morphology covered by numerous spikes (Fig. 1C).", [["Higher magnification", "PROBLEM", 0, 20], ["the characteristic bullet", "PROBLEM", 33, 58], ["characteristic", "OBSERVATION_MODIFIER", 37, 51], ["bullet", "OBSERVATION", 52, 58], ["shaped", "OBSERVATION_MODIFIER", 59, 65], ["morphology", "OBSERVATION_MODIFIER", 66, 76], ["numerous", "OBSERVATION_MODIFIER", 88, 96], ["spikes", "OBSERVATION_MODIFIER", 97, 103]]], ["The purity of the virion preparations was estimated by counting the proportion of virus particles among total particles in images of the three sets of purifications.", [["the virion preparations", "TREATMENT", 14, 37], ["virus particles", "TREATMENT", 82, 97]]], ["Of a total 1200 counts, 95.6% were RABV, consisting of 87% intact virions and 8.6% of damaged or DI particles.Virus Cultivation, Purification and Morphology ::: ResultsCryo-electron microscopy (cryo-EM) has become a robust imaging tool for determining the ultrastructure of viruses at near-atomic resolution (Yuan et al.2018).", [["virions", "ANATOMY", 66, 73], ["RABV", "ORGANISM", 35, 39], ["RABV", "SPECIES", 35, 39], ["a total 1200 counts", "TEST", 3, 22], ["RABV", "TEST", 35, 39], ["damaged or DI particles", "PROBLEM", 86, 109], ["Virus Cultivation", "TEST", 110, 127], ["ResultsCryo-electron microscopy", "TEST", 161, 192], ["the ultrastructure of viruses", "PROBLEM", 252, 281], ["DI particles", "OBSERVATION", 97, 109], ["viruses", "OBSERVATION", 274, 281]]], ["Images clearly showed four distinct electron-dense layers (Fig. 1D), in which the outermost layer, on the viral surface, consisted of spikes (G protein molecules) over the entire surface apart the planar end.", [["outermost layer", "ANATOMY", 82, 97], ["surface", "ANATOMY", 112, 119], ["surface", "ANATOMY", 179, 186], ["layers", "TISSUE", 51, 57], ["G protein molecules", "GENE_OR_GENE_PRODUCT", 142, 161], ["G protein molecules", "PROTEIN", 142, 161], ["Images", "TEST", 0, 6], ["four distinct electron-dense layers (Fig. 1D)", "PROBLEM", 22, 67], ["spikes (G protein molecules", "PROBLEM", 134, 161], ["distinct", "OBSERVATION_MODIFIER", 27, 35], ["electron", "OBSERVATION_MODIFIER", 36, 44], ["dense", "OBSERVATION_MODIFIER", 45, 50], ["layers", "OBSERVATION_MODIFIER", 51, 57], ["outermost", "OBSERVATION_MODIFIER", 82, 91], ["layer", "OBSERVATION_MODIFIER", 92, 97], ["viral surface", "OBSERVATION_MODIFIER", 106, 119], ["spikes", "OBSERVATION_MODIFIER", 134, 140], ["planar end", "OBSERVATION", 197, 207]]], ["The lipid bilayer of the envelope covering the entire capsid formed the second layer.", [["lipid bilayer", "ANATOMY", 4, 17], ["lipid bilayer", "CELLULAR_COMPONENT", 4, 17], ["capsid", "CELLULAR_COMPONENT", 54, 60], ["The lipid bilayer of the envelope", "TREATMENT", 0, 33], ["lipid bilayer", "OBSERVATION", 4, 17], ["envelope", "OBSERVATION_MODIFIER", 25, 33], ["second", "OBSERVATION_MODIFIER", 72, 78], ["layer", "OBSERVATION_MODIFIER", 79, 84]]], ["The third layer consisted of helical structures (M protein molecules), similar to that of vesicular stomatitis virus (VSV) (Ge et al.2010).", [["vesicular stomatitis", "DISEASE", 90, 110], ["vesicular stomatitis virus", "ORGANISM", 90, 116], ["VSV", "ORGANISM", 118, 121], ["helical structures", "PROTEIN", 29, 47], ["M protein molecules", "PROTEIN", 49, 68], ["stomatitis virus", "SPECIES", 100, 116], ["vesicular stomatitis virus", "SPECIES", 90, 116], ["VSV", "SPECIES", 118, 121], ["helical structures (M protein molecules", "PROBLEM", 29, 68], ["vesicular stomatitis virus", "PROBLEM", 90, 116], ["third", "OBSERVATION_MODIFIER", 4, 9], ["layer", "OBSERVATION_MODIFIER", 10, 15], ["vesicular stomatitis virus", "OBSERVATION", 90, 116]]], ["However, the EM images showed that both G and M layers of the rabies virions were absent from the planar ends, the result is consistent with that of previous publication (Guichard et al.2011).", [["rabies", "ORGANISM", 62, 68], ["the EM images", "TEST", 9, 22], ["the rabies virions", "PROBLEM", 58, 76], ["rabies virions", "OBSERVATION", 62, 76], ["consistent with", "UNCERTAINTY", 125, 140]]], ["The innermost layer was super-helical structure known to consist of the ribonucleoprotein (RNP) complex VSV (Ge et al.2010) and RABV (Luo et al.2007; Riedel et al.2019).Virus Cultivation, Purification and Morphology ::: ResultsIn order to understand the proteomic characteristics of rabies virions prepared from infected animals, attempts were made to purify the virus from CVS-11 infected mouse brain tissues.", [["innermost layer", "ANATOMY", 4, 19], ["brain tissues", "ANATOMY", 396, 409], ["RNP", "CELLULAR_COMPONENT", 91, 94], ["VSV", "ORGANISM", 104, 107], ["RABV", "ORGANISM", 128, 132], ["rabies", "ORGANISM", 283, 289], ["mouse", "ORGANISM", 390, 395], ["brain tissues", "TISSUE", 396, 409], ["super-helical structure", "PROTEIN", 24, 47], ["ribonucleoprotein (RNP) complex VSV", "PROTEIN", 72, 107], ["mouse", "SPECIES", 390, 395], ["RABV", "SPECIES", 128, 132], ["rabies", "SPECIES", 283, 289], ["mouse", "SPECIES", 390, 395], ["Virus Cultivation", "TEST", 169, 186], ["rabies virions", "TREATMENT", 283, 297], ["the virus", "PROBLEM", 359, 368], ["CVS", "TEST", 374, 377], ["infected mouse brain tissues", "PROBLEM", 381, 409], ["innermost", "OBSERVATION_MODIFIER", 4, 13], ["layer", "OBSERVATION_MODIFIER", 14, 19], ["ribonucleoprotein", "OBSERVATION", 72, 89], ["infected mouse", "OBSERVATION", 381, 395], ["brain tissues", "ANATOMY", 396, 409]]], ["Unfortunately, the experiment with various iodixanol density gradients and centrifugation programs failed to remove all brain tissue debris from the virion preparations.", [["brain tissue", "ANATOMY", 120, 132], ["iodixanol", "CHEMICAL", 43, 52], ["iodixanol", "CHEMICAL", 43, 52], ["iodixanol", "SIMPLE_CHEMICAL", 43, 52], ["brain tissue debris", "TISSUE", 120, 139], ["various iodixanol density gradients", "TREATMENT", 35, 70], ["centrifugation programs", "TREATMENT", 75, 98], ["all brain tissue debris", "PROBLEM", 116, 139], ["the virion preparations", "TREATMENT", 145, 168], ["density gradients", "OBSERVATION", 53, 70], ["brain tissue", "ANATOMY", 120, 132], ["debris", "OBSERVATION", 133, 139]]], ["Therefore the virus grown on N2a cell lines was eventually used for the proteomic analysis.SDS-PAGE and Western Blot Analysis of Purified Rabies Virions ::: ResultsSDS-PAGE of purified virions revealed six bands, including two forms of differentially glycosylated viral glycoprotein (GI and GII) (Fig. 2A).", [["N2a cell lines", "ANATOMY", 29, 43], ["virions", "ANATOMY", 185, 192], ["Rabies Virions", "DISEASE", 138, 152], ["N2a cell lines", "CELL", 29, 43], ["N2a cell lines", "CELL_LINE", 29, 43], ["differentially glycosylated viral glycoprotein", "PROTEIN", 236, 282], ["GII", "PROTEIN", 291, 294], ["Fig. 2A", "PROTEIN", 297, 304], ["the virus", "PROBLEM", 10, 19], ["N2a cell lines", "TREATMENT", 29, 43], ["the proteomic analysis", "TEST", 68, 90], ["ResultsSDS", "TEST", 157, 167], ["purified virions", "PROBLEM", 176, 192], ["six bands", "PROBLEM", 202, 211], ["glycosylated viral glycoprotein", "TREATMENT", 251, 282], ["virus", "OBSERVATION_MODIFIER", 14, 19], ["grown", "OBSERVATION_MODIFIER", 20, 25], ["N2a cell lines", "OBSERVATION", 29, 43], ["six bands", "OBSERVATION_MODIFIER", 202, 211]]], ["Following deglycosylation only one band (G0) was seen.", [["deglycosylation", "TREATMENT", 10, 25]]], ["Both glycosylated and deglycosylated G proteins were further identified by Western blotting (Fig. 2B).", [["deglycosylated G proteins", "GENE_OR_GENE_PRODUCT", 22, 47], ["glycosylated and deglycosylated G proteins", "PROTEIN", 5, 47], ["Both glycosylated", "TREATMENT", 0, 17], ["deglycosylated G proteins", "TREATMENT", 22, 47]]], ["In addition, analysis also revealed some fainter bands that may represent a low abundance of cellular proteins (Fig. 2A).", [["cellular", "ANATOMY", 93, 101], ["cellular", "CELL", 93, 101], ["cellular proteins", "PROTEIN", 93, 110], ["Fig. 2A", "PROTEIN", 112, 119], ["analysis", "TEST", 13, 21], ["some fainter bands", "PROBLEM", 36, 54], ["a low abundance of cellular proteins", "PROBLEM", 74, 110], ["fainter bands", "OBSERVATION", 41, 54], ["may represent", "UNCERTAINTY", 60, 73], ["low abundance", "OBSERVATION_MODIFIER", 76, 89], ["cellular proteins", "OBSERVATION", 93, 110]]], ["These results showed that the deglycosylation of proteins in purified virions was complete and that the virion proteins could be used for proteomic analysis.Proteomic Analysis ::: ResultsNano LC\u2013MS/MS was utilized to identify the protein composition of purified rabies virions, resulting in identification of 54 high-confidence proteins.", [["virions", "ANATOMY", 70, 77], ["rabies", "ORGANISM", 262, 268], ["virion proteins", "PROTEIN", 104, 119], ["54 high-confidence proteins", "PROTEIN", 309, 336], ["the deglycosylation of proteins in purified virions", "PROBLEM", 26, 77], ["the virion proteins", "TREATMENT", 100, 119], ["proteomic analysis", "TEST", 138, 156], ["Proteomic Analysis", "TEST", 157, 175], ["MS", "TEST", 198, 200], ["the protein composition", "TEST", 226, 249], ["purified rabies virions", "PROBLEM", 253, 276], ["identification", "TEST", 291, 305], ["high-confidence proteins", "PROBLEM", 312, 336], ["rabies virions", "OBSERVATION", 262, 276]]], ["These were considered to be incorporated into mature virions based on the following criteria: (1) the proteins were identified in each of three independently purified virion preparations; (2) the abundance of target proteins exceeded 106; (3) each target protein had at least 2 unique peptides.", [["virions", "ANATOMY", 53, 60], ["target proteins", "PROTEIN", 209, 224], ["the proteins", "TEST", 98, 110], ["target proteins", "TEST", 209, 224], ["each target protein", "TEST", 243, 262]]], ["Proteins identified in low abundance or as being unreproducible were likely randomly loaded contaminants or sticky proteins, and were therefore excluded from the viral proteomic composition.", [["sticky proteins", "PROTEIN", 108, 123], ["randomly loaded contaminants", "PROBLEM", 76, 104], ["sticky proteins", "PROBLEM", 108, 123], ["the viral proteomic composition", "PROBLEM", 158, 189], ["low abundance", "OBSERVATION_MODIFIER", 23, 36]]], ["Table 1 lists all high-confidence proteins ranked according to their average abundance values.", [["high-confidence proteins", "PROTEIN", 18, 42]]], ["The results are consistent with SDS-PAGE analysis, both showing that the five viral structural proteins were most abundant.Proteomic Analysis ::: ResultsThe 49 cellular proteins had significant abundance values ranging from 1.72E+09 to 2.58E+06, with sequence coverages of between 73.6% and 8.8%.", [["cellular", "ANATOMY", 160, 168], ["cellular", "CELL", 160, 168], ["viral structural proteins", "PROTEIN", 78, 103], ["49 cellular proteins", "PROTEIN", 157, 177], ["SDS", "TEST", 32, 35], ["PAGE analysis", "TEST", 36, 49], ["the five viral structural proteins", "PROBLEM", 69, 103], ["Proteomic Analysis", "TEST", 123, 141], ["cellular proteins", "TEST", 160, 177], ["significant abundance values", "PROBLEM", 182, 210], ["sequence coverages", "TEST", 251, 269], ["consistent with", "UNCERTAINTY", 16, 31], ["significant", "OBSERVATION_MODIFIER", 182, 193], ["abundance", "OBSERVATION_MODIFIER", 194, 203]]], ["Table 1 also lists their subcellular locations and incorporation into other virions as reported elsewhere.", [["subcellular", "ANATOMY", 25, 36], ["virions", "ANATOMY", 76, 83]]], ["According to the Uniprot Knowledge database, many of the proteins were localized at the cell membrane, cytoplasm and actin cytoskeleton.", [["cell membrane", "ANATOMY", 88, 101], ["cytoplasm", "ANATOMY", 103, 112], ["cytoskeleton", "ANATOMY", 123, 135], ["cell membrane", "CELLULAR_COMPONENT", 88, 101], ["cytoplasm", "ORGANISM_SUBSTANCE", 103, 112], ["actin", "GENE_OR_GENE_PRODUCT", 117, 122], ["cytoskeleton", "CELLULAR_COMPONENT", 123, 135], ["actin", "PROTEIN", 117, 122], ["the proteins", "PROBLEM", 53, 65], ["cell membrane", "OBSERVATION", 88, 101], ["actin cytoskeleton", "OBSERVATION", 117, 135]]], ["It is worth noting that more than half of these host proteins (34/49) were also found in the other viruses within 11 viral families (Table 1).", [["host proteins", "PROTEIN", 48, 61], ["these host proteins", "TEST", 42, 61], ["viruses", "OBSERVATION", 99, 106]]], ["Of them, CD9, CD81, cofilin-1, cyclophilin A, GAPDH, enolase, HSC70, HSP90\u03b2 and RAB5C were the most frequently identified in the virions of different viruses, indicating that they were widely recruited by these viruses to benefit their replicative cycles (Table 1).", [["virions", "ANATOMY", 129, 136], ["CD9", "GENE_OR_GENE_PRODUCT", 9, 12], ["CD81", "GENE_OR_GENE_PRODUCT", 14, 18], ["cofilin-1", "GENE_OR_GENE_PRODUCT", 20, 29], ["cyclophilin A", "GENE_OR_GENE_PRODUCT", 31, 44], ["GAPDH", "GENE_OR_GENE_PRODUCT", 46, 51], ["enolase", "GENE_OR_GENE_PRODUCT", 53, 60], ["HSC70", "GENE_OR_GENE_PRODUCT", 62, 67], ["HSP90\u03b2", "GENE_OR_GENE_PRODUCT", 69, 75], ["RAB5C", "GENE_OR_GENE_PRODUCT", 80, 85], ["CD9", "PROTEIN", 9, 12], ["CD81", "PROTEIN", 14, 18], ["cofilin", "PROTEIN", 20, 27], ["cyclophilin A", "PROTEIN", 31, 44], ["GAPDH", "PROTEIN", 46, 51], ["enolase", "PROTEIN", 53, 60], ["HSC70", "PROTEIN", 62, 67], ["HSP90\u03b2", "PROTEIN", 69, 75], ["RAB5C", "PROTEIN", 80, 85], ["CD9", "TEST", 9, 12], ["CD81", "TEST", 14, 18], ["cofilin", "TEST", 20, 27], ["cyclophilin A", "TEST", 31, 44], ["GAPDH", "TEST", 46, 51], ["enolase", "TEST", 53, 60], ["HSC70", "TEST", 62, 67], ["HSP90", "TEST", 69, 74], ["RAB5C", "TEST", 80, 85], ["different viruses", "PROBLEM", 140, 157], ["different viruses", "OBSERVATION", 140, 157]]], ["For example, the presence of cyclophilin A in the virions aids capsid stabilization in both influenza virus and HIV by interacting with capsid protein in the early stage of the viral replication (Liu et al.2009, 2016).", [["virions", "ANATOMY", 50, 57], ["influenza virus and HIV", "DISEASE", 92, 115], ["cyclophilin A", "GENE_OR_GENE_PRODUCT", 29, 42], ["influenza virus", "ORGANISM", 92, 107], ["HIV", "ORGANISM", 112, 115], ["cyclophilin A", "PROTEIN", 29, 42], ["capsid protein", "PROTEIN", 136, 150], ["influenza virus", "SPECIES", 92, 107], ["HIV", "SPECIES", 112, 115], ["influenza virus", "SPECIES", 92, 107], ["HIV", "SPECIES", 112, 115], ["cyclophilin A", "TREATMENT", 29, 42], ["capsid stabilization", "TREATMENT", 63, 83], ["both influenza virus", "PROBLEM", 87, 107], ["HIV", "PROBLEM", 112, 115], ["capsid protein", "TREATMENT", 136, 150], ["the viral replication", "TREATMENT", 173, 194], ["cyclophilin", "OBSERVATION", 29, 40], ["capsid stabilization", "OBSERVATION", 63, 83], ["influenza virus", "OBSERVATION", 92, 107], ["early stage", "OBSERVATION_MODIFIER", 158, 169], ["viral replication", "OBSERVATION", 177, 194]]], ["As reviewed in a recent publication, heat shock protein 90 is a crucial host factor required by many viruses for multiple phases of their life cycle (Wang et al.2017).", [["heat shock protein 90", "GENE_OR_GENE_PRODUCT", 37, 58], ["heat shock protein 90", "PROTEIN", 37, 58], ["heat shock protein", "TEST", 37, 55], ["a crucial host factor", "PROBLEM", 62, 83]]], ["These suggest that many viruses, especially enveloped ones, might utilize cellular proteins to complete their replicative cycle.Validation of Cellular Proteins Incorporated Into Purified RABV Particles ::: ResultsTo justify the claim of incorporation, 3 viral proteins and 11 host proteins from Table 1 of different abundances were analyzed by Western blotting and immunogold labeling.", [["cellular", "ANATOMY", 74, 82], ["cellular", "CELL", 74, 82], ["RABV", "ORGANISM", 187, 191], ["cellular proteins", "PROTEIN", 74, 91], ["Cellular Proteins", "PROTEIN", 142, 159], ["viral proteins", "PROTEIN", 254, 268], ["host proteins", "PROTEIN", 276, 289], ["RABV", "SPECIES", 187, 191], ["many viruses", "PROBLEM", 19, 31], ["cellular proteins", "PROBLEM", 74, 91], ["3 viral proteins", "TEST", 252, 268], ["host proteins", "TEST", 276, 289], ["immunogold labeling", "TEST", 365, 384], ["many", "OBSERVATION_MODIFIER", 19, 23], ["viruses", "OBSERVATION", 24, 31], ["Cellular Proteins", "OBSERVATION", 142, 159]]], ["A protease protection assay was performed using ProK to degrade any proteins on the surface of the virions, while internal proteins were protected by the lipid envelope.", [["surface", "ANATOMY", 84, 91], ["virions", "ANATOMY", 99, 106], ["ProK", "SIMPLE_CHEMICAL", 48, 52], ["surface", "CELLULAR_COMPONENT", 84, 91], ["protease", "PROTEIN", 2, 10], ["ProK", "PROTEIN", 48, 52], ["internal proteins", "PROTEIN", 114, 131], ["A protease protection assay", "TEST", 0, 27], ["ProK", "TREATMENT", 48, 52], ["internal proteins", "TREATMENT", 114, 131], ["virions", "ANATOMY", 99, 106], ["lipid envelope", "OBSERVATION", 154, 168]]], ["Absence of the viral glycoprotein and the presence of the viral nucleoprotein (N) and matrix protein (M) verified that the ProK digestion was 100% efficient (Fig. 3A).", [["matrix protein", "GENE_OR_GENE_PRODUCT", 86, 100], ["viral glycoprotein", "PROTEIN", 15, 33], ["viral nucleoprotein", "PROTEIN", 58, 77], ["matrix protein", "PROTEIN", 86, 100], ["ProK", "PROTEIN", 123, 127], ["the viral glycoprotein", "PROBLEM", 11, 33], ["the viral nucleoprotein (N) and matrix protein", "PROBLEM", 54, 100], ["the ProK digestion", "PROBLEM", 119, 137], ["viral glycoprotein", "OBSERVATION", 15, 33]]], ["Immunoblotting analysis revealed that HSC70, cofilin, CHMP4B, HSP40, ALIX, TSG101, CHMP2A, VPS37 and VPS4B were all present in the ProK-treated virions, indicating their locations within the virion (Fig. 3A).", [["virions", "ANATOMY", 144, 151], ["ProK", "CHEMICAL", 131, 135], ["HSC70", "GENE_OR_GENE_PRODUCT", 38, 43], ["cofilin", "GENE_OR_GENE_PRODUCT", 45, 52], ["CHMP4B", "GENE_OR_GENE_PRODUCT", 54, 60], ["HSP40", "GENE_OR_GENE_PRODUCT", 62, 67], ["ALIX", "GENE_OR_GENE_PRODUCT", 69, 73], ["TSG101", "GENE_OR_GENE_PRODUCT", 75, 81], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 83, 89], ["VPS37", "GENE_OR_GENE_PRODUCT", 91, 96], ["VPS4B", "GENE_OR_GENE_PRODUCT", 101, 106], ["ProK", "GENE_OR_GENE_PRODUCT", 131, 135], ["virion", "CELLULAR_COMPONENT", 191, 197], ["HSC70", "PROTEIN", 38, 43], ["cofilin", "PROTEIN", 45, 52], ["CHMP4B", "PROTEIN", 54, 60], ["HSP40", "PROTEIN", 62, 67], ["ALIX", "PROTEIN", 69, 73], ["TSG101", "PROTEIN", 75, 81], ["CHMP2A", "PROTEIN", 83, 89], ["VPS37", "PROTEIN", 91, 96], ["VPS4B", "PROTEIN", 101, 106], ["ProK", "PROTEIN", 131, 135], ["Immunoblotting analysis", "TEST", 0, 23], ["HSC70", "TEST", 38, 43], ["cofilin", "TEST", 45, 52], ["CHMP4B", "TEST", 54, 60], ["HSP40", "TEST", 62, 67], ["ALIX", "TEST", 69, 73], ["TSG101", "TEST", 75, 81], ["CHMP2A", "TEST", 83, 89], ["VPS37", "TEST", 91, 96], ["VPS4B", "TEST", 101, 106]]], ["Extracts from uninfected and infected N2a cells were included as controls to confirm the reactivity of the antibodies and size of the proteins.", [["Extracts", "ANATOMY", 0, 8], ["N2a cells", "ANATOMY", 38, 47], ["Extracts", "ORGANISM_SUBSTANCE", 0, 8], ["N2a cells", "CELL", 38, 47], ["N2a cells", "CELL_LINE", 38, 47], ["antibodies", "PROTEIN", 107, 117], ["Extracts from uninfected and infected N2a cells", "PROBLEM", 0, 47], ["the antibodies", "TEST", 103, 117], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["N2a cells", "OBSERVATION", 38, 47], ["size", "OBSERVATION_MODIFIER", 122, 126]]], ["CD9, however, was completely absent from ProK-treated virions while \u03b2-actin was reduced by about 50%, indicating that CD9 was present only on the virion surface, while \u03b2-actin was located both inside and outside (Fig. 3A).", [["virions", "ANATOMY", 54, 61], ["virion surface", "ANATOMY", 146, 160], ["ProK", "CHEMICAL", 41, 45], ["CD9", "GENE_OR_GENE_PRODUCT", 0, 3], ["ProK", "GENE_OR_GENE_PRODUCT", 41, 45], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 68, 75], ["CD9", "GENE_OR_GENE_PRODUCT", 118, 121], ["virion surface", "CELLULAR_COMPONENT", 146, 160], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 168, 175], ["CD9", "PROTEIN", 0, 3], ["ProK", "PROTEIN", 41, 45], ["\u03b2-actin", "PROTEIN", 68, 75], ["CD9", "PROTEIN", 118, 121], ["\u03b2-actin", "PROTEIN", 168, 175], ["CD9", "TEST", 0, 3], ["ProK", "TEST", 41, 45], ["virions", "TREATMENT", 54, 61], ["\u03b2-actin", "TREATMENT", 68, 75], ["CD9", "PROBLEM", 118, 121], ["CD9", "OBSERVATION", 118, 121]]], ["Immunogold labeling further confirmed the incorporation of these host proteins into the virion surface.", [["surface", "ANATOMY", 95, 102], ["virion surface", "CELLULAR_COMPONENT", 88, 102], ["host proteins", "PROTEIN", 65, 78], ["Immunogold labeling", "TEST", 0, 19], ["virion", "ANATOMY", 88, 94], ["surface", "ANATOMY_MODIFIER", 95, 102]]], ["As shown in Fig. 3B, gold particle labelling identified CD9 and \u03b2-actin as well as the viral G protein on the surface of virus particles.", [["surface", "ANATOMY", 110, 117], ["gold particle", "SIMPLE_CHEMICAL", 21, 34], ["CD9", "GENE_OR_GENE_PRODUCT", 56, 59], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 64, 71], ["viral G protein", "GENE_OR_GENE_PRODUCT", 87, 102], ["surface", "CELLULAR_COMPONENT", 110, 117], ["CD9", "PROTEIN", 56, 59], ["\u03b2-actin", "PROTEIN", 64, 71], ["viral G protein", "PROTEIN", 87, 102], ["gold particle labelling", "TEST", 21, 44], ["CD9", "TEST", 56, 59], ["\u03b2-actin", "TEST", 64, 71], ["the viral G protein", "TEST", 83, 102], ["virus particles", "PROBLEM", 121, 136], ["virus particles", "OBSERVATION", 121, 136]]], ["Although it was unrealistic to validate all 49 cellular proteins, confirmation of the incorporation of all 11 proteins demonstrated the high probability of incorporation of all 49 proteins into rabies virions.", [["cellular", "ANATOMY", 47, 55], ["cellular", "CELL", 47, 55], ["rabies", "ORGANISM", 194, 200], ["cellular proteins", "PROTEIN", 47, 64], ["49 proteins", "PROTEIN", 177, 188], ["the incorporation of all 11 proteins", "TEST", 82, 118], ["rabies virions", "OBSERVATION", 194, 208]]], ["Clearly, the potential roles of virion-packaged host proteins during RABV infection merit further investigation.Analysis of Virion-Packaged Host Proteins Involved in RABV InfectionAs is well known, many viruses hijack cellular machinery via host\u2013pathogen interactions to function in their replicative cycles (Robinson et al.2018).", [["cellular", "ANATOMY", 218, 226], ["RABV infection", "DISEASE", 69, 83], ["RABV", "ORGANISM", 69, 73], ["RABV", "ORGANISM", 166, 170], ["cellular", "CELL", 218, 226], ["host\u2013pathogen", "GENE_OR_GENE_PRODUCT", 241, 254], ["virion-packaged host proteins", "PROTEIN", 32, 61], ["Virion-Packaged Host Proteins", "PROTEIN", 124, 153], ["RABV", "SPECIES", 69, 73], ["RABV", "SPECIES", 166, 170], ["virion-packaged host proteins", "TREATMENT", 32, 61], ["RABV infection", "PROBLEM", 69, 83], ["further investigation", "TEST", 90, 111], ["Virion-Packaged Host Proteins", "TREATMENT", 124, 153], ["Host Proteins", "OBSERVATION_MODIFIER", 140, 153], ["RABV InfectionAs", "OBSERVATION", 166, 182]]], ["To better understand the biological significance of the host proteins ending up in mature rabies virions, functional predictions of the 49 virion-packaged cellular proteins were performed according to the Gene Ontology Database.", [["cellular", "ANATOMY", 155, 163], ["rabies virions", "ORGANISM", 90, 104], ["cellular", "CELL", 155, 163], ["host proteins", "PROTEIN", 56, 69], ["49 virion-packaged cellular proteins", "PROTEIN", 136, 172], ["rabies", "SPECIES", 90, 96], ["the host proteins", "PROBLEM", 52, 69]]], ["Results showed that they are grouped into 12 functional categories, including viral transport, protein localization, cytoskeleton organization, and transcription (Fig. 4, Supplementary Table S1).", [["cytoskeleton", "ANATOMY", 117, 129], ["cytoskeleton", "CELLULAR_COMPONENT", 117, 129], ["viral transport", "TEST", 78, 93], ["protein localization", "TEST", 95, 115], ["cytoskeleton organization", "OBSERVATION", 117, 142]]], ["Worth noting is that 24 of the 49 proteins were associated with viral processes such as entry (Galectin-1, CD9, CD81, CD151, CD63, IFITM2), genome replication (PCBP1, HSC70, ARF3, CyPA, DDX3X, ENO1, IFITM2, Rack1), assembly (HSP90\u03b2), budding (ALIX, CHMP4B, CHMP2A, VPS4B, TSG101, VPS37B, VPS28), release (Rab-7A, cofilin-1) and spread (PACSIN2) (Fig. 4 and Supplementary Table S1).Analysis of Virion-Packaged Host Proteins Involved in RABV InfectionTo identify clusters and interactions among the above host proteins, a protein\u2013protein interaction (PPI) network was constructed by Metascape using the BIOGRID6, InWeb_IM7 and OmniPath8 databases (https://metascape.org/).", [["Galectin-1", "GENE_OR_GENE_PRODUCT", 95, 105], ["CD9", "GENE_OR_GENE_PRODUCT", 107, 110], ["CD81", "GENE_OR_GENE_PRODUCT", 112, 116], ["CD151", "GENE_OR_GENE_PRODUCT", 118, 123], ["CD63", "GENE_OR_GENE_PRODUCT", 125, 129], ["IFITM2", "GENE_OR_GENE_PRODUCT", 131, 137], ["genome", "CELLULAR_COMPONENT", 140, 146], ["PCBP1", "GENE_OR_GENE_PRODUCT", 160, 165], ["HSC70", "GENE_OR_GENE_PRODUCT", 167, 172], ["ARF3", "GENE_OR_GENE_PRODUCT", 174, 178], ["CyPA", "GENE_OR_GENE_PRODUCT", 180, 184], ["DDX3X", "GENE_OR_GENE_PRODUCT", 186, 191], ["ENO1", "GENE_OR_GENE_PRODUCT", 193, 197], ["IFITM2", "GENE_OR_GENE_PRODUCT", 199, 205], ["Rack1", "GENE_OR_GENE_PRODUCT", 207, 212], ["HSP90\u03b2", "GENE_OR_GENE_PRODUCT", 225, 231], ["ALIX", "GENE_OR_GENE_PRODUCT", 243, 247], ["CHMP4B", "GENE_OR_GENE_PRODUCT", 249, 255], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 257, 263], ["VPS4B", "GENE_OR_GENE_PRODUCT", 265, 270], ["TSG101", "GENE_OR_GENE_PRODUCT", 272, 278], ["VPS37B", "GENE_OR_GENE_PRODUCT", 280, 286], ["VPS28", "GENE_OR_GENE_PRODUCT", 288, 293], ["Rab-7A", "GENE_OR_GENE_PRODUCT", 305, 311], ["cofilin-1", "GENE_OR_GENE_PRODUCT", 313, 322], ["RABV", "ORGANISM", 435, 439], ["Galectin", "PROTEIN", 95, 103], ["CD9", "PROTEIN", 107, 110], ["CD81", "PROTEIN", 112, 116], ["CD151", "PROTEIN", 118, 123], ["CD63", "PROTEIN", 125, 129], ["IFITM2", "PROTEIN", 131, 137], ["PCBP1", "PROTEIN", 160, 165], ["HSC70", "PROTEIN", 167, 172], ["ARF3", "PROTEIN", 174, 178], ["CyPA", "PROTEIN", 180, 184], ["DDX3X", "PROTEIN", 186, 191], ["ENO1", "PROTEIN", 193, 197], ["IFITM2", "PROTEIN", 199, 205], ["Rack1", "PROTEIN", 207, 212], ["HSP90\u03b2", "PROTEIN", 225, 231], ["ALIX", "DNA", 243, 247], ["CHMP4B", "DNA", 249, 255], ["CHMP2A", "DNA", 257, 263], ["VPS4B", "DNA", 265, 270], ["TSG101", "DNA", 272, 278], ["VPS37B", "DNA", 280, 286], ["VPS28", "DNA", 288, 293], ["Rab", "DNA", 305, 308], ["cofilin", "PROTEIN", 313, 320], ["PACSIN2", "DNA", 336, 343], ["Virion-Packaged Host Proteins", "PROTEIN", 393, 422], ["protein\u2013protein interaction (PPI) network", "PROTEIN", 520, 561], ["BIOGRID6, InWeb_IM7 and OmniPath8 databases", "DNA", 601, 644], ["RABV", "SPECIES", 435, 439], ["viral processes", "PROBLEM", 64, 79], ["Galectin", "TEST", 95, 103], ["CD9", "TEST", 107, 110], ["CD81", "TEST", 112, 116], ["CD151", "TEST", 118, 123], ["CD63", "TEST", 125, 129], ["IFITM2", "TEST", 131, 137], ["genome replication", "TEST", 140, 158], ["PCBP1", "TEST", 160, 165], ["HSC70", "TEST", 167, 172], ["ARF3", "TEST", 174, 178], ["CyPA", "TEST", 180, 184], ["DDX3X", "TEST", 186, 191], ["HSP90", "TEST", 225, 230], ["CHMP4B", "TEST", 249, 255], ["CHMP2A", "TEST", 257, 263], ["VPS4B", "TEST", 265, 270], ["TSG101", "TEST", 272, 278], ["VPS37B", "TEST", 280, 286], ["VPS28", "TEST", 288, 293], ["Rab", "TEST", 305, 308], ["cofilin", "TEST", 313, 320], ["Virion-Packaged Host Proteins", "TREATMENT", 393, 422], ["a protein\u2013protein interaction (PPI) network", "TREATMENT", 518, 561]]], ["As a result, the 49 cellular proteins were found to form a PPI network with 24 nodes and 25 edges, as shown in Fig. 5, in which three significant modules were identified by the MCODE algorithm to be linked to 9 cell processes (Supplementary Table S2).", [["cellular", "ANATOMY", 20, 28], ["nodes", "ANATOMY", 79, 84], ["cell", "ANATOMY", 211, 215], ["cellular", "CELL", 20, 28], ["cell", "CELL", 211, 215], ["49 cellular proteins", "PROTEIN", 17, 37], ["the 49 cellular proteins", "TEST", 13, 37], ["a PPI network", "TEST", 57, 70], ["the MCODE algorithm", "TEST", 173, 192], ["nodes", "OBSERVATION", 79, 84], ["25 edges", "OBSERVATION_MODIFIER", 89, 97], ["significant", "OBSERVATION_MODIFIER", 134, 145], ["modules", "OBSERVATION", 146, 153]]], ["Enrichment of the MCODE 2-related viral budding process was the most significant with the smallest p-value of 10\u221221.7, strongly implying the association of the candidate host proteins with viral budding through the endosomal sorting complex required for transport (ESCRT).DiscussionOur previous study identified 50 cellular proteins incorporated into virions of attenuated non-pathogenic RABV vaccine strain SRV9 propagated in epithelium cell line BHK-21 (Tu et al.2015).", [["endosomal", "ANATOMY", 215, 224], ["cellular", "ANATOMY", 315, 323], ["virions", "ANATOMY", 351, 358], ["epithelium cell line BHK-21", "ANATOMY", 427, 454], ["MCODE 2", "GENE_OR_GENE_PRODUCT", 18, 25], ["endosomal", "CELLULAR_COMPONENT", 215, 224], ["cellular", "CELL", 315, 323], ["RABV", "ORGANISM", 388, 392], ["SRV9", "CELL", 408, 412], ["epithelium cell line BHK-21", "CELL", 427, 454], ["MCODE 2", "DNA", 18, 25], ["candidate host proteins", "PROTEIN", 160, 183], ["endosomal sorting complex", "PROTEIN", 215, 240], ["ESCRT", "PROTEIN", 265, 270], ["cellular proteins", "PROTEIN", 315, 332], ["epithelium cell line BHK-21", "CELL_LINE", 427, 454], ["RABV", "SPECIES", 388, 392], ["SRV9", "SPECIES", 408, 412], ["BHK-21", "SPECIES", 448, 454], ["the MCODE 2", "TREATMENT", 14, 25], ["viral budding process", "PROBLEM", 34, 55], ["the smallest p-value", "TEST", 86, 106], ["viral budding", "PROBLEM", 189, 202], ["previous study", "TEST", 286, 300], ["50 cellular proteins", "PROBLEM", 312, 332], ["attenuated non-pathogenic RABV vaccine", "TREATMENT", 362, 400], ["BHK", "TEST", 448, 451], ["viral budding process", "OBSERVATION", 34, 55], ["most significant", "OBSERVATION_MODIFIER", 64, 80], ["smallest", "OBSERVATION_MODIFIER", 90, 98], ["endosomal sorting complex", "OBSERVATION", 215, 240], ["attenuated", "OBSERVATION_MODIFIER", 362, 372], ["non-pathogenic RABV", "OBSERVATION", 373, 392], ["epithelium cell line", "OBSERVATION", 427, 447]]], ["Although the number of host proteins identified in two studies was almost the same, their proteomic compositions were distinct.", [["host proteins", "PROTEIN", 23, 36], ["host proteins", "TEST", 23, 36], ["two studies", "TEST", 51, 62], ["distinct", "OBSERVATION_MODIFIER", 118, 126]]], ["To understand the proteomic composition of pathogenic RABV virions infecting nervous cells the present study was conducted, resulting in identification of 49 cellular proteins incorporated into CVS-11 with 11 of them validated by Western blotting or immuno-electron microscopy.", [["virions", "ANATOMY", 59, 66], ["nervous cells", "ANATOMY", 77, 90], ["cellular", "ANATOMY", 158, 166], ["RABV", "ORGANISM", 54, 58], ["virions", "ORGANISM", 59, 66], ["nervous cells", "CELL", 77, 90], ["cellular", "CELL", 158, 166], ["nervous cells", "CELL_TYPE", 77, 90], ["cellular proteins", "PROTEIN", 158, 175], ["RABV", "SPECIES", 54, 58], ["pathogenic RABV virions infecting nervous cells", "PROBLEM", 43, 90], ["49 cellular proteins", "PROBLEM", 155, 175], ["CVS", "TEST", 194, 197], ["immuno-electron microscopy", "TEST", 250, 276], ["pathogenic", "OBSERVATION_MODIFIER", 43, 53], ["RABV virions", "OBSERVATION", 54, 66]]], ["Of 49 cellular proteins identified in CVS-11 virions purified from infected N2a cells only 13 were identified in SRV9 virions purified from infected BHK-21 cells, which mainly included 4 cytoskeleton-related proteins (Cofilin-1,GAPDH, Tubulin \u03b2-5, \u03b2-actin) and 4 virus replication associated proteins (HSC70, ARF3, CyPA, ENO1).", [["cellular", "ANATOMY", 6, 14], ["virions", "ANATOMY", 45, 52], ["N2a cells", "ANATOMY", 76, 85], ["virions", "ANATOMY", 118, 125], ["BHK-21 cells", "ANATOMY", 149, 161], ["cytoskeleton", "ANATOMY", 187, 199], ["cellular", "CELL", 6, 14], ["N2a cells", "CELL", 76, 85], ["SRV9", "ORGANISM", 113, 117], ["BHK-21 cells", "CELL", 149, 161], ["cytoskeleton", "CELLULAR_COMPONENT", 187, 199], ["Cofilin-1", "GENE_OR_GENE_PRODUCT", 218, 227], ["GAPDH", "GENE_OR_GENE_PRODUCT", 228, 233], ["Tubulin \u03b2-5", "GENE_OR_GENE_PRODUCT", 235, 246], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 248, 255], ["HSC70", "GENE_OR_GENE_PRODUCT", 302, 307], ["ARF3", "GENE_OR_GENE_PRODUCT", 309, 313], ["CyPA", "GENE_OR_GENE_PRODUCT", 315, 319], ["ENO1", "GENE_OR_GENE_PRODUCT", 321, 325], ["cellular proteins", "PROTEIN", 6, 23], ["N2a cells", "CELL_LINE", 76, 85], ["SRV9 virions", "CELL_LINE", 113, 125], ["infected BHK-21 cells", "CELL_LINE", 140, 161], ["cytoskeleton-related proteins", "PROTEIN", 187, 216], ["Cofilin-1", "PROTEIN", 218, 227], ["GAPDH", "PROTEIN", 228, 233], ["Tubulin \u03b2-5", "PROTEIN", 235, 246], ["\u03b2-actin", "PROTEIN", 248, 255], ["virus replication associated proteins", "PROTEIN", 263, 300], ["HSC70", "PROTEIN", 302, 307], ["ARF3", "PROTEIN", 309, 313], ["CyPA", "PROTEIN", 315, 319], ["ENO1", "PROTEIN", 321, 325], ["SRV9", "SPECIES", 113, 117], ["BHK-21", "SPECIES", 149, 155], ["cellular proteins", "TEST", 6, 23], ["CVS", "TEST", 38, 41], ["infected N2a cells", "PROBLEM", 67, 85], ["SRV9 virions", "PROBLEM", 113, 125], ["infected BHK-21 cells", "PROBLEM", 140, 161], ["proteins", "TEST", 208, 216], ["Cofilin", "TEST", 218, 225], ["GAPDH", "TEST", 228, 233], ["Tubulin \u03b2", "TEST", 235, 244], ["HSC70", "TEST", 302, 307], ["ARF3", "TEST", 309, 313], ["CyPA", "TEST", 315, 319], ["cellular proteins", "OBSERVATION", 6, 23], ["11 virions", "OBSERVATION_MODIFIER", 42, 52], ["infected", "OBSERVATION_MODIFIER", 67, 75], ["N2a cells", "OBSERVATION", 76, 85], ["infected BHK", "OBSERVATION", 140, 152], ["21 cells", "OBSERVATION_MODIFIER", 153, 161]]], ["The rest 36 proteins were not identified in SRV9 virions.", [["SRV9 virions", "ANATOMY", 44, 56], ["SRV9 virions", "ORGANISM", 44, 56], ["The rest 36 proteins", "TEST", 0, 20]]], ["It is interesting to note that ESCRT proteins associated with viral budding identified on CVS-11 virions were not found on SRV9 virions.", [["ESCRT", "GENE_OR_GENE_PRODUCT", 31, 36], ["CVS-11 virions", "ORGANISM", 90, 104], ["SRV9", "GENE_OR_GENE_PRODUCT", 123, 127], ["ESCRT proteins", "PROTEIN", 31, 45], ["ESCRT proteins", "PROBLEM", 31, 45], ["viral budding", "PROBLEM", 62, 75], ["CVS", "TEST", 90, 93], ["SRV9 virions", "TREATMENT", 123, 135]]], ["This suggests that pathogenic and avirulent vaccine RABVs likely incorporate distinct cellular proteins into their virions during budding and release from host cells.DiscussionAmong the identified cellular proteins in CVS-11 virions, HSC70 and cofilin-1 had previously been reported to be involved in RABV infection.", [["cellular", "ANATOMY", 86, 94], ["virions", "ANATOMY", 115, 122], ["cells", "ANATOMY", 160, 165], ["cellular", "ANATOMY", 197, 205], ["virions", "ANATOMY", 225, 232], ["RABV infection", "DISEASE", 301, 315], ["cellular", "CELL", 86, 94], ["host cells", "CELL", 155, 165], ["cellular", "CELL", 197, 205], ["HSC70", "GENE_OR_GENE_PRODUCT", 234, 239], ["cofilin-1", "GENE_OR_GENE_PRODUCT", 244, 253], ["RABV", "ORGANISM", 301, 305], ["cellular proteins", "PROTEIN", 86, 103], ["host cells", "CELL_TYPE", 155, 165], ["cellular proteins", "PROTEIN", 197, 214], ["HSC70", "PROTEIN", 234, 239], ["cofilin", "PROTEIN", 244, 251], ["RABV", "SPECIES", 301, 305], ["pathogenic and avirulent vaccine RABVs", "PROBLEM", 19, 57], ["distinct cellular proteins into their virions", "PROBLEM", 77, 122], ["cellular proteins", "TEST", 197, 214], ["CVS", "TEST", 218, 221], ["HSC70", "TEST", 234, 239], ["cofilin", "TEST", 244, 251], ["RABV infection", "PROBLEM", 301, 315], ["pathogenic", "OBSERVATION_MODIFIER", 19, 29], ["avirulent", "OBSERVATION_MODIFIER", 34, 43], ["cellular proteins", "OBSERVATION", 86, 103], ["host cells", "OBSERVATION", 155, 165], ["RABV infection", "OBSERVATION", 301, 315]]], ["HSC70 protein was reported to interact with RABV leader RNA (leRNA), with its expression level dynamically regulated by RABV infection: down-regulated at an early stage with gradual up-regulation (Zhang et al.2017).", [["infection", "DISEASE", 125, 134], ["HSC70", "GENE_OR_GENE_PRODUCT", 0, 5], ["RABV leader RNA", "GENE_OR_GENE_PRODUCT", 44, 59], ["leRNA", "GENE_OR_GENE_PRODUCT", 61, 66], ["RABV", "ORGANISM", 120, 124], ["HSC70 protein", "PROTEIN", 0, 13], ["RABV leader RNA", "RNA", 44, 59], ["leRNA", "PROTEIN", 61, 66], ["RABV", "SPECIES", 44, 48], ["RABV", "SPECIES", 120, 124], ["HSC70 protein", "TEST", 0, 13], ["RABV infection", "PROBLEM", 120, 134], ["gradual up-regulation", "PROBLEM", 174, 195], ["RABV infection", "OBSERVATION", 120, 134]]], ["Here we demonstrate that HSC70 was packaged inside the virions.", [["virions", "ANATOMY", 55, 62], ["HSC70", "GENE_OR_GENE_PRODUCT", 25, 30], ["HSC70", "PROTEIN", 25, 30], ["HSC70", "TEST", 25, 30], ["virions", "ANATOMY", 55, 62]]], ["Cofilin is known to play an essential role in actin cytoskeleton dynamics, and while its knockdown did not affect the expression of RABV proteins, virion release was inhibited (Zan et al.2016).", [["cytoskeleton", "ANATOMY", 52, 64], ["Cofilin", "CHEMICAL", 0, 7], ["Cofilin", "GENE_OR_GENE_PRODUCT", 0, 7], ["actin", "GENE_OR_GENE_PRODUCT", 46, 51], ["cytoskeleton", "CELLULAR_COMPONENT", 52, 64], ["RABV", "ORGANISM", 132, 136], ["virion", "CELLULAR_COMPONENT", 147, 153], ["Cofilin", "PROTEIN", 0, 7], ["actin", "PROTEIN", 46, 51], ["RABV proteins", "PROTEIN", 132, 145], ["RABV", "SPECIES", 132, 136], ["RABV proteins", "TREATMENT", 132, 145], ["virion release", "TREATMENT", 147, 161]]], ["RABV infection has been reported to up-regulate the expression of phosphorylated cofilin to facilitate actin polymerization for virus budding (Zan et al.2016).", [["RABV infection", "DISEASE", 0, 14], ["RABV", "ORGANISM", 0, 4], ["cofilin", "GENE_OR_GENE_PRODUCT", 81, 88], ["actin", "GENE_OR_GENE_PRODUCT", 103, 108], ["phosphorylated cofilin", "PROTEIN", 66, 88], ["actin", "PROTEIN", 103, 108], ["RABV", "SPECIES", 0, 4], ["RABV infection", "PROBLEM", 0, 14], ["phosphorylated cofilin", "TREATMENT", 66, 88], ["actin polymerization", "TREATMENT", 103, 123], ["virus budding", "PROBLEM", 128, 141], ["infection", "OBSERVATION", 5, 14]]], ["Here, we also identified the phosphorylation of cofilin in RABV-infected cells but the protein found on virions was not phosphorylated (data not shown), indicating that cofilin was likely de-phosphorylated when packed into the rabies virion during budding.", [["cells", "ANATOMY", 73, 78], ["virions", "ANATOMY", 104, 111], ["cofilin", "GENE_OR_GENE_PRODUCT", 48, 55], ["RABV", "ORGANISM", 59, 63], ["cells", "CELL", 73, 78], ["cofilin", "GENE_OR_GENE_PRODUCT", 169, 176], ["rabies virion", "ORGANISM", 227, 240], ["cofilin", "PROTEIN", 48, 55], ["RABV-infected cells", "CELL_TYPE", 59, 78], ["cofilin", "PROTEIN", 169, 176], ["RABV", "SPECIES", 59, 63], ["the phosphorylation of cofilin", "PROBLEM", 25, 55], ["infected cells", "PROBLEM", 64, 78], ["the protein", "TEST", 83, 94], ["cofilin", "PROBLEM", 169, 176], ["de-phosphorylated", "PROBLEM", 188, 205], ["infected cells", "OBSERVATION", 64, 78], ["rabies virion", "OBSERVATION", 227, 240]]], ["In addition, PCBP1 was also identified as being incorporated into the rabies virion.", [["PCBP1", "GENE_OR_GENE_PRODUCT", 13, 18], ["rabies virion", "ORGANISM", 70, 83], ["PCBP1", "PROTEIN", 13, 18], ["PCBP1", "TEST", 13, 18], ["rabies virion", "OBSERVATION", 70, 83]]], ["PCBP1, an RNA-binding protein, has been reported to interact with the ORF57 gene of Kaposi\u2019s sarcoma-associated herpesvirus (KSHV), being involved in regulation of the expression of both cellular and viral genes through the activated internal ribosome entry site (IRES) (Nishimura et al.2004), however, its function in RABV infection remains unknown.", [["cellular", "ANATOMY", 187, 195], ["ribosome", "ANATOMY", 243, 251], ["PCBP1", "CHEMICAL", 0, 5], ["Kaposi\u2019s sarcoma", "DISEASE", 84, 100], ["RABV infection", "DISEASE", 319, 333], ["PCBP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF57", "GENE_OR_GENE_PRODUCT", 70, 75], ["Kaposi\u2019s sarcoma-associated herpesvirus", "ORGANISM", 84, 123], ["KSHV", "ORGANISM", 125, 129], ["cellular", "CELL", 187, 195], ["RABV", "ORGANISM", 319, 323], ["PCBP1", "PROTEIN", 0, 5], ["RNA-binding protein", "PROTEIN", 10, 29], ["ORF57 gene", "DNA", 70, 80], ["cellular and viral genes", "DNA", 187, 211], ["activated internal ribosome entry site", "DNA", 224, 262], ["IRES", "DNA", 264, 268], ["Kaposi\u2019s sarcoma-associated herpesvirus", "SPECIES", 84, 123], ["Kaposi\u2019s sarcoma-associated herpesvirus", "SPECIES", 84, 123], ["KSHV", "SPECIES", 125, 129], ["RABV", "SPECIES", 319, 323], ["PCBP1", "TEST", 0, 5], ["Kaposi\u2019s sarcoma", "PROBLEM", 84, 100], ["herpesvirus", "PROBLEM", 112, 123], ["both cellular and viral genes", "PROBLEM", 182, 211], ["RABV infection", "PROBLEM", 319, 333], ["Kaposi", "OBSERVATION", 84, 90], ["sarcoma", "OBSERVATION", 93, 100], ["viral genes", "OBSERVATION", 200, 211], ["RABV", "OBSERVATION_MODIFIER", 319, 323], ["infection", "OBSERVATION", 324, 333]]], ["A previous study showed that its highly conserved isoform, PCBP2 (90% aa identity with PCBP1), increased the stability of RABV glycoprotein mRNA through selective interaction with its 3\u2032 UTR (Palusa et al.2012).", [["PCBP2", "GENE_OR_GENE_PRODUCT", 59, 64], ["PCBP1", "GENE_OR_GENE_PRODUCT", 87, 92], ["RABV glycoprotein", "GENE_OR_GENE_PRODUCT", 122, 139], ["PCBP2", "PROTEIN", 59, 64], ["PCBP1", "PROTEIN", 87, 92], ["RABV glycoprotein mRNA", "RNA", 122, 144], ["UTR", "DNA", 187, 190], ["RABV", "SPECIES", 122, 126], ["A previous study", "TEST", 0, 16], ["PCBP2", "TEST", 59, 64], ["PCBP1", "TEST", 87, 92], ["RABV glycoprotein mRNA", "TREATMENT", 122, 144], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["stability", "OBSERVATION_MODIFIER", 109, 118], ["RABV glycoprotein", "OBSERVATION", 122, 139]]], ["This suggests that PCBP1 incorporated into virions might act as a functional partner for gene expression and posttranscriptional regulation.DiscussionMany enveloped viruses utilize the host ESCRT for budding from the plasma membrane of infected cells (Votteler and Sundquist 2013).", [["virions", "ANATOMY", 43, 50], ["plasma membrane", "ANATOMY", 217, 232], ["cells", "ANATOMY", 245, 250], ["PCBP1", "CHEMICAL", 19, 24], ["PCBP1", "GENE_OR_GENE_PRODUCT", 19, 24], ["ESCRT", "GENE_OR_GENE_PRODUCT", 190, 195], ["plasma membrane", "CELLULAR_COMPONENT", 217, 232], ["cells", "CELL", 245, 250], ["PCBP1", "PROTEIN", 19, 24], ["ESCRT", "PROTEIN", 190, 195], ["infected cells", "CELL_TYPE", 236, 250], ["posttranscriptional regulation", "TREATMENT", 109, 139], ["the host ESCRT", "TREATMENT", 181, 195], ["infected cells", "PROBLEM", 236, 250], ["viruses", "OBSERVATION", 165, 172], ["infected cells", "OBSERVATION", 236, 250]]], ["In this process viruses employ the ESCRT machinery by selectively using core consensus sequences PPxY, PS/TAP, YxxL and FPIV (in which x denotes any amino acid), of the virus-encoded late domain (L-domain), which results in recruitment of the proteins in ESCRT-I, ESCRT-II, ESCRT-III and VPS4 for viral budding and release (Chen and Lamb 2008).", [["amino acid", "CHEMICAL", 149, 159], ["amino acid", "CHEMICAL", 149, 159], ["ESCRT", "GENE_OR_GENE_PRODUCT", 35, 40], ["PPxY", "GENE_OR_GENE_PRODUCT", 97, 101], ["PS", "GENE_OR_GENE_PRODUCT", 103, 105], ["TAP", "GENE_OR_GENE_PRODUCT", 106, 109], ["YxxL", "GENE_OR_GENE_PRODUCT", 111, 115], ["FPIV", "GENE_OR_GENE_PRODUCT", 120, 124], ["amino acid", "AMINO_ACID", 149, 159], ["ESCRT-I", "GENE_OR_GENE_PRODUCT", 255, 262], ["ESCRT-II", "GENE_OR_GENE_PRODUCT", 264, 272], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 274, 283], ["VPS4", "GENE_OR_GENE_PRODUCT", 288, 292], ["core consensus sequences", "DNA", 72, 96], ["PPxY", "DNA", 97, 101], ["PS", "DNA", 103, 105], ["TAP", "PROTEIN", 106, 109], ["YxxL", "DNA", 111, 115], ["FPIV", "DNA", 120, 124], ["virus-encoded late domain", "PROTEIN", 169, 194], ["L-domain", "PROTEIN", 196, 204], ["ESCRT-I, ESCRT-II", "PROTEIN", 255, 272], ["ESCRT-III", "PROTEIN", 274, 283], ["VPS4", "PROTEIN", 288, 292], ["core consensus sequences", "TEST", 72, 96], ["PPxY", "TEST", 97, 101], ["PS/TAP", "TREATMENT", 103, 109], ["YxxL", "TREATMENT", 111, 115], ["FPIV", "TREATMENT", 120, 124], ["any amino acid", "TREATMENT", 145, 159], ["the virus", "PROBLEM", 165, 174], ["viral budding", "PROBLEM", 297, 310]]], ["In rabies virus, the M protein contains two L-domains, PPEY and YVPL, which are found in an overlapping fashion (35PPEYVPL41) near its N terminus.", [["N", "CHEMICAL", 135, 136], ["rabies virus", "ORGANISM", 3, 15], ["PPEY", "GENE_OR_GENE_PRODUCT", 55, 59], ["YVPL", "GENE_OR_GENE_PRODUCT", 64, 68], ["M protein", "PROTEIN", 21, 30], ["L-domains", "PROTEIN", 44, 53], ["PPEY", "PROTEIN", 55, 59], ["YVPL", "PROTEIN", 64, 68], ["35PPEYVPL41", "PROTEIN", 113, 124], ["N terminus", "PROTEIN", 135, 145], ["rabies virus", "SPECIES", 3, 15], ["rabies virus", "SPECIES", 3, 15], ["rabies virus", "PROBLEM", 3, 15], ["the M protein", "TEST", 17, 30], ["PPEY", "PROBLEM", 55, 59], ["rabies virus", "OBSERVATION", 3, 15], ["two", "OBSERVATION_MODIFIER", 40, 43], ["L", "OBSERVATION_MODIFIER", 44, 45], ["-domains", "OBSERVATION", 45, 53], ["terminus", "OBSERVATION_MODIFIER", 137, 145]]], ["Site-directed mutagenesis has confirmed that the PPEY motif is essential for efficient release of rabies virions (Wirblich et al.2008), but the cellular factors required for viral budding have yet to be determined.", [["cellular", "ANATOMY", 144, 152], ["PPEY", "GENE_OR_GENE_PRODUCT", 49, 53], ["rabies virions", "ORGANISM", 98, 112], ["cellular", "CELL", 144, 152], ["PPEY motif", "DNA", 49, 59], ["cellular factors", "PROTEIN", 144, 160], ["the PPEY motif", "TREATMENT", 45, 59], ["rabies virions", "TREATMENT", 98, 112], ["the cellular factors", "PROBLEM", 140, 160], ["viral budding", "PROBLEM", 174, 187]]], ["The PPPY motif has been reported to recruit TSG101 for the budding of Marburg VP40-induced virus-like particles its incorporation within (Urata et al.2007).", [["PPPY", "GENE_OR_GENE_PRODUCT", 4, 8], ["TSG101", "GENE_OR_GENE_PRODUCT", 44, 50], ["Marburg VP40", "ORGANISM", 70, 82], ["PPPY motif", "DNA", 4, 14], ["TSG101", "PROTEIN", 44, 50], ["Marburg VP40", "PROTEIN", 70, 82], ["The PPPY motif", "PROBLEM", 0, 14], ["TSG101", "TEST", 44, 50], ["Marburg VP40-induced virus", "PROBLEM", 70, 96]]], ["Likewise, our study has provided evidence for the incorporation of TSG101 into the rabies virion during budding (Fig. 3A), presumably mediated via its binding to the PPEY motif of the M protein.", [["TSG101", "GENE_OR_GENE_PRODUCT", 67, 73], ["rabies virion", "ORGANISM", 83, 96], ["Fig. 3A", "ORGANISM", 113, 120], ["M protein", "GENE_OR_GENE_PRODUCT", 184, 193], ["TSG101", "PROTEIN", 67, 73], ["PPEY motif", "PROTEIN", 166, 176], ["M protein", "PROTEIN", 184, 193], ["our study", "TEST", 10, 19], ["the incorporation of TSG101", "PROBLEM", 46, 73], ["TSG101", "OBSERVATION", 67, 73]]], ["In addition to TSG101, other downstream ESCRT members, VPS28 and VPS37 in ESCRT-I, CHMP2A and CHMP4B in ESCRT-III, and also VPS4B, have been found to be recruited into rabies virions (Fig. 3A and Supplementary Table S1).", [["TSG101", "GENE_OR_GENE_PRODUCT", 15, 21], ["ESCRT", "GENE_OR_GENE_PRODUCT", 40, 45], ["VPS28", "GENE_OR_GENE_PRODUCT", 55, 60], ["VPS37", "GENE_OR_GENE_PRODUCT", 65, 70], ["ESCRT-I", "GENE_OR_GENE_PRODUCT", 74, 81], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 83, 89], ["CHMP4B", "GENE_OR_GENE_PRODUCT", 94, 100], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 104, 113], ["VPS4B", "GENE_OR_GENE_PRODUCT", 124, 129], ["rabies", "ORGANISM", 168, 174], ["TSG101", "DNA", 15, 21], ["ESCRT members", "PROTEIN", 40, 53], ["VPS28", "PROTEIN", 55, 60], ["VPS37", "PROTEIN", 65, 70], ["ESCRT-I", "PROTEIN", 74, 81], ["CHMP2A", "PROTEIN", 83, 89], ["CHMP4B", "PROTEIN", 94, 100], ["ESCRT-III", "PROTEIN", 104, 113], ["VPS4B", "PROTEIN", 124, 129], ["TSG101", "TEST", 15, 21], ["VPS28", "TEST", 55, 60], ["VPS37", "TEST", 65, 70], ["ESCRT", "TEST", 74, 79], ["CHMP2A", "TEST", 83, 89], ["VPS4B", "TEST", 124, 129], ["TSG101", "OBSERVATION", 15, 21]]], ["Elsewhere, ESCRT-III proteins CHMP2A, CHMP4B and VPS4 have been reported associated with the budding of HIV, equine infectious anemia virus (EIAV), and murine leukemia virus (Morita et al.2011; Sandrin and Sundquist 2013; Bartusch and Prange 2016).", [["equine infectious anemia", "DISEASE", 109, 133], ["murine leukemia virus", "DISEASE", 152, 173], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 11, 20], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 30, 36], ["CHMP4B", "GENE_OR_GENE_PRODUCT", 38, 44], ["VPS4", "GENE_OR_GENE_PRODUCT", 49, 53], ["HIV", "ORGANISM", 104, 107], ["equine infectious anemia virus", "ORGANISM", 109, 139], ["EIAV", "ORGANISM", 141, 145], ["murine leukemia virus", "ORGANISM", 152, 173], ["ESCRT-III proteins", "PROTEIN", 11, 29], ["CHMP2A", "PROTEIN", 30, 36], ["CHMP4B", "PROTEIN", 38, 44], ["VPS4", "PROTEIN", 49, 53], ["HIV", "SPECIES", 104, 107], ["equine infectious anemia virus", "SPECIES", 109, 139], ["EIAV", "SPECIES", 141, 145], ["murine", "SPECIES", 152, 158], ["HIV", "SPECIES", 104, 107], ["equine infectious anemia virus", "SPECIES", 109, 139], ["EIAV", "SPECIES", 141, 145], ["murine leukemia virus", "SPECIES", 152, 173], ["ESCRT", "TEST", 11, 16], ["CHMP4B", "TEST", 38, 44], ["VPS4", "PROBLEM", 49, 53], ["HIV", "PROBLEM", 104, 107], ["equine infectious anemia virus (EIAV)", "PROBLEM", 109, 146], ["murine leukemia virus", "PROBLEM", 152, 173], ["infectious", "OBSERVATION_MODIFIER", 116, 126], ["murine leukemia virus", "OBSERVATION", 152, 173]]], ["It is likely from our results, therefore, that these ESCRT proteins are also important for the effective budding and release of RABV.", [["ESCRT", "GENE_OR_GENE_PRODUCT", 53, 58], ["RABV", "ORGANISM", 128, 132], ["ESCRT proteins", "PROTEIN", 53, 67], ["RABV", "SPECIES", 128, 132], ["these ESCRT proteins", "TREATMENT", 47, 67]]], ["Another L-domain, YxxL, is present as YVPL in RABV M protein, but its function is unknown; however, EIAV uses this motif (as YPDL) within the late assembly domain of the Gag p9 protein to recruit cellular protein ALIX (another rabies virion component) for its budding (Chen et al.2005).", [["cellular", "ANATOMY", 196, 204], ["L-domain", "GENE_OR_GENE_PRODUCT", 8, 16], ["YxxL", "GENE_OR_GENE_PRODUCT", 18, 22], ["YVPL", "GENE_OR_GENE_PRODUCT", 38, 42], ["RABV M protein", "GENE_OR_GENE_PRODUCT", 46, 60], ["EIAV", "ORGANISM", 100, 104], ["YPDL", "GENE_OR_GENE_PRODUCT", 125, 129], ["Gag p9", "GENE_OR_GENE_PRODUCT", 170, 176], ["cellular", "CELL", 196, 204], ["ALIX", "GENE_OR_GENE_PRODUCT", 213, 217], ["L-domain", "PROTEIN", 8, 16], ["YxxL", "PROTEIN", 18, 22], ["YVPL", "PROTEIN", 38, 42], ["RABV M protein", "PROTEIN", 46, 60], ["YPDL", "PROTEIN", 125, 129], ["late assembly domain", "PROTEIN", 142, 162], ["Gag p9 protein", "PROTEIN", 170, 184], ["cellular protein", "PROTEIN", 196, 212], ["ALIX", "PROTEIN", 213, 217], ["rabies virion component", "PROTEIN", 227, 250], ["RABV", "SPECIES", 46, 50], ["EIAV", "SPECIES", 100, 104], ["RABV M protein", "TEST", 46, 60], ["EIAV", "PROBLEM", 100, 104], ["the Gag p9 protein", "TREATMENT", 166, 184], ["cellular protein ALIX", "TREATMENT", 196, 217], ["another rabies virion component", "TREATMENT", 219, 250], ["its budding", "PROBLEM", 256, 267], ["protein ALIX", "OBSERVATION", 205, 217]]], ["Furthermore, ALIX binding to CHMP4 can recruit downstream ESCRT-III subunits (e.g., CHMP2A) and form the CHMP complex by polymerization, compressing the neck of budding viruses to facilitate fission and membrane scission (McCullough et al.2008; Johnson et al.2018).", [["neck", "ANATOMY", 153, 157], ["membrane", "ANATOMY", 203, 211], ["ALIX", "CHEMICAL", 13, 17], ["ALIX", "GENE_OR_GENE_PRODUCT", 13, 17], ["CHMP4", "GENE_OR_GENE_PRODUCT", 29, 34], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 58, 67], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 84, 90], ["CHMP", "GENE_OR_GENE_PRODUCT", 105, 109], ["membrane", "CELLULAR_COMPONENT", 203, 211], ["ALIX", "PROTEIN", 13, 17], ["CHMP4", "PROTEIN", 29, 34], ["ESCRT-III subunits", "PROTEIN", 58, 76], ["CHMP2A", "PROTEIN", 84, 90], ["CHMP complex", "PROTEIN", 105, 117], ["ALIX binding", "PROBLEM", 13, 25], ["the CHMP complex", "PROBLEM", 101, 117], ["budding viruses", "PROBLEM", 161, 176], ["membrane scission", "PROBLEM", 203, 220], ["neck", "ANATOMY", 153, 157], ["budding viruses", "OBSERVATION", 161, 176], ["membrane scission", "OBSERVATION", 203, 220]]], ["In addition, it is known that the AAA-type ATPase VPS4 A/B recruited by ESCRT-III is essential for disassembly of ESCRT-III spirals and is also likely to provide energy (Adell et al.2014).", [["AAA-type ATPase", "GENE_OR_GENE_PRODUCT", 34, 49], ["VPS4 A/B", "GENE_OR_GENE_PRODUCT", 50, 58], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 72, 81], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 114, 123], ["AAA-type ATPase", "PROTEIN", 34, 49], ["VPS4 A", "PROTEIN", 50, 56], ["B", "PROTEIN", 57, 58], ["ESCRT-III", "PROTEIN", 72, 81], ["ESCRT", "PROTEIN", 114, 119], ["the AAA", "TEST", 30, 37], ["A/B", "PROBLEM", 55, 58], ["AAA", "OBSERVATION", 34, 37]]], ["Here, VPS4B was identified in the RABV virion (Fig. 3A) and its function merits further investigation.DiscussionBased on the above analyses a process for RABV egress involving the ESCRT system is proposed in Fig. 6.", [["VPS4B", "GENE_OR_GENE_PRODUCT", 6, 11], ["RABV virion", "ORGANISM", 34, 45], ["Fig. 3A", "GENE_OR_GENE_PRODUCT", 47, 54], ["RABV", "ORGANISM", 154, 158], ["VPS4B", "PROTEIN", 6, 11], ["RABV", "SPECIES", 34, 38], ["RABV", "SPECIES", 154, 158], ["VPS4B", "TEST", 6, 11], ["further investigation", "TEST", 80, 101], ["RABV egress", "PROBLEM", 154, 165], ["the ESCRT system", "TREATMENT", 176, 192], ["RABV virion", "ANATOMY", 34, 45]]], ["Since cryo-EM has shown that M protein forms a helical layer it appears that viral morphogenesis takes place in specialized cytoplasmic areas.", [["cytoplasmic areas", "ANATOMY", 124, 141], ["M protein", "GENE_OR_GENE_PRODUCT", 29, 38], ["cytoplasmic", "ORGANISM_SUBSTANCE", 124, 135], ["M protein", "PROTEIN", 29, 38], ["a helical layer", "TREATMENT", 45, 60], ["viral morphogenesis", "PROBLEM", 77, 96], ["viral morphogenesis", "OBSERVATION", 77, 96], ["cytoplasmic areas", "OBSERVATION", 124, 141]]], ["The genome-containing nucleocapsid (NC) is enfolded within a layer of M helix, which is transported to the plasma membrane (PM) containing the viral G protein, causing extrusion of the membrane to form the bullet-shaped budding site (Schnell et al.1998; Johnson et al.2018).", [["plasma membrane", "ANATOMY", 107, 122], ["PM", "ANATOMY", 124, 126], ["membrane", "ANATOMY", 185, 193], ["genome", "CELLULAR_COMPONENT", 4, 10], ["nucleocapsid", "CELLULAR_COMPONENT", 22, 34], ["plasma membrane", "CELLULAR_COMPONENT", 107, 122], ["PM", "CELLULAR_COMPONENT", 124, 126], ["viral G protein", "GENE_OR_GENE_PRODUCT", 143, 158], ["membrane", "CELLULAR_COMPONENT", 185, 193], ["NC", "PROTEIN", 36, 38], ["viral G protein", "PROTEIN", 143, 158], ["bullet-shaped budding site", "DNA", 206, 232], ["nucleocapsid (NC)", "PROBLEM", 22, 39], ["the viral G protein", "PROBLEM", 139, 158], ["extrusion of the membrane", "PROBLEM", 168, 193], ["the bullet", "PROBLEM", 202, 212], ["shaped budding site", "PROBLEM", 213, 232], ["bullet", "OBSERVATION", 206, 212], ["shaped", "OBSERVATION_MODIFIER", 213, 219], ["budding site", "OBSERVATION", 220, 232]]], ["Recruitment of ESCRT at the assembly sites is likely mediated by M protein by two pathways: (1) the PPEY motif recruiting TSG101, VPS28, VPS37 (ESCRT\u00adI); and (2) the YVPL motif recruiting ALIX.", [["ESCRT", "GENE_OR_GENE_PRODUCT", 15, 20], ["M protein", "GENE_OR_GENE_PRODUCT", 65, 74], ["PPEY", "GENE_OR_GENE_PRODUCT", 100, 104], ["TSG101", "GENE_OR_GENE_PRODUCT", 122, 128], ["VPS28", "GENE_OR_GENE_PRODUCT", 130, 135], ["ESCRT\u00adI", "GENE_OR_GENE_PRODUCT", 144, 151], ["ALIX", "GENE_OR_GENE_PRODUCT", 188, 192], ["ESCRT", "PROTEIN", 15, 20], ["M protein", "PROTEIN", 65, 74], ["PPEY motif", "PROTEIN", 100, 110], ["TSG101", "DNA", 122, 128], ["VPS28", "PROTEIN", 130, 135], ["VPS37", "PROTEIN", 137, 142], ["ESCRT\u00adI", "PROTEIN", 144, 151], ["YVPL motif", "DNA", 166, 176], ["ALIX", "PROTEIN", 188, 192], ["ESCRT", "TREATMENT", 15, 20], ["TSG101", "TEST", 122, 128], ["VPS28", "TEST", 130, 135], ["VPS37", "TEST", 137, 142], ["recruiting ALIX", "OBSERVATION", 177, 192]]], ["Downstream CHMP2A and CHMP4B (ESCRT-III) would then be recruited to form the budding neck by polymerization of the ESCRT-III proteins (Shen et al.2014).", [["neck", "ANATOMY", 85, 89], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 11, 17], ["CHMP4B", "GENE_OR_GENE_PRODUCT", 22, 28], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 30, 39], ["neck", "ORGAN", 85, 89], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 115, 124], ["CHMP2A", "PROTEIN", 11, 17], ["CHMP4B", "PROTEIN", 22, 28], ["ESCRT-III", "PROTEIN", 30, 39], ["ESCRT-III proteins", "PROTEIN", 115, 133], ["Shen et al", "PROTEIN", 135, 145], ["Downstream CHMP2A", "TEST", 0, 17], ["CHMP4B", "TEST", 22, 28], ["neck", "ANATOMY", 85, 89]]], ["Since VPS4 can mediate disassembly/remodeling of CHMP2A (Van Engelenburg et al.2014), it may be that VPS4B can remodel CHMP2A and CHMP4B into a filamentous structure to drive membrane scission, ultimately resulting in the release of the mature RABV particles into a new round of infection.DiscussionThe present study has provided not only new insights into RABV virions but also a candidate protein list to further investigate the molecular mechanisms of RABV infection.", [["membrane", "ANATOMY", 175, 183], ["VPS4", "CHEMICAL", 6, 10], ["infection", "DISEASE", 279, 288], ["RABV infection", "DISEASE", 455, 469], ["VPS4", "GENE_OR_GENE_PRODUCT", 6, 10], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 49, 55], ["VPS4B", "GENE_OR_GENE_PRODUCT", 101, 106], ["CHMP2A", "GENE_OR_GENE_PRODUCT", 119, 125], ["CHMP4B", "GENE_OR_GENE_PRODUCT", 130, 136], ["membrane", "CELLULAR_COMPONENT", 175, 183], ["RABV", "ORGANISM", 244, 248], ["RABV", "ORGANISM", 357, 361], ["RABV", "ORGANISM", 455, 459], ["VPS4", "PROTEIN", 6, 10], ["CHMP2A", "PROTEIN", 49, 55], ["VPS4B", "PROTEIN", 101, 106], ["CHMP2A", "PROTEIN", 119, 125], ["CHMP4B", "PROTEIN", 130, 136], ["RABV", "SPECIES", 244, 248], ["RABV", "SPECIES", 357, 361], ["RABV", "SPECIES", 455, 459], ["VPS4", "PROBLEM", 6, 10], ["a filamentous structure", "PROBLEM", 142, 165], ["infection", "PROBLEM", 279, 288], ["The present study", "TEST", 299, 316], ["RABV infection", "PROBLEM", 455, 469], ["filamentous structure", "OBSERVATION", 144, 165], ["RABV particles", "OBSERVATION", 244, 258], ["new", "OBSERVATION_MODIFIER", 266, 269], ["round", "OBSERVATION_MODIFIER", 270, 275], ["infection", "OBSERVATION", 279, 288], ["RABV infection", "OBSERVATION", 455, 469]]], ["They will also benefit screening for target proteins in future development of anti-rabies therapies.", [["anti-rabies", "SIMPLE_CHEMICAL", 78, 89], ["target proteins", "PROTEIN", 37, 52], ["screening", "TEST", 23, 32], ["target proteins", "TREATMENT", 37, 52], ["anti-rabies therapies", "TREATMENT", 78, 99]]]]}